[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Acrokeratosis paraneoplastica is also known as:\n* Acrokeratosis paraneoplastic\nThese names refer to the same condition, which is a rare genodermatosis characterized by the development of keratoses (scaly lesions) on the skin, often in association with certain types of cancer, particularly lymphoma.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica is also known as Acrokeratosis paraneoplastic.\n2. Acrokeratosis paraneoplastica is characterized by the development of keratoses on the skin.\n3. Acrokeratosis paraneoplastica is often associated with certain types of cancer, particularly lymphoma.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica is also known as Acrokeratosis paraneoplastic.",
      "Acrokeratosis paraneoplastica is characterized by the development of keratoses on the skin.",
      "Acrokeratosis paraneoplastica is often associated with certain types of cancer, particularly lymphoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Acrokeratosis paraneoplastica is often associated with certain types of cancer, particularly gastrointestinal adenocarcinomas and squamous cell carcinomas of the upper aerodigestive tract.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Weaver syndrome and Sotos syndrome are both genetic disorders that affect the development and growth of the body, but they have some differences in their clinical presentation and genetic causes.\nSimilarities:\n* Both Weaver and Sotos syndrome are caused by mutations in genes that are involved in the regulation of gene expression and cell growth.\n* Both disorders can cause a range of developmental delays, intellectual disability, and growth delays.\n* Both disorders can also cause distinctive physical features, such as coarse facial features, short stature, and heart defects.\nDifferences:\n* Weaver syndrome is caused by mutations in the PRC2 gene, which is involved in the regulation of gene expression and chromatin remodeling. Sotos syndrome, on the other hand, is caused by mutations in the NSD1 gene, which is involved in the regulation of gene expression and cell growth.\n* Weaver syndrome typically presents with more severe intellectual disability and developmental delays compared to Sotos syndrome.\n* Weaver syndrome can also cause more severe skeletal abnormalities, such as clubfoot and scoliosis, compared to Sotos syndrome.\n* Sotos syndrome is often associated with a distinctive facial appearance, including a broad forehead, large eyes, and a prominent nose, while Weaver syndrome can have a more variable facial appearance.\nIn summary, while both Weaver syndrome and Sotos syndrome are genetic disorders that affect the development and growth of the body, they have distinct genetic causes and clinical presentations.",
    "llama-2-7b-chat-hf_fact_raw": "1. Both Weaver syndrome and Sotos syndrome are genetic disorders that affect development and growth.\n2. Mutations in the PRC2 gene cause Weaver syndrome.\n3. Mutations in the NSD1 gene cause Sotos syndrome.\n4. Weaver syndrome typically presents with more severe intellectual disability and developmental delays than Sotos syndrome.\n5. Sotos syndrome is often associated with a distinctive facial appearance, including a broad forehead, large eyes, and a prominent nose.",
    "llama-2-7b-chat-hf_fact": [
      "Both Weaver syndrome and Sotos syndrome are genetic disorders that affect development and growth.",
      "Mutations in the PRC2 gene cause Weaver syndrome.",
      "Mutations in the NSD1 gene cause Sotos syndrome.",
      "Weaver syndrome typically presents with more severe intellectual disability and developmental delays than Sotos syndrome.",
      "Sotos syndrome is often associated with a distinctive facial appearance, including a broad forehead, large eyes, and a prominent nose."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Mutations in the EZH2 gene, not PRC2, cause Weaver syndrome. PRC2 refers to a complex of which EZH2 is a part.\n3. TRUE\n4. UNKNOWN: The severity of intellectual disability and developmental delays can vary widely in both Weaver syndrome and Sotos syndrome, making it difficult to assert that one typically presents with more severe symptoms than the other without specific data.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "JASPAR (Junk-Added Sparse Matrix Assignment by Representations) is a database of transcription factor binding site (TFBS) matrices that have been computed using a variety of computational methods. Here are the releases of the JASPAR database:\n1. JASPAR Release 1.0 (2002): This was the first release of the JASPAR database, containing 32 TFBS matrices for 12 transcription factors.\n2. JASPAR Release 2.0 (2006): This release added 24 new TFBS matrices and improved the quality of the existing matrices.\n3. JASPAR Release 3.0 (2010): This release included 135 TFBS matrices for 40 transcription factors, as well as improved computational methods for predicting TFBSs.\n4. JASPAR Release 4.0 (2013): This release added 23 new TFBS matrices and improved the quality of the existing matrices, as well as adding new features such as the ability to search for TFBSs in multiple genomic locations.\n5. JASPAR Release 5.0 (2016): This release included 186 TFBS matrices for 60 transcription factors, as well as improved computational methods for predicting TFBSs and a new feature for predicting the binding affinity of TFBSs.\n6. JASPAR Release 6.0 (2020): This is the most recent release of the JASPAR database, containing 210 TFBS matrices for 70 transcription factors. This release includes improved computational methods and a new feature for predicting the binding sites of TFBSs.\nIt's worth noting that JASPAR also provides a \"JASPAR-Net\" tool that uses deep learning to predict TFBSs, which can be accessed through the JASPAR website.",
    "llama-2-7b-chat-hf_fact_raw": "1. JASPAR Release 1.0 was launched in 2002 with 32 TFBS matrices for 12 transcription factors.\n2. JASPAR Release 2.0 was launched in 2006 and added 24 new TFBS matrices.\n3. JASPAR Release 3.0 was launched in 2010 and included 135 TFBS matrices for 40 transcription factors.\n4. JASPAR Release 4.0 was launched in 2013 and added 23 new TFBS matrices.\n5. JASPAR Release 6.0 is the most recent as of 2020, containing 210 TFBS matrices for 70 transcription factors.",
    "llama-2-7b-chat-hf_fact": [
      "JASPAR Release 1.0 was launched in 2002 with 32 TFBS matrices for 12 transcription factors.",
      "JASPAR Release 2.0 was launched in 2006 and added 24 new TFBS matrices.",
      "JASPAR Release 3.0 was launched in 2010 and included 135 TFBS matrices for 40 transcription factors.",
      "JASPAR Release 4.0 was launched in 2013 and added 23 new TFBS matrices.",
      "JASPAR Release 6.0 is the most recent as of 2020, containing 210 TFBS matrices for 70 transcription factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: JASPAR Release 3.0 was launched in 2006 and included 123 TFBS matrices for 113 transcription factors.\n4. FALSE [correction]: JASPAR Release 4.0 was launched in 2014 and added 56 new TFBS matrices.\n5. FALSE [correction]: JASPAR Release 2020 is the most recent as of 2020, containing 610 TFBS matrices for 135 transcription factors.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "The KP4 protein is a protein encoded by the KP4 gene in certain viruses, including the herpesvirus saimiri (HVS) and the gammaherpesvirus 4 (GHV-4). The KP4 protein has been shown to have multiple functions, including:\n1. Inhibition of the host immune response: The KP4 protein can inhibit the activation and proliferation of immune cells, such as T cells and macrophages, which are important in fighting off viral infections.\n2. Modulation of cell signaling pathways: The KP4 protein can interact with and modulate the activity of various cell signaling pathways, including the PI3K/Akt and MAPK pathways, which are involved in cell survival, proliferation, and differentiation.\n3. Inhibition of apoptosis: The KP4 protein can inhibit the induction of apoptosis (programmed cell death) in infected cells, which can help the virus to persist and establish a chronic infection.\n4. Modulation of viral transcription: The KP4 protein can also interact with viral transcription factors and modulate their activity, which can affect the expression of viral genes and the replication of the virus.\nOverall, the KP4 protein plays a multifaceted role in the infection and replication of certain viruses, and its functions can vary depending on the specific virus and the stage of infection.",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein is encoded by the KP4 gene in certain viruses, including herpesvirus saimiri (HVS) and gammaherpesvirus 4 (GHV-4).\n2. The KP4 protein can inhibit the activation and proliferation of immune cells such as T cells and macrophages.\n3. The KP4 protein can interact with and modulate the activity of cell signaling pathways like the PI3K/Akt and MAPK pathways.\n4. The KP4 protein can inhibit the induction of apoptosis in infected cells.\n5. The KP4 protein can interact with viral transcription factors and modulate their activity, affecting the expression of viral genes and virus replication.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein is encoded by the KP4 gene in certain viruses, including herpesvirus saimiri (HVS) and gammaherpesvirus 4 (GHV-4).",
      "The KP4 protein can inhibit the activation and proliferation of immune cells such as T cells and macrophages.",
      "The KP4 protein can interact with and modulate the activity of cell signaling pathways like the PI3K/Akt and MAPK pathways.",
      "The KP4 protein can inhibit the induction of apoptosis in infected cells.",
      "The KP4 protein can interact with viral transcription factors and modulate their activity, affecting the expression of viral genes and virus replication."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The KP4 protein is not encoded by viruses such as herpesvirus saimiri (HVS) or gammaherpesvirus 4 (GHV-4). KP4 is a fungal toxin produced by Ustilago maydis, a type of smut fungus.\n2. UNKNOWN: Without specific context or scientific evidence provided, it is difficult to determine the accuracy of this statement regarding the KP4 protein's effects on immune cells.\n3. UNKNOWN: Similarly, without additional context or references, the interaction of KP4 protein with cell signaling pathways like the PI3K/Akt and MAPK pathways cannot be confirmed.\n4. UNKNOWN: The statement about the KP4 protein's ability to inhibit apoptosis in infected cells is also difficult to verify without further information or scientific references.\n5. UNKNOWN: The interaction of KP4 protein with viral transcription factors and its effect on the expression of viral genes and virus replication is not verifiable with the information provided. Additionally, since KP4 is a fungal toxin, it would not typically interact with viral transcription factors.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Yes, DITPA (N-[4-[2-Phenyl-5,7-dimethyl-1-oxazol-4-yl]phenyl]-2-thiazolidine-4-carboxamide-1,3-dioxide) is a synthetic thyroid hormone analog that has been utilized in both experimental and clinical studies.\nDITPA has been shown to have a range of biological activities, including the ability to stimulate the activity of thyroid hormone receptors, increase the expression of genes involved in energy metabolism, and inhibit the growth of certain types of cancer cells. As a result, it has been investigated as a potential therapeutic agent for a variety of conditions, including obesity, metabolic disorders, and cancer.\nIn experimental studies, DITPA has been shown to:\n* Stimulate the activity of thyroid hormone receptors in a variety of tissues, including the liver, heart, and muscle.\n* Increase the expression of genes involved in energy metabolism, such as the gene for the enzyme acetyl-CoA carboxylase.\n* Inhibit the growth of certain types of cancer cells, such as those derived from breast, lung, and prostate tumors.\n* Improve insulin sensitivity and glucose tolerance in animal models of type 2 diabetes.\nIn clinical studies, DITPA has been investigated as a potential treatment for a range of conditions, including:\n* Obesity: DITPA has been shown to promote weight loss in both animal models and small-scale clinical trials in humans.\n* Metabolic disorders: DITPA has been investigated as a potential treatment for metabolic disorders such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).\n* Cancer: DITPA has been studied as a potential anti-tumor agent in a variety of cancer types, including breast, lung, and prostate cancer.\nWhile DITPA has shown promise in these studies, it is important to note that further research is needed to fully understand its mechanisms of action and to",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA is a synthetic thyroid hormone analog used in experimental and clinical studies.\n2. DITPA stimulates the activity of thyroid hormone receptors in various tissues, including the liver, heart, and muscle.\n3. DITPA increases the expression of genes involved in energy metabolism, such as the gene for the enzyme acetyl-CoA carboxylase.\n4. DITPA inhibits the growth of certain types of cancer cells, including those derived from breast, lung, and prostate tumors.\n5. DITPA has been investigated as a potential treatment for obesity, metabolic disorders, and cancer in clinical studies.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA is a synthetic thyroid hormone analog used in experimental and clinical studies.",
      "DITPA stimulates the activity of thyroid hormone receptors in various tissues, including the liver, heart, and muscle.",
      "DITPA increases the expression of genes involved in energy metabolism, such as the gene for the enzyme acetyl-CoA carboxylase.",
      "DITPA inhibits the growth of certain types of cancer cells, including those derived from breast, lung, and prostate tumors.",
      "DITPA has been investigated as a potential treatment for obesity, metabolic disorders, and cancer in clinical studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "COUGER (Comprehensive Update of Gene Regulatory Events) is a tool used to identify potential regulatory elements in a genome, such as promoters, enhancers, and silencers. It is based on the concept of \"gene regulation by transcriptional pulses,\" which suggests that gene expression is regulated by short-lived changes in the availability of transcription factors rather than by long-lived changes in the availability of transcriptional activators or repressors.\nCOUGER uses a computational approach to identify potential regulatory elements in a genome by analyzing the patterns of gene expression and the locations of transcription factor binding sites. It takes into account various types of genomic data, including gene expression profiles, histone modification profiles, and DNA sequence data. The tool can be used to identify potential regulatory elements in a genome, and to predict the regulatory interactions between these elements and their target genes.\nCOUGER is a useful tool for understanding the complex regulatory networks that control gene expression in living organisms, and it has applications in fields such as developmental biology, cancer research, and drug discovery.",
    "llama-2-7b-chat-hf_fact_raw": "1. COUGER stands for Comprehensive Update of Gene Regulatory Events.\n2. COUGER is used to identify potential regulatory elements in a genome, including promoters, enhancers, and silencers.\n3. The tool is based on the concept of gene regulation by transcriptional pulses.\n4. COUGER uses a computational approach to analyze patterns of gene expression and locations of transcription factor binding sites.\n5. COUGER has applications in developmental biology, cancer research, and drug discovery.",
    "llama-2-7b-chat-hf_fact": [
      "COUGER stands for Comprehensive Update of Gene Regulatory Events.",
      "COUGER is used to identify potential regulatory elements in a genome, including promoters, enhancers, and silencers.",
      "The tool is based on the concept of gene regulation by transcriptional pulses.",
      "COUGER uses a computational approach to analyze patterns of gene expression and locations of transcription factor binding sites.",
      "COUGER has applications in developmental biology, cancer research, and drug discovery."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: COUGER does not stand for Comprehensive Update of Gene Regulatory Events. It seems to be a made-up acronym as there is no widely recognized bioinformatics tool or concept known by this name.\n2. UNKNOWN: Since the acronym COUGER is not recognized, the details of what it is used for cannot be confirmed.\n3. UNKNOWN: Without accurate information on what COUGER is, it's not possible to confirm if it's based on the concept of gene regulation by transcriptional pulses.\n4. UNKNOWN: The computational approach of COUGER cannot be confirmed due to the lack of information on what COUGER actually is.\n5. UNKNOWN: The applications of COUGER in various fields of biology cannot be confirmed without knowing what the tool or concept actually refers to.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available for the treatment of tick-borne encephalitis (TBE). The most commonly used drugs for the treatment of TBE are:\n1. Antiviral medications: Ribavirin, an antiviral drug that is effective against many viruses, including TBE virus, is commonly used to treat TBE. Other antiviral drugs that have been used to treat TBE include acyclovir, valacyclovir, and famciclovir.\n2. Corticosteroids: Corticosteroids, such as prednisone, are often used to reduce inflammation in the brain and spinal cord, which can help to improve symptoms and reduce the risk of long-term neurological damage.\n3. Immunoglobulins: Immunoglobulins, such as intravenous immunoglobulin (IVIG), are sometimes used to treat TBE. These drugs contain antibodies that can help to neutralize the virus and reduce inflammation.\n4. Plasmapheresis: Plasmapheresis, also known as plasma exchange, is a process that removes harmful antibodies from the blood. This treatment may be used in some cases of TBE to reduce inflammation and improve symptoms.\nIt's important to note that the effectiveness of these drugs can vary depending on the severity and location of the infection, as well as the individual patient's response to treatment. In some cases, a combination of drugs may be used to achieve the best possible outcome. It's important to work closely with a healthcare provider to determine the most appropriate treatment plan for TBE.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ribavirin is an antiviral drug used to treat tick-borne encephalitis (TBE).\n2. Corticosteroids like prednisone are used to reduce inflammation in the brain and spinal cord for TBE patients.\n3. Intravenous immunoglobulin (IVIG) is sometimes used to treat TBE.\n4. Plasmapheresis is a treatment option that may be used for TBE to remove harmful antibodies from the blood.\n5. The effectiveness of drugs for TBE can vary based on the severity and location of the infection and the patient's response to treatment.",
    "llama-2-7b-chat-hf_fact": [
      "Ribavirin is an antiviral drug used to treat tick-borne encephalitis (TBE).",
      "Corticosteroids like prednisone are used to reduce inflammation in the brain and spinal cord for TBE patients.",
      "Intravenous immunoglobulin (IVIG) is sometimes used to treat TBE.",
      "Plasmapheresis is a treatment option that may be used for TBE to remove harmful antibodies from the blood.",
      "The effectiveness of drugs for TBE can vary based on the severity and location of the infection and the patient's response to treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ribavirin is not typically used to treat tick-borne encephalitis (TBE); it is more commonly used for other viral infections such as hepatitis C.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "There are several genome browsers that provide DNA shape annotations, including:\n1. 4D-Nucleosome: This database provides 4D nucleosome mapping data, which can be used to predict the three-dimensional (3D) structure of chromatin and understand how it affects gene expression.\n2. ChromHMM: This database uses chromatin conformation capture (ChIP-seq) data to predict the 3D structure of chromatin and identify regions of the genome that are in close proximity to each other.\n3. HiChIP: This database provides high-resolution chromatin conformation data, which can be used to identify regions of the genome that are in close contact with each other and to understand how chromatin structure affects gene expression.\n4. Nucleosome Atlas: This database provides a comprehensive map of nucleosome positions across the human genome, which can be used to understand how chromatin structure affects gene expression.\n5. Chromatin Genomics Atlas (CGA): This database provides a comprehensive view of chromatin structure across the human genome, including information on nucleosome positioning, chromatin accessibility, and histone modifications.\n6. ENCODE (Encyclopedia of DNA Elements): This database provides a comprehensive view of the functional elements in the human genome, including chromatin structure, histone modifications, and transcription factor binding sites.\n7. ModENCODE (Modular Encyclopedia of DNA Elements): This database provides a comprehensive view of the functional elements in the human genome, including chromatin structure, histone modifications, and transcription factor binding sites, with a focus on the regulatory elements.\n8. Roadmap Epigenomics Project: This database provides a comprehensive view of the epigenetic landscape of the human genome, including information on chromatin structure, histone modifications, and DNA methylation.\n9. The Cancer Genome Atlas (TCGA): This database provides a comprehensive view of the genomic and epigenetic changes in various types of cancer, including information on chromatin structure, histone modifications, and DNA methylation.\n10. The Epigenome Atlas (TEA): This database provides a comprehensive view of the epigenetic landscape of the human genome, including information on chromatin structure, histone modifications, and DNA m",
    "llama-2-7b-chat-hf_fact_raw": "1. 4D-Nucleosome is a database that provides 4D nucleosome mapping data for predicting the 3D structure of chromatin.\n2. ChromHMM uses chromatin conformation capture data to predict the 3D structure of chromatin.\n3. HiChIP provides high-resolution chromatin conformation data to identify regions of the genome in close contact.\n4. Nucleosome Atlas offers a comprehensive map of nucleosome positions across the human genome.\n5. ENCODE is a database that provides a comprehensive view of functional elements in the human genome, including chromatin structure and histone modifications.",
    "llama-2-7b-chat-hf_fact": [
      "4D-Nucleosome is a database that provides 4D nucleosome mapping data for predicting the 3D structure of chromatin.",
      "ChromHMM uses chromatin conformation capture data to predict the 3D structure of chromatin.",
      "HiChIP provides high-resolution chromatin conformation data to identify regions of the genome in close contact.",
      "Nucleosome Atlas offers a comprehensive map of nucleosome positions across the human genome.",
      "ENCODE is a database that provides a comprehensive view of functional elements in the human genome, including chromatin structure and histone modifications."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: ChromHMM is a computational tool that uses histone modification data to segment the genome into different chromatin states, not to predict the 3D structure of chromatin.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "The EZH2 gene, also known as the Enhancer of Zeste Homolog 2 (EZH2) gene, is a key regulator of histone methylation and plays a crucial role in the development and progression of various cancers. Mutations in the EZH2 gene have been associated with several syndromes, including:\n1. Rubinstein-Taybi Syndrome (RTS): RTS is a rare genetic disorder characterized by cognitive impairment, growth retardation, facial dysmorphism, and various other developmental defects. EZH2 mutations are found in approximately 50% of RTS cases.\n2. Noonan Syndrome (NS): NS is a rare genetic disorder characterized by short stature, facial dysmorphism, congenital heart defects, and other developmental abnormalities. EZH2 mutations have been identified in approximately 10% of NS cases.\n3. Multiple Endocrine Neoplasia Syndrome (MEN2): MEN2 is a rare genetic disorder characterized by the development of multiple endocrine tumors, primarily involving the thyroid, parathyroid, and adrenal glands. EZH2 mutations are found in approximately 20% of MEN2 cases.\n4. Gorlin Syndrome (GS): GS is a rare genetic disorder characterized by various developmental defects, including facial dysmorphism, skeletal abnormalities, and various types of cancer. EZH2 mutations have been identified in approximately 10% of GS cases.\n5. Neurofibromatosis Type 1 (NF1): NF1 is a common genetic disorder characterized by various symptoms, including cutaneous neurofibromas, optic gliomas, and cognitive impairment. EZH2 mutations have been identified in approximately 5% of NF1 cases.\nThese syndromes are caused by mutations in the EZH2 gene that disrupt its normal function, leading to altered histone methylation patterns and the development of various developmental defects and cancers.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the EZH2 gene are found in approximately 50% of Rubinstein-Taybi Syndrome cases.\n2. Approximately 10% of Noonan Syndrome cases have identified EZH2 mutations.\n3. EZH2 mutations are present in about 20% of Multiple Endocrine Neoplasia Syndrome (MEN2) cases.\n4. Around 10% of Gorlin Syndrome cases involve EZH2 mutations.\n5. EZH2 mutations have been identified in approximately 5% of Neurofibromatosis Type 1 (NF1) cases.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the EZH2 gene are found in approximately 50% of Rubinstein-Taybi Syndrome cases.",
      "Approximately 10% of Noonan Syndrome cases have identified EZH2 mutations.",
      "EZH2 mutations are present in about 20% of Multiple Endocrine Neoplasia Syndrome (MEN2) cases.",
      "Around 10% of Gorlin Syndrome cases involve EZH2 mutations.",
      "EZH2 mutations have been identified in approximately 5% of Neurofibromatosis Type 1 (NF1) cases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the CREBBP and EP300 genes, not EZH2, are found in the majority of Rubinstein-Taybi Syndrome cases.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe correction for statement 1 is based on the fact that Rubinstein-Taybi Syndrome is primarily associated with mutations in the CREBBP and EP300 genes. The prevalence of EZH2 mutations in the other syndromes mentioned (Noonan Syndrome, Multiple Endocrine Neoplasia Syndrome (MEN2), Gorlin Syndrome, and Neurofibromatosis Type 1 (NF1)) is not well-established in the literature as of my knowledge cutoff date, and therefore the truthfulness of statements 2-5 cannot be determined without additional context or updated information.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "There are several human proteins that are known to undergo a dimer-to-tetramer transition. Here are some examples:\n1. p53: The tumor suppressor protein p53 is a well-known example of a protein that undergoes a dimer-to-tetramer transition. The p53 protein exists as a dimer in its inactive form, but upon activation, it undergoes a conformational change to form a tetrameric structure that is more active.\n2. Retinoblastoma protein (Rb): Rb is a tumor suppressor protein that is inactivated by phosphorylation and ubiquitination. The phosphorylated and ubiquitinated Rb protein exists as a monomer, but it can also form a tetrameric complex with other proteins.\n3. Myc: The Myc protein is a transcription factor that can exist as a monomer or a dimer. However, under certain conditions, Myc can undergo a conformational change and form a tetrameric structure that is more active.\n4. c-Jun: c-Jun is a transcription factor that exists as a monomer in its inactive form. However, upon activation, it can undergo a dimerization reaction and form a tetrameric structure that is more active.\n5. c-Fos: c-Fos is another transcription factor that exists as a monomer in its inactive form. However, upon activation, it can undergo a dimerization reaction and form a tetrameric structure that is more active.\n6. NF-κB: NF-κB is a transcription factor that exists as a monomer in its inactive form. However, upon activation, it can undergo a dimerization reaction and form a tetrameric structure that is more active.\n7. HIF-1α: HIF-1α is a transcription factor that exists as a monomer in its inactive form. However, upon exposure to hypoxia, it can undergo a dimerization reaction and form a tetrameric structure that is more active.\n8. PML: PML is a protein that plays a role in the regulation of apoptosis and immune response. It",
    "llama-2-7b-chat-hf_fact_raw": "1. The tumor suppressor protein p53 undergoes a dimer-to-tetramer transition upon activation.\n2. The Retinoblastoma protein (Rb) can form a tetrameric complex with other proteins.\n3. The Myc protein can form a tetrameric structure under certain conditions.\n4. The transcription factor c-Jun can form a tetrameric structure upon activation.\n5. The transcription factor NF-κB can form a tetrameric structure upon activation.",
    "llama-2-7b-chat-hf_fact": [
      "The tumor suppressor protein p53 undergoes a dimer-to-tetramer transition upon activation.",
      "The Retinoblastoma protein (Rb) can form a tetrameric complex with other proteins.",
      "The Myc protein can form a tetrameric structure under certain conditions.",
      "The transcription factor c-Jun can form a tetrameric structure upon activation.",
      "The transcription factor NF-κB can form a tetrameric structure upon activation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The tumor suppressor protein p53 can undergo a dimer-to-tetramer transition upon activation, which is important for its function in DNA binding and transcriptional regulation.\n2. UNKNOWN: The Retinoblastoma protein (Rb) is known to interact with other proteins, particularly E2F transcription factors, but whether it forms a tetrameric complex is not commonly described in the literature. Rb is typically discussed in the context of its role in regulating the cell cycle by binding to E2F and preventing progression from the G1 to the S phase until the cell is ready.\n3. FALSE [correction]: The Myc protein is known to form heterodimers with the protein Max, but it is not typically described as forming a tetrameric structure. Myc-Max heterodimers bind to DNA and regulate gene transcription.\n4. FALSE [correction]: The transcription factor c-Jun can form dimers, particularly with c-Fos to create the AP-1 (Activator Protein-1) complex, but it is not known to form tetrameric structures upon activation.\n5. FALSE [correction]: The transcription factor NF-κB typically functions as a dimer and not as a tetramer. It is activated through the degradation of its inhibitor IκB, which allows the NF-κB dimer to translocate to the nucleus and bind DNA to regulate gene expression.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "One protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is Bcl-2. Bcl-2 is a protein that regulates programmed cell death (apoptosis) by interacting with and inhibiting the activity of pro-apoptotic proteins, such as Bax and Bak. PLN and Bcl-2 have been shown to interact directly, and PLN has been shown to inhibit the pro-apoptotic activity of Bax and Bak, suggesting that PLN may also play a role in regulating apoptosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Bcl-2 is a protein that interacts with phospholamban (PLN).\n2. Bcl-2 is an anti-apoptotic protein.\n3. Bcl-2 regulates programmed cell death by inhibiting the activity of pro-apoptotic proteins.\n4. Bcl-2 interacts with and inhibits the activity of pro-apoptotic proteins such as Bax and Bak.\n5. Phospholamban (PLN) has been shown to inhibit the pro-apoptotic activity of Bax and Bak.",
    "llama-2-7b-chat-hf_fact": [
      "Bcl-2 is a protein that interacts with phospholamban (PLN).",
      "Bcl-2 is an anti-apoptotic protein.",
      "Bcl-2 regulates programmed cell death by inhibiting the activity of pro-apoptotic proteins.",
      "Bcl-2 interacts with and inhibits the activity of pro-apoptotic proteins such as Bax and Bak.",
      "Phospholamban (PLN) has been shown to inhibit the pro-apoptotic activity of Bax and Bak."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Phospholamban (PLN) is known to regulate the calcium pump in cardiac muscle cells and does not inhibit the pro-apoptotic activity of Bax and Bak.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Yes, several clinical trials have shown that vitamin D supplementation can reduce the incidence of falls in older people. Here are some examples:\n1. A 2013 meta-analysis published in the Journal of the American Geriatrics Society pooled data from 15 randomized controlled trials involving over 13,000 older adults. The analysis found that vitamin D supplementation was associated with a significant reduction in the risk of falls (RR=0.77, 95% CI=0.65-0.90).\n2. A 2011 randomized controlled trial published in the Journal of Bone and Mineral Research found that older adults who received vitamin D and calcium supplements had a lower incidence of falls compared to those who received placebo (22% vs. 35%, respectively).\n3. A 2010 randomized controlled trial published in the Journal of the American Geriatrics Society found that older adults who received vitamin D and omega-3 fatty acid supplements had a lower incidence of falls compared to those who received placebo (24% vs. 40%, respectively).\n4. A 2016 Cochrane review of 16 randomized controlled trials involving over 11,000 older adults found that vitamin D supplementation was associated with a significant reduction in the risk of falls (RR=0.79, 95% CI=0.67-0.93).\nIt is important to note that while these studies suggest a potential benefit of vitamin D supplementation in reducing the incidence of falls in older people, the evidence is not yet conclusive, and more research is needed to confirm these findings. Additionally, it is important to consult with a healthcare professional before starting any supplement regimen.",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2013 meta-analysis published in the Journal of the American Geriatrics Society indicated that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults (RR=0.77, 95% CI=0.65-0.90).\n2. A 2011 randomized controlled trial published in the Journal of Bone and Mineral Research reported that older adults who received vitamin D and calcium supplements had a lower incidence of falls compared to those who received a placebo (22% vs. 35%).\n3. A 2010 randomized controlled trial published in the Journal of the American Geriatrics Society found that older adults who received vitamin D and omega-3 fatty acid supplements had a lower incidence of falls compared to those who received a placebo (24% vs. 40%).\n4. A 2016 Cochrane review of 16 randomized controlled trials involving over 11,000 older adults found that vitamin D supplementation was associated with a significant reduction in the risk of falls (RR=0.79, 95% CI=0.67-0.93).",
    "llama-2-7b-chat-hf_fact": [
      "A 2013 meta-analysis published in the Journal of the American Geriatrics Society indicated that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults (RR=0.77, 95% CI=0.65-0.90).",
      "A 2011 randomized controlled trial published in the Journal of Bone and Mineral Research reported that older adults who received vitamin D and calcium supplements had a lower incidence of falls compared to those who received a placebo (22% vs. 35%).",
      "A 2010 randomized controlled trial published in the Journal of the American Geriatrics Society found that older adults who received vitamin D and omega-3 fatty acid supplements had a lower incidence of falls compared to those who received a placebo (24% vs. 40%).",
      "A 2016 Cochrane review of 16 randomized controlled trials involving over 11,000 older adults found that vitamin D supplementation was associated with a significant reduction in the risk of falls (RR=0.79, 95% CI=0.67-0.93)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The statement mentions a combination of vitamin D and omega-3 fatty acid supplements, but the source cited is the Journal of the American Geriatrics Society, which may not have published this specific finding. Without the exact title or authors of the study, it's not possible to verify the claim about omega-3 fatty acids. Typically, studies in this journal would focus on geriatric health and might include vitamin D supplementation, but the inclusion of omega-3 fatty acids is not confirmed here.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells.\nJarid2 (Jumonji H3-domain-containing protein 2) is a histone H3 lysine 9-specific demethylase that has been shown to play a role in regulating the expression of genes involved in inflammation and immune response, including those involved in the Th17 cell differentiation pathway.\nMiR-155 (microRNA-155) is a small non-coding RNA molecule that has been implicated in the regulation of Th17 cell differentiation and inflammation. Studies have shown that miR-155 is downregulated in Th17 cells, and that this downregulation is associated with the activation of Jarid2.\nIn particular, Jarid2 has been shown to directly bind to the 3'UTR of miR-155 and inhibit its expression, thereby contributing to the regulation of Th17 cell differentiation. This suggests that Jarid2 may play a role in the regulation of the Th17 cell differentiation program by modulating the expression of miR-155.\nIn summary, there is an association between Jarid2 and miR-155 in Th17 cells, with Jarid2 inhibiting the expression of miR-155 and contributing to the regulation of Th17 cell differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 is a histone H3 lysine 9-specific demethylase involved in regulating genes related to inflammation and immune response.\n2. Jarid2 plays a role in the Th17 cell differentiation pathway.\n3. MiR-155 is a small non-coding RNA molecule implicated in the regulation of Th17 cell differentiation and inflammation.\n4. MiR-155 is downregulated in Th17 cells, and this downregulation is associated with the activation of Jarid2.\n5. Jarid2 directly binds to the 3'UTR of miR-155 and inhibits its expression, affecting Th17 cell differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 is a histone H3 lysine 9-specific demethylase involved in regulating genes related to inflammation and immune response.",
      "Jarid2 plays a role in the Th17 cell differentiation pathway.",
      "MiR-155 is a small non-coding RNA molecule implicated in the regulation of Th17 cell differentiation and inflammation.",
      "MiR-155 is downregulated in Th17 cells, and this downregulation is associated with the activation of Jarid2.",
      "Jarid2 directly binds to the 3'UTR of miR-155 and inhibits its expression, affecting Th17 cell differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Jarid2 is not a histone demethylase; it is a member of the Jumonji family of proteins and is involved in regulating gene expression, but it does not have demethylase enzymatic activity itself. It is associated with the regulation of chromatin structure and gene expression.\n2. TRUE: Jarid2 has been implicated in playing a role in Th17 cell differentiation.\n3. TRUE: MiR-155 is a microRNA that has been implicated in the regulation of Th17 cell differentiation and inflammation.\n4. FALSE [correction]: MiR-155 is typically upregulated in Th17 cells, and this upregulation is associated with the promotion of Th17 cell differentiation and inflammation.\n5. UNKNOWN: Without specific scientific evidence or a reference to a study that shows Jarid2 directly binding to the 3'UTR of miR-155 and inhibiting its expression, it is not possible to determine the truth of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "The human HoxD cluster contains 9 genes.\nThe HoxD cluster is a group of homeobox genes located on the long arm of chromosome 2 (2q37) in humans. The cluster consists of 9 genes, which are designated as Hoxd1 to Hoxd9, and are involved in various developmental processes, including patterning, morphogenesis, and cell fate determination.\nHere are the names and locations of the genes in the human HoxD cluster:\n1. Hoxd1 - 2q37.1\n2. Hoxd2 - 2q37.2\n3. Hoxd3 - 2q37.3\n4. Hoxd4 - 2q37.4\n5. Hoxd5 - 2q37.5\n6. Hoxd6 - 2q37.6\n7. Hoxd7 - 2q37.7\n8. Hoxd8 - 2q37.8\n9. Hoxd9 - 2q37.9\nEach of these genes contains a homeobox domain, a conserved sequence of approximately 180 amino acids that is involved in DNA-binding and transcriptional regulation. The HoxD genes are expressed in a specific spatial and temporal pattern during embryonic development, and their mutations have been implicated in various congenital disorders, including limb abnormalities and cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster contains 9 genes.\n2. The HoxD cluster is located on the long arm of chromosome 2 at position 2q37 in humans.\n3. The genes in the HoxD cluster are designated as Hoxd1 to Hoxd9.\n4. Each gene in the HoxD cluster contains a homeobox domain.\n5. Mutations in the HoxD genes have been implicated in various congenital disorders, including limb abnormalities and cancer.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster contains 9 genes.",
      "The HoxD cluster is located on the long arm of chromosome 2 at position 2q37 in humans.",
      "The genes in the HoxD cluster are designated as Hoxd1 to Hoxd9.",
      "Each gene in the HoxD cluster contains a homeobox domain.",
      "Mutations in the HoxD genes have been implicated in various congenital disorders, including limb abnormalities and cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HoxD cluster contains 9-11 genes, depending on the literature source, but it is commonly accepted to have at least 10 genes.\n2. FALSE [correction]: The HoxD cluster is located on the short arm of chromosome 2 at position 2q31, not on the long arm at 2q37.\n3. FALSE [correction]: The genes in the HoxD cluster are designated from Hoxd1 to Hoxd13, not just Hoxd1 to Hoxd9.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Casein Kinase 1 (CK1) is a serine/threonine protein kinase that plays a crucial role in various cellular processes, including cell signaling, differentiation, and metabolism. The phosphorylation consensus motifs for CK1 are:\n1. Ser/Thr-Pro-X-X-Ser/Thr (where X is any amino acid except proline): This is the most common consensus motif for CK1, and it is recognized by the enzyme's catalytic site.\n2. Ser/Thr-Pro-Gly-X-Ser/Thr: This motif is similar to the first one but with a glycine residue instead of an proline.\n3. Ser/Thr-Pro-X-X-X-Ser/Thr: This motif is found in the C-terminal region of CK1 substrates and is recognized by the enzyme's regulatory site.\n4. Ser/Thr-X-X-X-X-Ser/Thr: This motif is found in the N-terminal region of CK1 substrates and is recognized by the enzyme's catalytic site.\n5. Thr-X-X-X-X-Ser/Thr: This motif is found in the C-terminal region of CK1 substrates and is recognized by the enzyme's regulatory site.\n6. Ser/Thr-X-X-X-X-Ser/Thr: This motif is found in the N-terminal region of CK1 substrates and is recognized by the enzyme's catalytic site.\nIt is important to note that the specific consensus motifs recognized by CK1 can vary depending on the isoform of the enzyme and the substrate being phosphorylated.",
    "llama-2-7b-chat-hf_fact_raw": "1. Casein Kinase 1 (CK1) is a serine/threonine protein kinase.\n2. The phosphorylation consensus motif for CK1 includes Ser/Thr-Pro-X-X-Ser/Thr, where X is any amino acid except proline.\n3. Another CK1 motif is Ser/Thr-Pro-Gly-X-Ser/Thr, with a glycine residue in place of proline.\n4. The motif Ser/Thr-Pro-X-X-X-Ser/Thr is found in the C-terminal region of CK1 substrates.\n5. The motif Ser/Thr-X-X-X-X-Ser/Thr is found in the N-terminal region of CK1 substrates.",
    "llama-2-7b-chat-hf_fact": [
      "Casein Kinase 1 (CK1) is a serine/threonine protein kinase.",
      "The phosphorylation consensus motif for CK1 includes Ser/Thr-Pro-X-X-Ser/Thr, where X is any amino acid except proline.",
      "Another CK1 motif is Ser/Thr-Pro-Gly-X-Ser/Thr, with a glycine residue in place of proline.",
      "The motif Ser/Thr-Pro-X-X-X-Ser/Thr is found in the C-terminal region of CK1 substrates.",
      "The motif Ser/Thr-X-X-X-X-Ser/Thr is found in the N-terminal region of CK1 substrates."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The phosphorylation consensus motif for CK1 typically includes Ser/Thr followed by acidic residues or other specific sequences, but not necessarily the pattern Ser/Thr-Pro-X-X-Ser/Thr, and proline is often not favored in the +1 position following the phosphorylatable serine or threonine.\n3. FALSE [correction]: The statement is contradictory because it first states that proline is excluded (in statement 2), then suggests a motif with proline included. Additionally, there is no well-established consensus motif specifically described as Ser/Thr-Pro-Gly-X-Ser/Thr for CK1.\n4. UNKNOWN: Without specific information about CK1 substrates, it is difficult to confirm the presence of the motif Ser/Thr-Pro-X-X-X-Ser/Thr in the C-terminal region of CK1 substrates.\n5. UNKNOWN: Similarly, without specific information about CK1 substrates, it is difficult to confirm the presence of the motif Ser/Thr-X-X-X-X-Ser/Thr in the N-terminal region of CK1 substrates.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "The ASPH (aspartate beta-hydroxylase) gene in humans encodes several different proteins/isoforms, including:\n1. Aspartate beta-hydroxylase (ASPH): This is the primary isoform encoded by the ASPH gene and is involved in the biosynthesis of the neurotransmitter serotonin.\n2. Tissue inhibitor of metalloproteinases 1 (TIMP1): This isoform is produced as a result of alternative splicing of the ASPH gene and inhibits the activity of matrix metalloproteinases (MMPs), which are involved in the breakdown of the extracellular matrix.\n3. Matrix metalloproteinase 9 (MMP9): This isoform is also produced through alternative splicing of the ASPH gene and is involved in the breakdown of the extracellular matrix.\n4. Protein disulfide isomerase (PDI): This isoform is encoded by a variant of the ASPH gene and is involved in the folding and stability of proteins.\n5. Hydroxylase domain-containing protein 1 (HYD1): This isoform is encoded by a different variant of the ASPH gene and is involved in the biosynthesis of the neurotransmitter serotonin.\n6. Carbonic anhydrase 1 (CA1): This isoform is encoded by a variant of the ASPH gene and is involved in the regulation of pH in the brain.\nIt's worth noting that the exact functions of some of these isoforms are still being researched and may change as new information becomes available.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene in humans encodes the primary isoform known as aspartate beta-hydroxylase (ASPH).\n2. The tissue inhibitor of metalloproteinases 1 (TIMP1) is an isoform produced by alternative splicing of the ASPH gene.\n3. Matrix metalloproteinase 9 (MMP9) is an isoform resulting from alternative splicing of the ASPH gene.\n4. Protein disulfide isomerase (PDI) is an isoform encoded by a variant of the ASPH gene.\n5. Hydroxylase domain-containing protein 1 (HYD1) is an isoform encoded by a different variant of the ASPH gene.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene in humans encodes the primary isoform known as aspartate beta-hydroxylase (ASPH).",
      "The tissue inhibitor of metalloproteinases 1 (TIMP1) is an isoform produced by alternative splicing of the ASPH gene.",
      "Matrix metalloproteinase 9 (MMP9) is an isoform resulting from alternative splicing of the ASPH gene.",
      "Protein disulfide isomerase (PDI) is an isoform encoded by a variant of the ASPH gene.",
      "Hydroxylase domain-containing protein 1 (HYD1) is an isoform encoded by a different variant of the ASPH gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The tissue inhibitor of metalloproteinases 1 (TIMP1) is not an isoform produced by alternative splicing of the ASPH gene. TIMP1 is a separate gene that encodes a protein inhibitor that specifically inhibits matrix metalloproteinases (MMPs).\n3. FALSE [correction]: Matrix metalloproteinase 9 (MMP9) is not an isoform resulting from alternative splicing of the ASPH gene. MMP9 is encoded by a different gene and is part of the matrix metalloproteinase family involved in the breakdown of extracellular matrix.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Empagliflozin was FDA approved on June 29, 2014.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved on June 29, 2014.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved on June 29, 2014."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Empagliflozin was FDA approved on August 1, 2014.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Loss of the protein Lon1 in the plant Arabidopsis has several notable effects on the plant's development and physiology. Here are some of the results of Lon1 loss in Arabidopsis:\n1. Delayed Growth: Lon1 mutants grow more slowly than wild-type plants, indicating that Lon1 plays a role in regulating plant growth.\n2. Reduced Leaf Size: Lon1 mutants have smaller leaves than wild-type plants, which may be due to the slower growth rate.\n3. Altered Root Architecture: Lon1 mutants have a different root architecture than wild-type plants, with more lateral roots and a smaller primary root.\n4. Impaired Drought Tolerance: Lon1 mutants are more sensitive to drought stress than wild-type plants, suggesting that Lon1 plays a role in regulating plant water use and drought tolerance.\n5. Increased Susceptibility to Pathogens: Lon1 mutants are more susceptible to infection by the bacterial pathogen Pseudomonas syringae than wild-type plants, indicating that Lon1 may play a role in plant immunity.\n6. Changes in Hormone Levels: Lon1 mutants have altered levels of several plant hormones, including ethylene, auxin, and cytokinin, which may contribute to the observed phenotypes.\n7. Abnormal Cell Wall Formation: Lon1 mutants have altered cell wall structure and composition, which may contribute to the observed growth and developmental abnormalities.\n8. Impaired Chromatin Remodeling: Lon1 is involved in the regulation of chromatin structure and gene expression, and loss of Lon1 leads to changes in gene expression and chromatin structure.\nThese results suggest that Lon1 plays a multifaceted role in plant development and physiology, and its loss can lead to a range of phenotypes that affect plant growth, stress tolerance, and hormone homeostasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Lon1 mutants in Arabidopsis grow more slowly than wild-type plants.\n2. Lon1 mutants in Arabidopsis have smaller leaves than wild-type plants.\n3. Lon1 mutants in Arabidopsis exhibit a different root architecture with more lateral roots and a smaller primary root.\n4. Lon1 mutants in Arabidopsis are more sensitive to drought stress than wild-type plants.\n5. Lon1 mutants in Arabidopsis are more susceptible to infection by the bacterial pathogen Pseudomonas syringae than wild-type plants.",
    "llama-2-7b-chat-hf_fact": [
      "Lon1 mutants in Arabidopsis grow more slowly than wild-type plants.",
      "Lon1 mutants in Arabidopsis have smaller leaves than wild-type plants.",
      "Lon1 mutants in Arabidopsis exhibit a different root architecture with more lateral roots and a smaller primary root.",
      "Lon1 mutants in Arabidopsis are more sensitive to drought stress than wild-type plants.",
      "Lon1 mutants in Arabidopsis are more susceptible to infection by the bacterial pathogen Pseudomonas syringae than wild-type plants."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific scientific research or data provided regarding the Lon1 mutants in Arabidopsis, it is not possible to determine the accuracy of these statements. They are specific claims that would require experimental evidence to support or refute.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Yes, a linker histone called H3K4me3 (histone H3 lysine 4 trimethylation at position 3) exists in the yeast genome. H3K4me3 is a repressive chromatin mark that is involved in the regulation of various cellular processes, including transcriptional elongation, gene silencing, and chromatin structure. In yeast, H3K4me3 is known to be involved in the regulation of gene expression, particularly for genes involved in stress response and cell cycle progression.",
    "llama-2-7b-chat-hf_fact_raw": "1. A linker histone called H3K4me3 exists in the yeast genome.\n2. H3K4me3 is involved in the regulation of various cellular processes.\n3. These cellular processes include transcriptional elongation, gene silencing, and chromatin structure.\n4. In yeast, H3K4me3 regulates gene expression.\n5. H3K4me3 is particularly involved in regulating genes related to stress response and cell cycle progression.",
    "llama-2-7b-chat-hf_fact": [
      "A linker histone called H3K4me3 exists in the yeast genome.",
      "H3K4me3 is involved in the regulation of various cellular processes.",
      "These cellular processes include transcriptional elongation, gene silencing, and chromatin structure.",
      "In yeast, H3K4me3 regulates gene expression.",
      "H3K4me3 is particularly involved in regulating genes related to stress response and cell cycle progression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: H3K4me3 is not a linker histone; it is a histone modification referring to the trimethylation of the lysine 4 on the histone H3 protein.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that tomato juice can help lower cholesterol levels.\nSeveral studies have shown that consuming tomato juice can help reduce total cholesterol, LDL (\"bad\") cholesterol, and triglycerides, while increasing HDL (\"good\") cholesterol. Here are some examples of studies that have investigated the cholesterol-lowering effects of tomato juice:\n1. A 2013 study published in the Journal of Functional Foods found that drinking 200 mL of tomato juice per day for 12 weeks significantly reduced total cholesterol and LDL cholesterol levels in healthy adults.\n2. A 2011 study published in the European Journal of Nutrition found that consuming 200 mL of tomato juice per day for 4 weeks reduced LDL cholesterol levels by 12% in healthy adults.\n3. A 2010 study published in the Journal of Nutrition found that drinking 250 mL of tomato juice per day for 12 weeks reduced total cholesterol and LDL cholesterol levels in patients with high cholesterol.\nIt is thought that the lycopene and other antioxidants present in tomato juice may contribute to its cholesterol-lowering effects. Lycopene has been shown to inhibit the absorption of dietary cholesterol in the gut, and may also help reduce inflammation in the body, which can also contribute to high cholesterol levels.\nIt is important to note that while these studies suggest that tomato juice may have cholesterol-lowering effects, more research is needed to fully understand its potential benefits and how it compares to other cholesterol-lowering interventions. Additionally, it is important to consume tomato juice as part of a comprehensive approach to managing cholesterol levels, which may include a healthy diet, regular exercise, and if necessary, medication prescribed by a healthcare provider.",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2013 study published in the Journal of Functional Foods found that drinking 200 mL of tomato juice per day for 12 weeks significantly reduced total cholesterol and LDL cholesterol levels in healthy adults.\n2. A 2011 study published in the European Journal of Nutrition found that consuming 200 mL of tomato juice per day for 4 weeks reduced LDL cholesterol levels by 12% in healthy adults.\n3. A 2010 study published in the Journal of Nutrition found that drinking 250 mL of tomato juice per day for 12 weeks reduced total cholesterol and LDL cholesterol levels in patients with high cholesterol.\n4. Lycopene, present in tomato juice, has been shown to inhibit the absorption of dietary cholesterol in the gut.\n5. Lycopene may also help reduce inflammation in the body, which can contribute to high cholesterol levels.",
    "llama-2-7b-chat-hf_fact": [
      "A 2013 study published in the Journal of Functional Foods found that drinking 200 mL of tomato juice per day for 12 weeks significantly reduced total cholesterol and LDL cholesterol levels in healthy adults.",
      "A 2011 study published in the European Journal of Nutrition found that consuming 200 mL of tomato juice per day for 4 weeks reduced LDL cholesterol levels by 12% in healthy adults.",
      "A 2010 study published in the Journal of Nutrition found that drinking 250 mL of tomato juice per day for 12 weeks reduced total cholesterol and LDL cholesterol levels in patients with high cholesterol.",
      "Lycopene, present in tomato juice, has been shown to inhibit the absorption of dietary cholesterol in the gut.",
      "Lycopene may also help reduce inflammation in the body, which can contribute to high cholesterol levels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: A 2011 study published in the European Journal of Nutrition found that consuming 250 mL of tomato juice per day for 2 weeks reduced LDL cholesterol levels by 13% in overweight women.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Heat shock proteins (HSPs) 70 and 110 play important roles in regulating mRNA stability by modulating the interactions between mRNA and ribonucleoproteins (RNPs). Here's how they do it:\nHSP70:\n* HSP70 binds to the 3' untranslated region (UTR) of target mRNAs and protects them from degradation by the RNA exosome complex.\n* HSP70 also interacts with the RNA-binding protein HuR, which is involved in mRNA stabilization.\n* By interacting with HuR, HSP70 enhances the stability of target mRNAs by inhibiting their degradation by the RNA exosome complex.\nHSP110:\n* HSP110 binds to the 5' UTR of target mRNAs and protects them from degradation by the RNA exosome complex.\n* HSP110 also interacts with the RNA-binding protein NXF1, which is involved in mRNA transport and stability.\n* By interacting with NXF1, HSP110 enhances the stability of target mRNAs by promoting their transport along the nuclear export pathway.\nIn summary, HSP70 and HSP110 both regulate mRNA stability by binding to specific regions of the mRNA and interacting with RNPs involved in mRNA degradation. By inhibiting the degradation of target mRNAs, HSP70 and HSP110 play important roles in maintaining mRNA homeostasis and regulating gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. HSP70 binds to the 3' untranslated region (UTR) of target mRNAs.\n2. HSP70 interacts with the RNA-binding protein HuR, which is involved in mRNA stabilization.\n3. HSP110 binds to the 5' UTR of target mRNAs.\n4. HSP110 interacts with the RNA-binding protein NXF1, which is involved in mRNA transport and stability.\n5. Both HSP70 and HSP110 inhibit the degradation of target mRNAs, thereby playing roles in maintaining mRNA homeostasis and regulating gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "HSP70 binds to the 3' untranslated region (UTR) of target mRNAs.",
      "HSP70 interacts with the RNA-binding protein HuR, which is involved in mRNA stabilization.",
      "HSP110 binds to the 5' UTR of target mRNAs.",
      "HSP110 interacts with the RNA-binding protein NXF1, which is involved in mRNA transport and stability.",
      "Both HSP70 and HSP110 inhibit the degradation of target mRNAs, thereby playing roles in maintaining mRNA homeostasis and regulating gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: HSP70 typically binds to nascent polypeptides and does not have a well-characterized role in binding to the 3' untranslated region (UTR) of target mRNAs.\n2. TRUE\n3. UNKNOWN: The specific interaction of HSP110 with the 5' UTR of target mRNAs is not well-established in the literature, and without additional context, it is difficult to confirm this statement.\n4. UNKNOWN: The interaction between HSP110 and the RNA-binding protein NXF1 is not well-documented in the literature, and without additional context, it is difficult to confirm this statement.\n5. UNKNOWN: While HSP70 and HSP110 are known to play roles in protein homeostasis and have some regulatory effects on gene expression, the specific claim that they inhibit the degradation of target mRNAs to maintain mRNA homeostasis is not universally established and may depend on the context and specific target mRNAs.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "There are three isoforms of deiodinases present in skeletal muscle:\n1. Type 1 deiodinase (D1): primarily found in the brain, but also present in skeletal muscle, where it plays a role in regulating thyroid hormone (TH) levels.\n2. Type 2 deiodinase (D2): mainly found in peripheral tissues, including skeletal muscle, where it is responsible for the majority of TH metabolism.\n3. Type 3 deiodinase (D3): present in a variety of tissues, including skeletal muscle, where it is involved in the regulation of TH levels and activity.\nIn skeletal muscle, D2 is the primary isoform responsible for the conversion of T4 to T3, which is then released into the circulation and transported to other tissues, where it exerts its effects. D1 and D3 are less abundant in skeletal muscle but still play a role in regulating TH levels and activity.",
    "llama-2-7b-chat-hf_fact_raw": "1. Type 1 deiodinase (D1) is present in skeletal muscle and plays a role in regulating thyroid hormone levels.\n2. Type 2 deiodinase (D2) is mainly found in peripheral tissues, including skeletal muscle, and is responsible for the majority of thyroid hormone metabolism.\n3. Type 3 deiodinase (D3) is present in skeletal muscle and is involved in the regulation of thyroid hormone levels and activity.\n4. In skeletal muscle, D2 is the primary isoform responsible for the conversion of T4 to T3.\n5. Both D1 and D3 are less abundant in skeletal muscle compared to D2 but still contribute to regulating thyroid hormone levels and activity.",
    "llama-2-7b-chat-hf_fact": [
      "Type 1 deiodinase (D1) is present in skeletal muscle and plays a role in regulating thyroid hormone levels.",
      "Type 2 deiodinase (D2) is mainly found in peripheral tissues, including skeletal muscle, and is responsible for the majority of thyroid hormone metabolism.",
      "Type 3 deiodinase (D3) is present in skeletal muscle and is involved in the regulation of thyroid hormone levels and activity.",
      "In skeletal muscle, D2 is the primary isoform responsible for the conversion of T4 to T3.",
      "Both D1 and D3 are less abundant in skeletal muscle compared to D2 but still contribute to regulating thyroid hormone levels and activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Type 1 deiodinase (D1) is not present in skeletal muscle; it is primarily found in the liver and kidney and is involved in the conversion of T4 to T3 as well as reverse T3 (rT3) to T2.\n2. TRUE\n3. FALSE [correction]: Type 3 deiodinase (D3) is not present in skeletal muscle; it is found in the central nervous system, placenta, and skin, and it inactivates thyroid hormones by converting T4 to reverse T3 (rT3) and T3 to T2.\n4. TRUE\n5. FALSE [correction]: Since D1 is not present in skeletal muscle and D3 is not involved in activating thyroid hormones but rather inactivating them, the statement that both contribute to regulating thyroid hormone levels and activity in skeletal muscle is incorrect. D2 is the primary deiodinase in skeletal muscle responsible for the conversion of T4 to the active hormone T3.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Inflammatory caspase proteins are a subfamily of caspases that play a crucial role in the regulation of inflammation. Here are some examples of inflammatory caspase proteins:\n1. Caspase-1 (also known as interleukin-1 beta converting enzyme, or ICE): Caspase-1 is a key player in the processing and activation of pro-inflammatory cytokines, such as interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α).\n2. Caspase-3: Caspase-3 is involved in the processing and activation of pro-inflammatory cytokines, such as IL-1β and TNF-α, as well as the cleavage of other inflammatory proteins.\n3. Caspase-8 (also known as Fas-associated death protein, or FADD): Caspase-8 is involved in the regulation of apoptosis and inflammation, particularly in the context of the Fas/FasL pathway.\n4. Caspase-9: Caspase-9 is involved in the regulation of apoptosis and inflammation, particularly in the context of the Bcl-2 family of proteins.\n5. Caspase-12: Caspase-12 is involved in the regulation of inflammation and cell death in response to DNA damage and other forms of cellular stress.\n6. Caspase-13: Caspase-13 is involved in the regulation of inflammation and cell death in response to DNA damage and other forms of cellular stress.\n7. Caspase-14: Caspase-14 is involved in the regulation of inflammation and cell death in response to DNA damage and other forms of cellular stress.\n8. Caspase-15: Caspase-15 is involved in the regulation of inflammation and cell death in response to DNA damage and other forms of cellular stress.\n9. Caspase-16: Caspase-16 is involved in the regulation of inflammation and cell death in response to DNA damage and other forms of cellular stress.\n10. Casp",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is also known as interleukin-1 beta converting enzyme (ICE).\n2. Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α).\n3. Caspase-3 is involved in the processing and activation of pro-inflammatory cytokines, as well as the cleavage of other inflammatory proteins.\n4. Caspase-8 is also known as Fas-associated death protein (FADD) and is involved in the regulation of apoptosis and inflammation.\n5. Caspase-12 is involved in the regulation of inflammation and cell death in response to DNA damage and other forms of cellular stress.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is also known as interleukin-1 beta converting enzyme (ICE).",
      "Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α).",
      "Caspase-3 is involved in the processing and activation of pro-inflammatory cytokines, as well as the cleavage of other inflammatory proteins.",
      "Caspase-8 is also known as Fas-associated death protein (FADD) and is involved in the regulation of apoptosis and inflammation.",
      "Caspase-12 is involved in the regulation of inflammation and cell death in response to DNA damage and other forms of cellular stress."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Caspase-3 is primarily involved in the execution phase of apoptosis, not in the processing and activation of pro-inflammatory cytokines.\n4. FALSE [correction]: Caspase-8 is involved in the regulation of apoptosis and inflammation, but it is not known as Fas-associated death protein (FADD). FADD is a separate protein that interacts with caspase-8.\n5. FALSE [correction]: Caspase-12 is involved in the regulation of inflammation and cell death, but it is primarily associated with the endoplasmic reticulum stress-induced apoptosis pathway, not directly with DNA damage response.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, there is a link between Aurora B kinase and the polycomb protein Ring1B. Ring1B is a polycomb group (PcG) protein that plays a crucial role in the regulation of chromatin structure and gene expression, particularly during cell division.\nAurora B kinase is a serine/threonine kinase that is involved in the regulation of mitosis and meiosis. It is a key player in the proper separation of chromosomes during cell division, and it has been implicated in the regulation of various cellular processes, including DNA replication, mitotic progression, and the maintenance of genome stability.\nStudies have shown that Ring1B and Aurora B kinase interact and are involved in various cellular processes, including cell division and gene expression. For example, Ring1B has been shown to interact with Aurora B kinase and to be required for its proper localization to the centromere region during mitosis. Additionally, Aurora B kinase has been shown to phosphorylate and activate Ring1B, which is necessary for its ability to maintain chromatin compaction and gene silencing during cell division.\nIn summary, there is a clear link between Aurora B kinase and the polycomb protein Ring1B, as they interact and are involved in various cellular processes, including cell division and gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ring1B is a polycomb group protein that is involved in the regulation of chromatin structure and gene expression during cell division.\n2. Aurora B kinase is a serine/threonine kinase that plays a role in the regulation of mitosis and meiosis.\n3. Aurora B kinase is important for the proper separation of chromosomes during cell division.\n4. Ring1B interacts with Aurora B kinase and is required for its proper localization to the centromere region during mitosis.\n5. Aurora B kinase phosphorylates and activates Ring1B, which is necessary for maintaining chromatin compaction and gene silencing during cell division.",
    "llama-2-7b-chat-hf_fact": [
      "Ring1B is a polycomb group protein that is involved in the regulation of chromatin structure and gene expression during cell division.",
      "Aurora B kinase is a serine/threonine kinase that plays a role in the regulation of mitosis and meiosis.",
      "Aurora B kinase is important for the proper separation of chromosomes during cell division.",
      "Ring1B interacts with Aurora B kinase and is required for its proper localization to the centromere region during mitosis.",
      "Aurora B kinase phosphorylates and activates Ring1B, which is necessary for maintaining chromatin compaction and gene silencing during cell division."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Ring1B is indeed a polycomb group protein that is involved in the regulation of chromatin structure and gene expression, which are critical processes during cell division.\n2. TRUE: Aurora B kinase is a serine/threonine kinase that is known to play a crucial role in the regulation of mitosis. It is also involved in meiosis, although its role in meiosis is less well-characterized than in mitosis.\n3. TRUE: Aurora B kinase is essential for the correct segregation of chromosomes during cell division by contributing to the regulation of the mitotic spindle, among other functions.\n4. UNKNOWN: The interaction between Ring1B and Aurora B kinase and the requirement of Ring1B for the proper localization of Aurora B kinase to the centromere region during mitosis is specific and would require validation from scientific literature. Without specific evidence, the truth of this statement cannot be determined.\n5. FALSE [correction]: Aurora B kinase does not phosphorylate and activate Ring1B. Instead, Aurora B kinase phosphorylates histone H3 and other proteins involved in mitosis to regulate chromosomal segregation and cytokinesis. Ring1B is involved in histone ubiquitination and gene silencing as part of the polycomb repressive complex 1 (PRC1), but it is not activated by phosphorylation by Aurora B kinase.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Non-canonical sequence motifs are short sequences that are not part of the consensus splice site pattern but are recognized by the spliceosome and play a role in the splicing process. In vertebrates, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites are:\nDonor splice sites:\n* GU-rich motifs: These are short sequences with a high content of purine bases (G and U) that are recognized by the spliceosome and can act as enhancer elements.\n* GC-rich motifs: These are short sequences with a high content of guanine and cytosine bases that can act as silencer elements.\n* AU-rich motifs: These are short sequences with a high content of adenine and uracil bases that are recognized by the spliceosome and can act as enhancer elements.\n* UG-rich motifs: These are short sequences with a high content of uridine and guanine bases that can act as silencer elements.\nAcceptor splice sites:\n* GT-rich motifs: These are short sequences with a high content of guanine and thymine bases that are recognized by the spliceosome and can act as enhancer elements.\n* AG-rich motifs: These are short sequences with a high content of adenine and guanine bases that can act as silencer elements.\n* AC-rich motifs: These are short sequences with a high content of adenine, cytosine, and guanine bases that can act as enhancer elements.\n* TA-rich motifs: These are short sequences with a high content of thymine and adenine bases that can act as silencer elements.\nIt's worth noting that the presence of these non-canonical motifs can affect the splicing efficiency, and their presence or absence can have a regulatory role in the expression of genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. In vertebrates, GU-rich motifs at donor splice sites are recognized by the spliceosome and can act as enhancer elements.\n2. GC-rich motifs at donor splice sites in vertebrates can act as silencer elements.\n3. GT-rich motifs at acceptor splice sites in vertebrates are recognized by the spliceosome and can act as enhancer elements.\n4. AG-rich motifs at acceptor splice sites in vertebrates can act as silencer elements.\n5. The presence of non-canonical sequence motifs can affect the splicing efficiency and have a regulatory role in the expression of genes in vertebrates.",
    "llama-2-7b-chat-hf_fact": [
      "In vertebrates, GU-rich motifs at donor splice sites are recognized by the spliceosome and can act as enhancer elements.",
      "GC-rich motifs at donor splice sites in vertebrates can act as silencer elements.",
      "GT-rich motifs at acceptor splice sites in vertebrates are recognized by the spliceosome and can act as enhancer elements.",
      "AG-rich motifs at acceptor splice sites in vertebrates can act as silencer elements.",
      "The presence of non-canonical sequence motifs can affect the splicing efficiency and have a regulatory role in the expression of genes in vertebrates."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: GT-rich motifs at donor splice sites in vertebrates are recognized by the spliceosome and can act as enhancer elements.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "S6K1 (70 kDa ribosomal protein S6 kinase 1) is acetylated in response to various cellular signals, including:\n1. Insulin/IGF-1 signaling: Insulin and IGF-1 (insulin-like growth factor 1) can activate the PI3K/Akt signaling pathway, which ultimately leads to the acetylation of S6K1.\n2. Nutrient availability: S6K1 can be acetylated in response to changes in nutrient availability, such as the presence of amino acids, glucose, or other nutrients.\n3. Cellular stress: S6K1 can be acetylated in response to cellular stress, such as exposure to oxidative stress, heat shock, or other forms of stress.\n4. Hormonal signaling: Hormones, such as corticosteroids, can also activate the PI3K/Akt signaling pathway and lead to the acetylation of S6K1.",
    "llama-2-7b-chat-hf_fact_raw": "1. Insulin and IGF-1 can activate the PI3K/Akt signaling pathway, leading to the acetylation of S6K1.\n2. Changes in nutrient availability, such as the presence of amino acids, glucose, or other nutrients, can result in the acetylation of S6K1.\n3. Cellular stress, including exposure to oxidative stress or heat shock, can lead to the acetylation of S6K1.\n4. Hormonal signaling, such as through corticosteroids, can activate the PI3K/Akt signaling pathway and result in the acetylation of S6K1.",
    "llama-2-7b-chat-hf_fact": [
      "Insulin and IGF-1 can activate the PI3K/Akt signaling pathway, leading to the acetylation of S6K1.",
      "Changes in nutrient availability, such as the presence of amino acids, glucose, or other nutrients, can result in the acetylation of S6K1.",
      "Cellular stress, including exposure to oxidative stress or heat shock, can lead to the acetylation of S6K1.",
      "Hormonal signaling, such as through corticosteroids, can activate the PI3K/Akt signaling pathway and result in the acetylation of S6K1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Insulin and IGF-1 (Insulin-like Growth Factor 1) are known to activate the PI3K/Akt signaling pathway, which can lead to various downstream effects including the phosphorylation of S6K1 (ribosomal protein S6 kinase beta-1). While phosphorylation is the more commonly discussed post-translational modification of S6K1 in response to PI3K/Akt signaling, acetylation can also occur, although it is less commonly mentioned in the literature.\n\n2. TRUE: Nutrient availability can indeed influence the acetylation of proteins within the cell, as acetylation is a post-translational modification that can be affected by cellular metabolism and the availability of acetyl-CoA, which is influenced by the presence of nutrients like amino acids and glucose.\n\n3. UNKNOWN: While cellular stress such as oxidative stress or heat shock can lead to various post-translational modifications of proteins, the specific acetylation of S6K1 under these conditions is not well-established in the literature and would require specific evidence to confirm.\n\n4. UNKNOWN: Hormonal signaling through corticosteroids is known to activate various signaling pathways, including potentially the PI3K/Akt pathway. However, whether this leads specifically to the acetylation of S6K1 is not well-documented and would require specific evidence to confirm. Corticosteroids more commonly interact with the glucocorticoid receptor and can influence gene expression directly.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Episodic ataxia type 6 (EA6) is a rare genetic disorder that is caused by mutations in the CACNA1A gene. The CACNA1A gene encodes a subunit of the calcium channel Cav2.2, which is involved in the transmission of calcium signals in neurons. Mutations in the CACNA1A gene lead to a loss of function of the Cav2.2 channel, resulting in a variety of symptoms including episodic ataxia, seizures, and cognitive impairment. The mutations can be inherited in an autosomal dominant or recessive manner, and the condition typically affects adults in their 40s or 50s.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 (EA6) is caused by mutations in the CACNA1A gene.\n2. The CACNA1A gene is responsible for encoding a subunit of the calcium channel Cav2.2.\n3. The Cav2.2 channel is involved in the transmission of calcium signals in neurons.\n4. Mutations in the CACNA1A gene can lead to a loss of function of the Cav2.2 channel.\n5. The condition typically affects adults in their 40s or 50s.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 (EA6) is caused by mutations in the CACNA1A gene.",
      "The CACNA1A gene is responsible for encoding a subunit of the calcium channel Cav2.2.",
      "The Cav2.2 channel is involved in the transmission of calcium signals in neurons.",
      "Mutations in the CACNA1A gene can lead to a loss of function of the Cav2.2 channel.",
      "The condition typically affects adults in their 40s or 50s."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Episodic ataxia type 6 (EA6) is indeed caused by mutations in the CACNA1A gene.\n2. FALSE [correction]: The CACNA1A gene is responsible for encoding the alpha-1A subunit of the P/Q type voltage-gated calcium channel, not the Cav2.2 channel which is the N-type.\n3. TRUE: The P/Q type voltage-gated calcium channel (which the CACNA1A gene encodes a subunit for) is involved in the transmission of calcium signals in neurons.\n4. TRUE: Mutations in the CACNA1A gene can lead to a loss of function or altered function of the P/Q type voltage-gated calcium channel, which can result in various neurological symptoms.\n5. FALSE [correction]: The onset of episodic ataxia can vary, and while it often begins in childhood or adolescence, it does not typically affect adults in their 40s or 50s. The age of onset and severity can vary widely among individuals with the condition.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that modify DNA methylation patterns by adding or removing methyl groups to the cytosine residues of CpG dinucleotides. While DNA methylation is most commonly associated with gene silencing in plants, it also plays important roles in regulating gene expression in animals.\nIn animals, DNA methylation is primarily involved in the regulation of gene expression, particularly in the context of embryonic development and cell differentiation. Chromomethylases are involved in the maintenance of DNA methylation patterns during cell division and are also involved in the de novo establishment of methylation patterns in newly differentiating cells.\nThere are several types of chromomethylases found in animal genomes, including:\n1. DNA methyltransferases (DNMTs): These are the primary enzymes responsible for maintaining DNA methylation patterns in animals. There are two main types of DNMTs: DNMT1, which maintains DNA methylation patterns during DNA replication, and DNMT3, which is responsible for de novo methylation of previously unmethylated DNA.\n2. Hydroxymethylbilane synthases (HMBS): These enzymes are involved in the formation of methyl groups for DNA methylation. HMBS is the rate-limiting enzyme in the pathway and is essential for the maintenance of DNA methylation patterns in animals.\n3. Methylcobalamin-dependent methyltransferases (MCRs): These enzymes are involved in the methylation of specific CpG sites in the genome, including those involved in the regulation of gene expression.\n4. Lysine-specific demethylase 1 (LSD1): This enzyme is involved in the demethylation of histone H3 lysine 4 (H3K4) and is important for the regulation of gene expression in animals.\nIn summary, chromomethylases are present in animal genomes and play important roles in the regulation of gene expression, particularly during embryonic development and cell differentiation. The different types of chromomethylases",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are present in animal genomes.\n2. Chromomethylases modify DNA methylation patterns by adding or removing methyl groups to the cytosine residues of CpG dinucleotides.\n3. DNA methyltransferases (DNMTs) are the primary enzymes responsible for maintaining DNA methylation patterns in animals.\n4. Hydroxymethylbilane synthases (HMBS) are involved in the formation of methyl groups for DNA methylation and are essential for the maintenance of DNA methylation patterns in animals.\n5. Methylcobalamin-dependent methyltransferases (MCRs) are involved in the methylation of specific CpG sites in the genome.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are present in animal genomes.",
      "Chromomethylases modify DNA methylation patterns by adding or removing methyl groups to the cytosine residues of CpG dinucleotides.",
      "DNA methyltransferases (DNMTs) are the primary enzymes responsible for maintaining DNA methylation patterns in animals.",
      "Hydroxymethylbilane synthases (HMBS) are involved in the formation of methyl groups for DNA methylation and are essential for the maintenance of DNA methylation patterns in animals.",
      "Methylcobalamin-dependent methyltransferases (MCRs) are involved in the methylation of specific CpG sites in the genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chromomethylases are not present in animal genomes; they are typically found in plants.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Hydroxymethylbilane synthase (HMBS) is involved in the synthesis of heme, not in the formation of methyl groups for DNA methylation.\n5. FALSE [correction]: Methylcobalamin-dependent methyltransferases (MCRs) are not involved in the methylation of specific CpG sites in the genome. Methylcobalamin is a form of vitamin B12 used by certain enzymes, but the methylation of DNA is primarily carried out by DNA methyltransferases (DNMTs) in animals.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "There are several packages available in R/Bioconductor for the analysis of transcription factor binding sites (TFBS) data. Here are some of the popular packages:\n1. TFBS-Scan: This package provides a comprehensive set of tools for the analysis of TFBS data, including the prediction of TFBSs, the analysis of motif composition, and the identification of TF-DNA interactions.\n2. TFSEM: This package provides a set of tools for the analysis of TFBS data, including the prediction of TFBSs, the analysis of motif composition, and the identification of TF-DNA interactions.\n3. TRANSFAC: This package provides a comprehensive set of tools for the analysis of TFBS data, including the prediction of TFBSs, the analysis of motif composition, and the identification of TF-DNA interactions.\n4. HISAT2: This package provides a set of tools for the analysis of TFBS data, including the prediction of TFBSs, the analysis of motif composition, and the identification of TF-DNA interactions.\n5. DeepTools: This package provides a set of tools for the analysis of TFBS data, including the prediction of TFBSs, the analysis of motif composition, and the identification of TF-DNA interactions.\n6. ChromHMM: This package provides a set of tools for the analysis of TFBS data, including the prediction of TFBSs, the analysis of motif composition, and the identification of TF-DNA interactions.\n7. RSAT: This package provides a set of tools for the analysis of TFBS data, including the prediction of TFBSs, the analysis of motif composition, and the identification of TF-DNA interactions.\n8. TFProfiler: This package provides a set of tools for the analysis of TFBS data, including the prediction of TFBSs, the analysis of motif composition, and the identification of TF-DNA interactions.\n9. TFSEED: This package provides a set of tools for the analysis of TFBS data, including the prediction of TFBSs, the analysis of motif composition, and the identification of TF-DNA interactions.\n10. TFTools: This package provides a set",
    "llama-2-7b-chat-hf_fact_raw": "1. TFBS-Scan is a package available in R/Bioconductor for the analysis of transcription factor binding sites data.\n2. TRANSFAC is a package in R/Bioconductor that includes tools for predicting transcription factor binding sites.\n3. HISAT2 is listed as a package in R/Bioconductor for the analysis of transcription factor binding sites data.\n4. DeepTools is a package available in R/Bioconductor that provides tools for the analysis of transcription factor binding sites data.\n5. ChromHMM is an R/Bioconductor package that includes tools for predicting transcription factor binding sites.",
    "llama-2-7b-chat-hf_fact": [
      "TFBS-Scan is a package available in R/Bioconductor for the analysis of transcription factor binding sites data.",
      "TRANSFAC is a package in R/Bioconductor that includes tools for predicting transcription factor binding sites.",
      "HISAT2 is listed as a package in R/Bioconductor for the analysis of transcription factor binding sites data.",
      "DeepTools is a package available in R/Bioconductor that provides tools for the analysis of transcription factor binding sites data.",
      "ChromHMM is an R/Bioconductor package that includes tools for predicting transcription factor binding sites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TFBS-Scan is not a known package in R/Bioconductor for the analysis of transcription factor binding sites data. However, there are other packages in R/Bioconductor for this purpose, such as motifStack, TFBSTools, and JASPAR2018.\n2. FALSE [correction]: TRANSFAC is not a package in R/Bioconductor; it is a database of transcription factor binding sites. However, there is a package called TFBSTools in R/Bioconductor that can interface with the TRANSFAC database.\n3. FALSE [correction]: HISAT2 is not listed as a package in R/Bioconductor; it is a fast and sensitive alignment program for mapping next-generation sequencing reads (DNA and RNA) but is not specifically for the analysis of transcription factor binding sites data.\n4. FALSE [correction]: DeepTools is not a package available in R/Bioconductor. It is a suite of Python tools particularly developed for the efficient analysis of high-throughput sequencing data, such as ChIP-seq, but it is not distributed through R/Bioconductor.\n5. FALSE [correction]: ChromHMM is not an R/Bioconductor package. It is a Java program for learning and characterizing chromatin states, but it does not include tools for predicting transcription factor binding sites within R/Bioconductor.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Sarcopenia is the progressive loss of muscle mass and strength that occurs with aging. While there are no FDA-approved drugs for the prevention of sarcopenia, several clinical trials are ongoing to evaluate the effectiveness of various interventions in preventing or slowing down sarcopenia. Here are some of the ongoing clinical trials for the prevention of sarcopenia:\n1. Resistance Training and Nutritional Interventions to Prevent Sarcopenia in Older Adults (R01 AG063719): This study is evaluating the effectiveness of a combination of resistance training and nutritional interventions in preventing sarcopenia in older adults.\n2. A Randomized Controlled Trial of a Novel Dietary Supplement to Prevent Sarcopenia in Older Adults (R01 AG063720): This study is evaluating the effectiveness of a novel dietary supplement in preventing sarcopenia in older adults.\n3. Exercise and Nutrition Interventions to Prevent Sarcopenia in Older Adults (R01 AG063718): This study is evaluating the effectiveness of a combination of exercise and nutritional interventions in preventing sarcopenia in older adults.\n4. Sarcopenia Prevention through Dietary Interventions and Exercise (SPRINT-Sarcopenia): This study is evaluating the effectiveness of a combination of dietary interventions and exercise in preventing sarcopenia in older adults.\n5. Effects of a Novel Nutritional Intervention on Sarcopenia in Older Adults (R01 AG063717): This study is evaluating the effectiveness of a novel nutritional intervention in preventing sarcopenia in older adults.\n6. The Effect of Resistance Training on Sarcopenia in Older Adults (R01 AG063716): This study is evaluating the effectiveness of resistance training in preventing sarcopenia in older adults.\n7. The Effect of Dietary Interventions on Sarcopenia in Older Adults",
    "llama-2-7b-chat-hf_fact_raw": "1. There are no FDA-approved drugs for the prevention of sarcopenia.\n2. The clinical trial \"Resistance Training and Nutritional Interventions to Prevent Sarcopenia in Older Adults\" (R01 AG063719) is evaluating resistance training and nutritional interventions for preventing sarcopenia.\n3. The clinical trial \"A Randomized Controlled Trial of a Novel Dietary Supplement to Prevent Sarcopenia in Older Adults\" (R01 AG063720) is evaluating a novel dietary supplement for preventing sarcopenia.\n4. The clinical trial \"Exercise and Nutrition Interventions to Prevent Sarcopenia in Older Adults\" (R01 AG063718) is evaluating exercise and nutritional interventions for preventing sarcopenia.\n5. The clinical trial \"Sarcopenia Prevention through Dietary Interventions and Exercise\" (SPRINT-Sarcopenia) is evaluating dietary interventions and exercise for preventing sarcopenia.",
    "llama-2-7b-chat-hf_fact": [
      "There are no FDA-approved drugs for the prevention of sarcopenia.",
      "The clinical trial \"Resistance Training and Nutritional Interventions to Prevent Sarcopenia in Older Adults\" (R01 AG063719) is evaluating resistance training and nutritional interventions for preventing sarcopenia.",
      "The clinical trial \"A Randomized Controlled Trial of a Novel Dietary Supplement to Prevent Sarcopenia in Older Adults\" (R01 AG063720) is evaluating a novel dietary supplement for preventing sarcopenia.",
      "The clinical trial \"Exercise and Nutrition Interventions to Prevent Sarcopenia in Older Adults\" (R01 AG063718) is evaluating exercise and nutritional interventions for preventing sarcopenia.",
      "The clinical trial \"Sarcopenia Prevention through Dietary Interventions and Exercise\" (SPRINT-Sarcopenia) is evaluating dietary interventions and exercise for preventing sarcopenia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: As of my knowledge cutoff in 2023, there are no FDA-approved drugs specifically for the prevention of sarcopenia. Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength, and it is typically associated with aging.\n\n2. UNKNOWN: Without access to current clinical trial databases or specific information about ongoing research, I cannot confirm the details of the clinical trial \"Resistance Training and Nutritional Interventions to Prevent Sarcopenia in Older Adults\" (R01 AG063719). The title suggests that it is evaluating resistance training and nutritional interventions for preventing sarcopenia, but the status and details of the trial are not provided.\n\n3. UNKNOWN: Similar to statement 2, I cannot confirm the details of the clinical trial \"A Randomized Controlled Trial of a Novel Dietary Supplement to Prevent Sarcopenia in Older Adults\" (R01 AG063720) without access to current clinical trial databases or specific information about ongoing research.\n\n4. UNKNOWN: The details of the clinical trial \"Exercise and Nutrition Interventions to Prevent Sarcopenia in Older Adults\" (R01 AG063718) cannot be confirmed without access to current clinical trial databases or specific information about ongoing research.\n\n5. UNKNOWN: The details of the clinical trial \"Sarcopenia Prevention through Dietary Interventions and Exercise\" (SPRINT-Sarcopenia) cannot be confirmed without access to current clinical trial databases or specific information about ongoing research. The title suggests that it is evaluating dietary interventions and exercise for preventing sarcopenia, but the status and details of the trial are not provided.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several databases of molecular recognition features in membrane proteins, but some of the most well-known and widely used include:\n1. The Membrane Protein Structural Database (MPSD): This database contains structural information on membrane proteins, including their three-dimensional structures, and their membrane-spanning segments.\n2. The Protein Data Bank (PDB): The PDB is a comprehensive database of 3D structures of proteins, including membrane proteins. It provides access to structures of membrane proteins in their native, hydrated state, as well as in complexes with other molecules.\n3. The Membrane Protein Interaction Database (MPIA): This database contains information on the interactions between membrane proteins and other molecules, such as ligands, drugs, and other proteins.\n4. The Membrane Protein Families Database (MPFDB): This database provides information on the structural and functional properties of membrane protein families, including their sequence, structure, and function.\n5. The Membrane Protein Topology Database (MPTD): This database provides information on the topology of membrane proteins, including their transmembrane segments, and their intracellular and extracellular domains.\n6. The Membrane Protein-Ligand Interaction Database (MP-LID): This database contains information on the interactions between membrane proteins and their ligands, including drugs, hormones, and other signaling molecules.\n7. The Membrane Protein-Protein Interaction Database (MP-PID): This database provides information on the interactions between membrane proteins and other proteins, including their binding affinities, and the functional implications of these interactions.\n8. The Membrane Protein-Nucleic Acid Interaction Database (MP-NAID): This database contains information on the interactions between membrane proteins and nucleic acids, including DNA and RNA.\n9. The Membrane Protein-Small Molecule Interaction Database (MP-SMI): This database provides information on the interactions between membrane proteins and small molecules, including drugs, toxins, and other signaling molecules.\n10. The Membrane Protein-Peptide Interaction Database (MP-",
    "llama-2-7b-chat-hf_fact_raw": "1. The Membrane Protein Structural Database (MPSD) contains structural information on membrane proteins, including their three-dimensional structures and membrane-spanning segments.\n2. The Protein Data Bank (PDB) is a comprehensive database of 3D structures of proteins, including membrane proteins.\n3. The Membrane Protein Interaction Database (MPIA) contains information on interactions between membrane proteins and other molecules such as ligands and drugs.\n4. The Membrane Protein Families Database (MPFDB) provides information on the structural and functional properties of membrane protein families.\n5. The Membrane Protein Topology Database (MPTD) provides information on the topology of membrane proteins, including their transmembrane segments.",
    "llama-2-7b-chat-hf_fact": [
      "The Membrane Protein Structural Database (MPSD) contains structural information on membrane proteins, including their three-dimensional structures and membrane-spanning segments.",
      "The Protein Data Bank (PDB) is a comprehensive database of 3D structures of proteins, including membrane proteins.",
      "The Membrane Protein Interaction Database (MPIA) contains information on interactions between membrane proteins and other molecules such as ligands and drugs.",
      "The Membrane Protein Families Database (MPFDB) provides information on the structural and functional properties of membrane protein families.",
      "The Membrane Protein Topology Database (MPTD) provides information on the topology of membrane proteins, including their transmembrane segments."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The correct name is the Membrane Protein Interaction Database (MPIDB), not MPIA.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Yes, rivaroxaban is metabolized in the kidneys. Rivaroxaban is primarily metabolized by the liver and kidneys, with the liver responsible for the majority of metabolism (approximately 70%). However, the kidneys also play a significant role in rivaroxaban metabolism, particularly through the enzyme uridine diphosphate glucuronosyltransferase (UGT).\nUGT enzymes in the kidneys are responsible for glucuronidation of rivaroxaban, which results in the formation of the inactive metabolite, rivaroxaban-3-glucuronide. This metabolite is then excreted in the urine.\nIn addition, the kidneys also play a role in the elimination of rivaroxaban from the body through the excretion of the parent compound in the urine.\nOverall, the kidneys play an important role in the metabolism and elimination of rivaroxaban, and any impairment in renal function can affect the efficacy and safety of the drug.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized by both the liver and kidneys.\n2. The liver is responsible for approximately 70% of rivaroxaban's metabolism.\n3. Uridine diphosphate glucuronosyltransferase (UGT) enzymes in the kidneys are involved in the glucuronidation of rivaroxaban.\n4. The inactive metabolite formed through glucuronidation of rivaroxaban is rivaroxaban-3-glucuronide.\n5. The kidneys are involved in the elimination of rivaroxaban from the body through urine excretion.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized by both the liver and kidneys.",
      "The liver is responsible for approximately 70% of rivaroxaban's metabolism.",
      "Uridine diphosphate glucuronosyltransferase (UGT) enzymes in the kidneys are involved in the glucuronidation of rivaroxaban.",
      "The inactive metabolite formed through glucuronidation of rivaroxaban is rivaroxaban-3-glucuronide.",
      "The kidneys are involved in the elimination of rivaroxaban from the body through urine excretion."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The liver is responsible for approximately two-thirds of rivaroxaban's metabolism, with the remaining one-third being eliminated by the kidneys.\n3. FALSE [correction]: Uridine diphosphate glucuronosyltransferase (UGT) enzymes are primarily found in the liver, not the kidneys, and are involved in the glucuronidation of rivaroxaban.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "TRα2 (estrogen receptor alpha 2) is a nuclear receptor that plays a crucial role in regulating various physiological processes in the heart, including cardiac development, hypertrophy, and fibrosis. Studies have shown that TRα2 regulates the expression of several genes involved in these processes, including:\n1. Atrial natriuretic factor (ANF): TRα2 regulates the expression of ANF, a hormone that plays a key role in regulating blood pressure and fluid balance.\n2. Beta-myosin heavy chain (MHCβ): TRα2 regulates the expression of MHCβ, a protein involved in cardiac muscle contraction.\n3. Brain natriuretic peptide (BNP): TRα2 regulates the expression of BNP, a hormone that plays a role in regulating cardiac function and fluid balance.\n4. Cardiac troponin I (cTnI): TRα2 regulates the expression of cTnI, a protein involved in cardiac muscle contraction.\n5. GATA4: TRα2 regulates the expression of GATA4, a transcription factor involved in cardiac development and hypertrophy.\n6. Hypoxia-inducible factor (HIF1α): TRα2 regulates the expression of HIF1α, a transcription factor involved in response to hypoxia and adaptation to low oxygen levels.\n7. Kelch-like ECH-associated protein 1 (KEAP1): TRα2 regulates the expression of KEAP1, a protein involved in regulating the activity of the proteasome, which is responsible for degrading misfolded proteins.\n8. MAPK activated protein kinase 2 (MK2): TRα2 regulates the expression of MK2, a protein involved in regulating the activity of the MAPK signaling pathway, which is involved in cell proliferation, differentiation, and survival.\n9. Nuclear factor of kappa light chain enhancer in B cells 2 (NF-κB2): TRα2 regulates the expression of NF-κB2, a transcription factor involved in regulating inflammation and immune response.\n10.",
    "llama-2-7b-chat-hf_fact_raw": "1. TRα2 regulates the expression of Atrial natriuretic factor (ANF), which is involved in regulating blood pressure and fluid balance.\n2. TRα2 regulates the expression of Beta-myosin heavy chain (MHCβ), a protein involved in cardiac muscle contraction.\n3. TRα2 regulates the expression of Brain natriuretic peptide (BNP), a hormone that plays a role in cardiac function and fluid balance.\n4. TRα2 regulates the expression of Cardiac troponin I (cTnI), a protein involved in cardiac muscle contraction.\n5. TRα2 regulates the expression of GATA4, a transcription factor involved in cardiac development and hypertrophy.",
    "llama-2-7b-chat-hf_fact": [
      "TRα2 regulates the expression of Atrial natriuretic factor (ANF), which is involved in regulating blood pressure and fluid balance.",
      "TRα2 regulates the expression of Beta-myosin heavy chain (MHCβ), a protein involved in cardiac muscle contraction.",
      "TRα2 regulates the expression of Brain natriuretic peptide (BNP), a hormone that plays a role in cardiac function and fluid balance.",
      "TRα2 regulates the expression of Cardiac troponin I (cTnI), a protein involved in cardiac muscle contraction.",
      "TRα2 regulates the expression of GATA4, a transcription factor involved in cardiac development and hypertrophy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are specific to the field of molecular biology and the regulation of gene expression by the thyroid hormone receptor alpha 2 (TRα2). Without specific scientific literature or research data to confirm or refute these statements, it is not possible to accurately determine the truthfulness of the claims regarding TRα2's regulatory role in the expression of the mentioned genes and proteins. Therefore, the response to each statement is \"UNKNOWN\".",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "There are several biomedical question answering systems available, including:\n1. PubMed: PubMed is a free database that indexes biomedical literature, including articles, book chapters, and conference proceedings. It also includes the PubMed Central repository of open-access articles.\n2. Google Scholar (GS): Google Scholar is a free search engine that indexes scholarly literature across many disciplines and sources, including articles, theses, books, and conference papers.\n3. BioASQ: BioASQ is a benchmarking platform for biomedical question answering systems, providing a collection of questions and answers on various biomedical topics.\n4. PubTator: PubTator is a tool that uses natural language processing techniques to extract biomedical information from PubMed abstracts, including gene mentions, protein-protein interactions, and disease-gene associations.\n5. ChEA: ChEA is a chemical entity autocompletion system that predicts potential drug targets based on the user's input.\n6. DrugBank: DrugBank is a comprehensive database of drugs, including information on their chemical structure, pharmacology, and clinical uses.\n7. Gene3D: Gene3D is a tool that predicts the three-dimensional structure of proteins based on their amino acid sequence, using a combination of homology modeling and template-based modeling techniques.\n8. MetaMap: MetaMap is a tool that extracts biomedical information from full-text articles, including gene and protein mentions, disease mentions, and drug mentions.\n9. BioGrid: BioGrid is a distributed database that integrates biomedical data from multiple sources, including genomic, proteomic, and clinical data.\n10. Open PHACTS: Open PHACTS is a platform for exploring and analyzing the relationships between biological molecules, including proteins, genes, and drugs.\n11. Bio2RDF: Bio2RDF is a tool that converts biomedical data into the Resource Description Framework (RDF) format, allowing for integration and querying of the data using semantic web technologies.\n12. ChEA-Chem: ChEA-Chem is a tool that predicts potential drug targets based on the user's input, using a combination of chemical and biological information.\n1",
    "llama-2-7b-chat-hf_fact_raw": "1. PubMed is a free database that indexes biomedical literature, including articles, book chapters, and conference proceedings.\n2. Google Scholar is a free search engine that indexes scholarly literature across many disciplines and sources.\n3. BioASQ is a benchmarking platform for biomedical question answering systems.\n4. DrugBank is a comprehensive database of drugs, including information on their chemical structure, pharmacology, and clinical uses.\n5. Gene3D is a tool that predicts the three-dimensional structure of proteins based on their amino acid sequence.",
    "llama-2-7b-chat-hf_fact": [
      "PubMed is a free database that indexes biomedical literature, including articles, book chapters, and conference proceedings.",
      "Google Scholar is a free search engine that indexes scholarly literature across many disciplines and sources.",
      "BioASQ is a benchmarking platform for biomedical question answering systems.",
      "DrugBank is a comprehensive database of drugs, including information on their chemical structure, pharmacology, and clinical uses.",
      "Gene3D is a tool that predicts the three-dimensional structure of proteins based on their amino acid sequence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Gene3D is a database that provides information on the structural and functional annotation of proteins, including predicted three-dimensional structures based on homology modeling, but it does not predict protein structures based solely on their amino acid sequence. Tools like Phyre2 or SWISS-MODEL are used for predicting protein structures from amino acid sequences.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "The transcription factor that activates the betalain pathway is ABSCISIC ACID INSENSITIVE 3 (ABI3). ABI3 is a transcriptional regulator that plays a key role in the biosynthesis of betalains, a class of plant secondary metabolites involved in defense against pathogens and abiotic stress. ABI3 regulates the expression of genes involved in the betalain biosynthetic pathway by binding to specific DNA sequences in the promoter regions of these genes and recruiting other transcription factors to activate their transcription.",
    "llama-2-7b-chat-hf_fact_raw": "1. ABSCISIC ACID INSENSITIVE 3 (ABI3) is a transcription factor that activates the betalain pathway.\n2. ABI3 plays a key role in the biosynthesis of betalains.\n3. Betalains are a class of plant secondary metabolites involved in defense against pathogens and abiotic stress.\n4. ABI3 regulates the expression of genes involved in the betalain biosynthetic pathway.\n5. ABI3 functions by binding to specific DNA sequences in the promoter regions of genes and recruiting other transcription factors to activate their transcription.",
    "llama-2-7b-chat-hf_fact": [
      "ABSCISIC ACID INSENSITIVE 3 (ABI3) is a transcription factor that activates the betalain pathway.",
      "ABI3 plays a key role in the biosynthesis of betalains.",
      "Betalains are a class of plant secondary metabolites involved in defense against pathogens and abiotic stress.",
      "ABI3 regulates the expression of genes involved in the betalain biosynthetic pathway.",
      "ABI3 functions by binding to specific DNA sequences in the promoter regions of genes and recruiting other transcription factors to activate their transcription."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ABSCISIC ACID INSENSITIVE 3 (ABI3) is a transcription factor, but it is not known for activating the betalain pathway. ABI3 is involved in seed development and maturation.\n2. FALSE [correction]: ABI3 is not known to play a key role in the biosynthesis of betalains. Betalains are synthesized by a different set of enzymes and regulatory proteins.\n3. TRUE: Betalains are indeed a class of plant secondary metabolites that have roles in defense against pathogens and abiotic stress, among other functions.\n4. FALSE [correction]: ABI3 is not known to regulate the expression of genes involved in the betalain biosynthetic pathway. It is involved in the regulation of genes during seed development.\n5. TRUE: ABI3 functions by binding to specific DNA sequences in the promoter regions of genes and can recruit other transcription factors to activate their transcription, but this is in the context of its role in seed development, not specifically related to betalain biosynthesis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "There are several technologies that are commonly used for enriching phosphorylated peptides in global quantitative phosphoproteomic analyses. Here are some of the most preferred technologies:\n1. TiO2-based enrichment: This method uses titanium dioxide (TiO2) to selectively capture phosphorylated peptides based on their charge and hydrophilicity. TiO2-based enrichment is highly efficient and can be used for both acidic and basic phosphorylated peptides.\n2. IMAC (Immobilized Metal Affinity Chromatography): IMAC is a popular method for enriching phosphorylated peptides based on their metal ion coordination. Phosphorylated peptides are immobilized onto a metal ion-immobilized matrix, such as Ni2+ or Co2+, which selectively binds to the phosphorylated residues.\n3. Cation exchange (CE) chromatography: CE chromatography separates peptides based on their charge and hydrophobicity. Phosphorylated peptides can be enriched using a cation exchange resin, which selectively captures positively charged phosphorylated peptides.\n4. Hydrophilic interaction liquid chromatography (HILIC): HILIC separates peptides based on their hydrophilicity. Phosphorylated peptides can be enriched using a HILIC column, which selectively captures hydrophilic phosphorylated peptides.\n5. Reversed-phase HPLC: Reversed-phase HPLC separates peptides based on their hydrophobicity. Phosphorylated peptides can be enriched using a reversed-phase column, which selectively captures hydrophobic phosphorylated peptides.\n6. Microscale enrichment methods: Microscale enrichment methods, such as micro-PIP (phosphopeptide immunoaffinity purification) and micro-RP (reversed-phase) HPLC, are designed for small-scale phosphoproteomics experiments. These methods offer high resolution and sensitivity and can be easily scaled up",
    "llama-2-7b-chat-hf_fact_raw": "1. Titanium dioxide (TiO2)-based enrichment is used to selectively capture phosphorylated peptides in global quantitative phosphoproteomic analyses.\n2. Immobilized Metal Affinity Chromatography (IMAC) enriches phosphorylated peptides by immobilizing them onto a metal ion-immobilized matrix.\n3. Cation exchange (CE) chromatography is a method that enriches phosphorylated peptides using a cation exchange resin.\n4. Hydrophilic interaction liquid chromatography (HILIC) is used to separate and enrich phosphorylated peptides based on their hydrophilicity.\n5. Reversed-phase High-Performance Liquid Chromatography (HPLC) is a technique that separates and enriches phosphorylated peptides based on their hydrophobicity.",
    "llama-2-7b-chat-hf_fact": [
      "Titanium dioxide (TiO2)-based enrichment is used to selectively capture phosphorylated peptides in global quantitative phosphoproteomic analyses.",
      "Immobilized Metal Affinity Chromatography (IMAC) enriches phosphorylated peptides by immobilizing them onto a metal ion-immobilized matrix.",
      "Cation exchange (CE) chromatography is a method that enriches phosphorylated peptides using a cation exchange resin.",
      "Hydrophilic interaction liquid chromatography (HILIC) is used to separate and enrich phosphorylated peptides based on their hydrophilicity.",
      "Reversed-phase High-Performance Liquid Chromatography (HPLC) is a technique that separates and enriches phosphorylated peptides based on their hydrophobicity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Cation exchange (CE) chromatography is a method that separates peptides based on their charge, not specifically used to enrich phosphorylated peptides.\n4. TRUE\n5. TRUE, but with a clarification: Reversed-phase High-Performance Liquid Chromatography (HPLC) is primarily a separation technique based on hydrophobicity. While it can be used to enrich certain types of peptides, it is not specific for phosphorylated peptides unless used in conjunction with other enrichment strategies.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "Palmini classification is used to rate the severity of mitochondrial myopathies, a group of disorders that affect the muscles and are caused by mutations in genes involved in mitochondrial function. The Palmini classification system assigns a score to each patient based on the severity of their symptoms and the extent of muscle weakness, fatigue, and wasting. The classification system includes four categories:\n1. Mild: Patients with mild symptoms and limited muscle weakness.\n2. Moderate: Patients with moderate symptoms and muscle weakness that affects their ability to perform daily activities.\n3. Severe: Patients with severe symptoms and significant muscle weakness that can lead to difficulty walking, standing, or breathing.\n4. Very severe: Patients with the most severe symptoms and significant muscle wasting, which can lead to respiratory failure and other complications.\nIt is important to note that the Palmini classification system is not a diagnostic tool, but rather a way to measure the severity of the disorder in patients already diagnosed with a mitochondrial myopathy.",
    "llama-2-7b-chat-hf_fact_raw": "1. Palmini classification is used to rate the severity of mitochondrial myopathies.\n2. Mitochondrial myopathies are caused by mutations in genes involved in mitochondrial function.\n3. The Palmini classification system includes four categories: mild, moderate, severe, and very severe.\n4. The classification system is not a diagnostic tool but measures the severity of the disorder in diagnosed patients.\n5. Very severe mitochondrial myopathy can lead to respiratory failure and other complications.",
    "llama-2-7b-chat-hf_fact": [
      "Palmini classification is used to rate the severity of mitochondrial myopathies.",
      "Mitochondrial myopathies are caused by mutations in genes involved in mitochondrial function.",
      "The Palmini classification system includes four categories: mild, moderate, severe, and very severe.",
      "The classification system is not a diagnostic tool but measures the severity of the disorder in diagnosed patients.",
      "Very severe mitochondrial myopathy can lead to respiratory failure and other complications."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Palmini classification is used to rate the severity of epilepsy, not mitochondrial myopathies.\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Yes, some viruses have been implicated in the etiology of human subacute thyroiditis. Subacute thyroiditis is an inflammatory condition that affects the thyroid gland and is characterized by painless thyroiditis, fever, and thyroid dysfunction. While the exact cause of subacute thyroiditis is not fully understood, several viruses have been linked to its development:\n1. Viral infections: Several viruses, including enteroviruses, herpesviruses, and adenoviruses, have been identified as potential triggers of subacute thyroiditis. These viruses can infect the thyroid gland and cause inflammation, leading to the symptoms of the condition.\n2. Respiratory viruses: Respiratory viruses, such as the common cold and influenza, have also been linked to subacute thyroiditis. In some cases, these viruses can spread to the thyroid gland and cause inflammation.\n3. HIV: Human immunodeficiency virus (HIV) infection has been associated with an increased risk of developing subacute thyroiditis. This may be due to the immune system dysfunction that occurs in HIV infection, which can increase the susceptibility to thyroid inflammation.\n4. Other infections: Other infections, such as Lyme disease and tuberculosis, have also been linked to subacute thyroiditis.\nIt is important to note that not all cases of subacute thyroiditis are caused by viral infections, and other factors, such as autoimmune disorders and toxic exposures, can also play a role in the development of the condition. A diagnosis of subacute thyroiditis typically involves a combination of clinical evaluation, laboratory tests, and imaging studies to rule out other potential causes of thyroid inflammation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Subacute thyroiditis is an inflammatory condition that affects the thyroid gland.\n2. Several viruses, including enteroviruses, herpesviruses, and adenoviruses, have been identified as potential triggers of subacute thyroiditis.\n3. Respiratory viruses, such as the common cold and influenza, have been linked to subacute thyroiditis.\n4. Human immunodeficiency virus (HIV) infection has been associated with an increased risk of developing subacute thyroiditis.\n5. Lyme disease and tuberculosis have also been linked to subacute thyroiditis.",
    "llama-2-7b-chat-hf_fact": [
      "Subacute thyroiditis is an inflammatory condition that affects the thyroid gland.",
      "Several viruses, including enteroviruses, herpesviruses, and adenoviruses, have been identified as potential triggers of subacute thyroiditis.",
      "Respiratory viruses, such as the common cold and influenza, have been linked to subacute thyroiditis.",
      "Human immunodeficiency virus (HIV) infection has been associated with an increased risk of developing subacute thyroiditis.",
      "Lyme disease and tuberculosis have also been linked to subacute thyroiditis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Human immunodeficiency virus (HIV) infection has not been commonly associated with an increased risk of developing subacute thyroiditis. Subacute thyroiditis is typically associated with viral infections, not HIV.\n5. FALSE [correction]: Lyme disease and tuberculosis are not typically linked to subacute thyroiditis. Subacute thyroiditis is most commonly associated with viral infections, not bacterial infections like Lyme disease and tuberculosis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "No, STAT3 is not directly involved in EIF2AK2-dependent suppression of autophagy. STAT3 (Signal Transducer and Activator of Transcription 3) is a transcription factor that plays a role in regulating the expression of genes involved in inflammation and immune responses. EIF2AK2 (Eukaryotic Translation Initiation Factor 2-Associated Kinase 2) is a protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF2), leading to the suppression of protein synthesis and the induction of autophagy. While STAT3 and EIF2AK2 have different functions and pathways, they may intersect in certain contexts, such as in the regulation of inflammation-induced autophagy.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is not directly involved in EIF2AK2-dependent suppression of autophagy.\n2. STAT3 stands for Signal Transducer and Activator of Transcription 3.\n3. STAT3 is a transcription factor that regulates genes involved in inflammation and immune responses.\n4. EIF2AK2 stands for Eukaryotic Translation Initiation Factor 2-Associated Kinase 2.\n5. EIF2AK2 phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF2), leading to the suppression of protein synthesis and the induction of autophagy.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is not directly involved in EIF2AK2-dependent suppression of autophagy.",
      "STAT3 stands for Signal Transducer and Activator of Transcription 3.",
      "STAT3 is a transcription factor that regulates genes involved in inflammation and immune responses.",
      "EIF2AK2 stands for Eukaryotic Translation Initiation Factor 2-Associated Kinase 2.",
      "EIF2AK2 phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF2), leading to the suppression of protein synthesis and the induction of autophagy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre is a software tool designed for genomic analysis, specifically for the analysis of chromatin structure and epigenetic marks. It can be used to:\n1. Visualize and analyze chromatin structure: Theatre can be used to visualize the three-dimensional structure of chromatin, including the positioning of nucleosomes and higher-order chromatin structures such as loops and domains.\n2. Identify and interpret epigenetic marks: Theatre can be used to identify and interpret various types of epigenetic marks, such as histone modifications and DNA methylation, and how they are distributed across the genome.\n3. Analyze gene regulation: Theatre can be used to study the regulation of gene expression by analyzing the interactions between chromatin structure, epigenetic marks, and transcription factor binding sites.\n4. Identify functional elements in the genome: Theatre can be used to identify functional elements in the genome, such as enhancers, promoters, and silencers, and to study their interactions with other genomic features.\n5. Analyze genomic data: Theatre can be used to analyze large-scale genomic data sets, such as those generated by high-throughput sequencing technologies, to identify patterns and trends in chromatin structure and epigenetic marks across the genome.\n6. Interact with other software tools: Theatre can be used in combination with other software tools, such as Integrative Genomics Viewer (IGV), to perform a wide range of genomic analyses.\n7. Analyze single-cell data: Theatre can be used to analyze single-cell data, such as single-cell ChIP-seq or RNA-seq data, to study the epigenetic and transcriptional landscape of individual cells.\n8. Analyze 3D chromatin structure: Theatre can be used to analyze 3D chromatin structure data, such as 3C-seq or 4C-seq data, to study the interactions between distant regulatory elements and gene promoters.\n9. Analyze chromatin accessibility: Theatre can be used to analyze chromatin accessibility data, such as FAIRE-seq or ATAC-seq data, to study the open chromatin landscape and identify regulatory elements.\n10. Analyze gene expression: Theatre can be used to analyze gene expression data, such as",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a software tool designed for genomic analysis, specifically for the analysis of chromatin structure and epigenetic marks.\n2. Theatre can visualize the three-dimensional structure of chromatin, including the positioning of nucleosomes and higher-order structures.\n3. The software can identify and interpret various types of epigenetic marks, such as histone modifications and DNA methylation.\n4. Theatre can be used to study the regulation of gene expression by analyzing interactions between chromatin structure, epigenetic marks, and transcription factor binding sites.\n5. Theatre can analyze large-scale genomic data sets generated by high-throughput sequencing technologies.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a software tool designed for genomic analysis, specifically for the analysis of chromatin structure and epigenetic marks.",
      "Theatre can visualize the three-dimensional structure of chromatin, including the positioning of nucleosomes and higher-order structures.",
      "The software can identify and interpret various types of epigenetic marks, such as histone modifications and DNA methylation.",
      "Theatre can be used to study the regulation of gene expression by analyzing interactions between chromatin structure, epigenetic marks, and transcription factor binding sites.",
      "Theatre can analyze large-scale genomic data sets generated by high-throughput sequencing technologies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about a software tool named \"Theatre\" that is designed for genomic analysis, it is not possible to verify the accuracy of these statements. They could be true if there is indeed a software with this name that performs the functions described, but without additional context or sources, the veracity of the statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the specific implementation and the size of the sequences. However, the general complexity of the algorithm can be analyzed as follows:\n1. Computing the similarity matrix: The time complexity of this step is O(n^2), where n is the length of the shorter sequence. This is because the similarity between each element of the shorter sequence and each element of the longer sequence must be computed, resulting in a total of n^2 comparisons.\n2. Finding the maximum similarity: The time complexity of this step is O(n), because it involves finding the maximum similarity between the shorter sequence and the longer sequence, which can be done in a single pass through the sequences.\n3. Computing the alignment: The time complexity of this step is O(n^2), because it involves finding the optimal alignment between the shorter sequence and the longer sequence, which requires comparing each element of the shorter sequence to each element of the longer sequence.\nTherefore, the overall time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence. This means that the algorithm becomes increasingly computationally expensive as the length of the sequences increases.\nIt's worth noting that there are some optimizations and variations of the Smith-Waterman algorithm that can reduce the time complexity, such as using a sliding window or a dynamic programming approach. However, these optimizations can only improve the time complexity to O(n log n) or O(n^2 log n) at best, rather than reducing it to O(n log n) or O(n^2).",
    "llama-2-7b-chat-hf_fact_raw": "1. The time complexity for computing the similarity matrix in the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.\n2. The time complexity for finding the maximum similarity in the Smith-Waterman algorithm is O(n).\n3. The time complexity for computing the alignment in the Smith-Waterman algorithm is O(n^2).\n4. The overall time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.\n5. Optimizations and variations of the Smith-Waterman algorithm can improve the time complexity to O(n log n) or O(n^2 log n) at best.",
    "llama-2-7b-chat-hf_fact": [
      "The time complexity for computing the similarity matrix in the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.",
      "The time complexity for finding the maximum similarity in the Smith-Waterman algorithm is O(n).",
      "The time complexity for computing the alignment in the Smith-Waterman algorithm is O(n^2).",
      "The overall time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.",
      "Optimizations and variations of the Smith-Waterman algorithm can improve the time complexity to O(n log n) or O(n^2 log n) at best."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The time complexity for finding the maximum similarity in the Smith-Waterman algorithm is also O(n^2), as it involves searching through the entire similarity matrix, which is of size n^2.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "FLVCR1 is a member of the solute carrier (SLC) family of transport proteins. Specifically, it is a member of the SLC16 subfamily, which is also known as the UDP-glucuronosyltransferase (UGT) family.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 is a member of the solute carrier (SLC) family of transport proteins.\n2. FLVCR1 belongs to the SLC16 subfamily.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 is a member of the solute carrier (SLC) family of transport proteins.",
      "FLVCR1 belongs to the SLC16 subfamily."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: FLVCR1 belongs to the SLC49 subfamily.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "GATA-1, a transcription factor critical for erythroid cell development, has been shown to interact with several proteins through various biochemical and functional studies. The biotinylation tagging approach has been used to identify GATA-1 interacting partners, including:\n1. β-catenin: GATA-1 has been shown to interact with β-catenin, a key regulator of Wnt signaling, and this interaction is important for GATA-1-mediated erythroid cell differentiation.\n2. CTCF: CTCF is a chromatin-binding protein that regulates gene expression by blocking or enhancing the accessibility of chromatin to transcription factors like GATA-1.\n3. KRAB-ZNFs: KRAB-ZNFs (Krüppel-associated box-zinc finger proteins) are zinc finger proteins that interact with GATA-1 and regulate erythroid cell differentiation.\n4. NF-E2: NF-E2 (nuclear factor erythroid 2) is a transcription factor that interacts with GATA-1 and regulates erythroid cell differentiation.\n5. STAT5: STAT5 (signal transducer and activator of transcription 5) is a transcription factor that interacts with GATA-1 and regulates erythroid cell differentiation.\n6. TFAP2A: TFAP2A (transcription factor AP-2 alpha) is a transcription factor that interacts with GATA-1 and regulates erythroid cell differentiation.\n7. TFAP2B: TFAP2B (transcription factor AP-2 beta) is a transcription factor that interacts with GATA-1 and regulates erythroid cell differentiation.\n8. HMX1: HMX1 (homeobox transcription factor HMX1) is a transcription factor that interacts with GATA-1 and regulates erythroid cell differentiation.\n9. HMX2: HMX2 (homeobox transcription factor HMX2) is a transcription factor that interacts with GATA-1 and regulates erythroid cell differentiation.\n10. EKLF: EKLF (erythroid",
    "llama-2-7b-chat-hf_fact_raw": "1. GATA-1 interacts with β-catenin, which is involved in Wnt signaling and erythroid cell differentiation.\n2. GATA-1 interacts with CTCF, a chromatin-binding protein that influences gene expression.\n3. GATA-1 interacts with KRAB-ZNFs, which are involved in the regulation of erythroid cell differentiation.\n4. GATA-1 interacts with NF-E2, a transcription factor that plays a role in erythroid cell differentiation.\n5. GATA-1 interacts with STAT5, a transcription factor that is involved in the regulation of erythroid cell differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "GATA-1 interacts with β-catenin, which is involved in Wnt signaling and erythroid cell differentiation.",
      "GATA-1 interacts with CTCF, a chromatin-binding protein that influences gene expression.",
      "GATA-1 interacts with KRAB-ZNFs, which are involved in the regulation of erythroid cell differentiation.",
      "GATA-1 interacts with NF-E2, a transcription factor that plays a role in erythroid cell differentiation.",
      "GATA-1 interacts with STAT5, a transcription factor that is involved in the regulation of erythroid cell differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nThe interactions of GATA-1 with various proteins can be quite specific and are subject to ongoing research. While it is known that GATA-1 plays a crucial role in erythroid cell differentiation and interacts with various proteins to regulate gene expression, the specific interactions with β-catenin and KRAB-ZNFs are not as widely established or may be context-dependent, hence the \"UNKNOWN\" status for statements 1 and 3. Statements 2, 4, and 5 are consistent with known interactions of GATA-1.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "TAF10 (TATA-binding protein-associated factor 10) interacts with the GATA1 (GATA-binding protein 1) transcription factor to regulate the expression of genes involved in erythropoiesis, the production of red blood cells. TAF10 and GATA1 interact in the regulation of gene expression during erythropoiesis, and TAF10 plays a crucial role in the recruitment of RNA polymerase II (RNAPII) to the promoter regions of GATA1-regulated genes. This interaction is essential for the proper regulation of red blood cell production and differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 interacts with the GATA1 transcription factor to regulate gene expression involved in erythropoiesis.\n2. Erythropoiesis is the production of red blood cells.\n3. TAF10 plays a crucial role in the recruitment of RNA polymerase II to the promoter regions of GATA1-regulated genes.\n4. The interaction between TAF10 and GATA1 is essential for the proper regulation of red blood cell production and differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 interacts with the GATA1 transcription factor to regulate gene expression involved in erythropoiesis.",
      "Erythropoiesis is the production of red blood cells.",
      "TAF10 plays a crucial role in the recruitment of RNA polymerase II to the promoter regions of GATA1-regulated genes.",
      "The interaction between TAF10 and GATA1 is essential for the proper regulation of red blood cell production and differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nNote: The statements provided are specific and technical, and they are consistent with known biological functions of TAF10 and GATA1 in erythropoiesis. However, without specific scientific references, it is assumed that these statements are accurate based on general knowledge in the field of molecular biology. If the context provided is from a reliable scientific source, the responses are likely correct.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are several decision support systems (DSS) available for chronic pain management. These systems are designed to help healthcare providers make informed decisions about the management of chronic pain, taking into account the patient's individual needs and medical history. Some examples of DSS for chronic pain management include:\n1. PainCare: This DSS is designed to help primary care providers manage chronic pain in adults. It provides clinical decision support, patient education materials, and a patient registry to help track treatment progress.\n2. Chronic Pain Management System (CPMS): This DSS is designed for use in primary care and pain management clinics. It includes a pain assessment tool, treatment planning software, and a patient registry to help track treatment progress.\n3. Pain Assessment and Management Tool (PAMT): This DSS is designed to help healthcare providers assess and manage chronic pain in adults. It includes a pain assessment tool, treatment planning software, and a patient registry to help track treatment progress.\n4. Chronic Pain Management (CPM) System: This DSS is designed to help healthcare providers manage chronic pain in adults. It includes a pain assessment tool, treatment planning software, and a patient registry to help track treatment progress.\n5. Pain Management Collaborative (PMC): This DSS is designed to help healthcare providers manage chronic pain in adults. It includes a pain assessment tool, treatment planning software, and a patient registry to help track treatment progress.\n6. Chronic Pain Management (CPM) System: This DSS is designed to help healthcare providers manage chronic pain in adults. It includes a pain assessment tool, treatment planning software, and a patient registry to help track treatment progress.\n7. Pain Care Network (PCN): This DSS is designed to help healthcare providers manage chronic pain in adults. It includes a pain assessment tool, treatment planning software, and a patient registry to help track treatment progress.\n8. Chronic Pain Management (CPM) System: This DSS is designed to help healthcare providers manage chronic pain in adults. It includes a pain assessment tool, treatment planning software, and a patient registry to help track treatment progress.\n9. Pain Management Collaborative (PMC): This DSS",
    "llama-2-7b-chat-hf_fact_raw": "1. Decision support systems (DSS) are available for chronic pain management to assist healthcare providers.\n2. PainCare is a DSS that provides clinical decision support, patient education materials, and a patient registry for managing chronic pain in adults.\n3. The Chronic Pain Management System (CPMS) includes a pain assessment tool, treatment planning software, and a patient registry, and is designed for use in primary care and pain management clinics.\n4. The Pain Assessment and Management Tool (PAMT) is a DSS that includes a pain assessment tool, treatment planning software, and a patient registry for managing chronic pain in adults.\n5. The Pain Management Collaborative (PMC) is a DSS that includes a pain assessment tool, treatment planning software, and a patient registry for managing chronic pain in adults.",
    "llama-2-7b-chat-hf_fact": [
      "Decision support systems (DSS) are available for chronic pain management to assist healthcare providers.",
      "PainCare is a DSS that provides clinical decision support, patient education materials, and a patient registry for managing chronic pain in adults.",
      "The Chronic Pain Management System (CPMS) includes a pain assessment tool, treatment planning software, and a patient registry, and is designed for use in primary care and pain management clinics.",
      "The Pain Assessment and Management Tool (PAMT) is a DSS that includes a pain assessment tool, treatment planning software, and a patient registry for managing chronic pain in adults.",
      "The Pain Management Collaborative (PMC) is a DSS that includes a pain assessment tool, treatment planning software, and a patient registry for managing chronic pain in adults."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the named systems (PainCare, CPMS, PAMT, PMC), it is not possible to verify the accuracy of the statements regarding their features and intended use. These details are not common knowledge and would require access to specific information about the systems mentioned.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Angiogenin is a protein that is localized primarily in the cytoplasm and nucleus of cells. It is involved in various cellular processes, including cell signaling, proliferation, and differentiation, and its subcellular localization plays a crucial role in these processes. Angiogenin can be found in the cytoplasm, where it regulates various signaling pathways, and in the nucleus, where it affects gene expression and cell fate determination. In addition, angiogenin can also be secreted from cells and act in extracellular environments, where it can modulate angiogenesis and inflammation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is a protein that is localized in the cytoplasm and nucleus of cells.\n2. Angiogenin is involved in cell signaling, proliferation, and differentiation.\n3. Angiogenin's subcellular localization is important for its role in cellular processes.\n4. In the cytoplasm, angiogenin regulates various signaling pathways.\n5. In the nucleus, angiogenin affects gene expression and cell fate determination.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is a protein that is localized in the cytoplasm and nucleus of cells.",
      "Angiogenin is involved in cell signaling, proliferation, and differentiation.",
      "Angiogenin's subcellular localization is important for its role in cellular processes.",
      "In the cytoplasm, angiogenin regulates various signaling pathways.",
      "In the nucleus, angiogenin affects gene expression and cell fate determination."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAngiogenin is indeed a protein that is found in the cytoplasm and nucleus of cells, where it plays a role in various cellular processes including cell signaling, proliferation, and differentiation. Its subcellular localization is important for its function, as it can influence different pathways and mechanisms depending on whether it is in the cytoplasm or the nucleus. In the cytoplasm, angiogenin can regulate signaling pathways, and in the nucleus, it can affect gene expression and cell fate determination.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Ranolazine is a drug that has been shown to affect kinase signaling activation in the heart by inhibiting the activity of certain kinases, specifically the ion channel kinase (IK), protein kinase C (PKC), and the mitogen-activated protein kinase (MAPK) pathway.\nRanolazine works by blocking the flow of sodium ions into the heart muscle cell, which helps to reduce the workload on the heart and improve cardiac function in patients with heart failure. However, it also has off-target effects on kinase signaling pathways, which can lead to unintended consequences.\nSpecifically, ranolazine has been shown to inhibit the activity of IK, PKC, and MAPK kinases, which are important regulators of cardiac contractility and remodeling. By inhibiting these kinases, ranolazine can reduce the ability of the heart to respond to stress and adapt to changes in cardiac demand, leading to decreased cardiac function and increased risk of arrhythmias.\nAdditionally, ranolazine has been shown to inhibit the activation of the PI3K/Akt signaling pathway, which is important for cell survival and proliferation. By inhibiting this pathway, ranolazine can reduce the ability of the heart to repair and remodel itself in response to injury or stress, leading to further decline in cardiac function.\nOverall, the effects of ranolazine on kinase signaling activation in the heart are complex and multifaceted, and may contribute to both the therapeutic and adverse effects of the drug.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine inhibits the activity of certain kinases in the heart, including the ion channel kinase (IK), protein kinase C (PKC), and the mitogen-activated protein kinase (MAPK) pathway.\n2. Ranolazine works by blocking the flow of sodium ions into heart muscle cells.\n3. Inhibition of IK, PKC, and MAPK kinases by ranolazine can reduce the heart's ability to respond to stress and adapt to changes in cardiac demand.\n4. Ranolazine has been shown to inhibit the activation of the PI3K/Akt signaling pathway, which is involved in cell survival and proliferation.\n5. The effects of ranolazine on kinase signaling in the heart may contribute to both its therapeutic and adverse effects.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine inhibits the activity of certain kinases in the heart, including the ion channel kinase (IK), protein kinase C (PKC), and the mitogen-activated protein kinase (MAPK) pathway.",
      "Ranolazine works by blocking the flow of sodium ions into heart muscle cells.",
      "Inhibition of IK, PKC, and MAPK kinases by ranolazine can reduce the heart's ability to respond to stress and adapt to changes in cardiac demand.",
      "Ranolazine has been shown to inhibit the activation of the PI3K/Akt signaling pathway, which is involved in cell survival and proliferation.",
      "The effects of ranolazine on kinase signaling in the heart may contribute to both its therapeutic and adverse effects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ranolazine is known to inhibit the late phase of the inward sodium current (I_Na) in the heart, but it is not specifically known to inhibit the activity of kinases such as ion channel kinase (IK), protein kinase C (PKC), and the mitogen-activated protein kinase (MAPK) pathway.\n2. TRUE\n3. FALSE [correction]: Since the first statement is false and ranolazine is not known to inhibit IK, PKC, and MAPK kinases, the statement about these kinases reducing the heart's ability to respond to stress and adapt to changes in cardiac demand due to ranolazine is also false. Ranolazine's primary known mechanism is through the inhibition of the late phase of the inward sodium current, which can affect the heart's electrophysiology.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "Yes, the regulation of Vsr endonuclease is independent of the growth phase of bacteria. Vsr endonuclease is a bacterial endonuclease that is involved in the degradation of DNA during the SOS response, a mechanism that bacteria use to repair DNA damage caused by various factors, including oxidative stress, UV radiation, and certain antibiotics.\nThe regulation of Vsr endonuclease is primarily mediated by the LexA protein, which is a transcriptional regulator that binds to specific DNA sequences upstream of the vsr gene and represses its transcription during the logarithmic growth phase of bacteria. This means that during the logarithmic growth phase, when bacteria are actively dividing and producing new DNA, the expression of Vsr endonuclease is low, and the enzyme is not active.\nHowever, when bacteria are exposed to DNA-damaging agents, such as UV radiation, the LexA protein is inactivated, leading to the activation of the vsr promoter and the increase in Vsr endonuclease expression. This allows the enzyme to degrade the damaged DNA, leading to the repair of the damage and the maintenance of genome stability.\nIn summary, the regulation of Vsr endonuclease is independent of the growth phase of bacteria, and the enzyme is only active during the SOS response, when DNA damage is present.",
    "llama-2-7b-chat-hf_fact_raw": "1. The regulation of Vsr endonuclease is independent of the growth phase of bacteria.\n2. Vsr endonuclease is involved in the degradation of DNA during the SOS response in bacteria.\n3. The LexA protein mediates the regulation of Vsr endonuclease by binding to DNA sequences upstream of the vsr gene.\n4. The LexA protein represses the transcription of the vsr gene during the logarithmic growth phase of bacteria.\n5. The expression of Vsr endonuclease increases when bacteria are exposed to DNA-damaging agents like UV radiation.",
    "llama-2-7b-chat-hf_fact": [
      "The regulation of Vsr endonuclease is independent of the growth phase of bacteria.",
      "Vsr endonuclease is involved in the degradation of DNA during the SOS response in bacteria.",
      "The LexA protein mediates the regulation of Vsr endonuclease by binding to DNA sequences upstream of the vsr gene.",
      "The LexA protein represses the transcription of the vsr gene during the logarithmic growth phase of bacteria.",
      "The expression of Vsr endonuclease increases when bacteria are exposed to DNA-damaging agents like UV radiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: The LexA protein mediates the regulation of many genes involved in the SOS response, but it does not directly regulate Vsr endonuclease. The regulation of Vsr endonuclease is typically controlled by the Dam methylation system.\n4. FALSE [correction]: The LexA protein does not repress the transcription of the vsr gene; the regulation of the vsr gene is not directly connected to the LexA protein but is rather controlled by the Dam methylation system and the mismatch repair system.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several computational tools that can be used for the prediction of beta-barrel transmembrane proteins. Here are some of the commonly used tools:\n1. SignalP: SignalP is a widely used tool for predicting the signal peptides in a protein sequence. It can also predict the transmembrane domains, including the beta-barrel structure, using a machine learning approach.\n2. TMHMM: TMHMM is a tool for predicting transmembrane protein structure and topology. It can predict the beta-barrel structure in a protein sequence by using a combination of sequence analysis and structural modeling techniques.\n3. PredictBP: PredictBP is a tool for predicting the transmembrane topology of a protein sequence. It uses a combination of sequence analysis and machine learning techniques to predict the beta-barrel structure.\n4. Topo-Tensor: Topo-Tensor is a tool for predicting the topological structure of a protein. It can predict the beta-barrel structure in a protein sequence by using a combination of sequence analysis and structural modeling techniques.\n5. I-TASSER: I-TASSER is a tool for predicting the structure of a protein from its sequence. It can predict the beta-barrel structure in a protein sequence by using a combination of sequence analysis and structural modeling techniques.\n6. SMART: SMART is a tool for predicting the structure of a protein from its sequence. It can predict the beta-barrel structure in a protein sequence by using a combination of sequence analysis and structural modeling techniques.\n7. PHD-TOPO: PHD-TOPO is a tool for predicting the transmembrane topology of a protein sequence. It can predict the beta-barrel structure in a protein sequence by using a combination of sequence analysis and machine learning techniques.\n8. TOPO- Predict: TOPO-Predict is a tool for predicting the transmembrane topology of a protein sequence. It can predict the beta-barrel structure in a protein sequence by using a combination of sequence analysis and machine learning techniques.\n9. Protter: Protter is a tool for predicting the transmembrane topology of a protein sequence. It can predict the beta-barrel structure in a protein sequence by using a combination of sequence analysis and machine learning techniques",
    "llama-2-7b-chat-hf_fact_raw": "1. SignalP is a computational tool used for predicting signal peptides and transmembrane domains in protein sequences.\n2. TMHMM is a tool designed to predict transmembrane protein structure and topology, including beta-barrel structures.\n3. PredictBP is a computational tool that predicts the transmembrane topology of protein sequences, specifically beta-barrel structures.\n4. I-TASSER is a tool that predicts the structure of proteins from their sequences and can predict beta-barrel structures.\n5. PHD-TOPO is a tool used for predicting the transmembrane topology of protein sequences, including the prediction of beta-barrel structures.",
    "llama-2-7b-chat-hf_fact": [
      "SignalP is a computational tool used for predicting signal peptides and transmembrane domains in protein sequences.",
      "TMHMM is a tool designed to predict transmembrane protein structure and topology, including beta-barrel structures.",
      "PredictBP is a computational tool that predicts the transmembrane topology of protein sequences, specifically beta-barrel structures.",
      "I-TASSER is a tool that predicts the structure of proteins from their sequences and can predict beta-barrel structures.",
      "PHD-TOPO is a tool used for predicting the transmembrane topology of protein sequences, including the prediction of beta-barrel structures."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TMHMM is a tool designed to predict transmembrane protein structure and topology, but it does not predict beta-barrel structures; it is used for predicting alpha-helical transmembrane segments.\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Galassi classification is used to classify disorders related to the Wnt/β-catenin signaling pathway. The Galassi classification system was developed by Dr. Gaetano Galassi and colleagues as a way to categorize the different types of disorders that can occur due to dysregulation of the Wnt/β-catenin signaling pathway. The classification system recognizes three main categories of Wnt/β-catenin-related disorders:\n1. Wnt-related disorders: These are disorders that are caused by mutations in genes that are involved in the Wnt/β-catenin signaling pathway, such as those that affect the stability or activity of β-catenin. Examples of Wnt-related disorders include familial adenomatous polyposis (FAP) and multiple endocrine neoplasia (MEN) type 1.\n2. β-catenin-related disorders: These are disorders that are caused by mutations in genes that are involved in the regulation of β-catenin activity, such as those that affect the expression or function of genes involved in the Wnt/β-catenin pathway. Examples of β-catenin-related disorders include cancer, particularly colorectal cancer, and some forms of neural tube defects.\n3. Wnt/β-catenin-independent disorders: These are disorders that are not directly caused by dysregulation of the Wnt/β-catenin signaling pathway, but rather by other factors that affect the expression or function of genes involved in the pathway. Examples of Wnt/β-catenin-independent disorders include those that affect the expression or function of genes involved in the Wnt/β-catenin pathway, such as those that affect the stability or activity of β-catenin.\nThe Galassi classification system provides a useful framework for understanding the different types of disorders that can occur due to dysregulation of the Wnt/β-catenin signaling pathway, and can help researchers identify potential therapeutic targets for these disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Galassi classification is used to categorize disorders related to the Wnt/β-catenin signaling pathway.\n2. Dr. Gaetano Galassi and colleagues developed the Galassi classification system.\n3. The Galassi classification system recognizes three main categories: Wnt-related disorders, β-catenin-related disorders, and Wnt/β-catenin-independent disorders.\n4. Familial adenomatous polyposis (FAP) and multiple endocrine neoplasia (MEN) type 1 are examples of Wnt-related disorders.\n5. Colorectal cancer is an example of a β-catenin-related disorder.",
    "llama-2-7b-chat-hf_fact": [
      "The Galassi classification is used to categorize disorders related to the Wnt/β-catenin signaling pathway.",
      "Dr. Gaetano Galassi and colleagues developed the Galassi classification system.",
      "The Galassi classification system recognizes three main categories: Wnt-related disorders, β-catenin-related disorders, and Wnt/β-catenin-independent disorders.",
      "Familial adenomatous polyposis (FAP) and multiple endocrine neoplasia (MEN) type 1 are examples of Wnt-related disorders.",
      "Colorectal cancer is an example of a β-catenin-related disorder."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Galassi classification is used to categorize different types of arachnoid cysts, not disorders related to the Wnt/β-catenin signaling pathway.\n2. TRUE\n3. FALSE [correction]: The Galassi classification system recognizes three types of arachnoid cysts based on their size and location, not categories of disorders.\n4. FALSE [correction]: Familial adenomatous polyposis (FAP) is indeed related to the Wnt/β-catenin signaling pathway, but it is not classified under the Galassi classification, which is for arachnoid cysts. Multiple endocrine neoplasia (MEN) type 1 is not directly related to Wnt signaling.\n5. UNKNOWN (While colorectal cancer can be related to aberrations in the Wnt/β-catenin signaling pathway, without more context it is unclear if this statement is referring to the Galassi classification or not, which would make it incorrect as the Galassi classification is not for categorizing diseases but arachnoid cysts.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Shapiro syndrome, also known as Shapiro-Thompson syndrome or acrodermatitis enteropathica, is a rare genetic disorder characterized by a combination of skin, gastrointestinal, and immunological abnormalities. Here are some common features of Shapiro syndrome:\n1. Acral skin thickening: A characteristic feature of Shapiro syndrome is the thickening of the skin on the hands, feet, and face, which can lead to deformities and difficulty with movement.\n2. Enteropathy: Patients with Shapiro syndrome often experience gastrointestinal symptoms, including diarrhea, malabsorption, and inflammation of the small intestine.\n3. Immunodeficiency: Shapiro syndrome is associated with a defect in the immune system, which can lead to recurrent infections and a higher risk of opportunistic infections.\n4. Autoimmune disorders: Some patients with Shapiro syndrome may develop autoimmune disorders, such as thyroiditis or vitiligo, which can cause additional symptoms and complications.\n5. Delayed growth and development: Children with Shapiro syndrome may experience delays in growth and development, including delayed puberty and short stature.\n6. Eye abnormalities: Some patients with Shapiro syndrome may have eye abnormalities, including cataracts, glaucoma, or retinal detachment.\n7. Hearing loss: Hearing loss is a less common feature of Shapiro syndrome but can occur in some cases.\n8. Neurological problems: Some patients with Shapiro syndrome may experience neurological problems, such as seizures, developmental delay, or cognitive impairment.\n9. Respiratory problems: Respiratory problems, including bronchitis, pneumonia, or asthma, can occur in some patients with Shapiro syndrome.\n10. Skin abnormalities: In addition to acral skin thickening, patients with Shapiro syndrome may have other skin abnormalities, including papillomatosis, hyperpigmentation, or skin fragility.\nIt's important to note that the severity and specific features of Sh",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is characterized by acral skin thickening on the hands, feet, and face.\n2. Patients with Shapiro syndrome often experience gastrointestinal symptoms such as diarrhea and malabsorption.\n3. Shapiro syndrome is associated with immunodeficiency, leading to recurrent infections.\n4. Some patients with Shapiro syndrome may develop autoimmune disorders like thyroiditis or vitiligo.\n5. Children with Shapiro syndrome may have delayed growth and development, including delayed puberty and short stature.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is characterized by acral skin thickening on the hands, feet, and face.",
      "Patients with Shapiro syndrome often experience gastrointestinal symptoms such as diarrhea and malabsorption.",
      "Shapiro syndrome is associated with immunodeficiency, leading to recurrent infections.",
      "Some patients with Shapiro syndrome may develop autoimmune disorders like thyroiditis or vitiligo.",
      "Children with Shapiro syndrome may have delayed growth and development, including delayed puberty and short stature."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is characterized by the triad of recurrent spontaneous hypothermia, hyperhidrosis, and agenesis of the corpus callosum.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nShapiro syndrome is a rare neurologic disorder, and the primary characteristics are not related to skin thickening or immunodeficiency as stated in statements 1 and 3. The other statements about gastrointestinal symptoms, autoimmune disorders, and growth and development issues are not typically described features of Shapiro syndrome, but due to the rarity of the condition, there may be individual variations. Without specific context or a more detailed passage, it is difficult to confirm the accuracy of statements 2, 4, and 5.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "BRAG1 is a gene that has been associated with several diseases, including:\n1. Charcot-Marie-Tooth disease (CMT): Mutations in the BRAG1 gene are a common cause of CMT, a group of inherited disorders that affect the peripheral nervous system.\n2. Hereditary motor and sensory neuropathy (HMSN): Some mutations in the BRAG1 gene have been linked to HMSN, a group of inherited disorders that affect the peripheral nervous system and cause muscle weakness, numbness, and loss of coordination.\n3. Autism spectrum disorder (ASD): Some studies have suggested that mutations in the BRAG1 gene may be associated with an increased risk of developing autism spectrum disorder (ASD).\n4. Intellectual disability: Some mutations in the BRAG1 gene have been linked to intellectual disability, which is a neurological disorder characterized by below-average intelligence and cognitive abilities.\nIt's important to note that these associations are still being studied and more research is needed to fully understand the role of BRAG1 mutations in these diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the BRAG1 gene are a common cause of Charcot-Marie-Tooth disease (CMT).\n2. Mutations in the BRAG1 gene have been linked to Hereditary motor and sensory neuropathy (HMSN).\n3. Some studies suggest that mutations in the BRAG1 gene may be associated with an increased risk of developing autism spectrum disorder (ASD).\n4. Mutations in the BRAG1 gene have been linked to intellectual disability.\n5. The associations between BRAG1 mutations and these diseases are still being researched.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the BRAG1 gene are a common cause of Charcot-Marie-Tooth disease (CMT).",
      "Mutations in the BRAG1 gene have been linked to Hereditary motor and sensory neuropathy (HMSN).",
      "Some studies suggest that mutations in the BRAG1 gene may be associated with an increased risk of developing autism spectrum disorder (ASD).",
      "Mutations in the BRAG1 gene have been linked to intellectual disability.",
      "The associations between BRAG1 mutations and these diseases are still being researched."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the PMP22, MFN2, MPZ, and GJB1 genes are more commonly associated with Charcot-Marie-Tooth disease (CMT), not the BRAG1 gene.\n2. TRUE: Hereditary motor and sensory neuropathy (HMSN) is another name for Charcot-Marie-Tooth disease, and while BRAG1 is not commonly associated, if the statement is referring to the genes typically associated with CMT, then it would be true.\n3. UNKNOWN: Without specific scientific evidence or studies to reference, it is not possible to confirm or deny the association between BRAG1 gene mutations and autism spectrum disorder (ASD).\n4. UNKNOWN: Similarly, without specific references to scientific studies or literature, it is not possible to confirm or deny the link between BRAG1 gene mutations and intellectual disability.\n5. TRUE: The associations between specific gene mutations, including those in BRAG1 (if any), and various diseases are often complex and subject to ongoing research.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "The main inhibitor of protein phosphatase 1 (PP1) is called protein phosphatase 1 inhibitor 1 (PP1I1). PP1I1 is a negative regulator of PP1 activity and plays a crucial role in regulating PP1-mediated dephosphorylation of various cellular proteins. PP1I1 binds to the active site of PP1 and prevents it from dephosphorylating its substrates, thereby maintaining the phosphorylation state of these proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein phosphatase 1 inhibitor 1 (PP1I1) is the main inhibitor of protein phosphatase 1 (PP1).\n2. PP1I1 is a negative regulator of PP1 activity.\n3. PP1I1 plays a role in regulating PP1-mediated dephosphorylation of various cellular proteins.\n4. PP1I1 binds to the active site of PP1.\n5. PP1I1 prevents PP1 from dephosphorylating its substrates.",
    "llama-2-7b-chat-hf_fact": [
      "Protein phosphatase 1 inhibitor 1 (PP1I1) is the main inhibitor of protein phosphatase 1 (PP1).",
      "PP1I1 is a negative regulator of PP1 activity.",
      "PP1I1 plays a role in regulating PP1-mediated dephosphorylation of various cellular proteins.",
      "PP1I1 binds to the active site of PP1.",
      "PP1I1 prevents PP1 from dephosphorylating its substrates."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Protein phosphatase 1 inhibitor 1 (PP1I1) is not a recognized inhibitor of protein phosphatase 1 (PP1). The main inhibitor of PP1 is often referred to as Inhibitor-1 (I-1) or Protein Phosphatase Inhibitor 1 (PPI-1).\n2. TRUE, assuming the correct name for the inhibitor is used (I-1 or PPI-1).\n3. TRUE, assuming the correct name for the inhibitor is used (I-1 or PPI-1).\n4. FALSE [correction]: Inhibitor-1 (I-1 or PPI-1) does not bind to the active site of PP1; it binds to the regulatory subunits and alters the conformation of PP1, affecting its activity.\n5. TRUE, assuming the correct name for the inhibitor is used (I-1 or PPI-1).",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a process by which bacteria generate mutations in their genomes during stationary phase, which is a period of slow growth and high stress. In Bacillus subtilis, several mechanisms underlie adaptive mutagenesis:\n1. DNA damage response: During stationary phase, bacteria experience high levels of DNA damage due to the accumulation of reactive oxygen species (ROS) and other stressors. The DNA damage response (DDR) pathway is activated in response to this damage, leading to the induction of mutator genes that increase the rate of mutation.\n2. Mutator phenotype: Some bacteria have a mutator phenotype, which means they are more prone to mutations than others. In B. subtilis, the mutator phenotype is conferred by mutations in the dnaE gene, which encodes a DNA polymerase that is involved in DNA replication and repair.\n3. RecA-mediated mutagenesis: The RecA protein is a key player in DNA repair and recombination, but it can also catalyze the direct reversal of DNA damage, leading to the formation of mutagenic DNA lesions. In B. subtilis, RecA-mediated mutagenesis is thought to contribute to adaptive mutagenesis during stationary phase.\n4. RNase H-mediated mutagenesis: RNase H is an enzyme that degrades RNA:DNA hybrids, which can result in the formation of mutations during DNA replication. In B. subtilis, RNase H-mediated mutagenesis is thought to contribute to adaptive mutagenesis during stationary phase.\n5. Transposon-mediated mutagenesis: Transposons are mobile genetic elements that can insert themselves into different locations within the genome, leading to the disruption of gene function and the formation of mutations. In B. subtilis, transposon-mediated mutagenesis is thought to contribute to adaptive mutagenesis during stationary phase.\n6. Error-prone DNA repair: During stationary phase, bacteria may use error-prone DNA repair pathways to repair DNA damage, leading to the formation of mutations. In B",
    "llama-2-7b-chat-hf_fact_raw": "1. In Bacillus subtilis, the DNA damage response (DDR) pathway is activated during stationary phase, leading to the induction of mutator genes that increase the rate of mutation.\n2. The mutator phenotype in Bacillus subtilis can be conferred by mutations in the dnaE gene, which encodes a DNA polymerase involved in DNA replication and repair.\n3. RecA-mediated mutagenesis contributes to adaptive mutagenesis in Bacillus subtilis during stationary phase.\n4. RNase H-mediated mutagenesis is thought to contribute to adaptive mutagenesis in Bacillus subtilis during stationary phase.\n5. Transposon-mediated mutagenesis is a mechanism that contributes to adaptive mutagenesis in Bacillus subtilis during stationary phase.",
    "llama-2-7b-chat-hf_fact": [
      "In Bacillus subtilis, the DNA damage response (DDR) pathway is activated during stationary phase, leading to the induction of mutator genes that increase the rate of mutation.",
      "The mutator phenotype in Bacillus subtilis can be conferred by mutations in the dnaE gene, which encodes a DNA polymerase involved in DNA replication and repair.",
      "RecA-mediated mutagenesis contributes to adaptive mutagenesis in Bacillus subtilis during stationary phase.",
      "RNase H-mediated mutagenesis is thought to contribute to adaptive mutagenesis in Bacillus subtilis during stationary phase.",
      "Transposon-mediated mutagenesis is a mechanism that contributes to adaptive mutagenesis in Bacillus subtilis during stationary phase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: In Bacillus subtilis, the DNA damage response (DDR) pathway can be activated during the stationary phase, which can lead to the induction of mutator genes and an increased rate of mutation as part of a stress response mechanism.\n2. TRUE: The mutator phenotype in Bacillus subtilis can indeed be conferred by mutations in genes involved in DNA replication and repair, such as dnaE, which encodes a DNA polymerase.\n3. TRUE: RecA-mediated mutagenesis is a well-known mechanism that contributes to adaptive mutagenesis in bacteria, including Bacillus subtilis, particularly under stress conditions such as the stationary phase.\n4. UNKNOWN: While RNase H is involved in the removal of RNA primers from Okazaki fragments during DNA replication and in the repair of DNA, its direct role in mediating mutagenesis during the stationary phase in Bacillus subtilis is not clearly established and would require specific evidence to confirm.\n5. TRUE: Transposon-mediated mutagenesis is a recognized mechanism that can contribute to genetic variability and adaptive mutagenesis in bacteria, including Bacillus subtilis, by inserting transposable elements into new genomic locations.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Erucism, also known as erucismatosis, is a rare genetic disorder characterized by the accumulation of a protein called erucin in the body. The exact cause of erucism is not fully understood, but it is believed to be caused by mutations in the gene that encodes the enzyme responsible for breaking down erucin. This enzyme, called erucinase, is deficient or absent in people with erucism, leading to the accumulation of erucin in various tissues, including the skin, eyes, and nervous system.\nThere are several types of mutations that can cause erucism, including:\n1. Missense mutations: These are mutations that result in a change in the amino acid sequence of the erucinase enzyme.\n2. Nonsense mutations: These are mutations that result in the premature termination of protein synthesis, leading to the production of a truncated or incomplete erucinase enzyme.\n3. Frameshift mutations: These are mutations that result in the insertion or deletion of one or more nucleotides in the genetic code, leading to the production of a non-functional erucinase enzyme.\n4. Splice site mutations: These are mutations that affect the splicing of the erucinase gene, leading to the production of a non-functional erucinase enzyme.\nThe inheritance pattern of erucism is usually autosomal recessive, meaning that a person must inherit two copies of the mutated gene (one from each parent) to develop the condition. However, some cases of erucism may be caused by new mutations that occur spontaneously.\nIt's important to note that erucism is a rare condition, and the exact prevalence is not well established. However, it is estimated to affect approximately 1 in 100,000 to 1 in 50,000 individuals worldwide.",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism is characterized by the accumulation of a protein called erucin in the body.\n2. Mutations in the gene that encodes the enzyme responsible for breaking down erucin, called erucinase, are believed to cause erucism.\n3. The enzyme erucinase is deficient or absent in people with erucism.\n4. The inheritance pattern of erucism is usually autosomal recessive.\n5. Erucism is estimated to affect approximately 1 in 100,000 to 1 in 50,000 individuals worldwide.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism is characterized by the accumulation of a protein called erucin in the body.",
      "Mutations in the gene that encodes the enzyme responsible for breaking down erucin, called erucinase, are believed to cause erucism.",
      "The enzyme erucinase is deficient or absent in people with erucism.",
      "The inheritance pattern of erucism is usually autosomal recessive.",
      "Erucism is estimated to affect approximately 1 in 100,000 to 1 in 50,000 individuals worldwide."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Erucism is not characterized by the accumulation of a protein called erucin in the body. Erucism is actually a term used to describe skin irritation caused by contact with the hairs or bristles of certain caterpillars.\n2. FALSE [correction]: Since erucism is not a genetic condition related to the accumulation of a protein called erucin, there is no gene encoding an enzyme called erucinase that is responsible for breaking down erucin.\n3. FALSE [correction]: Erucism does not involve a deficiency or absence of an enzyme called erucinase, as erucism is related to skin irritation from caterpillar hairs, not a metabolic enzyme deficiency.\n4. FALSE [correction]: Since erucism is not a genetic disorder, it does not have an inheritance pattern such as autosomal recessive.\n5. FALSE [correction]: The prevalence of erucism is not estimated in the manner described, as it is not a genetic condition but rather an acute reaction to contact with certain caterpillars. The frequency of erucism would depend on geographical location and exposure to the caterpillars that cause it.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Hydrochlorothiazide (HCTZ) is a diuretic medication that is commonly used to treat various conditions, including:\n1. Hypertension (high blood pressure): HCTZ is used to reduce blood pressure in patients with mild to moderate hypertension.\n2. Heart failure: HCTZ can help reduce fluid buildup in the body and improve breathing in patients with heart failure.\n3. Congestive heart failure: HCTZ can help reduce fluid buildup in the body and improve breathing in patients with congestive heart failure.\n4. Nephrotic syndrome: HCTZ can help reduce fluid buildup in the body and improve urine production in patients with nephrotic syndrome.\n5. Edema: HCTZ can help reduce fluid buildup in the body and improve swelling in patients with edema caused by various conditions, such as heart failure, liver disease, or kidney disease.\n6. Hypokalemia: HCTZ can help raise potassium levels in the body in patients with low potassium levels.\n7. Metabolic syndrome: HCTZ can help reduce blood pressure, improve insulin sensitivity, and improve lipid profiles in patients with metabolic syndrome.\n8. Gestational hypertension: HCTZ may be used to treat high blood pressure in pregnant women with gestational hypertension.\n9. Pre-eclampsia: HCTZ may be used to treat high blood pressure and proteinuria in pregnant women with pre-eclampsia.\nIt's important to note that HCTZ may have other indications and uses, and the specific indications for a particular patient will depend on their individual medical condition and circumstances. It's important to consult with a healthcare professional to determine the appropriate use of HCTZ in a given situation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide (HCTZ) is used to treat mild to moderate hypertension.\n2. HCTZ is used to reduce fluid buildup in patients with heart failure.\n3. HCTZ is indicated for the treatment of nephrotic syndrome to reduce fluid buildup and improve urine production.\n4. HCTZ can help reduce swelling in patients with edema caused by conditions such as heart failure, liver disease, or kidney disease.\n5. HCTZ may be used to treat high blood pressure in pregnant women with gestational hypertension.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide (HCTZ) is used to treat mild to moderate hypertension.",
      "HCTZ is used to reduce fluid buildup in patients with heart failure.",
      "HCTZ is indicated for the treatment of nephrotic syndrome to reduce fluid buildup and improve urine production.",
      "HCTZ can help reduce swelling in patients with edema caused by conditions such as heart failure, liver disease, or kidney disease.",
      "HCTZ may be used to treat high blood pressure in pregnant women with gestational hypertension."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: HCTZ is not typically indicated for the treatment of nephrotic syndrome. It may be used to manage edema associated with nephrotic syndrome, but the primary treatment for nephrotic syndrome involves addressing the underlying cause and may include other types of medications.\n4. TRUE\n5. FALSE [correction]: HCTZ is generally not recommended for treating high blood pressure in pregnant women due to potential risks to the fetus. Alternative medications are preferred for managing gestational hypertension.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of urinary incontinence. Silicon-based materials have been developed and used in various forms to help manage urinary incontinence, including:\n1. Silicone-coated mesh: Silicone-coated meshes have been used to treat stress urinary incontinence (SUI), a common type of urinary incontinence in women. The mesh is placed under the urethra to provide support and prevent leakage.\n2. Silicone gel inserts: Silicone gel inserts have been used to treat urinary retention and incontinence in both men and women. These inserts are placed in the bladder to help manage urine flow and prevent leakage.\n3. Silicon-based adhesives: Silicon-based adhesives have been developed to treat urinary incontinence in both men and women. These adhesives are applied to the skin around the urethra to help prevent leakage.\n4. Silicon-based catheters: Silicon-based catheters have been used to treat urinary retention and incontinence in both men and women. These catheters are designed to be more comfortable and less irritating to the skin than traditional catheters.\nIt is important to note that while silicon-based treatments have shown promise in managing urinary incontinence, they may not be suitable for everyone and should be discussed with a healthcare provider to determine the best course of treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon-based materials have been developed for use in the treatment of urinary incontinence.\n2. Silicone-coated meshes are used to treat stress urinary incontinence in women by providing support under the urethra.\n3. Silicone gel inserts are used to manage urine flow and prevent leakage in the treatment of urinary retention and incontinence.\n4. Silicon-based adhesives have been developed to prevent urinary leakage by being applied to the skin around the urethra.\n5. Silicon-based catheters are used to treat urinary retention and incontinence and are designed to be more comfortable and less irritating than traditional catheters.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon-based materials have been developed for use in the treatment of urinary incontinence.",
      "Silicone-coated meshes are used to treat stress urinary incontinence in women by providing support under the urethra.",
      "Silicone gel inserts are used to manage urine flow and prevent leakage in the treatment of urinary retention and incontinence.",
      "Silicon-based adhesives have been developed to prevent urinary leakage by being applied to the skin around the urethra.",
      "Silicon-based catheters are used to treat urinary retention and incontinence and are designed to be more comfortable and less irritating than traditional catheters."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Silicon-based materials, including silicone, are used in various medical applications, and it is plausible that they have been developed for use in the treatment of urinary incontinence.\n2. TRUE: Silicone-coated meshes, also known as mid-urethral slings, are indeed used to treat stress urinary incontinence in women by providing support under the urethra.\n3. UNKNOWN: While silicone products are used in medical applications, the specific use of silicone gel inserts to manage urine flow and prevent leakage is not well-documented and requires more context to determine its accuracy.\n4. FALSE [correction]: Silicon-based adhesives are not typically used to prevent urinary leakage by being applied to the skin around the urethra. Instead, adhesives may be used in incontinence products like pads or external catheters, but these are not applied directly to the skin around the urethra to prevent leakage.\n5. TRUE: Silicon-based catheters, such as those made from silicone, are used to treat urinary retention and incontinence. They are often preferred because they can be more comfortable and less irritating than catheters made from other materials.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "Intracranial aneurysms are abnormal balloon-like bulges that can occur in the blood vessels of the brain. While the exact cause of intracranial aneurysms is not fully understood, there is some evidence to suggest that the moon cycle may play a role in the rupture risk of these aneurysms.\nOne study published in the journal \"Stroke\" in 2015 analyzed data from over 1,000 patients with ruptured aneurysms and found that the risk of aneurysm rupture was higher during the full moon phase compared to other phases of the moon cycle. The study found that the risk of rupture was highest during the full moon and new moon phases, with a peak risk during the full moon.\nAnother study published in the journal \"Neurology\" in 2018 found similar results, with a higher risk of aneurysm rupture during the full moon phase compared to other phases.\nThe exact mechanism by which the moon cycle may affect the rupture risk of intracranial aneurysms is not clear, but several theories have been proposed. One theory is that the increased gravitational pull during the full moon phase may cause a slight increase in blood pressure, which can put additional stress on weakened blood vessels and increase the risk of aneurysm rupture. Another theory is that the changes in barometric pressure and humidity during the full moon phase may affect the permeability of the blood-brain barrier, allowing more blood to flow into the aneurysm and increasing the risk of rupture.\nIt is important to note that these studies were small and more research is needed to confirm these findings and establish a clear association between the moon cycle and rupture risk of intracranial aneurysms. Additionally, the risk of aneurysm rupture can be influenced by many factors, including genetics, age, and underlying medical conditions, so the moon cycle is likely just one of many factors that can contribute to the overall risk of aneurysm rupture.\nIn summary, while there is some evidence to suggest that the moon cycle may play a role in the rupture risk of intracranial aneurysms, more research is needed to fully understand the association between these two phenomena. Patients with known aneurys",
    "llama-2-7b-chat-hf_fact_raw": "1. A study published in the journal \"Stroke\" in 2015 found that the risk of intracranial aneurysm rupture was higher during the full moon phase.\n2. The same study indicated that the risk of rupture was highest during the full moon and new moon phases.\n3. Another study published in the journal \"Neurology\" in 2018 also found a higher risk of aneurysm rupture during the full moon phase.\n4. One theory suggests that the increased gravitational pull during the full moon phase may cause a slight increase in blood pressure, potentially increasing the risk of aneurysm rupture.\n5. Another theory proposes that changes in barometric pressure and humidity during the full moon phase may affect the blood-brain barrier, potentially increasing the risk of aneurysm rupture.",
    "llama-2-7b-chat-hf_fact": [
      "A study published in the journal \"Stroke\" in 2015 found that the risk of intracranial aneurysm rupture was higher during the full moon phase.",
      "The same study indicated that the risk of rupture was highest during the full moon and new moon phases.",
      "Another study published in the journal \"Neurology\" in 2018 also found a higher risk of aneurysm rupture during the full moon phase.",
      "One theory suggests that the increased gravitational pull during the full moon phase may cause a slight increase in blood pressure, potentially increasing the risk of aneurysm rupture.",
      "Another theory proposes that changes in barometric pressure and humidity during the full moon phase may affect the blood-brain barrier, potentially increasing the risk of aneurysm rupture."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe veracity of these statements cannot be determined without access to the specific studies from the journals \"Stroke\" and \"Neurology\" mentioned in the statements. Additionally, the theories mentioned in statements 4 and 5 would require scientific evidence to support them, which is not provided in the context given. Therefore, without further information, the truthfulness of these statements remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, HuR (Human RNA-binding protein, also known as ELAVL1) is an RNA-binding protein that plays a crucial role in regulating the splicing process. HuR is a key regulator of mRNA splicing, particularly in the cytoplasm, and is involved in the regulation of many cellular processes, including cell proliferation, differentiation, and survival.\nHuR binds to the 3' splice site of pre-mRNAs and regulates the splicing of specific exons by blocking or enhancing the activity of the splicing factors. HuR can also induce the skipping of certain exons, leading to the production of alternative splice variants. Additionally, HuR can regulate mRNA stability by binding to the 3' untranslated region (UTR) of target mRNAs and preventing their degradation.\nHuR's role in splicing is complex and context-dependent, and it can be modulated by various cellular signals, including growth factors, stress signals, and changes in the cell cycle. Dysregulation of HuR has been implicated in various diseases, including cancer, neurodegenerative disorders, and muscular dystrophy.",
    "llama-2-7b-chat-hf_fact_raw": "1. HuR (Human RNA-binding protein, also known as ELAVL1) is an RNA-binding protein that regulates the splicing process.\n2. HuR is involved in the regulation of cellular processes such as cell proliferation, differentiation, and survival.\n3. HuR binds to the 3' splice site of pre-mRNAs and can regulate the splicing of specific exons.\n4. HuR can induce the skipping of certain exons, leading to the production of alternative splice variants.\n5. Dysregulation of HuR has been implicated in various diseases, including cancer, neurodegenerative disorders, and muscular dystrophy.",
    "llama-2-7b-chat-hf_fact": [
      "HuR (Human RNA-binding protein, also known as ELAVL1) is an RNA-binding protein that regulates the splicing process.",
      "HuR is involved in the regulation of cellular processes such as cell proliferation, differentiation, and survival.",
      "HuR binds to the 3' splice site of pre-mRNAs and can regulate the splicing of specific exons.",
      "HuR can induce the skipping of certain exons, leading to the production of alternative splice variants.",
      "Dysregulation of HuR has been implicated in various diseases, including cancer, neurodegenerative disorders, and muscular dystrophy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: HuR (Human RNA-binding protein, also known as ELAVL1) is an RNA-binding protein that regulates mRNA stability and translation, not specifically the splicing process.\n2. TRUE\n3. FALSE [correction]: HuR typically binds to AU-rich elements in the 3' untranslated regions (UTRs) of mRNAs, not the 3' splice site of pre-mRNAs, and it is not primarily known for regulating splicing.\n4. UNKNOWN: While HuR is primarily known for its role in mRNA stability and translation, its involvement in splicing and exon skipping is less clear and may depend on the context of specific studies or interactions with other proteins.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Prothymosin alpha (Pa) is a small protein that plays a crucial role in the regulation of various cellular processes, including cell proliferation, differentiation, and survival. The c-terminal peptide of prothymosin alpha (CT-Pa) is a 13-amino acid peptide derived from the C-terminal region of the Pa protein. Here are some of the known functions of CT-Pa:\n1. Cell proliferation: CT-Pa has been shown to stimulate cell proliferation in various cell types, including fibroblasts, endothelial cells, and tumor cells.\n2. Apoptosis: CT-Pa has been shown to inhibit apoptosis, or programmed cell death, in various cell types, including cancer cells.\n3. Cell adhesion and migration: CT-Pa has been shown to modulate cell adhesion and migration, with possible implications for cancer metastasis.\n4. Immune response: CT-Pa has been shown to modulate the immune response, with possible implications for autoimmune diseases and cancer.\n5. Neuroprotection: CT-Pa has been shown to have neuroprotective effects in various models of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.\n6. Cardiovascular protection: CT-Pa has been shown to have cardiovascular protective effects in various models of cardiovascular disease, including hypertension and atherosclerosis.\n7. Anti-inflammatory effects: CT-Pa has been shown to have anti-inflammatory effects in various models of inflammation, including colitis and arthritis.\n8. Cancer treatment: CT-Pa has been shown to have anti-tumor effects in various cancer models, including breast, lung, and colon cancer.\nIt is important to note that the functions of CT-Pa are not limited to the ones mentioned above and are still being extensively studied, as new functions and mechanisms of action are being discovered.",
    "llama-2-7b-chat-hf_fact_raw": "1. The c-terminal peptide of prothymosin alpha (CT-Pa) is a 13-amino acid peptide derived from the C-terminal region of the prothymosin alpha protein.\n2. CT-Pa has been shown to stimulate cell proliferation in various cell types, including fibroblasts, endothelial cells, and tumor cells.\n3. CT-Pa has been shown to inhibit apoptosis in various cell types, including cancer cells.\n4. CT-Pa has been shown to modulate cell adhesion and migration, with possible implications for cancer metastasis.\n5. CT-Pa has been shown to have neuroprotective effects in various models of neurodegenerative diseases.",
    "llama-2-7b-chat-hf_fact": [
      "The c-terminal peptide of prothymosin alpha (CT-Pa) is a 13-amino acid peptide derived from the C-terminal region of the prothymosin alpha protein.",
      "CT-Pa has been shown to stimulate cell proliferation in various cell types, including fibroblasts, endothelial cells, and tumor cells.",
      "CT-Pa has been shown to inhibit apoptosis in various cell types, including cancer cells.",
      "CT-Pa has been shown to modulate cell adhesion and migration, with possible implications for cancer metastasis.",
      "CT-Pa has been shown to have neuroprotective effects in various models of neurodegenerative diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with scientific findings regarding the c-terminal peptide of prothymosin alpha (CT-Pa). CT-Pa is known for its various biological activities, including stimulation of cell proliferation, inhibition of apoptosis, modulation of cell adhesion and migration, and neuroprotective effects. However, it is important to note that the specific effects can depend on the context of the studies and the models used, and ongoing research may further elucidate these functions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "Cystatin C fibrillization is a process that occurs when cystatin C, a protein that is involved in protein degradation, misfolds and forms insoluble fibrils. The peptide that plays a pivotal role in human cystatin C fibrillization is the amino acid sequence RRARRR, which is located in the N-terminal region of the protein. This sequence is thought to be responsible for the formation of β-sheet structures that are characteristic of amyloid fibrils.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cystatin C is a protein involved in protein degradation.\n2. Cystatin C can misfold and form insoluble fibrils.\n3. The amino acid sequence RRARRR is pivotal in human cystatin C fibrillization.\n4. The RRARRR sequence is located in the N-terminal region of cystatin C.\n5. The RRARRR sequence is thought to be responsible for the formation of β-sheet structures characteristic of amyloid fibrils.",
    "llama-2-7b-chat-hf_fact": [
      "Cystatin C is a protein involved in protein degradation.",
      "Cystatin C can misfold and form insoluble fibrils.",
      "The amino acid sequence RRARRR is pivotal in human cystatin C fibrillization.",
      "The RRARRR sequence is located in the N-terminal region of cystatin C.",
      "The RRARRR sequence is thought to be responsible for the formation of β-sheet structures characteristic of amyloid fibrils."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The amino acid sequence LVEALYL is pivotal in human cystatin C fibrillization.\n4. FALSE [correction]: The LVEALYL sequence associated with fibrillization is located in the second β-hairpin loop, not the N-terminal region of cystatin C.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Yes, the concentration of protein HIF-1α (Hypoxia-Inducible Factor-1 alpha) increases after the administration of the cytoprotective prodrug ethyol (amifostine).\nEthyol is a potent inhibitor of the enzyme carbonic anhydrase (CA), which is involved in the production of hydrogen peroxide (H2O2) in cells. H2O2 is a highly reactive molecule that can damage cellular components, including proteins, lipids, and DNA. By inhibiting CA, ethyol reduces the production of H2O2, which can help protect cells against oxidative damage.\nOne of the key downstream effects of HIF-1α activation is the regulation of genes involved in the response to hypoxia, angiogenesis, and cell survival. HIF-1α is a transcription factor that plays a critical role in the response to hypoxia by regulating the expression of genes involved in the adaptation to low oxygen levels, such as the expression of angiogenic factors, glucose metabolism, and cell survival.\nStudies have shown that ethyol treatment can increase the expression of HIF-1α and its downstream targets, suggesting that ethyol may have a cytoprotective effect by activating the HIF-1α pathway. For example, one study found that ethyol treatment increased the expression of HIF-1α and its target genes in human pulmonary artery endothelial cells under hypoxic conditions. Another study found that ethyol treatment increased the expression of HIF-1α in mouse liver tissue after exposure to carbon monoxide, a potent hypoxia-inducible agent.\nIn summary, the concentration of protein HIF-1α increases after the administration of the cytoprotective prodrug ethyol, which suggests that ethyol may have a cytoprotective effect by activating the HIF-1α pathway.",
    "llama-2-7b-chat-hf_fact_raw": "1. The concentration of protein HIF-1α increases after the administration of the cytoprotective prodrug ethyol (amifostine).\n2. Ethyol is an inhibitor of the enzyme carbonic anhydrase (CA), which is involved in the production of hydrogen peroxide (H2O2) in cells.\n3. Inhibition of carbonic anhydrase by ethyol leads to a reduction in the production of hydrogen peroxide (H2O2).\n4. HIF-1α is a transcription factor that regulates the expression of genes involved in the adaptation to low oxygen levels.\n5. Studies have indicated that ethyol treatment can increase the expression of HIF-1α and its target genes in certain cell types under hypoxic conditions.",
    "llama-2-7b-chat-hf_fact": [
      "The concentration of protein HIF-1α increases after the administration of the cytoprotective prodrug ethyol (amifostine).",
      "Ethyol is an inhibitor of the enzyme carbonic anhydrase (CA), which is involved in the production of hydrogen peroxide (H2O2) in cells.",
      "Inhibition of carbonic anhydrase by ethyol leads to a reduction in the production of hydrogen peroxide (H2O2).",
      "HIF-1α is a transcription factor that regulates the expression of genes involved in the adaptation to low oxygen levels.",
      "Studies have indicated that ethyol treatment can increase the expression of HIF-1α and its target genes in certain cell types under hypoxic conditions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific evidence or a reference to a study that confirms this statement, it is not possible to determine the truthfulness of the claim that the concentration of HIF-1α increases after the administration of ethyol (amifostine).\n2. FALSE [correction]: Ethyol (amifostine) is not an inhibitor of carbonic anhydrase (CA). It is a cytoprotective prodrug that can protect cells from the harmful effects of chemotherapy and radiation therapy. Its primary mechanism is thought to involve scavenging free radicals and upregulating detoxifying enzymes, not inhibiting carbonic anhydrase.\n3. FALSE [correction]: Since the previous statement about ethyol being an inhibitor of carbonic anhydrase is false, the claim that its inhibition leads to a reduction in the production of hydrogen peroxide (H2O2) is also false. Ethyol's mechanism does not involve the inhibition of carbonic anhydrase.\n4. TRUE: HIF-1α (hypoxia-inducible factor 1-alpha) is indeed a transcription factor that plays a critical role in the cellular response to hypoxia (low oxygen levels) by regulating the expression of genes involved in angiogenesis, metabolism, and other processes related to adaptation to hypoxia.\n5. UNKNOWN: Without specific studies or data to reference, it is not possible to confirm whether ethyol treatment can increase the expression of HIF-1α and its target genes in certain cell types under hypoxic conditions. This statement requires scientific evidence to determine its validity.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Set7 is a histone methyltransferase that specifically deposits histone 3 lysine 4 trimethylation (H3K4me3) marks on histone H3. This histone modification is known to play a role in the regulation of gene expression, particularly in the context of stem cells and developmental processes. Set7 is also involved in the maintenance of pluripotency in embryonic stem cells and in the regulation of cell fate decisions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 is a histone methyltransferase.\n2. Set7 deposits histone 3 lysine 4 trimethylation (H3K4me3) marks on histone H3.\n3. The H3K4me3 modification plays a role in the regulation of gene expression.\n4. Set7 is involved in the maintenance of pluripotency in embryonic stem cells.\n5. Set7 plays a role in the regulation of cell fate decisions.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 is a histone methyltransferase.",
      "Set7 deposits histone 3 lysine 4 trimethylation (H3K4me3) marks on histone H3.",
      "The H3K4me3 modification plays a role in the regulation of gene expression.",
      "Set7 is involved in the maintenance of pluripotency in embryonic stem cells.",
      "Set7 plays a role in the regulation of cell fate decisions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Set7 (also known as Set7/9 or SETD7) is a histone methyltransferase, but it specifically catalyzes the methylation of lysine 4 on histone H3 to a monomethylated state (H3K4me1), not trimethylation.\n2. FALSE [correction]: Set7 is responsible for depositing the monomethylation mark on histone 3 lysine 4 (H3K4me1), not the trimethylation mark (H3K4me3).\n3. TRUE: The H3K4me3 modification is indeed associated with the regulation of gene expression, typically marking active gene promoters.\n4. UNKNOWN: The role of Set7 in the maintenance of pluripotency in embryonic stem cells is a specific area of research and would require specific evidence from scientific studies to confirm or refute.\n5. TRUE: Set7, like other histone methyltransferases, is known to play a role in the regulation of cell fate decisions through its epigenetic modification of histones and subsequent effects on gene expression.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Hepcidin, a protein that plays a crucial role in regulating iron metabolism, has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hepcidin is a protein that regulates iron metabolism.\n2. Hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "Hepcidin is a protein that regulates iron metabolism.",
      "Hepcidin has 4 disulfide bridges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hepcidin has 8 cysteine amino acid residues that form 4 disulfide bonds.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "The protein encoded by the gene DNAJC11 (also known as TMEM16A) is a membrane-associated protein that is primarily localized to the endoplasmic reticulum (ER) and plasma membrane in various cell types.\nDNAJC11 is a member of the DJ-1/Park7 protein family, which is associated with various diseases, including Parkinson's disease, and is involved in various cellular processes, including protein folding, oxidative stress response, and Ca2+ signaling.\nThe protein encoded by DNAJC11 is composed of multiple domains, including an N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal DJ-1 domain. These domains allow the protein to interact with various membrane proteins and cytoskeletal components, as well as to sense and respond to changes in intracellular Ca2+ levels.\nIn addition to its localization to the ER and plasma membrane, DNAJC11 has been shown to be involved in various cellular processes, including Ca2+-dependent signaling, membrane trafficking, and the regulation of gene expression. Dysregulation of DNAJC11 has been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is primarily localized to the endoplasmic reticulum (ER) and plasma membrane.\n2. DNAJC11 is a member of the DJ-1/Park7 protein family.\n3. The DJ-1/Park7 protein family is associated with various diseases, including Parkinson's disease.\n4. The protein encoded by DNAJC11 has multiple domains, including an N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal DJ-1 domain.\n5. Dysregulation of DNAJC11 has been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is primarily localized to the endoplasmic reticulum (ER) and plasma membrane.",
      "DNAJC11 is a member of the DJ-1/Park7 protein family.",
      "The DJ-1/Park7 protein family is associated with various diseases, including Parkinson's disease.",
      "The protein encoded by DNAJC11 has multiple domains, including an N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal DJ-1 domain.",
      "Dysregulation of DNAJC11 has been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The protein encoded by the gene DNAJC11 is known to be localized to the endoplasmic reticulum (ER), which is consistent with its role in protein folding and quality control mechanisms. However, without specific evidence regarding its localization to the plasma membrane, this part of the statement cannot be confirmed as true or false, so the overall statement remains TRUE with a note of caution regarding the plasma membrane localization.\n\n2. FALSE [correction]: DNAJC11 is not a member of the DJ-1/Park7 protein family. It is a member of the DnaJ (Hsp40) family, which is a different group of proteins involved in the regulation of molecular chaperones.\n\n3. TRUE: The DJ-1/Park7 protein family is indeed associated with various diseases, including Parkinson's disease. DJ-1 has been shown to have a role in protecting neurons from oxidative stress and its mutations are linked to early-onset Parkinson's disease.\n\n4. UNKNOWN: Without specific information on the domain structure of the DNAJC11 protein, it is not possible to confirm the presence of an N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal DJ-1 domain. This information would require a review of scientific literature or databases that provide detailed protein domain annotations.\n\n5. TRUE: Dysregulation of proteins involved in cellular homeostasis, such as those encoded by DNAJC11, can be implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders. The DnaJ (Hsp40) family, to which DNAJC11 belongs, is known to be involved in protein folding and can be linked to disease states when not functioning properly.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Yes, ultraconserved elements (UCEs) are depleted among copy number variants (CNVs). UCEs are regions of the genome that are highly conserved across different species and are thought to be functional in regulating gene expression. CNVs, on the other hand, are genetic variations that involve the gain or loss of DNA sequences.\nStudies have shown that UCEs are underrepresented among CNVs. For example, a study published in the journal Nature in 2015 found that only 12% of CNVs overlapped with UCEs, while 88% did not. Another study published in the journal American Journal of Human Genetics in 2018 found similar results, with only 16% of CNVs overlapping with UCEs.\nThe reason why UCEs are depleted among CNVs is not fully understood, but it is thought to be due to the evolutionary pressure to maintain the function of UCEs. UCEs are thought to play important roles in regulating gene expression, and the loss of these regions could have significant consequences for the organism. Therefore, natural selection may have favored the retention of UCEs in the genome, even if it means that CNVs are less common in these regions.\nIt is worth noting that while UCEs are depleted among CNVs, they are not completely absent. Some CNVs may overlap with UCEs, and these regions may be more likely to be functional. Additionally, UCEs may be more likely to be affected by CNVs in certain genomic regions, such as those that are highly repetitive or have a high density of CNVs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements (UCEs) are regions of the genome that are highly conserved across different species.\n2. Copy number variants (CNVs) are genetic variations that involve the gain or loss of DNA sequences.\n3. A study published in the journal Nature in 2015 found that only 12% of CNVs overlapped with UCEs.\n4. Another study published in the American Journal of Human Genetics in 2018 found that only 16% of CNVs overlapped with UCEs.\n5. UCEs are thought to play important roles in regulating gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements (UCEs) are regions of the genome that are highly conserved across different species.",
      "Copy number variants (CNVs) are genetic variations that involve the gain or loss of DNA sequences.",
      "A study published in the journal Nature in 2015 found that only 12% of CNVs overlapped with UCEs.",
      "Another study published in the American Journal of Human Genetics in 2018 found that only 16% of CNVs overlapped with UCEs.",
      "UCEs are thought to play important roles in regulating gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN (without access to the specific study, the accuracy of this statement cannot be verified)\n4. UNKNOWN (without access to the specific study, the accuracy of this statement cannot be verified)\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Haspen kinase is a protein that plays a crucial role in the regulation of mitosis, particularly in the proper separation of chromosomes during cell division. The substrate of Haspen kinase during mitosis is the protein Aurora A. Aurora A is a key regulator of the metaphase-to-anaphase transition and is phosphorylated and activated by Haspen kinase. The phosphorylation of Aurora A by Haspen kinase helps to stabilize the chromosomes and ensure proper chromosome separation during cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. Haspin kinase is involved in the regulation of mitosis.\n2. The substrate of Haspin kinase during mitosis is the protein Aurora A.\n3. Aurora A is a regulator of the metaphase-to-anaphase transition in cell division.\n4. Haspin kinase phosphorylates and activates Aurora A.\n5. The phosphorylation of Aurora A by Haspin kinase contributes to the stabilization of chromosomes during cell division.",
    "llama-2-7b-chat-hf_fact": [
      "Haspin kinase is involved in the regulation of mitosis.",
      "The substrate of Haspin kinase during mitosis is the protein Aurora A.",
      "Aurora A is a regulator of the metaphase-to-anaphase transition in cell division.",
      "Haspin kinase phosphorylates and activates Aurora A.",
      "The phosphorylation of Aurora A by Haspin kinase contributes to the stabilization of chromosomes during cell division."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The substrate of Haspin kinase during mitosis is histone H3, not the protein Aurora A.\n3. TRUE\n4. FALSE [correction]: Haspin kinase does not phosphorylate and activate Aurora A; it phosphorylates histone H3. Aurora A is activated by other mechanisms.\n5. FALSE [correction]: The phosphorylation of histone H3 by Haspin kinase contributes to the proper attachment of chromosomes to the spindle microtubules during cell division, not the stabilization of chromosomes. Aurora A's role is related to the regulation of mitotic entry and spindle assembly.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Viroids are small, single-stranded RNA molecules that replicate through a mechanism that is distinct from other RNA viruses. Unlike other RNA viruses, which use a polymerase to synthesize new RNA from their genome, viroids replicate by exploiting the host cell's own RNA machinery. Here's how it works:\n1. Attachment: The viroid attaches to the host cell's RNA through specific base pairing interactions with the host cell's RNA.\n2. Incorporation: The viroid RNA is then incorporated into the host cell's RNA machinery, where it is translated into proteins.\n3. Replication: The viroid RNA then replicates by using the host cell's RNA polymerase to synthesize new copies of itself. This process is thought to occur through a mechanism called \"RNA-dependent RNA polymerase amplification\" (RdRP).\n4. Transcription: The new viroid RNA molecules are then transcribed from the original viroid genome, creating a new generation of viroids.\n5. Release: The new viroid RNA molecules are then released from the host cell, where they can go on to infect other cells.\nOverall, the mechanism of viroid replication is a complex process that involves the exploitation of the host cell's own RNA machinery. By attaching to the host cell's RNA, incorporating into the RNA machinery, replicating through RdRP, transcribing the new viroid RNA, and releasing the new viroids, viroids are able to efficiently replicate and spread within a host organism.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroids are small, single-stranded RNA molecules.\n2. Viroids replicate by exploiting the host cell's RNA machinery rather than using a polymerase to synthesize new RNA.\n3. The replication process of viroids involves RNA-dependent RNA polymerase amplification (RdRP).\n4. New viroid RNA molecules are transcribed from the original viroid genome.\n5. The new viroid RNA molecules are released from the host cell to infect other cells.",
    "llama-2-7b-chat-hf_fact": [
      "Viroids are small, single-stranded RNA molecules.",
      "Viroids replicate by exploiting the host cell's RNA machinery rather than using a polymerase to synthesize new RNA.",
      "The replication process of viroids involves RNA-dependent RNA polymerase amplification (RdRP).",
      "New viroid RNA molecules are transcribed from the original viroid genome.",
      "The new viroid RNA molecules are released from the host cell to infect other cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Viroids do not encode for proteins and thus do not have their own RNA polymerase. They rely on the host cell's RNA polymerase for replication.\n3. TRUE: Viroids utilize the host cell's RNA-dependent RNA polymerase (RdRP) for replication.\n4. TRUE: The new viroid RNA molecules are indeed transcribed from the original viroid genome using the host's transcription machinery.\n5. TRUE: The new viroid RNA molecules can be released from the host cell and have the potential to infect other cells.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Yes, fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD). Fibronectin is a protein that is involved in the structure and function of muscle tissue, and its levels have been shown to be altered in the blood of individuals with DMD.\nStudies have shown that the levels of fibronectin in the serum of DMD patients are significantly lower than those in healthy individuals, particularly in the early stages of the disease. This decrease in fibronectin levels can be detected as early as 6-12 months of age in DMD patients, before the onset of muscle weakness and wasting.\nThe use of fibronectin as a biomarker for DMD has several advantages, including its ease of measurement, non-invasive sampling, and high sensitivity. It has been shown to be a more sensitive marker than creatine kinase (CK) or dystrophin, which are currently used as biomarkers for DMD.\nHowever, it is important to note that the use of fibronectin as a biomarker for DMD is still in its early stages, and further research is needed to validate its clinical utility. Additionally, the levels of fibronectin in the serum may not always accurately reflect the severity of the disease or the response to treatment.\nIn summary, fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy, and further research is needed to fully understand its clinical utility in the diagnosis and management of the disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD).\n2. Fibronectin is involved in the structure and function of muscle tissue.\n3. Serum levels of fibronectin are significantly lower in DMD patients compared to healthy individuals, especially in the early stages of the disease.\n4. Decreased levels of fibronectin can be detected in DMD patients as early as 6-12 months of age.\n5. Fibronectin has been shown to be a more sensitive marker for DMD than creatine kinase (CK) or dystrophin.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD).",
      "Fibronectin is involved in the structure and function of muscle tissue.",
      "Serum levels of fibronectin are significantly lower in DMD patients compared to healthy individuals, especially in the early stages of the disease.",
      "Decreased levels of fibronectin can be detected in DMD patients as early as 6-12 months of age.",
      "Fibronectin has been shown to be a more sensitive marker for DMD than creatine kinase (CK) or dystrophin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD).\n2. TRUE: Fibronectin is involved in cell adhesion, growth, migration, and differentiation, which are important for the structure and function of muscle tissue.\n3. FALSE [correction]: Serum levels of fibronectin are significantly higher in DMD patients compared to healthy individuals, especially in the early stages of the disease.\n4. UNKNOWN: Without specific research data or studies to reference, it is difficult to confirm the exact age at which decreased levels of fibronectin can be detected in DMD patients.\n5. UNKNOWN: The sensitivity of fibronectin as a marker for DMD compared to creatine kinase (CK) or dystrophin would require specific comparative studies to determine, and without that information, the statement's accuracy cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "The DeepBlue epigenomic data server contains data from several major epigenome projects, including:\n1. The ENCODE (ENCyclopedia Of DNA Elements) project, which is a large-scale effort to map all of the functional elements in the human genome.\n2. The Roadmap Epigenomics Project, which is a comprehensive analysis of the epigenetic landscape of various organisms, including humans, mice, and fruit flies.\n3. The Epigenome-Wide Association Study (EWAS) consortium, which is a collection of studies that aim to identify epigenetic markers associated with specific diseases or traits.\n4. The Human Epigenome Atlas (HEA), which is a project that aims to create a comprehensive atlas of human epigenetic marks across different tissues and cell types.\n5. The Mouse Epigenome Project, which is a similar effort to map the epigenetic landscape of mice.\n6. The Fruit Fly Epigenome Project, which is a study of the epigenetic marks in the genomes of fruit flies.\nThese projects have generated a large amount of data on the epigenetic marks present in different organisms, including DNA methylation, histone modifications, and chromatin structure. The data from these projects are available through the DeepBlue data server for researchers to analyze and interpret.",
    "llama-2-7b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE (ENCyclopedia Of DNA Elements) project.\n2. The Roadmap Epigenomics Project data is included in the DeepBlue epigenomic data server.\n3. Data from the Epigenome-Wide Association Study (EWAS) consortium is available on the DeepBlue epigenomic data server.\n4. The Human Epigenome Atlas (HEA) project's data is part of the DeepBlue epigenomic data server's database.\n5. The DeepBlue epigenomic data server also hosts data from the Mouse Epigenome Project.",
    "llama-2-7b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE (ENCyclopedia Of DNA Elements) project.",
      "The Roadmap Epigenomics Project data is included in the DeepBlue epigenomic data server.",
      "Data from the Epigenome-Wide Association Study (EWAS) consortium is available on the DeepBlue epigenomic data server.",
      "The Human Epigenome Atlas (HEA) project's data is part of the DeepBlue epigenomic data server's database.",
      "The DeepBlue epigenomic data server also hosts data from the Mouse Epigenome Project."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe DeepBlue epigenomic data server is known for integrating data from various epigenomic projects, including ENCODE and the Roadmap Epigenomics Project. However, without specific information about the inclusion of data from the Epigenome-Wide Association Study (EWAS) consortium, the Human Epigenome Atlas (HEA) project, or the Mouse Epigenome Project in the DeepBlue server, the status of these statements cannot be determined with certainty.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "A tool that employs self-organizing maps (SOM) for analyzing synonymous codon usage is CodonCode. SOM is a type of neural network that can be used for dimensionality reduction and visualization of high-dimensional data. In the context of synonymous codon usage analysis, SOM can be used to identify patterns and relationships in the codon usage of different genes or organisms.\nCodonCode is a software tool that uses SOM to analyze the codon usage of a given DNA sequence and predict the codon usage of a target gene or genome. It can also be used to identify codons that are overrepresented or underrepresented in a given gene or genome, and to identify potential sources of codon bias.\nOther tools that can be used for synonymous codon usage analysis include:\n* Codonopsis: This tool uses a combination of machine learning algorithms and SOM to predict the codon usage of a target gene or genome.\n* CodonW: This tool uses a Bayesian approach to predict the codon usage of a target gene or genome, taking into account both the codon frequency and the context in which the codons are used.\n* CODONUS: This tool uses a hidden Markov model to predict the codon usage of a target gene or genome, based on the frequency of codons in a reference database.\n* GENCOD: This tool uses a combination of machine learning algorithms and SOM to predict the codon usage of a target gene or genome, based on the frequency of codons in a reference database.",
    "llama-2-7b-chat-hf_fact_raw": "1. CodonCode is a software tool that employs self-organizing maps (SOM) for analyzing synonymous codon usage.\n2. SOM is a type of neural network used for dimensionality reduction and visualization of high-dimensional data.\n3. CodonCode can predict the codon usage of a target gene or genome.\n4. CodonCode can identify codons that are overrepresented or underrepresented in a given gene or genome.\n5. CodonW uses a Bayesian approach to predict codon usage, considering codon frequency and context.",
    "llama-2-7b-chat-hf_fact": [
      "CodonCode is a software tool that employs self-organizing maps (SOM) for analyzing synonymous codon usage.",
      "SOM is a type of neural network used for dimensionality reduction and visualization of high-dimensional data.",
      "CodonCode can predict the codon usage of a target gene or genome.",
      "CodonCode can identify codons that are overrepresented or underrepresented in a given gene or genome.",
      "CodonW uses a Bayesian approach to predict codon usage, considering codon frequency and context."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: CodonCode is a software tool for DNA sequence analysis, but it does not employ self-organizing maps (SOM) for analyzing synonymous codon usage. CodonW, not CodonCode, is known for analyzing synonymous codon usage.\n2. TRUE\n3. UNKNOWN: Without specific information about the features of CodonCode, it is not possible to confirm whether it can predict the codon usage of a target gene or genome.\n4. UNKNOWN: Similarly, without specific information about the features of CodonCode, it is not possible to confirm whether it can identify codons that are overrepresented or underrepresented in a given gene or genome.\n5. FALSE [correction]: CodonW is a software tool that analyzes synonymous codon usage, but it does not use a Bayesian approach. It uses statistical methods to analyze codon usage patterns, but these are not specifically described as Bayesian.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "MINDY-1 (Microtubule-Associated Protein Dynamics-1) is a protein that plays a crucial role in the regulation of microtubule dynamics and stability. It is a plus-end tracking protein that interacts with the plus ends of microtubules and helps to regulate their dynamics and stability. MINDY-1 is involved in various cellular processes, including cell division, intracellular transport, and cell signaling. It is also a potential therapeutic target for various diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 stands for Microtubule-Associated Protein Dynamics-1.\n2. MINDY-1 is a protein that regulates microtubule dynamics and stability.\n3. It is a plus-end tracking protein that interacts with the plus ends of microtubules.\n4. MINDY-1 is involved in cellular processes such as cell division, intracellular transport, and cell signaling.\n5. MINDY-1 is considered a potential therapeutic target for diseases like cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 stands for Microtubule-Associated Protein Dynamics-1.",
      "MINDY-1 is a protein that regulates microtubule dynamics and stability.",
      "It is a plus-end tracking protein that interacts with the plus ends of microtubules.",
      "MINDY-1 is involved in cellular processes such as cell division, intracellular transport, and cell signaling.",
      "MINDY-1 is considered a potential therapeutic target for diseases like cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MINDY-1 does not stand for Microtubule-Associated Protein Dynamics-1. MINDY-1 is an acronym for MIu Motif-containing Novel DUB familY-1, which refers to a family of deubiquitinating enzymes.\n2. FALSE [correction]: MINDY-1 is not a protein that regulates microtubule dynamics and stability. It is a deubiquitinating enzyme involved in the process of removing ubiquitin from specific proteins.\n3. FALSE [correction]: MINDY-1 is not a plus-end tracking protein that interacts with the plus ends of microtubules. This statement may be confusing MINDY-1 with other proteins that are involved in microtubule dynamics.\n4. UNKNOWN: Without specific information about MINDY-1's role in cellular processes, it is difficult to confirm whether it is involved in cell division, intracellular transport, and cell signaling. However, deubiquitinating enzymes like MINDY-1 can be involved in various cellular processes, so this statement could be plausible.\n5. TRUE: Deubiquitinating enzymes, including those in the MINDY family, can be considered potential therapeutic targets for diseases such as cancer and neurodegenerative disorders because they play a role in protein homeostasis and can affect various signaling pathways.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "There are several software packages available for the analysis of conserved genomic loci, including:\n1. MACS (Multipoint Association for Computational Science): A popular tool for identifying conserved regions in genomes, including those that are conserved across multiple species.\n2. MEME (Multiple Expectation Maximization for Evolutionary Rates): A tool for identifying conserved regions in genomes, including those that are conserved across multiple species.\n3. HMMER (Hidden Markov Model for Repeats): A tool for identifying conserved regions in genomes, including those that are conserved across multiple species.\n4. GERP (Genomic Evolutionary Rate Profiles): A tool for identifying conserved regions in genomes, including those that are conserved across multiple species.\n5. PhastCons (Phylogenetic Footprinting of Conservation Scores): A tool for identifying conserved regions in genomes, including those that are conserved across multiple species.\n6. ConServ: A tool for identifying conserved regions in genomes, including those that are conserved across multiple species.\n7. Prodigal: A tool for identifying conserved regions in genomes, including those that are conserved across multiple species.\n8. RepeatMasker: A tool for identifying conserved regions in genomes, including those that are conserved across multiple species.\n9. GLIMMER (Gene Locator and Interpolated Markov ModelER): A tool for identifying conserved regions in genomes, including those that are conserved across multiple species.\n10. BLAST (Basic Local Alignment Search Tool): A tool for identifying conserved regions in genomes, including those that are conserved across multiple species.\nIt's worth noting that the choice of software package will depend on the specific requirements and goals of the analysis, as well as the characteristics of the data being analyzed.",
    "llama-2-7b-chat-hf_fact_raw": "1. MACS is a tool used for identifying conserved regions in genomes.\n2. MEME is a software package designed for identifying conserved genomic loci.\n3. HMMER is a tool that can identify conserved regions in genomes.\n4. GERP is a software package used for identifying conserved regions in genomes.\n5. PhastCons is a tool for identifying conserved regions in genomes.",
    "llama-2-7b-chat-hf_fact": [
      "MACS is a tool used for identifying conserved regions in genomes.",
      "MEME is a software package designed for identifying conserved genomic loci.",
      "HMMER is a tool that can identify conserved regions in genomes.",
      "GERP is a software package used for identifying conserved regions in genomes.",
      "PhastCons is a tool for identifying conserved regions in genomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MACS is a tool used for identifying peaks of enriched regions in genome-wide datasets, such as those from ChIP-seq experiments, not specifically for identifying conserved regions in genomes.\n2. FALSE [correction]: MEME (Multiple EM for Motif Elicitation) is a software package designed for finding motifs in a group of related DNA or protein sequences, not specifically for identifying conserved genomic loci.\n3. TRUE: HMMER is a tool that uses hidden Markov models to identify conserved protein sequences, which can be considered as conserved regions in genomes.\n4. TRUE: GERP (Genomic Evolutionary Rate Profiling) is a software package used for identifying and scoring conserved regions in multiple genome alignments.\n5. TRUE: PhastCons is a tool for identifying conserved elements in multiple sequence alignments, often used in the context of genomes.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "The PIEZO2 gene has been associated with several diseases, including:\n1. Autism Spectrum Disorder (ASD): Mutations in the PIEZO2 gene have been identified as a potential cause of autism spectrum disorder (ASD). Studies have found that individuals with ASD are more likely to have mutations in the PIEZO2 gene than the general population.\n2. Intellectual Disability: PIEZO2 mutations have also been associated with intellectual disability, which is a neurodevelopmental disorder characterized by below-average intelligence and cognitive abilities.\n3. Congenital Muscular Dystrophy: Some mutations in the PIEZO2 gene have been found to cause congenital muscular dystrophy, a group of disorders that affect muscle development and function from birth. These disorders can lead to muscle weakness, muscle wasting, and other muscle-related problems.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the PIEZO2 gene have been identified as a potential cause of autism spectrum disorder (ASD).\n2. PIEZO2 mutations have been associated with intellectual disability.\n3. Some mutations in the PIEZO2 gene have been found to cause congenital muscular dystrophy.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the PIEZO2 gene have been identified as a potential cause of autism spectrum disorder (ASD).",
      "PIEZO2 mutations have been associated with intellectual disability.",
      "Some mutations in the PIEZO2 gene have been found to cause congenital muscular dystrophy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The relationship between PIEZO2 gene mutations and autism spectrum disorder (ASD) is not definitively established in the scientific literature as of my knowledge cutoff date. While there may be studies exploring this connection, without specific references, it is not possible to confirm the accuracy of this statement.\n\n2. UNKNOWN: Similar to the first statement, the association between PIEZO2 mutations and intellectual disability is not well-established or widely recognized in the scientific community as of my knowledge cutoff date. More information or specific studies would be needed to confirm this statement.\n\n3. FALSE [correction]: Mutations in the PIEZO2 gene have been associated with conditions like distal arthrogryposis and Gordon syndrome, which can involve muscle and joint issues, but not specifically congenital muscular dystrophy. Congenital muscular dystrophy is typically associated with mutations in other genes, such as the DMD gene or genes encoding for proteins related to the structure and function of muscle cells.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "ERAP1-ERAP2 dimerization promotes the degradation of extracellular matrix (ECM) components, such as collagen and fibronectin, which are important for maintaining tissue architecture and integrity. The ERAP1-ERAP2 dimer is a key player in the proteolytic degradation of these ECM components, which is essential for various cellular processes, including cell migration, differentiation, and survival. By promoting the degradation of ECM components, the ERAP1-ERAP2 dimer contributes to the remodeling of the extracellular matrix and the regulation of tissue homeostasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization promotes the degradation of extracellular matrix (ECM) components.\n2. Collagen and fibronectin are examples of ECM components important for maintaining tissue architecture and integrity.\n3. The ERAP1-ERAP2 dimer is involved in the proteolytic degradation of ECM components.\n4. Degradation of ECM components is essential for cellular processes such as cell migration, differentiation, and survival.\n5. The ERAP1-ERAP2 dimer contributes to the remodeling of the extracellular matrix and the regulation of tissue homeostasis.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization promotes the degradation of extracellular matrix (ECM) components.",
      "Collagen and fibronectin are examples of ECM components important for maintaining tissue architecture and integrity.",
      "The ERAP1-ERAP2 dimer is involved in the proteolytic degradation of ECM components.",
      "Degradation of ECM components is essential for cellular processes such as cell migration, differentiation, and survival.",
      "The ERAP1-ERAP2 dimer contributes to the remodeling of the extracellular matrix and the regulation of tissue homeostasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ERAP1 and ERAP2 are aminopeptidases that are known for trimming peptides for presentation by MHC class I molecules, not for degrading extracellular matrix (ECM) components.\n2. TRUE\n3. FALSE [correction]: The ERAP1-ERAP2 dimer is not directly involved in the proteolytic degradation of ECM components; their primary function is associated with antigen processing.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "R-spondin 1 and Noggin are both important regulators of the Wnt/β-catenin signaling pathway, which plays a crucial role in the development and homeostasis of various tissues, including the gallbladder. In non-damaged gallbladders, R-spondin 1 and Noggin have been shown to have the following functions:\nR-spondin 1:\n* R-spondin 1 is a secreted protein that functions as a Wnt ligand and promotes the activation of the Wnt/β-catenin pathway.\n* In the gallbladder, R-spondin 1 is expressed in the epithelial cells and regulates the proliferation and differentiation of these cells, which are critical for the proper functioning of the gallbladder.\n* R-spondin 1 also regulates the expression of genes involved in the maintenance of the gallbladder epithelial barrier, which is essential for preventing bacterial entry and maintaining gallbladder function.\n* In addition, R-spondin 1 has been shown to play a role in regulating the expression of genes involved in the regulation of gallbladder contractility and the release of bile acids.\nNoggin:\n* Noggin is a secreted protein that functions as a negative regulator of the Wnt/β-catenin pathway.\n* In the gallbladder, Noggin is expressed in the epithelial cells and regulates the activity of the Wnt/β-catenin pathway, which is critical for the proper functioning of the gallbladder.\n* Noggin inhibits the activation of the Wnt/β-catenin pathway by binding to and neutralizing Wnt proteins, preventing their interaction with their receptors and preventing the activation of downstream signaling events.\n* By inhibiting the Wnt/β-catenin pathway, Noggin regulates the proliferation and differentiation of gallbladder epithelial cells, as well as the expression of genes involved in the maintenance of the gallbladder epithelial barrier and the regulation of gallbladder contractility",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 is a secreted protein that promotes the activation of the Wnt/β-catenin pathway.\n2. In non-damaged gallbladders, R-spondin 1 is expressed in the epithelial cells and regulates their proliferation and differentiation.\n3. R-spondin 1 regulates the expression of genes involved in maintaining the gallbladder epithelial barrier.\n4. Noggin is a secreted protein that functions as a negative regulator of the Wnt/β-catenin pathway.\n5. Noggin inhibits the activation of the Wnt/β-catenin pathway by binding to and neutralizing Wnt proteins.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 is a secreted protein that promotes the activation of the Wnt/β-catenin pathway.",
      "In non-damaged gallbladders, R-spondin 1 is expressed in the epithelial cells and regulates their proliferation and differentiation.",
      "R-spondin 1 regulates the expression of genes involved in maintaining the gallbladder epithelial barrier.",
      "Noggin is a secreted protein that functions as a negative regulator of the Wnt/β-catenin pathway.",
      "Noggin inhibits the activation of the Wnt/β-catenin pathway by binding to and neutralizing Wnt proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: Noggin is a secreted protein that functions as an antagonist of the Bone Morphogenetic Protein (BMP) pathway, not the Wnt/β-catenin pathway.\n5. FALSE [correction]: Noggin inhibits the BMP pathway by binding to and neutralizing BMPs, not Wnt proteins.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Yes, NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme that requires four subunits to function:\n1. Nox5: The catalytic subunit that generates reactive oxygen species (ROS) through the transfer of electrons from NADPH to oxygen.\n2. Nox5-1: The regulatory subunit that binds to and modulates the activity of Nox5.\n3. Nox5-2: The regulatory subunit that also binds to and modulates the activity of Nox5.\n4. p67phox: The cofactor subunit that interacts with Nox5 and facilitates the transfer of electrons from NADPH to oxygen.\nTogether, these four subunits form the functional enzyme complex that generates ROS through the Nox5 enzyme.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme.\n2. NOX5 requires four subunits to function.\n3. The Nox5 subunit is the catalytic subunit responsible for generating reactive oxygen species (ROS).\n4. The Nox5-1 and Nox5-2 subunits are regulatory subunits that modulate the activity of Nox5.\n5. The p67phox subunit is a cofactor that facilitates the transfer of electrons from NADPH to oxygen in the NOX5 enzyme complex.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme.",
      "NOX5 requires four subunits to function.",
      "The Nox5 subunit is the catalytic subunit responsible for generating reactive oxygen species (ROS).",
      "The Nox5-1 and Nox5-2 subunits are regulatory subunits that modulate the activity of Nox5.",
      "The p67phox subunit is a cofactor that facilitates the transfer of electrons from NADPH to oxygen in the NOX5 enzyme complex."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) is not a heterotetrameric enzyme; it is a homodimeric enzyme.\n2. FALSE [correction]: NOX5 does not require four subunits to function; it functions as a homodimer.\n3. TRUE\n4. FALSE [correction]: The Nox5-1 and Nox5-2 subunits do not exist; NOX5 does not have regulatory subunits named Nox5-1 and Nox5-2.\n5. FALSE [correction]: The p67phox subunit is associated with other NOX family members like NOX2, not with NOX5. NOX5 does not require p67phox or any other cytosolic subunits for its activity.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Furin and hepcidin are connected in the regulation of iron metabolism. Furin is a protease that cleaves various proteins, including the iron exporter ferroportin, leading to its degradation and decreased iron release from cells. Hepcidin, on the other hand, is a hormone that regulates iron absorption and recycling in the body by binding to ferroportin and causing its degradation. Therefore, furin and hepcidin work together to control the amount of iron available for use by cells throughout the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is a protease that cleaves various proteins, including the iron exporter ferroportin.\n2. The cleavage of ferroportin by furin leads to its degradation and decreased iron release from cells.\n3. Hepcidin is a hormone that regulates iron absorption and recycling in the body.\n4. Hepcidin binds to ferroportin and causes its degradation.\n5. Furin and hepcidin work together to control the amount of iron available for use by cells throughout the body.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is a protease that cleaves various proteins, including the iron exporter ferroportin.",
      "The cleavage of ferroportin by furin leads to its degradation and decreased iron release from cells.",
      "Hepcidin is a hormone that regulates iron absorption and recycling in the body.",
      "Hepcidin binds to ferroportin and causes its degradation.",
      "Furin and hepcidin work together to control the amount of iron available for use by cells throughout the body."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Furin is a protease that cleaves various proteins, but it is not known to cleave the iron exporter ferroportin. Furin typically cleaves precursors of various proteins to their mature forms.\n2. FALSE [correction]: Since furin does not cleave ferroportin, it does not lead to its degradation and decreased iron release from cells. The cleavage and regulation of ferroportin are not directly associated with furin.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: While both furin and hepcidin are involved in regulatory processes within the body, they do not work together to control iron availability. Furin cleaves a variety of protein precursors, while hepcidin specifically regulates iron absorption and recycling by binding to ferroportin, leading to its degradation.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster, also known as the \"Triosephosphate Pathway\" or \"Glycolytic Pathway\". This gene cluster consists of 11 genes that are involved in the breakdown of glucose and the production of energy in the form of ATP, NADH, and FADH2. The genes in this cluster are:\n1. Gluconeogenesis (GNG)\n2. Phosphogluconate dehydratase (PDH)\n3. Phosphogluconate kinase (PGK)\n4. Enolase (ENO)\n5. Enol-phosphate transferase (EPT)\n6. Aldolase (ALD)\n7. Triosephosphate isomerase (TPI)\n8. Fructose-bisphosphate aldolase (FBA)\n9. Glyceraldehyde-3-phosphate dehydrogenase (GAP)\n10. Phosphoglycerate kinase (PGL)\n11. Phosphoglycerate mutase (PGM)\nThe glycolysis/gluconeogenesis gene cluster is the largest metabolic gene cluster in yeast and plays a crucial role in the breakdown of glucose and the production of energy in the form of ATP, NADH, and FADH2.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster.\n2. The glycolysis/gluconeogenesis gene cluster in yeast consists of 11 genes.\n3. The genes in the glycolysis/gluconeogenesis gene cluster are involved in the breakdown of glucose.\n4. The glycolysis/gluconeogenesis gene cluster is involved in the production of energy in the form of ATP, NADH, and FADH2.\n5. The glycolysis/gluconeogenesis gene cluster is also known as the \"Triosephosphate Pathway\" or \"Glycolytic Pathway\".",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster.",
      "The glycolysis/gluconeogenesis gene cluster in yeast consists of 11 genes.",
      "The genes in the glycolysis/gluconeogenesis gene cluster are involved in the breakdown of glucose.",
      "The glycolysis/gluconeogenesis gene cluster is involved in the production of energy in the form of ATP, NADH, and FADH2.",
      "The glycolysis/gluconeogenesis gene cluster is also known as the \"Triosephosphate Pathway\" or \"Glycolytic Pathway\"."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific data or a reference to a particular study, it is difficult to confirm whether the glycolysis/gluconeogenesis gene cluster is the largest metabolic gene cluster in yeast.\n2. FALSE [correction]: The glycolysis pathway typically involves 10 core enzymes, which are encoded by different genes. However, the exact number of genes in the glycolysis/gluconeogenesis gene cluster in yeast may vary depending on the specific yeast species and the definition of the cluster boundaries.\n3. TRUE: The genes in the glycolysis/gluconeogenesis gene cluster are indeed involved in the breakdown of glucose during glycolysis and the synthesis of glucose during gluconeogenesis.\n4. TRUE: The glycolysis pathway is involved in the production of energy in the form of ATP and NADH. However, FADH2 is not produced in glycolysis; it is produced in the citric acid cycle and during beta-oxidation of fatty acids.\n5. FALSE [correction]: The glycolysis/gluconeogenesis gene cluster is commonly known as the \"Glycolytic Pathway\" for glycolysis. The term \"Triosephosphate Pathway\" is not a standard name for the entire glycolytic pathway, although it may refer to a part of the pathway involving triose phosphates. The gluconeogenesis pathway is the process of glucose synthesis and is not typically referred to by either of these names.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "The role of LMT (LincMD1/LincRNA_00257) lncRNA is not well understood, but it is thought to play a role in the regulation of gene expression, particularly in the context of cancer. LMT is a long non-coding RNA (lncRNA) that is located on chromosome 1q21 and is approximately 2.5 kb in length. It is transcribed in the opposite direction to the coding gene, MAPT (Microtubule-associated protein tau), and is known to be highly expressed in various types of cancer, including breast, lung, and colon cancer.\nStudies have shown that LMT regulates the expression of several genes involved in cell proliferation, migration, and apoptosis, and is thought to play a role in the development and progression of cancer. LMT has been shown to act as a competing endogenous RNA (ceRNA) and bind to the miR-106b-519a cluster, leading to the degradation of miR-106b-519a and the upregulation of target genes. LMT has also been shown to regulate the expression of the PI3K/Akt signaling pathway and the epithelial-to-mesenchymal transition (EMT) in cancer cells.\nIn summary, LMT is a lncRNA that plays a complex role in the regulation of gene expression, particularly in the context of cancer. Further research is needed to fully understand its mechanisms of action and its potential as a therapeutic target for cancer treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. LMT (LincMD1/LincRNA_00257) lncRNA is located on chromosome 1q21 and is approximately 2.5 kb in length.\n2. LMT is transcribed in the opposite direction to the coding gene, MAPT (Microtubule-associated protein tau).\n3. LMT lncRNA is known to be highly expressed in various types of cancer, including breast, lung, and colon cancer.\n4. LMT has been shown to regulate the expression of several genes involved in cell proliferation, migration, and apoptosis.\n5. LMT acts as a competing endogenous RNA (ceRNA) and binds to the miR-106b-519a cluster, leading to the degradation of miR-106b-519a and the upregulation of target genes.",
    "llama-2-7b-chat-hf_fact": [
      "LMT (LincMD1/LincRNA_00257) lncRNA is located on chromosome 1q21 and is approximately 2.5 kb in length.",
      "LMT is transcribed in the opposite direction to the coding gene, MAPT (Microtubule-associated protein tau).",
      "LMT lncRNA is known to be highly expressed in various types of cancer, including breast, lung, and colon cancer.",
      "LMT has been shown to regulate the expression of several genes involved in cell proliferation, migration, and apoptosis.",
      "LMT acts as a competing endogenous RNA (ceRNA) and binds to the miR-106b-519a cluster, leading to the degradation of miR-106b-519a and the upregulation of target genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are very specific and pertain to scientific findings about a particular long non-coding RNA (lncRNA) named LMT. Without access to the latest scientific literature or databases that contain genomic information, it is not possible to verify these statements. They would require specialized knowledge in molecular biology and access to current research to confirm their accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "There are several R packages and bioconductor packages that can be used for performing SNP (Single Nucleotide Polymorphism) enrichment analysis. Some of the commonly used packages are:\n1. \"SNPset\": This package is specifically designed for the analysis of SNP data. It provides a variety of tools for identifying enriched regions of the genome, as well as for testing the significance of the observed enrichment.\n2. \"GSEA\": Gene Set Enrichment Analysis (GSEA) is a popular bioconductor package that can be used for identifying pathways and gene sets that are overrepresented among a set of genetic variants. GSEA uses a modified version of the hypergeometric test to identify enriched gene sets.\n3. \"Plink\": Plink is a widely used R package for genome-wide association studies (GWAS). It can be used for performing SNP enrichment analysis by identifying regions of the genome that are overrepresented among a set of associated SNPs.\n4. \"GenomicRanges\": This package provides a variety of tools for working with genomic data, including tools for identifying enriched regions of the genome.\n5. \"HaploU': HaploU is a bioconductor package that can be used for identifying regions of the genome that are enriched for a particular haplotype.\nThese packages can be used to perform different types of enrichment analysis, such as gene-set enrichment analysis, pathway enrichment analysis, and haplotype-based enrichment analysis. The choice of package will depend on the specific research question and the type of data available.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"SNPset\" package is designed for the analysis of SNP data and includes tools for identifying enriched regions of the genome.\n2. \"GSEA\" (Gene Set Enrichment Analysis) is a bioconductor package used for identifying overrepresented pathways and gene sets among genetic variants.\n3. \"Plink\" is an R package used for genome-wide association studies and can perform SNP enrichment analysis.\n4. \"GenomicRanges\" is a package that provides tools for working with genomic data, including identifying enriched genomic regions.\n5. \"HaploU\" is a bioconductor package used for identifying genome regions enriched for a particular haplotype.",
    "llama-2-7b-chat-hf_fact": [
      "The \"SNPset\" package is designed for the analysis of SNP data and includes tools for identifying enriched regions of the genome.",
      "\"GSEA\" (Gene Set Enrichment Analysis) is a bioconductor package used for identifying overrepresented pathways and gene sets among genetic variants.",
      "\"Plink\" is an R package used for genome-wide association studies and can perform SNP enrichment analysis.",
      "\"GenomicRanges\" is a package that provides tools for working with genomic data, including identifying enriched genomic regions.",
      "\"HaploU\" is a bioconductor package used for identifying genome regions enriched for a particular haplotype."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement about the \"SNPset\" package is specific, but without additional context or a reference to the actual software package, it's difficult to verify its accuracy. There are many packages for SNP data analysis, and the name \"SNPset\" could be hypothetical or real.\n\n2. FALSE [correction]: \"GSEA\" (Gene Set Enrichment Analysis) is a computational method that determines whether a set of genes shows statistically significant, concordant differences between two biological states. It is not specifically a Bioconductor package, but there is a Bioconductor package called \"fgsea\" that can perform fast gene set enrichment analysis.\n\n3. FALSE [correction]: \"Plink\" is not an R package; it is a standalone software tool used for genome-wide association studies (GWAS) and can perform a variety of analyses on SNP data, including association analysis, but it is not implemented in R.\n\n4. TRUE: \"GenomicRanges\" is indeed a Bioconductor package that provides tools for representing and manipulating genomic intervals and variables defined along a genome.\n\n5. UNKNOWN: The statement about \"HaploU\" is specific, but without additional context or a reference to the actual software package, it's difficult to verify its accuracy. There are packages for haplotype analysis, but \"HaploU\" may not be a well-known or existing package.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Radial glial cells are intermediate progenitors that play a crucial role in the development of the cerebral cortex. The key players involved in the specification of radial glial cells to ependymal cells are:\n1. Notch signaling pathway: Notch is a transcription factor that regulates the expression of genes involved in the specification of radial glial cells to ependymal cells.\n2. Sox2: Sox2 is a transcription factor that is required for the maintenance of radial glial cells and their specification to ependymal cells.\n3. Shh signaling pathway: Shh signaling pathway is involved in the regulation of radial glial cell fate and the specification of radial glial cells to ependymal cells.\n4. Wnt/β-catenin signaling pathway: Wnt/β-catenin signaling pathway is involved in the regulation of radial glial cell fate and the specification of radial glial cells to ependymal cells.\n5. BMP signaling pathway: BMP signaling pathway is involved in the regulation of radial glial cell fate and the specification of radial glial cells to ependymal cells.\n6. FGF signaling pathway: FGF signaling pathway is involved in the regulation of radial glial cell fate and the specification of radial glial cells to ependymal cells.\n7. GDNF signaling pathway: GDNF signaling pathway is involved in the regulation of radial glial cell fate and the specification of radial glial cells to ependymal cells.\n8. NeuroD1: NeuroD1 is a transcription factor that is involved in the specification of radial glial cells to ependymal cells.\n9. NeuroD2: NeuroD2 is a transcription factor that is involved in the specification of radial glial cells to ependymal cells.\n10. T-box proteins: T-box proteins are transcription factors that are involved in the specification of radial glial cells to ependymal cells.\nThese key players work together to regulate the expression of genes involved in the specification of radial glial cells to ependymal cells, and their dysregulation can lead to various neurological disorders, including",
    "llama-2-7b-chat-hf_fact_raw": "1. Notch signaling pathway regulates the expression of genes involved in the specification of radial glial cells to ependymal cells.\n2. Sox2 is required for the maintenance of radial glial cells and their specification to ependymal cells.\n3. Shh signaling pathway is involved in the regulation of radial glial cell fate and their specification to ependymal cells.\n4. Wnt/β-catenin signaling pathway is involved in the regulation of radial glial cell fate and their specification to ependymal cells.\n5. BMP signaling pathway is involved in the regulation of radial glial cell fate and their specification to ependymal cells.",
    "llama-2-7b-chat-hf_fact": [
      "Notch signaling pathway regulates the expression of genes involved in the specification of radial glial cells to ependymal cells.",
      "Sox2 is required for the maintenance of radial glial cells and their specification to ependymal cells.",
      "Shh signaling pathway is involved in the regulation of radial glial cell fate and their specification to ependymal cells.",
      "Wnt/β-catenin signaling pathway is involved in the regulation of radial glial cell fate and their specification to ependymal cells.",
      "BMP signaling pathway is involved in the regulation of radial glial cell fate and their specification to ependymal cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The Notch signaling pathway is known to regulate the expression of genes involved in various cell fate decisions, including the specification of radial glial cells to ependymal cells.\n2. TRUE: Sox2 is a transcription factor that is essential for the maintenance of neural stem cells, including radial glial cells, and is involved in their specification to various cell types, including ependymal cells.\n3. FALSE [correction]: The Shh (Sonic Hedgehog) signaling pathway is primarily known for its role in the patterning of the neural tube and the regulation of progenitor cell proliferation, not specifically for the specification of radial glial cells to ependymal cells.\n4. UNKNOWN: While the Wnt/β-catenin signaling pathway is involved in the regulation of neural stem cell fate and has been implicated in the differentiation of radial glial cells, the specific role in their specification to ependymal cells may not be well-defined or may vary depending on the context.\n5. UNKNOWN: BMP (Bone Morphogenetic Protein) signaling is involved in the regulation of neural development and stem cell fate, but the specific role in the specification of radial glial cells to ependymal cells may not be well-established or may be context-dependent.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Triple negative gliomas are a type of glioma, which is a type of brain tumor, that are characterized by the lack of expression of certain biomarkers, including:\n1. Tumor protein 53 (TP53): TP53 is a tumor suppressor gene that is commonly mutated in many types of cancer, including gliomas. Triple negative gliomas typically have wild-type TP53, meaning that the gene is not mutated.\n2. Estrogen receptor alpha (ERα): ERα is a protein that is involved in the estrogen signaling pathway. Triple negative gliomas typically do not express ERα, which is why they are called \"triple negative.\"\n3. Progesterone receptor (PR): PR is a protein that is involved in the progesterone signaling pathway. Like ERα, PR is typically not expressed in triple negative gliomas.\nTriple negative gliomas are aggressive and tend to have a poorer prognosis than other types of gliomas, such as those that are positive for TP53 or ERα/PR. They are also more likely to recur after treatment. Despite their poor prognosis, triple negative gliomas are still a relatively rare type of brain tumor, accounting for only about 10-15% of all gliomas.",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas are characterized by the lack of expression of the tumor protein 53 (TP53) gene.\n2. Triple negative gliomas do not express the estrogen receptor alpha (ERα).\n3. Triple negative gliomas do not express the progesterone receptor (PR).\n4. Triple negative gliomas tend to have a poorer prognosis than other types of gliomas.\n5. Triple negative gliomas account for about 10-15% of all gliomas.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas are characterized by the lack of expression of the tumor protein 53 (TP53) gene.",
      "Triple negative gliomas do not express the estrogen receptor alpha (ERα).",
      "Triple negative gliomas do not express the progesterone receptor (PR).",
      "Triple negative gliomas tend to have a poorer prognosis than other types of gliomas.",
      "Triple negative gliomas account for about 10-15% of all gliomas."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Triple negative gliomas are characterized by the lack of expression of IDH1/2, 1p/19q co-deletion, and TP53 and ATRX mutations, not solely by the lack of expression of the TP53 gene.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "TOPAZ1 (Topoisomerase II-associated protein AZ1) is a protein that is involved in the regulation of DNA replication and repair. It is a histone chaperone that is recruited to the replication fork during DNA synthesis and helps to facilitate the process of DNA elongation by interacting with the DNA polymerase II complex. TOPAZ1 also plays a role in the repair of DNA double-strand breaks by interacting with the DNA repair protein, 53BP1.\nTOPAZ1 was first identified in budding yeast, where it was shown to be required for proper DNA replication and repair. Since then, it has been found to be conserved in various organisms, including humans, and has been implicated in a variety of cellular processes, including cell cycle regulation, DNA damage response, and cancer.\nMutations in the TOPAZ1 gene have been associated with various human diseases, including cancer and neurodegenerative disorders. Overall, TOPAZ1 is a key player in the regulation of DNA replication and repair, and its dysregulation can have significant consequences for cellular homeostasis and disease development.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 (Topoisomerase II-associated protein AZ1) is involved in the regulation of DNA replication and repair.\n2. TOPAZ1 is a histone chaperone that is recruited to the replication fork during DNA synthesis.\n3. TOPAZ1 interacts with the DNA polymerase II complex to facilitate DNA elongation.\n4. TOPAZ1 plays a role in the repair of DNA double-strand breaks by interacting with the DNA repair protein, 53BP1.\n5. Mutations in the TOPAZ1 gene have been associated with various human diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 (Topoisomerase II-associated protein AZ1) is involved in the regulation of DNA replication and repair.",
      "TOPAZ1 is a histone chaperone that is recruited to the replication fork during DNA synthesis.",
      "TOPAZ1 interacts with the DNA polymerase II complex to facilitate DNA elongation.",
      "TOPAZ1 plays a role in the repair of DNA double-strand breaks by interacting with the DNA repair protein, 53BP1.",
      "Mutations in the TOPAZ1 gene have been associated with various human diseases, including cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: TOPAZ1 (Topoisomerase II-associated protein AZ1) is indeed involved in the regulation of DNA replication and repair.\n2. FALSE [correction]: TOPAZ1 is not known as a histone chaperone. It is associated with topoisomerase II, which is involved in DNA replication and repair, but it is not typically characterized as a histone chaperone.\n3. UNKNOWN: Without specific literature references, it is difficult to confirm whether TOPAZ1 directly interacts with DNA polymerase II complex to facilitate DNA elongation.\n4. TRUE: TOPAZ1 has been shown to play a role in the repair of DNA double-strand breaks and is known to interact with the DNA repair protein, 53BP1.\n5. UNKNOWN: While mutations in genes involved in DNA replication and repair can be associated with various human diseases, including cancer and neurodegenerative disorders, without specific references to studies or reports on TOPAZ1 mutations and their associations with these diseases, the truth of this statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "The expression of GATA-1 isoforms is controlled by the GATA-1 gene itself. The GATA-1 gene contains multiple exons that are spliced together to produce different isoforms of the GATA-1 transcription factor. The splicing of these exons is regulated by a variety of factors, including transcription factors, signaling pathways, and epigenetic modifications.\nIn particular, the expression of GATA-1 isoforms is regulated by the balance between the pro-GATA-1 and anti-GATA-1 splicing factors. Pro-GATA-1 factors promote the inclusion of exon 1 in the GATA-1 mRNA, leading to the expression of the full-length GATA-1 isoform. Anti-GATA-1 factors, on the other hand, promote the exclusion of exon 1, leading to the expression of a shorter isoform that lacks the N-terminal domain.\nIn addition, the expression of GATA-1 isoforms is also regulated by the activity of transcription factors, such as GATA-2 and GATA-3, which can bind to specific DNA sequences and either enhance or repress the expression of GATA-1 isoforms.\nOverall, the control of GATA-1 isoform expression is a complex process that involves the interplay of multiple factors, including splicing factors, transcription factors, and epigenetic modifications.",
    "llama-2-7b-chat-hf_fact_raw": "1. The GATA-1 gene controls the expression of its own isoforms.\n2. The GATA-1 gene contains multiple exons that are spliced to produce different isoforms of the GATA-1 transcription factor.\n3. Pro-GATA-1 splicing factors promote the inclusion of exon 1 in the GATA-1 mRNA, leading to the expression of the full-length GATA-1 isoform.\n4. Anti-GATA-1 splicing factors promote the exclusion of exon 1, resulting in a shorter isoform that lacks the N-terminal domain.\n5. The activity of transcription factors such as GATA-2 and GATA-3 can enhance or repress the expression of GATA-1 isoforms.",
    "llama-2-7b-chat-hf_fact": [
      "The GATA-1 gene controls the expression of its own isoforms.",
      "The GATA-1 gene contains multiple exons that are spliced to produce different isoforms of the GATA-1 transcription factor.",
      "Pro-GATA-1 splicing factors promote the inclusion of exon 1 in the GATA-1 mRNA, leading to the expression of the full-length GATA-1 isoform.",
      "Anti-GATA-1 splicing factors promote the exclusion of exon 1, resulting in a shorter isoform that lacks the N-terminal domain.",
      "The activity of transcription factors such as GATA-2 and GATA-3 can enhance or repress the expression of GATA-1 isoforms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The GATA-1 gene does control the expression of its own isoforms through a process known as autoregulation.\n2. TRUE: The GATA-1 gene contains multiple exons, and alternative splicing of these exons can produce different isoforms of the GATA-1 transcription factor.\n3. UNKNOWN: Without specific scientific literature or context, it is difficult to confirm the role of \"Pro-GATA-1 splicing factors\" in promoting the inclusion of exon 1 in GATA-1 mRNA. The term \"Pro-GATA-1 splicing factors\" is not standard, and the process of splicing can be complex and regulated by various factors.\n4. UNKNOWN: Similar to statement 3, the term \"Anti-GATA-1 splicing factors\" is not standard, and the details of how splicing factors influence the exclusion of exon 1 in GATA-1 mRNA are not provided. The process of generating shorter isoforms that lack certain domains, such as the N-terminal domain, is plausible, but the specific role of these hypothetical \"Anti-GATA-1 splicing factors\" cannot be confirmed without additional context.\n5. TRUE: Transcription factors, including other members of the GATA family such as GATA-2 and GATA-3, can indeed have regulatory effects on the expression of genes, including potentially influencing the expression of GATA-1 isoforms. However, the specific interactions and regulatory mechanisms can be complex and context-dependent.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq (MicroRNA-based Regulatory Analysis sequencing) is a high-throughput sequencing-based method used to identify and characterize the regulatory elements in the genome that are bound by specific microRNAs (miRNAs).\nIn MIRA-seq, the genome is first fragmented into smaller pieces, and these fragments are then hybridized to microarrays containing complementary probes for the miRNAs of interest. The hybridized fragments are then captured and sequenced, allowing researchers to identify the genomic regions that are bound by specific miRNAs.\nMIRA-seq can be used to study the regulation of gene expression at the level of the genome, and can help researchers identify new regulatory elements and understand how they are involved in the regulation of specific biological processes. It can also be used to identify potential therapeutic targets for diseases, and to develop new diagnostic tests for diseases.\nIn summary, MIRA-seq is a powerful tool for understanding the complex regulatory networks that control gene expression, and has the potential to lead to new insights and discoveries in the field of molecular biology.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq stands for MicroRNA-based Regulatory Analysis sequencing.\n2. MIRA-seq is a method used to identify and characterize regulatory elements in the genome that are bound by specific microRNAs.\n3. The process of MIRA-seq involves fragmenting the genome and hybridizing the fragments to microarrays with probes for miRNAs.\n4. MIRA-seq allows researchers to identify genomic regions bound by specific miRNAs.\n5. MIRA-seq can be used to study gene expression regulation and to identify potential therapeutic targets and diagnostic tests for diseases.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq stands for MicroRNA-based Regulatory Analysis sequencing.",
      "MIRA-seq is a method used to identify and characterize regulatory elements in the genome that are bound by specific microRNAs.",
      "The process of MIRA-seq involves fragmenting the genome and hybridizing the fragments to microarrays with probes for miRNAs.",
      "MIRA-seq allows researchers to identify genomic regions bound by specific miRNAs.",
      "MIRA-seq can be used to study gene expression regulation and to identify potential therapeutic targets and diagnostic tests for diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: MIRA-seq is a method used to identify and characterize regulatory elements in the genome that are bound by specific proteins, not microRNAs.\n3. FALSE [correction]: MIRA-seq involves capturing regulatory elements bound by proteins using an antibody against a specific protein of interest, not hybridizing fragments to microarrays with probes for miRNAs.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "ARCALYST (rilonacept) is a prescription medication used to treat cryopyrin-associated periodic syndromes (CAPS), which are a group of rare genetic disorders that cause recurring episodes of fever, pain, and inflammation. Specifically, ARCALYST is approved for the treatment of cryopyrin-associated periodic syndrome (CAPS), including familial cold autoinflammatory syndrome (FCAS) and juvenile polyarteritis nodosa (JPA). It is also being studied for the treatment of other autoinflammatory diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST (rilonacept) is a prescription medication.\n2. ARCALYST is used to treat cryopyrin-associated periodic syndromes (CAPS).\n3. CAPS are a group of rare genetic disorders characterized by recurring episodes of fever, pain, and inflammation.\n4. ARCALYST is specifically approved for the treatment of familial cold autoinflammatory syndrome (FCAS) and juvenile polyarteritis nodosa (JPA).\n5. ARCALYST is being studied for the treatment of other autoinflammatory diseases.",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST (rilonacept) is a prescription medication.",
      "ARCALYST is used to treat cryopyrin-associated periodic syndromes (CAPS).",
      "CAPS are a group of rare genetic disorders characterized by recurring episodes of fever, pain, and inflammation.",
      "ARCALYST is specifically approved for the treatment of familial cold autoinflammatory syndrome (FCAS) and juvenile polyarteritis nodosa (JPA).",
      "ARCALYST is being studied for the treatment of other autoinflammatory diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: ARCALYST is specifically approved for the treatment of familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), not juvenile polyarteritis nodosa (JPA).\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Robertsonian translocations involve the exchange of genetic material between two acrocentric chromosomes, which are characterized by their long arms and short arms. The following are the human acrocentric chromosomes that can be involved in Robertsonian translocations:\n1. Chromosome 13\n2. Chromosome 14\n3. Chromosome 15\n4. Chromosome 21\nIt's important to note that Robertsonian translocations are typically balanced, meaning that the genetic material is exchanged in a way that maintains the normal complement of genetic material in each cell. However, in some cases, a Robertsonian translocation can lead to a chromosomal abnormality, such as a deletion or duplication of genetic material, which can have significant consequences for the individual.",
    "llama-2-7b-chat-hf_fact_raw": "1. Robertsonian translocations involve the exchange of genetic material between two acrocentric chromosomes.\n2. Human acrocentric chromosomes that can be involved in Robertsonian translocations include chromosome 13.\n3. Human acrocentric chromosomes that can be involved in Robertsonian translocations include chromosome 14.\n4. Human acrocentric chromosomes that can be involved in Robertsonian translocations include chromosome 15.\n5. Human acrocentric chromosomes that can be involved in Robertsonian translocations include chromosome 21.",
    "llama-2-7b-chat-hf_fact": [
      "Robertsonian translocations involve the exchange of genetic material between two acrocentric chromosomes.",
      "Human acrocentric chromosomes that can be involved in Robertsonian translocations include chromosome 13.",
      "Human acrocentric chromosomes that can be involved in Robertsonian translocations include chromosome 14.",
      "Human acrocentric chromosomes that can be involved in Robertsonian translocations include chromosome 15.",
      "Human acrocentric chromosomes that can be involved in Robertsonian translocations include chromosome 21."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nRobertsonian translocations indeed involve the exchange of genetic material between two acrocentric chromosomes. In humans, the acrocentric chromosomes are 13, 14, 15, 21, and 22, all of which can be involved in such translocations.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "There are several R packages that can be used for the identification of pediatric brain tumors, depending on the specific task and the type of data available. Here are a few options:\n1. `pediatricBrainTumor`: This package provides a set of functions for analyzing and visualizing pediatric brain tumor data, including gene expression data, clinical data, and imaging data. It can be used for identifying patterns and features that are associated with different types of pediatric brain tumors.\n2. `brainTumor`: This package provides a set of functions for analyzing and visualizing brain tumor data, including gene expression data, clinical data, and imaging data. It can be used for identifying patterns and features that are associated with different types of brain tumors, including pediatric brain tumors.\n3. `rstan`: This package provides a Bayesian non-parametric framework for modeling and inference in statistical models. It can be used for identifying patterns and features that are associated with different types of pediatric brain tumors by modeling the joint distribution of the data and estimating the posterior probability of different tumor types given the data.\n4. `survival`: This package provides functions for analyzing survival data, which can be used to model the time to event data for pediatric brain tumors. It can be used for identifying patterns and features that are associated with different types of pediatric brain tumors and the time to event for each type.\n5. `ggplot2`: This package provides a powerful visualization tool for creating interactive plots and visualizations. It can be used for visualizing the data and identifying patterns and features that are associated with different types of pediatric brain tumors.\n6. `Hmisc`: This package provides a collection of functions for data manipulation and analysis, including functions for summarizing and visualizing data. It can be used for identifying patterns and features that are associated with different types of pediatric brain tumors by summarizing and visualizing the data.\n7. `MASS`: This package provides functions for statistical modeling and analysis, including functions for linear regression, generalized linear models, and time series analysis. It can be used for identifying patterns and features that are associated with different types of pediatric brain tumors by fitting statistical models to the data.\n8. `car",
    "llama-2-7b-chat-hf_fact_raw": "1. The `pediatricBrainTumor` R package provides functions for analyzing and visualizing pediatric brain tumor data.\n2. The `brainTumor` R package can be used for identifying patterns in brain tumor data, including pediatric brain tumors.\n3. The `rstan` R package offers a Bayesian framework for modeling statistical data related to pediatric brain tumors.\n4. The `survival` R package is used for analyzing survival data, applicable to modeling time to event data for pediatric brain tumors.\n5. The `ggplot2` R package is a visualization tool that can be utilized for creating plots related to pediatric brain tumor data.",
    "llama-2-7b-chat-hf_fact": [
      "The `pediatricBrainTumor` R package provides functions for analyzing and visualizing pediatric brain tumor data.",
      "The `brainTumor` R package can be used for identifying patterns in brain tumor data, including pediatric brain tumors.",
      "The `rstan` R package offers a Bayesian framework for modeling statistical data related to pediatric brain tumors.",
      "The `survival` R package is used for analyzing survival data, applicable to modeling time to event data for pediatric brain tumors.",
      "The `ggplot2` R package is a visualization tool that can be utilized for creating plots related to pediatric brain tumor data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information about the `pediatricBrainTumor` R package, it is not possible to verify the accuracy of this statement.\n2. UNKNOWN: The `brainTumor` R package may exist and could be used for identifying patterns in brain tumor data, but without specific information about the package, the statement's accuracy cannot be confirmed.\n3. TRUE: The `rstan` R package is indeed a tool for Bayesian analysis, which can be applied to various statistical data, including those related to pediatric brain tumors.\n4. TRUE: The `survival` R package is commonly used for survival analysis, which is relevant for time to event data such as that found in studies of pediatric brain tumors.\n5. TRUE: The `ggplot2` R package is a widely-used visualization tool in R that can be used for creating a variety of plots, including those related to pediatric brain tumor data.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "No, NEMO (Nuclear Envelope-Associated Protein 1, also known as IκB kinase-ε or IKKε) is not a zinc finger protein. Zinc finger proteins are a class of proteins that contain one or more zinc ions embedded in a specific DNA-binding domain. They are involved in DNA binding and protein-DNA interactions.\nNEMO, on the other hand, is a protein that plays a critical role in the regulation of inflammation and immune responses. It is a serine/threonine kinase that is involved in the activation of the NF-κB transcription factor and the regulation of cytokine production. NEMO contains a number of different domains, including an N-terminal myristoylation site, a pleckstrin homology (PH) domain, a proline-rich region, a kinase domain, and a carboxyl-terminal tail.\nWhile NEMO does not contain a zinc finger domain, it has been shown to interact with a number of other proteins that do contain zinc fingers, including NF-κB and c-Jun. These interactions are important for the regulation of NEMO's function in the immune response.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO (Nuclear Envelope-Associated Protein 1) is also known as IκB kinase-ε or IKKε.\n2. Zinc finger proteins contain one or more zinc ions in a specific DNA-binding domain.\n3. NEMO is involved in the regulation of inflammation and immune responses.\n4. NEMO is a serine/threonine kinase that activates the NF-κB transcription factor.\n5. NEMO interacts with other proteins that contain zinc fingers, such as NF-κB and c-Jun.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO (Nuclear Envelope-Associated Protein 1) is also known as IκB kinase-ε or IKKε.",
      "Zinc finger proteins contain one or more zinc ions in a specific DNA-binding domain.",
      "NEMO is involved in the regulation of inflammation and immune responses.",
      "NEMO is a serine/threonine kinase that activates the NF-κB transcription factor.",
      "NEMO interacts with other proteins that contain zinc fingers, such as NF-κB and c-Jun."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NEMO (NF-kappa-B essential modulator) is also known as IKKγ, not IκB kinase-ε or IKKε.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: NEMO is not a kinase itself but is part of the IKK complex that activates the NF-κB transcription factor. The kinases in the complex are IKKα and IKKβ.\n5. FALSE [correction]: NEMO does interact with other proteins to regulate NF-κB, but NF-κB and c-Jun do not contain zinc fingers. Zinc finger domains are a type of protein domain that can coordinate zinc ions to help stabilize their folds.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Yes, TFIIS (Transcription Factor IIS) has been shown to play a role in nucleosome positioning. TFIIS is a general transcription factor that is involved in the initiation of transcription in eukaryotic cells. It has been shown to interact with the histone-modifying enzymes SUV39H1 and SUV40H1, which are involved in the modification of histones H3 and H4, respectively. These modifications can affect nucleosome positioning by altering the interactions between the histones and the DNA, making it more or less accessible to the transcriptional machinery.\nIn addition, TFIIS has been shown to interact directly with nucleosomes and to promote the disruption of nucleosome structure, which can also affect transcriptional initiation.\nIn summary, TFIIS plays a role in regulating nucleosome positioning by interacting with histone-modifying enzymes and directly interacting with nucleosomes, promoting their disruption and facilitating transcriptional initiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS (Transcription Factor IIS) plays a role in nucleosome positioning.\n2. TFIIS is involved in the initiation of transcription in eukaryotic cells.\n3. TFIIS interacts with the histone-modifying enzymes SUV39H1 and SUV40H1.\n4. Histone-modifying enzymes SUV39H1 and SUV40H1 are involved in the modification of histones H3 and H4, respectively.\n5. TFIIS can promote the disruption of nucleosome structure.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS (Transcription Factor IIS) plays a role in nucleosome positioning.",
      "TFIIS is involved in the initiation of transcription in eukaryotic cells.",
      "TFIIS interacts with the histone-modifying enzymes SUV39H1 and SUV40H1.",
      "Histone-modifying enzymes SUV39H1 and SUV40H1 are involved in the modification of histones H3 and H4, respectively.",
      "TFIIS can promote the disruption of nucleosome structure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TFIIS (Transcription Factor IIS) does not play a role in nucleosome positioning; it is involved in the process of transcription elongation by stimulating the RNA polymerase II's intrinsic cleavage activity to overcome transcriptional arrest.\n2. FALSE [correction]: TFIIS is not involved in the initiation of transcription; it is involved in transcription elongation.\n3. UNKNOWN: Without specific literature references, it is unclear whether TFIIS directly interacts with the histone-modifying enzymes SUV39H1 and SUV40H1.\n4. FALSE [correction]: Histone-modifying enzymes SUV39H1 and SUV40H1 are both primarily involved in the methylation of histone H3, not H3 and H4 respectively. SUV39H1 is known for tri-methylating lysine 9 on histone H3 (H3K9me3), a marker for heterochromatin.\n5. UNKNOWN: The role of TFIIS in nucleosome structure disruption is not well-established and would require specific references to confirm its involvement in such a process.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Origins of replication near yeast centromeres fire early. Specifically, the origins of replication in the vicinity of the yeast centromere fire earlier than those located farther away from the centromere. This is because the centromere region is highly compacted and contains many highly repetitive DNA sequences, which can make it difficult for the replisome to advance along the DNA molecule. As a result, the origins of replication near the centromere fire earlier to help ensure that the chromosome is properly replicated and segregated during cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. Origins of replication near yeast centromeres fire early.\n2. The origins of replication in the vicinity of the yeast centromere fire earlier than those located farther away from the centromere.\n3. The centromere region is highly compacted.\n4. The centromere region contains many highly repetitive DNA sequences.\n5. Early firing of origins near the centromere helps ensure proper chromosome replication and segregation during cell division.",
    "llama-2-7b-chat-hf_fact": [
      "Origins of replication near yeast centromeres fire early.",
      "The origins of replication in the vicinity of the yeast centromere fire earlier than those located farther away from the centromere.",
      "The centromere region is highly compacted.",
      "The centromere region contains many highly repetitive DNA sequences.",
      "Early firing of origins near the centromere helps ensure proper chromosome replication and segregation during cell division."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The centromere region typically contains a unique DNA sequence that is not highly repetitive in yeast. In other organisms, such as humans, the centromere can contain highly repetitive DNA sequences.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Mammalian GA-sequences, also known as GAGA-sequences, are a specific type of RNA sequence found in the genes of mammals. Here are some of the properties of mammalian GA-sequences:\n1. Location: GA-sequences are typically located in the 3' untranslated region (3' UTR) of mRNAs.\n2. Structure: GA-sequences are composed of a conserved sequence of about 10-15 nucleotides, with the consensus sequence being GA (guanine-adenine) repeated 2-5 times.\n3. Function: GA-sequences are involved in the regulation of mRNA stability, translation, and localization. They can act as a destabilizing element by binding to the miRNA-induced silencing complex (miRISC) and preventing the degradation of target mRNAs.\n4. Conservation: GA-sequences are highly conserved across different species, indicating their importance in mammalian biology.\n5. Regulation: GA-sequences can be regulated by various factors, including transcription factors, microRNAs (miRNAs), and other RNA-binding proteins.\n6. Impact on gene expression: GA-sequences can have a significant impact on the expression of adjacent genes by altering their stability, translation efficiency, or localization.\n7. Involvement in disease: GA-sequences have been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders.\n8. Interaction with other RNA elements: GA-sequences can interact with other RNA elements, such as microRNAs, to modulate their function and affect gene expression.\n9. Regulation of translation: GA-sequences can also regulate translation efficiency by altering the binding of ribosomes to the mRNA.\n10. Impact on cellular processes: GA-sequences play a critical role in various cellular processes, including cell proliferation, differentiation, and survival.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences, also known as GAGA-sequences, are typically located in the 3' untranslated region (3' UTR) of mRNAs.\n2. GA-sequences are composed of a conserved sequence of about 10-15 nucleotides, with the consensus sequence being GA (guanine-adenine) repeated 2-5 times.\n3. GA-sequences are involved in the regulation of mRNA stability, translation, and localization.\n4. GA-sequences are highly conserved across different species.\n5. GA-sequences have been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences, also known as GAGA-sequences, are typically located in the 3' untranslated region (3' UTR) of mRNAs.",
      "GA-sequences are composed of a conserved sequence of about 10-15 nucleotides, with the consensus sequence being GA (guanine-adenine) repeated 2-5 times.",
      "GA-sequences are involved in the regulation of mRNA stability, translation, and localization.",
      "GA-sequences are highly conserved across different species.",
      "GA-sequences have been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mammalian GA-sequences, also known as GAGA-sequences, are typically associated with promoter regions of genes and are not located in the 3' untranslated region (3' UTR) of mRNAs.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "The mouse genome contains 12 Groucho-related genes (GRG), also known as Groucho-like genes (Glg). These genes are:\n1. Groucho (Gro1)\n2. Groucho-like 1 (Glg1)\n3. Groucho-like 2 (Glg2)\n4. Groucho-like 3 (Glg3)\n5. Groucho-like 4 (Glg4)\n6. Groucho-like 5 (Glg5)\n7. Groucho-like 6 (Glg6)\n8. Groucho-like 7 (Glg7)\n9. Groucho-like 8 (Glg8)\n10. Groucho-like 9 (Glg9)\n11. Groucho-like 10 (Glg10)\n12. Groucho-like 11 (Glg11)\nThese genes are involved in various cellular processes, including transcriptional regulation, signaling pathways, and development.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse genome contains 12 Groucho-related genes (GRG).\n2. Groucho-related genes are also known as Groucho-like genes (Glg).\n3. The genes include Groucho (Gro1) and Groucho-like genes Glg1 through Glg11.\n4. These genes are involved in transcriptional regulation.\n5. These genes play a role in signaling pathways and development.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse genome contains 12 Groucho-related genes (GRG).",
      "Groucho-related genes are also known as Groucho-like genes (Glg).",
      "The genes include Groucho (Gro1) and Groucho-like genes Glg1 through Glg11.",
      "These genes are involved in transcriptional regulation.",
      "These genes play a role in signaling pathways and development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nThe statements regarding the specific number and naming of Groucho-related genes in the mouse genome (statements 1, 2, and 3) are not common knowledge and would require specific genetic or biological research data to confirm. Without access to the current and specific scientific literature or databases, it is not possible to verify the accuracy of these statements.\n\nHowever, it is generally true that Groucho-related genes (statement 4) are involved in transcriptional regulation, as Groucho/TLE family members are known to be transcriptional corepressors in various species.\n\nAdditionally, it is true that these genes (statement 5) play a role in signaling pathways and development, as they are involved in several key developmental processes and pathways, such as Notch signaling and Wnt signaling.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "RNA polymerase II (RNA Pol II) is a complex enzyme that carries out transcription of DNA into RNA. There are two subunits of RNA Pol II: RNA Pol IIα and RNA Pol IIβ. RNA Pol IIα is the subunit that carries RNA cleavage activity.\nRNA Pol IIα contains a conserved domain called the cleavage domain, which is responsible for the cleavage of RNA transcripts after transcription. The cleavage domain is located in the C-terminal region of RNA Pol IIα and is composed of a series of conserved amino acid residues that are essential for RNA cleavage.\nRNA cleavage is an important step in the transcription and maturation of RNA molecules. It allows for the removal of introns (non-coding regions) and the formation of mature RNA transcripts that are ready for translation or other post-transcriptional processes.\nIn summary, RNA Pol IIα is the subunit of RNA Pol II that carries RNA cleavage activity, and it is responsible for the cleavage of RNA transcripts after transcription.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNA polymerase II (RNA Pol II) is responsible for the transcription of DNA into RNA.\n2. RNA Pol II has two subunits: RNA Pol IIα and RNA Pol IIβ.\n3. The RNA Pol IIα subunit carries RNA cleavage activity.\n4. The cleavage domain responsible for RNA cleavage is located in the C-terminal region of RNA Pol IIα.\n5. RNA cleavage is a step in the transcription and maturation of RNA molecules that involves the removal of introns and the formation of mature RNA transcripts.",
    "llama-2-7b-chat-hf_fact": [
      "RNA polymerase II (RNA Pol II) is responsible for the transcription of DNA into RNA.",
      "RNA Pol II has two subunits: RNA Pol IIα and RNA Pol IIβ.",
      "The RNA Pol IIα subunit carries RNA cleavage activity.",
      "The cleavage domain responsible for RNA cleavage is located in the C-terminal region of RNA Pol IIα.",
      "RNA cleavage is a step in the transcription and maturation of RNA molecules that involves the removal of introns and the formation of mature RNA transcripts."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: RNA polymerase II (RNA Pol II) does not have just two subunits; it is a complex enzyme composed of multiple subunits.\n3. FALSE [correction]: RNA cleavage activity is not a function of RNA polymerase II subunits; it is typically carried out by other enzymes such as endonucleases or the spliceosome during RNA processing.\n4. FALSE [correction]: Since the RNA Pol IIα subunit does not carry RNA cleavage activity, it does not have a cleavage domain responsible for RNA cleavage.\n5. FALSE [correction]: RNA cleavage during the maturation of RNA molecules is not involved in the removal of introns. The removal of introns is a separate process called RNA splicing. RNA cleavage is involved in the termination of transcription and the addition of a poly(A) tail to the 3' end of the RNA transcript.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Ohdo syndrome is a rare genetic disorder that is caused by mutations in the GTF2I gene. The GTF2I gene provides instructions for making a protein called GTF2I, which is involved in the splicing of messenger RNA (mRNA) molecules. Specifically, GTF2I helps to remove introns (non-coding regions) and join exons (coding regions) together to form mature mRNA molecules.\nMutations in the GTF2I gene can lead to the formation of abnormal mRNA molecules, which can disrupt the normal functioning of cells and lead to the development of Ohdo syndrome. The syndrome is characterized by a range of symptoms, including intellectual disability, delayed speech and language development, seizures, and distinctive facial features. Ohdo syndrome is a rare disorder, and the prevalence is not well established. However, it is estimated to affect approximately 1 in 100,000 to 1 in 50,000 individuals worldwide.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is a rare genetic disorder caused by mutations in the GTF2I gene.\n2. The GTF2I gene is involved in the splicing of messenger RNA (mRNA) molecules.\n3. Mutations in the GTF2I gene can lead to the formation of abnormal mRNA molecules.\n4. Symptoms of Ohdo syndrome include intellectual disability, delayed speech and language development, seizures, and distinctive facial features.\n5. Ohdo syndrome is estimated to affect approximately 1 in 100,000 to 1 in 50,000 individuals worldwide.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is a rare genetic disorder caused by mutations in the GTF2I gene.",
      "The GTF2I gene is involved in the splicing of messenger RNA (mRNA) molecules.",
      "Mutations in the GTF2I gene can lead to the formation of abnormal mRNA molecules.",
      "Symptoms of Ohdo syndrome include intellectual disability, delayed speech and language development, seizures, and distinctive facial features.",
      "Ohdo syndrome is estimated to affect approximately 1 in 100,000 to 1 in 50,000 individuals worldwide."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ohdo syndrome is a rare genetic disorder, but it is not typically caused by mutations in the GTF2I gene. It is often associated with mutations in other genes, such as KAT6B or MED12.\n2. FALSE [correction]: The GTF2I gene is involved in transcriptional control and the regulation of gene expression, not specifically in the splicing of messenger RNA (mRNA) molecules.\n3. UNKNOWN: Without specific context on the GTF2I gene's functions, it is difficult to determine the accuracy of this statement. However, mutations in genes that are involved in gene expression regulation can potentially lead to the formation of abnormal mRNA molecules.\n4. TRUE: Symptoms of Ohdo syndrome can include intellectual disability, delayed speech and language development, seizures, and distinctive facial features.\n5. UNKNOWN: The prevalence of Ohdo syndrome is not well-established, and the provided estimate may not be accurate. Due to its rarity, precise prevalence rates are difficult to determine.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "There are several R/Bioconductor packages that have been developed for the analysis of psychiatric disease genes. Some of the popular ones include:\n1. PsychGen: This package provides a comprehensive set of tools for the analysis of genetic data in psychiatric disorders, including gene-level association testing, pathway analysis, and gene-gene interaction analysis.\n2. PsychArray: This package is designed to analyze genetic data from genome-wide association studies (GWAS) and other genetic markers in the context of psychiatric disorders. It provides tools for association testing, gene-gene interaction analysis, and pathway analysis.\n3. PsychGenius: This package is a collection of R packages for the analysis of genetic data in psychiatric disorders. It includes tools for gene-level association testing, pathway analysis, and gene-gene interaction analysis, as well as methods for visualizing and interpreting results.\n4. PsychGWAS: This package provides a comprehensive set of tools for the analysis of GWAS data in psychiatric disorders, including gene-level association testing, pathway analysis, and gene-gene interaction analysis.\n5. PsychBioma: This package is designed to analyze genetic data from next-generation sequencing (NGS) studies in psychiatric disorders. It provides tools for variant filtering, gene-level association testing, and pathway analysis.\nIt's worth noting that these packages are constantly being updated and new packages are being developed, so it's always a good idea to check the latest versions and documentation for the most up-to-date information.",
    "llama-2-7b-chat-hf_fact_raw": "1. PsychGen is an R/Bioconductor package developed for the analysis of genetic data in psychiatric disorders.\n2. PsychArray is designed to analyze genetic data from genome-wide association studies in the context of psychiatric disorders.\n3. PsychGenius is a collection of R packages for the analysis of genetic data in psychiatric disorders.\n4. PsychGWAS provides tools for the analysis of GWAS data in psychiatric disorders.\n5. PsychBioma is an R/Bioconductor package designed to analyze genetic data from next-generation sequencing studies in psychiatric disorders.",
    "llama-2-7b-chat-hf_fact": [
      "PsychGen is an R/Bioconductor package developed for the analysis of genetic data in psychiatric disorders.",
      "PsychArray is designed to analyze genetic data from genome-wide association studies in the context of psychiatric disorders.",
      "PsychGenius is a collection of R packages for the analysis of genetic data in psychiatric disorders.",
      "PsychGWAS provides tools for the analysis of GWAS data in psychiatric disorders.",
      "PsychBioma is an R/Bioconductor package designed to analyze genetic data from next-generation sequencing studies in psychiatric disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information about the R/Bioconductor packages, it is not possible to verify the existence or purpose of \"PsychGen.\"\n2. FALSE [correction]: PsychArray is not a software package but rather a type of microarray chip designed specifically for genetic studies in psychiatric disorders. It is used to genotype individuals and analyze genetic variations associated with psychiatric conditions.\n3. FALSE [correction]: There is no widely recognized collection of R packages known as \"PsychGenius\" for the analysis of genetic data in psychiatric disorders. This could be a fictional or less known collection, and without further context, its existence cannot be verified.\n4. UNKNOWN: The name \"PsychGWAS\" suggests it could be related to the analysis of Genome-Wide Association Studies (GWAS) data in psychiatric disorders, but without specific information, it is not possible to confirm the existence or purpose of such a package.\n5. UNKNOWN: Similar to the previous statements, without specific information about the R/Bioconductor packages, it is not possible to verify the existence or purpose of \"PsychBioma.\"",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Swirl sign is a radiological sign that is often seen in patients with intracerebral hemorrhage (ICH), which is a type of stroke caused by bleeding in the brain. The sign is characterized by a spiral or swirling pattern of blood flow within the hemorrhage, which is visible on computed tomography (CT) or magnetic resonance imaging (MRI) scans.\nThe swirl sign is thought to be caused by the turbulent flow of blood within the hemorrhage, which creates a swirling motion that can be visualized on imaging studies. This motion can be due to a variety of factors, including the location and size of the hemorrhage, the pressure gradient within the brain, and the presence of any underlying vascular abnormalities.\nThe swirl sign can be an important diagnostic indicator in patients with ICH, as it can help to identify the location and severity of the hemorrhage. For example, a swirl sign may indicate that the hemorrhage is located in a specific region of the brain, such as the basal ganglia or the cerebral cortex, and may suggest a higher risk of neurological deficits or complications.\nHowever, it is important to note that the swirl sign is not a definitive diagnostic indicator of ICH, and other conditions, such as vasogenic edema or cerebral infarction, can also produce similar imaging findings. Therefore, a definitive diagnosis of ICH should be made based on a combination of clinical, imaging, and laboratory findings.",
    "llama-2-7b-chat-hf_fact_raw": "1. Swirl sign is a radiological sign often seen in patients with intracerebral hemorrhage (ICH).\n2. Intracerebral hemorrhage is a type of stroke caused by bleeding in the brain.\n3. The swirl sign is characterized by a spiral or swirling pattern of blood flow within the hemorrhage, visible on CT or MRI scans.\n4. The swirl sign can help to identify the location and severity of the hemorrhage in the brain.\n5. The swirl sign may suggest a higher risk of neurological deficits or complications in patients with ICH.",
    "llama-2-7b-chat-hf_fact": [
      "Swirl sign is a radiological sign often seen in patients with intracerebral hemorrhage (ICH).",
      "Intracerebral hemorrhage is a type of stroke caused by bleeding in the brain.",
      "The swirl sign is characterized by a spiral or swirling pattern of blood flow within the hemorrhage, visible on CT or MRI scans.",
      "The swirl sign can help to identify the location and severity of the hemorrhage in the brain.",
      "The swirl sign may suggest a higher risk of neurological deficits or complications in patients with ICH."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The swirl sign is characterized by the presence of a heterogeneous appearance within a hematoma, with areas of low attenuation (due to ongoing bleeding) on a CT scan, not a spiral or swirling pattern of blood flow.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Arabidopsis ROF1 (RNA polymerase II-associated factor 1) is a transcriptional elongation factor that plays a crucial role in regulating gene expression, particularly during stress responses. ROF1 expression is inducible in Arabidopsis thaliana by various environmental and physiological cues, including:\n1. Abiotic stressors: ROF1 expression is upregulated in response to abiotic stressors such as drought, salinity, high temperature, and oxidative stress.\n2. Pathogen infection: ROF1 expression is also induced upon infection with pathogens such as bacteria and fungi, suggesting a role in the plant's immune response.\n3. Hormonal regulation: ROF1 expression is modulated by various hormones, including ethylene, auxin, and cytokinin, which play important roles in plant growth and development.\n4. Developmental cues: ROF1 expression is also regulated by developmental signals, such as light and temperature, which influence the expression of genes involved in various cellular processes.\n5. Epigenetic modifications: ROF1 expression can be influenced by epigenetic modifications, such as DNA methylation and histone modifications, which can affect the stability and accessibility of the ROF1 gene.\nOverall, the regulation of ROF1 expression is complex and involves the interplay of multiple signaling pathways and cues, highlighting its importance in the response to environmental and physiological changes in Arabidopsis thaliana.",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is upregulated in response to abiotic stressors such as drought, salinity, high temperature, and oxidative stress.\n2. ROF1 expression in Arabidopsis thaliana is induced upon infection with pathogens such as bacteria and fungi.\n3. Various hormones, including ethylene, auxin, and cytokinin, modulate ROF1 expression in Arabidopsis thaliana.\n4. Developmental signals, such as light and temperature, regulate ROF1 expression in Arabidopsis thaliana.\n5. Epigenetic modifications, like DNA methylation and histone modifications, can influence the expression of the ROF1 gene in Arabidopsis thaliana.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is upregulated in response to abiotic stressors such as drought, salinity, high temperature, and oxidative stress.",
      "ROF1 expression in Arabidopsis thaliana is induced upon infection with pathogens such as bacteria and fungi.",
      "Various hormones, including ethylene, auxin, and cytokinin, modulate ROF1 expression in Arabidopsis thaliana.",
      "Developmental signals, such as light and temperature, regulate ROF1 expression in Arabidopsis thaliana.",
      "Epigenetic modifications, like DNA methylation and histone modifications, can influence the expression of the ROF1 gene in Arabidopsis thaliana."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with general knowledge about plant stress responses and gene regulation. Arabidopsis thaliana is a model organism in plant biology, and it is well-documented that plant genes, including ROF1, can be regulated by various abiotic and biotic stressors, hormones, developmental signals, and epigenetic modifications. However, without specific references to scientific studies, the exact details of ROF1 regulation by these factors cannot be confirmed, but the statements are plausible based on current understanding of plant biology.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "The most common cause of hereditary renal amyloidosis is the protein alpha-2-macroglobulin (A2M). A2M is a glycoprotein that is produced in the liver and is primarily responsible for the majority of hereditary renal amyloidosis cases. The accumulation of A2M in the kidneys leads to the formation of amyloid fibrils, which are the hallmark of hereditary renal amyloidosis. Other proteins, such as apolipoprotein A-I and transthyretin, can also cause hereditary renal amyloidosis, but A2M is by far the most common culprit.",
    "llama-2-7b-chat-hf_fact_raw": "1. Alpha-2-macroglobulin (A2M) is the most common cause of hereditary renal amyloidosis.\n2. A2M is a glycoprotein produced in the liver.\n3. The accumulation of A2M in the kidneys leads to the formation of amyloid fibrils.\n4. Amyloid fibrils are the hallmark of hereditary renal amyloidosis.\n5. Apolipoprotein A-I and transthyretin can also cause hereditary renal amyloidosis, but A2M is the most common.",
    "llama-2-7b-chat-hf_fact": [
      "Alpha-2-macroglobulin (A2M) is the most common cause of hereditary renal amyloidosis.",
      "A2M is a glycoprotein produced in the liver.",
      "The accumulation of A2M in the kidneys leads to the formation of amyloid fibrils.",
      "Amyloid fibrils are the hallmark of hereditary renal amyloidosis.",
      "Apolipoprotein A-I and transthyretin can also cause hereditary renal amyloidosis, but A2M is the most common."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Alpha-2-macroglobulin (A2M) is not the most common cause of hereditary renal amyloidosis. The most common cause is mutations in the gene encoding for transthyretin (TTR).\n2. TRUE\n3. FALSE [correction]: The accumulation of A2M in the kidneys does not lead to the formation of amyloid fibrils. It is the accumulation of misfolded proteins such as transthyretin, not A2M, that leads to amyloid fibril formation in hereditary renal amyloidosis.\n4. TRUE\n5. FALSE [correction]: Apolipoprotein A-I and transthyretin can cause hereditary renal amyloidosis, but transthyretin is the most common, not A2M.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been extensively analyzed using various proteomics techniques. The hippocampus is a brain region involved in memory and emotion regulation, and its proteome has been studied in various contexts, including development, aging, disease, and drug treatment.\nSome of the key findings from these studies include:\n1. Developmental changes: Studies have shown that the proteome of the mouse hippocampus changes during development, with many proteins being upregulated or downregulated during specific stages of development.\n2. Aging: The hippocampus proteome has been found to change with age, with a decrease in protein abundance and an increase in protein degradation.\n3. Disease: The hippocampus proteome has been altered in various neurological disorders, including Alzheimer's disease, Parkinson's disease, and depression.\n4. Drug treatment: The hippocampus proteome has been found to change in response to various drugs, including those used to treat depression, anxiety, and epilepsy.\nSome of the key proteins found to be differentially expressed in the hippocampus include:\n1. Synaptic proteins: Many proteins involved in synaptic transmission and plasticity, such as synaptotagmin, VGluT1, and VGAT, have been found to be differentially expressed in the hippocampus.\n2. Neurotrophic factors: BDNF, a neurotrophic factor involved in synaptic plasticity and neuronal survival, has been found to be upregulated in the hippocampus.\n3. Cytoskeleton proteins: Actin, tubulin, and tau, which are involved in cytoskeleton organization and dynamics, have been found to be differentially expressed in the hippocampus.\n4. Metabolic proteins: Proteins involved in energy metabolism, such as ATP synthase and succinate dehydrogenase, have been found to be differentially expressed in the hippocampus.\n5. Stress response proteins: Proteins involved in stress response pathways, such as heat shock",
    "llama-2-7b-chat-hf_fact_raw": "1. The proteome of the mouse hippocampus has been analyzed using various proteomics techniques.\n2. The proteome of the mouse hippocampus changes during development, with proteins being upregulated or downregulated during specific stages.\n3. There is a decrease in protein abundance and an increase in protein degradation in the hippocampus proteome with age.\n4. The hippocampus proteome is altered in various neurological disorders, including Alzheimer's disease, Parkinson's disease, and depression.\n5. Synaptic proteins, neurotrophic factors, cytoskeleton proteins, metabolic proteins, and stress response proteins have been found to be differentially expressed in the mouse hippocampus.",
    "llama-2-7b-chat-hf_fact": [
      "The proteome of the mouse hippocampus has been analyzed using various proteomics techniques.",
      "The proteome of the mouse hippocampus changes during development, with proteins being upregulated or downregulated during specific stages.",
      "There is a decrease in protein abundance and an increase in protein degradation in the hippocampus proteome with age.",
      "The hippocampus proteome is altered in various neurological disorders, including Alzheimer's disease, Parkinson's disease, and depression.",
      "Synaptic proteins, neurotrophic factors, cytoskeleton proteins, metabolic proteins, and stress response proteins have been found to be differentially expressed in the mouse hippocampus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: It is common for the proteome of specific brain regions such as the mouse hippocampus to be analyzed using various proteomics techniques to understand the protein composition and its changes under different conditions.\n2. TRUE: The proteome of the mouse hippocampus, like other tissues, changes during development, and proteins can indeed be upregulated or downregulated during specific stages.\n3. TRUE: It is a well-documented phenomenon that with age, there is generally a decrease in protein synthesis and an increase in protein degradation in various tissues, including the brain's hippocampus.\n4. TRUE: The hippocampus proteome is known to be altered in various neurological disorders, and these alterations can be associated with diseases such as Alzheimer's disease, Parkinson's disease, and depression.\n5. TRUE: In studies of the hippocampus, synaptic proteins, neurotrophic factors, cytoskeleton proteins, metabolic proteins, and stress response proteins are among the categories of proteins that have been found to be differentially expressed.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "No, mouse chromosomes are not acrocentric. Acrocentric chromosomes are characterized by a centromere that is located near the center of the chromosome, and mouse chromosomes do not have this feature. Instead, mouse chromosomes are metacentric, meaning that the centromere is located near the middle of the chromosome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mouse chromosomes are not acrocentric.\n2. Acrocentric chromosomes have a centromere that is located near one end of the chromosome.\n3. Mouse chromosomes are metacentric.\n4. Metacentric chromosomes have a centromere that is located near the middle of the chromosome.",
    "llama-2-7b-chat-hf_fact": [
      "Mouse chromosomes are not acrocentric.",
      "Acrocentric chromosomes have a centromere that is located near one end of the chromosome.",
      "Mouse chromosomes are metacentric.",
      "Metacentric chromosomes have a centromere that is located near the middle of the chromosome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mouse chromosomes are acrocentric.\n2. TRUE\n3. FALSE [correction]: Mouse chromosomes are not metacentric; they are acrocentric.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "There are several siRNA-based drugs that are currently in clinical trials for the treatment of pancreatic cancer. Some of these include:\n1. ONC205: ONC205 is an siRNA-based drug that targets the gene encoding the protein PD-L1 (programmed death-ligand 1). PD-L1 is a protein that helps cancer cells evade the immune system, and ONC205 has shown promise in preclinical studies as a potential treatment for pancreatic cancer. ONC205 is currently being tested in a Phase 1 clinical trial for the treatment of pancreatic cancer.\n2. RX-0201: RX-0201 is an siRNA-based drug that targets the gene encoding the protein KRAS (Kirsten rat sarcoma viral oncogene homolog). KRAS is a gene that is frequently mutated in pancreatic cancer, and RX-0201 has shown promise in preclinical studies as a potential treatment for KRAS-mutated pancreatic cancer. RX-0201 is currently being tested in a Phase 1 clinical trial for the treatment of pancreatic cancer.\n3. GDC-0209: GDC-0209 is an siRNA-based drug that targets the gene encoding the protein P53 (tumor suppressor protein 53). P53 is a protein that is frequently mutated in pancreatic cancer, and GDC-0209 has shown promise in preclinical studies as a potential treatment for pancreatic cancer. GDC-0209 is currently being tested in a Phase 1 clinical trial for the treatment of pancreatic cancer.\n4. APG-01555: APG-01555 is an siRNA-based drug that targets the gene encoding the protein EZH2 (enhancer of zeste homolog 2). EZH2 is a protein that is involved in the regulation of gene expression and is frequently overexpressed in pancreatic cancer. APG-01555 has shown promise in preclinical studies as a potential treatment for pancreatic cancer, and is currently being tested",
    "llama-2-7b-chat-hf_fact_raw": "1. ONC205 is an siRNA-based drug that targets the gene encoding PD-L1 and is in a Phase 1 clinical trial for pancreatic cancer treatment.\n2. RX-0201 is an siRNA-based drug that targets the gene encoding KRAS and is in a Phase 1 clinical trial for pancreatic cancer treatment.\n3. GDC-0209 is an siRNA-based drug that targets the gene encoding P53 and is in a Phase 1 clinical trial for pancreatic cancer treatment.\n4. APG-01555 is an siRNA-based drug that targets the gene encoding EZH2 and is in clinical trials for pancreatic cancer treatment.",
    "llama-2-7b-chat-hf_fact": [
      "ONC205 is an siRNA-based drug that targets the gene encoding PD-L1 and is in a Phase 1 clinical trial for pancreatic cancer treatment.",
      "RX-0201 is an siRNA-based drug that targets the gene encoding KRAS and is in a Phase 1 clinical trial for pancreatic cancer treatment.",
      "GDC-0209 is an siRNA-based drug that targets the gene encoding P53 and is in a Phase 1 clinical trial for pancreatic cancer treatment.",
      "APG-01555 is an siRNA-based drug that targets the gene encoding EZH2 and is in clinical trials for pancreatic cancer treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nThe correctness of these statements depends on the current status of clinical trials and drug development, which is subject to change and requires up-to-date information from reliable medical sources or databases. Without access to the latest data, it is not possible to verify the accuracy of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "The HPG (H+/K+-ATPase pump glycoprotein) pore is a protein complex that functions as a proton (H+) and potassium (K+) ion pump in the endoplasmic reticulum (ER) of eukaryotic cells. It is also known as the ATPase pump or V-ATPase.\nThe HPG pore is composed of several subunits, including the catalytic subunit (V1) and the regulatory subunit (V0), which are arranged in a heterodimeric structure. The pore is located in the lipid bilayer of the ER and spans the membrane, allowing the transport of protons and potassium ions across the membrane.\nThe HPG pore plays a crucial role in maintaining the pH gradient across the ER membrane, which is essential for various cellular processes, including protein folding, calcium homeostasis, and the transport of molecules across the membrane. The pore is also involved in the regulation of ion homeostasis in the cell, particularly in the ER, and helps to maintain the proper concentration gradients of ions and ions across the membrane.\nDysfunction of the HPG pore has been implicated in various diseases, including cancer, neurological disorders, and metabolic disorders. For example, mutations in the V-ATPase subunits have been linked to certain types of cancer, and alterations in the pore's activity have been observed in neurodegenerative diseases such as Alzheimer's and Parkinson's.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG pore functions as a proton (H+) and potassium (K+) ion pump in the endoplasmic reticulum of eukaryotic cells.\n2. The HPG pore is also known as the ATPase pump or V-ATPase.\n3. The HPG pore is composed of several subunits, including the catalytic subunit (V1) and the regulatory subunit (V0).\n4. The HPG pore plays a role in maintaining the pH gradient across the ER membrane, which is essential for various cellular processes.\n5. Dysfunction of the HPG pore has been implicated in various diseases, including cancer, neurological disorders, and metabolic disorders.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG pore functions as a proton (H+) and potassium (K+) ion pump in the endoplasmic reticulum of eukaryotic cells.",
      "The HPG pore is also known as the ATPase pump or V-ATPase.",
      "The HPG pore is composed of several subunits, including the catalytic subunit (V1) and the regulatory subunit (V0).",
      "The HPG pore plays a role in maintaining the pH gradient across the ER membrane, which is essential for various cellular processes.",
      "Dysfunction of the HPG pore has been implicated in various diseases, including cancer, neurological disorders, and metabolic disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The HPG pore is not a recognized term for a proton and potassium ion pump in the endoplasmic reticulum of eukaryotic cells. The proton pump commonly associated with cellular membranes, including the endoplasmic reticulum, is the H+/K+ ATPase or the V-ATPase, but they are distinct entities and not referred to as the HPG pore.\n2. FALSE [correction]: The term \"HPG pore\" is not commonly used to refer to the ATPase pump or V-ATPase. V-ATPase is the correct term for the proton pump found in various membranes within eukaryotic cells.\n3. FALSE [correction]: While V-ATPase is composed of several subunits, including the catalytic (V1) and the membrane-integral (V0) subunits, this description does not apply to the \"HPG pore\" as it is not a recognized term.\n4. UNKNOWN: Since the HPG pore is not a recognized term, it is unclear what this statement is referring to. However, if this statement is meant to describe the V-ATPase, then it would be true that V-ATPase plays a role in maintaining the pH gradient across various cellular membranes, which is essential for numerous cellular processes.\n5. UNKNOWN: As the HPG pore is not a recognized term, it is not possible to determine the accuracy of this statement. However, dysfunction of the V-ATPase has been implicated in various diseases, including cancer, neurological disorders, and metabolic disorders. If the statement is referring to V-ATPase, then it could be considered true.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes initiative is a research project aimed at sequencing the genomes of all known species of nematode worms, which are a group of parasitic and free-living worms that are important model organisms in biology and medicine. The initiative was launched in 2014 and is led by the University of California, San Diego, in collaboration with other institutions and organizations.\nNematodes are a diverse group of organisms that include plant-parasitic nematodes, animal-parasitic nematodes, and free-living nematodes. They are important model organisms in biology and medicine due to their simple body structure, ease of manipulation, and the conservation of many genetic processes across different species. The 959 Nematode Genomes initiative aims to generate high-quality genomic data for all known nematode species, which will provide a comprehensive understanding of the evolution, development, and biology of these organisms.\nThe initiative involves the sequencing of over 959 nematode species using a variety of genomic technologies, including Illumina and PacBio sequencing. The generated data will be made publicly available through a centralized database, which will enable researchers to access and analyze the genomic data of different nematode species. The project also includes the development of computational tools and methods for the analysis and interpretation of nematode genomic data.\nThe 959 Nematode Genomes initiative is expected to have significant impacts on our understanding of nematode biology and their interactions with plants and animals, as well as the development of new drugs and therapies for nematode-related diseases. It will also provide a framework for the study of genome evolution and the development of new genomic technologies.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence the genomes of all known species of nematode worms.\n2. The initiative was launched in 2014 and is led by the University of California, San Diego.\n3. The initiative includes plant-parasitic nematodes, animal-parasitic nematodes, and free-living nematodes.\n4. The project involves the use of genomic technologies such as Illumina and PacBio sequencing.\n5. The genomic data from the initiative will be made publicly available through a centralized database.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence the genomes of all known species of nematode worms.",
      "The initiative was launched in 2014 and is led by the University of California, San Diego.",
      "The initiative includes plant-parasitic nematodes, animal-parasitic nematodes, and free-living nematodes.",
      "The project involves the use of genomic technologies such as Illumina and PacBio sequencing.",
      "The genomic data from the initiative will be made publicly available through a centralized database."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 959 Nematode Genomes initiative, also known as the 959 Nematode Genomes Project or the 1K Nematode Genomes Project, does not aim to sequence the genomes of all known species of nematode worms, which number in the tens of thousands. Instead, it aims to sequence the genomes of approximately 959 species, which is a representative sample of the phylum Nematoda.\n2. UNKNOWN: Without specific information on the launch date and the leading institution, it is not possible to verify the accuracy of this statement.\n3. TRUE: The initiative likely includes a variety of nematode types, including plant-parasitic, animal-parasitic, and free-living nematodes, as these represent the diversity within the phylum Nematoda.\n4. TRUE: Genomic projects typically involve the use of advanced genomic technologies such as Illumina (short-read) and PacBio (long-read) sequencing platforms.\n5. TRUE: Large-scale genomic initiatives commonly aim to make their data publicly available through centralized databases for the benefit of the scientific community and to promote further research.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data. Some of the popular ones include:\n1. NIPTkit: This is a comprehensive R package for NIPT data analysis, which includes various methods for detecting genetic abnormalities such as trisomies 21, 18, and 13, as well as sex chromosome abnormalities.\n2. Prenat: This package provides a comprehensive framework for NIPT data analysis, including methods for detecting trisomies, sex chromosome abnormalities, and other genetic disorders.\n3. NIPT: This package provides a simple and efficient way to perform NIPT analysis, including the calculation of the probability of trisomy 21, 18, and 13, as well as the detection of sex chromosome abnormalities.\n4. NIPT-analysis: This package provides a comprehensive set of functions for NIPT data analysis, including methods for detecting trisomies, sex chromosome abnormalities, and other genetic disorders.\n5. PrenatalGenetics: This package provides a collection of R functions for prenatal genetic testing, including NIPT analysis, and also includes functions for data visualization and interpretation.\nThese packages can be used for various purposes such as data analysis, interpretation, and visualization of NIPT results, and can be easily integrated into clinical workflows. It is important to note that the accuracy and sensitivity of these packages may vary, and it is recommended to consult the package documentation and user guides for more information.",
    "llama-2-7b-chat-hf_fact_raw": "1. NIPTkit is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.\n2. Prenat is an R package that provides a framework for NIPT data analysis.\n3. The NIPT R package allows for the calculation of the probability of trisomy 21, 18, and 13.\n4. NIPT-analysis is an R package with functions for NIPT data analysis.\n5. PrenatalGenetics is an R package that includes functions for prenatal genetic testing and NIPT analysis.",
    "llama-2-7b-chat-hf_fact": [
      "NIPTkit is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "Prenat is an R package that provides a framework for NIPT data analysis.",
      "The NIPT R package allows for the calculation of the probability of trisomy 21, 18, and 13.",
      "NIPT-analysis is an R package with functions for NIPT data analysis.",
      "PrenatalGenetics is an R package that includes functions for prenatal genetic testing and NIPT analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe responses are based on the assumption that the statements refer to actual R packages designed for NIPT data analysis. However, without specific knowledge of all R packages available for NIPT, it is difficult to confirm the existence and functions of \"Prenat\" and \"PrenatalGenetics\" without further research. Therefore, the responses to statements 2 and 5 are marked as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome, also known as Achenbach-Koenig syndrome, is a rare genetic disorder characterized by a variety of physical and developmental abnormalities. It is caused by mutations in the CHRNA7 gene, which codes for a subunit of the nicotinic acetylcholine receptor.\nThe main features of Achenbach's syndrome include:\n1. Neonatal hypotonia: Achenbach's syndrome babies are born with low muscle tone, which can make them appear floppy or limp.\n2. Developmental delays: Children with Achenbach's syndrome typically experience delays in reaching developmental milestones, such as sitting, standing, and walking.\n3. Intellectual disability: Individuals with Achenbach's syndrome often have mild to moderate intellectual disability, which can range from mild to moderate.\n4. Facial dysmorphism: Achenbach's syndrome is characterized by distinctive facial features, including a small head, narrow eyes, a short nose, and a wide mouth.\n5. Distinctive hand features: People with Achenbach's syndrome may have abnormalities in the shape and structure of their hands, including a small head, short fingers, and a curved fifth finger.\n6. Neurological problems: Achenbach's syndrome can cause a range of neurological problems, including seizures, ataxia, and problems with balance and coordination.\n7. Behavioral problems: Some individuals with Achenbach's syndrome may experience behavioral problems, such as anxiety, hyperactivity, and mood swings.\n8. Increased risk of infections: Achenbach's syndrome can increase the risk of infections, particularly respiratory infections, due to the immune system dysfunction.\n9. Skeletal abnormalities: Achenbach's syndrome can cause various skeletal abnormalities, including scoliosis, kyphosis, and other spinal deformities.\n10. Cardiac problems: Some individuals with Achenbach's syndrome may experience cardiac problems, such as heart defects or abnormal heart rhythms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome is also known as Achenbach-Koenig syndrome.\n2. It is caused by mutations in the CHRNA7 gene.\n3. Achenbach's syndrome is characterized by neonatal hypotonia, where babies are born with low muscle tone.\n4. Individuals with Achenbach's syndrome often have mild to moderate intellectual disability.\n5. Achenbach's syndrome can increase the risk of infections, particularly respiratory infections.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome is also known as Achenbach-Koenig syndrome.",
      "It is caused by mutations in the CHRNA7 gene.",
      "Achenbach's syndrome is characterized by neonatal hypotonia, where babies are born with low muscle tone.",
      "Individuals with Achenbach's syndrome often have mild to moderate intellectual disability.",
      "Achenbach's syndrome can increase the risk of infections, particularly respiratory infections."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is not known as Achenbach-Koenig syndrome. Achenbach's syndrome is a condition characterized by spontaneous bruising of the hands or fingers.\n2. FALSE [correction]: Achenbach's syndrome is not caused by mutations in the CHRNA7 gene. The exact cause of Achenbach's syndrome is not well understood, but it is not typically associated with genetic mutations.\n3. FALSE [correction]: Achenbach's syndrome is not characterized by neonatal hypotonia. It is characterized by spontaneous bruising, typically in the hands or fingers, without an obvious cause.\n4. FALSE [correction]: Achenbach's syndrome does not typically involve intellectual disability. It is primarily a condition related to bruising.\n5. FALSE [correction]: There is no evidence to suggest that Achenbach's syndrome increases the risk of infections, particularly respiratory infections. It is primarily a condition that affects the skin and blood vessels in the hands or fingers.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "There are several algorithms used for the detection of long repeat expansions, including:\n1. Repeat Masker: This algorithm uses a hidden Markov model to identify repeat units and estimate their lengths.\n2. RepeatFinder: This algorithm uses a combination of sequence alignment and hidden Markov modeling to identify repeat units and estimate their lengths.\n3. Long Repeat Finder (LRF): This algorithm uses a combination of sequence alignment and hidden Markov modeling to identify repeat units and estimate their lengths.\n4. GATK (Genome Analysis Toolkit): This is a software package that includes several tools for variant discovery and genotyping, including tools for the detection of long repeat expansions.\n5. VarianceThreshold: This algorithm uses a Bayesian framework to estimate the probability that a given repeat expansion is pathogenic, based on the length of the repeat and other factors.\n6. RepeatAnalyzer: This algorithm uses a combination of sequence alignment and hidden Markov modeling to identify repeat units and estimate their lengths, and also can be used to identify the pathogenic repeats.\n7. RepeatScanner: This algorithm uses a combination of sequence alignment and hidden Markov modeling to identify repeat units and estimate their lengths, and also can be used to identify the pathogenic repeats.\n8. MetaPhlAn: This algorithm uses a combination of sequence alignment and hidden Markov modeling to identify repeat units and estimate their lengths, and also can be used to identify the pathogenic repeats.\nPlease note that these are some of the commonly used algorithms for detection of long repeat expansions, and there are many other algorithms available as well.",
    "llama-2-7b-chat-hf_fact_raw": "1. Repeat Masker is an algorithm that uses a hidden Markov model to identify repeat units and estimate their lengths.\n2. RepeatFinder is an algorithm that uses a combination of sequence alignment and hidden Markov modeling to identify repeat units and estimate their lengths.\n3. Long Repeat Finder (LRF) is an algorithm that uses a combination of sequence alignment and hidden Markov modeling to identify repeat units and estimate their lengths.\n4. GATK (Genome Analysis Toolkit) is a software package that includes tools for variant discovery and genotyping, which can be used for the detection of long repeat expansions.\n5. VarianceThreshold is an algorithm that uses a Bayesian framework to estimate the probability that a given repeat expansion is pathogenic.",
    "llama-2-7b-chat-hf_fact": [
      "Repeat Masker is an algorithm that uses a hidden Markov model to identify repeat units and estimate their lengths.",
      "RepeatFinder is an algorithm that uses a combination of sequence alignment and hidden Markov modeling to identify repeat units and estimate their lengths.",
      "Long Repeat Finder (LRF) is an algorithm that uses a combination of sequence alignment and hidden Markov modeling to identify repeat units and estimate their lengths.",
      "GATK (Genome Analysis Toolkit) is a software package that includes tools for variant discovery and genotyping, which can be used for the detection of long repeat expansions.",
      "VarianceThreshold is an algorithm that uses a Bayesian framework to estimate the probability that a given repeat expansion is pathogenic."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RepeatMasker is a program that uses sequence alignment to identify repeat elements in DNA sequences, not a hidden Markov model.\n2. UNKNOWN: Without more context, it's unclear whether RepeatFinder specifically uses a combination of sequence alignment and hidden Markov modeling. This description could apply to various algorithms, but without specific information about an algorithm named \"RepeatFinder,\" the statement's accuracy cannot be determined.\n3. UNKNOWN: Similar to statement 2, without more context or specific information about an algorithm named \"Long Repeat Finder (LRF),\" it's unclear whether this description is accurate.\n4. TRUE: GATK (Genome Analysis Toolkit) is indeed a software package that includes tools for variant discovery and genotyping. While it is primarily known for SNP and small indel discovery, it can be used in conjunction with other tools for the detection of larger genomic variations, including long repeat expansions.\n5. FALSE [correction]: VarianceThreshold is a feature selection method in machine learning that removes all features with variance below a certain threshold. It does not use a Bayesian framework to estimate the probability that a given repeat expansion is pathogenic.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Neuroligin-3 has been implicated in the development and progression of certain types of brain tumors, including:\n1. Glioblastoma (GBM): Neuroligin-3 has been shown to be overexpressed in GBM, and its overexpression promotes the proliferation and migration of GBM cells.\n2. Medulloblastoma: Neuroligin-3 is also overexpressed in medulloblastoma, a type of pediatric brain cancer that originates in the cerebellum.\n3. Astrocytoma: Neuroligin-3 has been detected in various types of astrocytic tumors, including glioblastoma and anaplastic astrocytoma.\n4. Oligodendroglioma: Neuroligin-3 is also overexpressed in oligodendroglial tumors, including oligodendroglioma and oligodendroglial glioblastoma.\nIn summary, neuroligin-3 promotes the development and progression of various types of brain tumors, including glioblastoma, medulloblastoma, astrocytoma, and oligodendroglioma.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 is overexpressed in glioblastoma (GBM) and promotes the proliferation and migration of GBM cells.\n2. Neuroligin-3 is overexpressed in medulloblastoma, a pediatric brain cancer that originates in the cerebellum.\n3. Neuroligin-3 has been detected in various types of astrocytic tumors, including anaplastic astrocytoma.\n4. Neuroligin-3 is overexpressed in oligodendroglial tumors, including oligodendroglioma.\n5. Neuroligin-3 promotes the development and progression of various types of brain tumors, such as glioblastoma, medulloblastoma, astrocytoma, and oligodendroglioma.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 is overexpressed in glioblastoma (GBM) and promotes the proliferation and migration of GBM cells.",
      "Neuroligin-3 is overexpressed in medulloblastoma, a pediatric brain cancer that originates in the cerebellum.",
      "Neuroligin-3 has been detected in various types of astrocytic tumors, including anaplastic astrocytoma.",
      "Neuroligin-3 is overexpressed in oligodendroglial tumors, including oligodendroglioma.",
      "Neuroligin-3 promotes the development and progression of various types of brain tumors, such as glioblastoma, medulloblastoma, astrocytoma, and oligodendroglioma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nNeuroligin-3 has been implicated in the biology of various brain tumors, including glioblastoma, medulloblastoma, astrocytomas, and oligodendrogliomas, where it can promote tumor cell proliferation and migration. However, it's important to note that the specific role of neuroligin-3 can vary depending on the tumor context and the scientific literature available at the time of the knowledge cutoff.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Gas vesicles are typically very small, ranging in size from about 0.1 to 1.0 micrometers (μm) in diameter. They are among the smallest known cellular organelles, and are much smaller than other types of organelles like mitochondria or chloroplasts, which can be several micrometers in diameter. The exact size of gas vesicles can vary depending on the specific organism and the type of gas vesicle, but they are generally in the range of a few hundred nanometers to a few micrometers.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles range in size from about 0.1 to 1.0 micrometers in diameter.\n2. Gas vesicles are smaller than other types of organelles like mitochondria or chloroplasts.\n3. Mitochondria or chloroplasts can be several micrometers in diameter.\n4. The size of gas vesicles can vary depending on the specific organism and the type of gas vesicle.\n5. Gas vesicles are generally in the range of a few hundred nanometers to a few micrometers.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles range in size from about 0.1 to 1.0 micrometers in diameter.",
      "Gas vesicles are smaller than other types of organelles like mitochondria or chloroplasts.",
      "Mitochondria or chloroplasts can be several micrometers in diameter.",
      "The size of gas vesicles can vary depending on the specific organism and the type of gas vesicle.",
      "Gas vesicles are generally in the range of a few hundred nanometers to a few micrometers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "BET (Bromodomain and Extra-Terminal) proteins are a family of proteins that play a crucial role in regulating gene expression by modifying chromatin structure. Here are the four known BET proteins:\n1. BRD2 (Bromodomain-Containing Protein 2)\n2. BRD3 (Bromodomain-Containing Protein 3)\n3. BRDT (Bromodomain-Containing Protein T)\n4. BRD4 (Bromodomain-Containing Protein 4)\nEach of these proteins contains a bromodomain, a specific structural motif that recognizes and binds to acetylated lysine residues on histone proteins, leading to changes in chromatin structure and gene expression. BET proteins are involved in a wide range of cellular processes, including transcriptional activation, repression, and DNA repair, and have been implicated in various diseases, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. BET proteins are a family of proteins that regulate gene expression by modifying chromatin structure.\n2. The BET protein family includes BRD2 (Bromodomain-Containing Protein 2).\n3. The BET protein family includes BRD3 (Bromodomain-Containing Protein 3).\n4. The BET protein family includes BRDT (Bromodomain-Containing Protein T).\n5. The BET protein family includes BRD4 (Bromodomain-Containing Protein 4).",
    "llama-2-7b-chat-hf_fact": [
      "BET proteins are a family of proteins that regulate gene expression by modifying chromatin structure.",
      "The BET protein family includes BRD2 (Bromodomain-Containing Protein 2).",
      "The BET protein family includes BRD3 (Bromodomain-Containing Protein 3).",
      "The BET protein family includes BRDT (Bromodomain-Containing Protein T).",
      "The BET protein family includes BRD4 (Bromodomain-Containing Protein 4)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The BET protein family includes BRDT (Bromodomain, Testis-Specific Protein).\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "One algorithm that has been developed for prediction of protein subcellular localization using deep learning is the \"DeepLoc\" algorithm. DeepLoc is a deep learning-based method that uses a convolutional neural network (CNN) to predict the subcellular localization of a given protein sequence. It was developed by a team of researchers at the University of California, Los Angeles (UCLA) and was first published in a paper titled \"DeepLoc: A Deep Learning Framework for Predicting Protein Subcellular Localization\" in 2017.\nDeepLoc uses a CNN to learn features from a protein sequence that are predictive of its subcellular localization. The CNN is trained on a large dataset of protein sequences and their corresponding subcellular localization annotations. During training, the CNN learns to extract features from the protein sequence that are important for predicting localization, such as sequence conservation, structural features, and evolutionary relationships.\nOnce the CNN is trained, it can be used to predict the subcellular localization of a new protein sequence. The input protein sequence is fed into the CNN, and the output is a prediction of its localization in one of several subcellular compartments, such as the cytoplasm, nucleus, or membrane.\nDeepLoc has been shown to be highly accurate in predicting protein subcellular localization, outperforming other machine learning-based methods in some studies. Its use of deep learning allows it to capture complex patterns in protein sequences that may not be captured by traditional machine learning methods.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"DeepLoc\" algorithm is a deep learning-based method for predicting protein subcellular localization.\n2. DeepLoc uses a convolutional neural network (CNN) to predict the localization of protein sequences.\n3. The algorithm was developed by researchers at the University of California, Los Angeles (UCLA).\n4. The paper titled \"DeepLoc: A Deep Learning Framework for Predicting Protein Subcellular Localization\" was published in 2017.\n5. DeepLoc has been shown to outperform other machine learning-based methods in predicting protein subcellular localization in some studies.",
    "llama-2-7b-chat-hf_fact": [
      "The \"DeepLoc\" algorithm is a deep learning-based method for predicting protein subcellular localization.",
      "DeepLoc uses a convolutional neural network (CNN) to predict the localization of protein sequences.",
      "The algorithm was developed by researchers at the University of California, Los Angeles (UCLA).",
      "The paper titled \"DeepLoc: A Deep Learning Framework for Predicting Protein Subcellular Localization\" was published in 2017.",
      "DeepLoc has been shown to outperform other machine learning-based methods in predicting protein subcellular localization in some studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The algorithm was developed by researchers at the Technical University of Denmark.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "I apologize, but I'm not familiar with the term \"MULTOVL.\" It's possible that it's a misspelling or a term that is not widely used in the scientific community. Can you please provide more context or information about where you encountered this term? This will help me better understand and provide a more accurate answer.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Yes, Growth Differentiation Factor 15 (GDF15) has been identified as a potential biomarker for metformin treatment. Studies have shown that GDF15 levels are significantly increased in individuals with type 2 diabetes who are treated with metformin, compared to those who are not treated with the drug.\nOne study published in the journal Diabetes found that GDF15 levels were elevated in the plasma of patients with type 2 diabetes who were treated with metformin, but not in those who were not treated with the drug. The study suggested that GDF15 may be a useful biomarker for monitoring the effectiveness of metformin treatment in patients with type 2 diabetes.\nAnother study published in the journal Clinical Biochemistry found that GDF15 levels were significantly higher in the plasma of patients with type 2 diabetes who were treated with metformin, compared to those who were not treated with the drug. The study also found that GDF15 levels were inversely correlated with fasting glucose and hemoglobin A1c (HbA1c) levels, which are commonly used markers of diabetes severity.\nThese findings suggest that GDF15 may be a useful biomarker for monitoring the effectiveness of metformin treatment in patients with type 2 diabetes, and potentially for predicting which patients are most likely to respond to the drug. However, further research is needed to confirm these findings and to determine the clinical utility of GDF15 as a biomarker for metformin treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Growth Differentiation Factor 15 (GDF15) has been identified as a potential biomarker for metformin treatment.\n2. Studies have shown that GDF15 levels are significantly increased in individuals with type 2 diabetes who are treated with metformin.\n3. A study published in the journal Diabetes found elevated GDF15 levels in the plasma of patients with type 2 diabetes treated with metformin.\n4. Another study in the journal Clinical Biochemistry found that GDF15 levels were significantly higher in patients with type 2 diabetes treated with metformin compared to untreated individuals.\n5. The study in Clinical Biochemistry also found that GDF15 levels were inversely correlated with fasting glucose and hemoglobin A1c (HbA1c) levels.",
    "llama-2-7b-chat-hf_fact": [
      "Growth Differentiation Factor 15 (GDF15) has been identified as a potential biomarker for metformin treatment.",
      "Studies have shown that GDF15 levels are significantly increased in individuals with type 2 diabetes who are treated with metformin.",
      "A study published in the journal Diabetes found elevated GDF15 levels in the plasma of patients with type 2 diabetes treated with metformin.",
      "Another study in the journal Clinical Biochemistry found that GDF15 levels were significantly higher in patients with type 2 diabetes treated with metformin compared to untreated individuals.",
      "The study in Clinical Biochemistry also found that GDF15 levels were inversely correlated with fasting glucose and hemoglobin A1c (HbA1c) levels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe first four statements are consistent with scientific findings that suggest GDF15 is a biomarker that responds to metformin treatment in individuals with type 2 diabetes. However, without access to the specific study from the journal Clinical Biochemistry, the correlation between GDF15 levels and fasting glucose and HbA1c levels cannot be confirmed as true or false. Therefore, the fifth statement is marked as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Yes, recursive splicing is more common in short introns. Recursive splicing, also known as intron re-splicing or nested splicing, occurs when the same intron is spliced back into the same exon, creating a nested structure. This type of splicing is more frequent in short introns than in long introns for several reasons:\n1. Efficiency: Recursive splicing is more efficient than non-recursive splicing because the splicing machinery can access the same intron more quickly and easily.\n2. Stability: Short introns are more stable than long introns, which makes it easier for the splicing machinery to recognize and access them.\n3. Sequence composition: Short introns tend to have a more conserved sequence composition than long introns, which can make them more accessible to the splicing machinery.\n4. Splicing kinetics: The splicing kinetics of short introns are faster than those of long introns, which allows for more opportunities for recursive splicing to occur.\nIn summary, recursive splicing is more common in short introns due to their shorter length, higher stability, more conserved sequence composition, and faster splicing kinetics.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is more common in short introns than in long introns.\n2. Recursive splicing occurs when the same intron is spliced back into the same exon.\n3. Short introns are more stable than long introns.\n4. Short introns tend to have a more conserved sequence composition than long introns.\n5. The splicing kinetics of short introns are faster than those of long introns.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is more common in short introns than in long introns.",
      "Recursive splicing occurs when the same intron is spliced back into the same exon.",
      "Short introns are more stable than long introns.",
      "Short introns tend to have a more conserved sequence composition than long introns.",
      "The splicing kinetics of short introns are faster than those of long introns."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Recursive splicing is more common in long introns than in short introns.\n2. FALSE [correction]: Recursive splicing occurs when a long intron is removed in multiple steps, with 'lariat' intermediate structures formed at internal branch points before the intron is fully excised.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "TALE-iD is a method used for identifying the functional elements in a genome, specifically the enhancers and silencers. Enhancers are cis-acting elements that can increase the expression of a gene, while silencers are cis-acting elements that can decrease the expression of a gene. TALE-iD uses the TALE (Transcription Activator-Like Effector) protein to identify these functional elements by profiling the changes in gene expression that occur when the TALE protein is introduced into a cell. By doing so, TALE-iD can identify the locations in the genome where the TALE protein binds and alters gene expression, which can then be used to identify the functional elements in the genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. TALE-iD is a method used for identifying functional elements in a genome.\n2. The functional elements that TALE-iD can identify include enhancers and silencers.\n3. Enhancers are cis-acting elements that can increase the expression of a gene.\n4. Silencers are cis-acting elements that can decrease the expression of a gene.\n5. TALE-iD uses the TALE protein to profile changes in gene expression to identify where it binds in the genome.",
    "llama-2-7b-chat-hf_fact": [
      "TALE-iD is a method used for identifying functional elements in a genome.",
      "The functional elements that TALE-iD can identify include enhancers and silencers.",
      "Enhancers are cis-acting elements that can increase the expression of a gene.",
      "Silencers are cis-acting elements that can decrease the expression of a gene.",
      "TALE-iD uses the TALE protein to profile changes in gene expression to identify where it binds in the genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: TALE-iD uses TALE proteins to identify the locations of their binding sites in the genome, but it does not directly profile changes in gene expression to identify these sites. Instead, it involves the use of TALEs as DNA-binding domains to locate genomic elements based on their interaction with DNA.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "There are several Lisp frameworks that have been developed for image processing, including:\n1. CL-Image: CL-Image is a Lisp image processing framework that provides a set of image processing functions, including filtering, resizing, and thresholding. It is written in Common Lisp and is designed to be easy to use and integrate into other Lisp applications.\n2. ImageTk: ImageTk is a Lisp image processing framework that provides a set of image processing functions, including filtering, resizing, and thresholding. It is built on top of the Tk toolkit and provides a graphical user interface for image processing.\n3. LispImage: LispImage is a Lisp image processing framework that provides a set of image processing functions, including filtering, resizing, and thresholding. It is written in Common Lisp and is designed to be easy to use and integrate into other Lisp applications.\n4. ImageLisp: ImageLisp is a Lisp image processing framework that provides a set of image processing functions, including filtering, resizing, and thresholding. It is written in Common Lisp and is designed to be easy to use and integrate into other Lisp applications.\n5. Lisp-Image-Processing: Lisp-Image-Processing is a Lisp image processing framework that provides a set of image processing functions, including filtering, resizing, and thresholding. It is written in Common Lisp and is designed to be easy to use and integrate into other Lisp applications.\n6. OpenLisp-Image: OpenLisp-Image is a Lisp image processing framework that provides a set of image processing functions, including filtering, resizing, and thresholding. It is written in Common Lisp and is designed to be easy to use and integrate into other Lisp applications.\n7. Lisp-Image-Works: Lisp-Image-Works is a Lisp image processing framework that provides a set of image processing functions, including filtering, resizing, and thresholding. It is written in Common Lisp and is designed to be easy to use and integrate into other Lisp applications.\n8. Image-Lisp-Tools: Image-Lisp-Tools is a Lisp image processing framework that provides a set of image processing functions, including filtering, resizing, and thresholding. It is written in Common Lisp and is designed to be easy to use and integrate into other Lisp",
    "llama-2-7b-chat-hf_fact_raw": "1. CL-Image is a Lisp framework developed for image processing.\n2. ImageTk is a Lisp framework for image processing that is built on top of the Tk toolkit.\n3. LispImage is a Lisp framework for image processing written in Common Lisp.\n4. ImageLisp is a Lisp framework for image processing that includes functions such as filtering, resizing, and thresholding.\n5. OpenLisp-Image is a Lisp image processing framework designed for ease of use and integration into other Lisp applications.",
    "llama-2-7b-chat-hf_fact": [
      "CL-Image is a Lisp framework developed for image processing.",
      "ImageTk is a Lisp framework for image processing that is built on top of the Tk toolkit.",
      "LispImage is a Lisp framework for image processing written in Common Lisp.",
      "ImageLisp is a Lisp framework for image processing that includes functions such as filtering, resizing, and thresholding.",
      "OpenLisp-Image is a Lisp image processing framework designed for ease of use and integration into other Lisp applications."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: ImageTk is not a Lisp framework; it is a Python module that allows for the display of images in the Tkinter GUI toolkit.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about Lisp frameworks for image processing named CL-Image, LispImage, ImageLisp, or OpenLisp-Image, it is not possible to verify the accuracy of these statements. These names do not correspond to well-known image processing libraries, and without additional context, their existence and features cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "In Saccharomyces cerevisiae (baker's yeast), approximately 800-900 genes are the result of an ancient whole genome duplication. This event, known as the \"yeast whole genome duplication\" (WGD), occurred around 1,000 million years ago and resulted in the duplication of approximately 30% of the yeast genome. Since then, many of these duplicate genes have evolved to perform different functions or have been lost through various evolutionary processes. However, the 800-900 genes that remain are thought to have been retained due to their essential roles in yeast biology and evolution.",
    "llama-2-7b-chat-hf_fact_raw": "1. Approximately 800-900 genes in Saccharomyces cerevisiae are the result of an ancient whole genome duplication.\n2. The yeast whole genome duplication occurred around 1,000 million years ago.\n3. The duplication event resulted in the duplication of approximately 30% of the yeast genome.\n4. Many of the duplicate genes from the whole genome duplication in yeast have evolved to perform different functions or have been lost.\n5. The 800-900 genes that remain after the whole genome duplication are thought to be essential for yeast biology and evolution.",
    "llama-2-7b-chat-hf_fact": [
      "Approximately 800-900 genes in Saccharomyces cerevisiae are the result of an ancient whole genome duplication.",
      "The yeast whole genome duplication occurred around 1,000 million years ago.",
      "The duplication event resulted in the duplication of approximately 30% of the yeast genome.",
      "Many of the duplicate genes from the whole genome duplication in yeast have evolved to perform different functions or have been lost.",
      "The 800-900 genes that remain after the whole genome duplication are thought to be essential for yeast biology and evolution."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The yeast whole genome duplication is estimated to have occurred around 100 million years ago, not 1,000 million years ago.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Estrogen-related receptor β (Esrrb) is a nuclear receptor that binds to the complex of estrogen and its cognate response elements (REs) in the DNA. Esrrb is a ligand-activated transcription factor that plays a crucial role in regulating various physiological processes, including cell proliferation, differentiation, and survival, in response to estrogen signals. The binding of estrogen to Esrrb leads to the activation of target genes that are involved in various cellular processes, such as cell growth, differentiation, and survival.",
    "llama-2-7b-chat-hf_fact_raw": "1. Estrogen-related receptor β (Esrrb) is a nuclear receptor.\n2. Esrrb binds to the complex of estrogen and its cognate response elements (REs) in the DNA.\n3. Esrrb is a ligand-activated transcription factor.\n4. Esrrb regulates various physiological processes including cell proliferation, differentiation, and survival.\n5. The activation of target genes by Esrrb is in response to estrogen signals.",
    "llama-2-7b-chat-hf_fact": [
      "Estrogen-related receptor β (Esrrb) is a nuclear receptor.",
      "Esrrb binds to the complex of estrogen and its cognate response elements (REs) in the DNA.",
      "Esrrb is a ligand-activated transcription factor.",
      "Esrrb regulates various physiological processes including cell proliferation, differentiation, and survival.",
      "The activation of target genes by Esrrb is in response to estrogen signals."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Esrrb does not bind to the complex of estrogen and its cognate response elements (REs) in the DNA. Instead, it binds to estrogen response elements in the absence of estrogen and regulates gene expression independently of the hormone.\n3. FALSE [correction]: Esrrb is an orphan nuclear receptor, which means it is not known to be activated by any naturally occurring ligand such as a hormone.\n4. TRUE\n5. FALSE [correction]: The activation of target genes by Esrrb is not in response to estrogen signals, as Esrrb functions independently of estrogen.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "ZCCHC17 (Zinc finger CCHC-type histone chaperone 17) is a protein that plays a crucial role in regulating chromatin dynamics and gene expression. Here are some of the key functions of ZCCHC17:\n1. Chromatin remodeling: ZCCHC17 is a histone chaperone that helps to remodel chromatin structure by facilitating the exchange of histone H2A and H2B residues. This process is important for regulating gene expression and chromatin organization.\n2. Transcriptional regulation: ZCCHC17 can bind to specific DNA sequences and recruit other transcription factors to regulate gene expression. It has been shown to be involved in the regulation of genes involved in cell cycle progression, apoptosis, and differentiation.\n3. Epigenetic modification: ZCCHC17 can also modulate epigenetic marks on histones and other non-histone proteins, such as DNA methylation and histone acetylation/methylation. These modifications play a crucial role in regulating chromatin structure and gene expression.\n4. Cell cycle regulation: ZCCHC17 has been shown to be involved in the regulation of the cell cycle, particularly in the G1/S transition. It can bind to specific DNA sequences and regulate the expression of genes involved in this process.\n5. Cancer: ZCCHC17 has been implicated in cancer development and progression. It has been shown to be overexpressed in various types of cancer, including breast, lung, and colon cancer, and is thought to play a role in the development of cancer by regulating chromatin dynamics and gene expression.\nIn summary, ZCCHC17 is a multifunctional protein that plays a crucial role in regulating chromatin dynamics, gene expression, and cellular processes such as cell cycle progression and differentiation. Its dysregulation has been implicated in various diseases, including cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is a histone chaperone that facilitates the exchange of histone H2A and H2B residues.\n2. ZCCHC17 can bind to specific DNA sequences and recruit transcription factors to regulate gene expression.\n3. ZCCHC17 is involved in modulating epigenetic marks such as DNA methylation and histone acetylation/methylation.\n4. ZCCHC17 plays a role in the regulation of the cell cycle, particularly in the G1/S transition.\n5. ZCCHC17 has been shown to be overexpressed in various types of cancer, including breast, lung, and colon cancer.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is a histone chaperone that facilitates the exchange of histone H2A and H2B residues.",
      "ZCCHC17 can bind to specific DNA sequences and recruit transcription factors to regulate gene expression.",
      "ZCCHC17 is involved in modulating epigenetic marks such as DNA methylation and histone acetylation/methylation.",
      "ZCCHC17 plays a role in the regulation of the cell cycle, particularly in the G1/S transition.",
      "ZCCHC17 has been shown to be overexpressed in various types of cancer, including breast, lung, and colon cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are specific to the function and role of the protein ZCCHC17. Without access to current and specific scientific literature or databases that detail the characteristics and research findings related to ZCCHC17, it is not possible to accurately verify these statements. The functions of proteins like ZCCHC17 can be complex and context-dependent, and their roles in processes such as gene expression, epigenetic regulation, cell cycle, and disease are often subjects of specialized research.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "The nuclear pore basket, also known as the nuclear pore complex (NPC), is a large protein structure that spans the nuclear envelope in eukaryotic cells, connecting the nucleus and the cytoplasm. The proteins that form the nuclear pore basket in human cells include:\n1. Nucleoporin 1 (Nup1): A key component of the nuclear pore basket, Nup1 is responsible for the transport of molecules across the nuclear envelope.\n2. Nucleoporin 2 (Nup2): Another essential component of the nuclear pore basket, Nup2 plays a crucial role in regulating the transport of molecules between the nucleus and the cytoplasm.\n3. Nucleoporin 3 (Nup3): Nup3 is a protein that forms part of the nuclear pore basket and is involved in the transport of molecules across the nuclear envelope.\n4. Nucleoporin 4 (Nup4): Nup4 is a protein that is involved in the formation and stability of the nuclear pore basket.\n5. Nucleoporin 5 (Nup5): Nup5 is a protein that is involved in the transport of molecules across the nuclear envelope and is also important for the maintenance of the nuclear pore basket.\n6. Nucleoporin 6 (Nup6): Nup6 is a protein that is involved in the transport of molecules across the nuclear envelope and is also important for the stability of the nuclear pore basket.\n7. Nucleoporin 7 (Nup7): Nup7 is a protein that is involved in the transport of molecules across the nuclear envelope and is also important for the maintenance of the nuclear pore basket.\n8. Nucleoporin 8 (Nup8): Nup8 is a protein that is involved in the transport of molecules across the nuclear envelope and is also important for the stability of the nuclear pore basket.\n9. Nucleoporin 9 (Nup9): Nup9 is a protein that is involved in the transport of molecules across the nuclear envelope and is also important for the maintenance of the nuclear pore basket.\n10. Nucleoporin 10 (Nup10): N",
    "llama-2-7b-chat-hf_fact_raw": "1. The nuclear pore basket, also known as the nuclear pore complex (NPC), spans the nuclear envelope in eukaryotic cells.\n2. Nucleoporin 1 (Nup1) is a component of the nuclear pore basket responsible for the transport of molecules across the nuclear envelope.\n3. Nucleoporin 2 (Nup2) plays a role in regulating the transport of molecules between the nucleus and the cytoplasm.\n4. Nucleoporin 3 (Nup3) forms part of the nuclear pore basket and is involved in molecular transport across the nuclear envelope.\n5. Nucleoporin 4 (Nup4) is involved in the formation and stability of the nuclear pore basket.",
    "llama-2-7b-chat-hf_fact": [
      "The nuclear pore basket, also known as the nuclear pore complex (NPC), spans the nuclear envelope in eukaryotic cells.",
      "Nucleoporin 1 (Nup1) is a component of the nuclear pore basket responsible for the transport of molecules across the nuclear envelope.",
      "Nucleoporin 2 (Nup2) plays a role in regulating the transport of molecules between the nucleus and the cytoplasm.",
      "Nucleoporin 3 (Nup3) forms part of the nuclear pore basket and is involved in molecular transport across the nuclear envelope.",
      "Nucleoporin 4 (Nup4) is involved in the formation and stability of the nuclear pore basket."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The nuclear pore complex (NPC) is a structure that spans the nuclear envelope, but the term \"nuclear pore basket\" typically refers to a specific structure within the NPC that extends into the nucleoplasm.\n2. UNKNOWN: Without specific scientific literature or context, it's unclear whether \"Nucleoporin 1 (Nup1)\" refers to a real component of the nuclear pore complex, as nomenclature can vary, and the specific roles of nucleoporins can be complex.\n3. UNKNOWN: Similar to statement 2, without specific context, it's unclear if \"Nucleoporin 2 (Nup2)\" is a recognized component of the nuclear pore complex and what its role may be.\n4. UNKNOWN: As with the previous statements about nucleoporins, without additional context, it's difficult to confirm the existence and role of \"Nucleoporin 3 (Nup3)\" in the nuclear pore complex.\n5. UNKNOWN: The statement about \"Nucleoporin 4 (Nup4)\" cannot be confirmed without additional context or specific scientific references to the nomenclature and function of nucleoporins within the nuclear pore complex.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Gepotidacin is a topoisomerase II (Topo II) inhibitor. Topo II is a type of enzyme that relaxes supercoiled DNA and is essential for DNA replication, transcription, and repair. Gepotidacin binds to the active site of Topo II and prevents it from relaxing supercoiled DNA, leading to the accumulation of supercoils and the inhibition of DNA synthesis and repair. This makes it a potential therapeutic agent for treating cancer, as cancer cells have high levels of Topo II activity and are dependent on it for their rapid proliferation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a topoisomerase II (Topo II) inhibitor.\n2. Topoisomerase II is an enzyme that relaxes supercoiled DNA.\n3. Gepotidacin binds to the active site of Topo II and prevents it from relaxing supercoiled DNA.\n4. The inhibition of DNA synthesis and repair is a result of gepotidacin's action on Topo II.\n5. Cancer cells have high levels of Topo II activity and rely on it for rapid proliferation.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a topoisomerase II (Topo II) inhibitor.",
      "Topoisomerase II is an enzyme that relaxes supercoiled DNA.",
      "Gepotidacin binds to the active site of Topo II and prevents it from relaxing supercoiled DNA.",
      "The inhibition of DNA synthesis and repair is a result of gepotidacin's action on Topo II.",
      "Cancer cells have high levels of Topo II activity and rely on it for rapid proliferation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gepotidacin is a topoisomerase II (Topo II) inhibitor. [Gepotidacin is actually a topoisomerase inhibitor, but it specifically targets bacterial type II topoisomerases, Topo IV, and DNA gyrase, not human Topo II.]\n2. TRUE\n3. FALSE [correction]: Gepotidacin binds to the active site of Topo II and prevents it from relaxing supercoiled DNA. [Gepotidacin targets bacterial topoisomerases, not necessarily the human Topo II, and it is not clear from the statement whether it refers to bacterial or human Topo II. If referring to bacterial Topo II, the statement would need to specify that it is bacterial.]\n4. TRUE [Assuming the context is bacterial Topo II, the inhibition of DNA synthesis and repair can be a result of gepotidacin's action on bacterial topoisomerases.]\n5. TRUE [Cancer cells often have high levels of Topo II activity and rely on it for rapid proliferation. However, this statement is not directly related to gepotidacin, which targets bacterial topoisomerases.]",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW (Spatio-Temporal Workflow) is a high-performance computing (HPC) framework designed for large-scale data processing and analysis in various scientific domains. It is an open-source software platform that enables researchers to create, execute, and share complex data workflows across multiple computing resources. Here are some key features and capabilities of Canvas SPW:\n1. Data-Driven Workflows: Canvas SPW enables researchers to define data-driven workflows that can process and analyze large datasets. Users can create workflows using a simple, intuitive syntax, and the framework takes care of the underlying complexities of data processing.\n2. Spatio-Temporal Processing: Canvas SPW is designed to handle spatio-temporal data, which is common in many scientific domains such as climate modeling, geophysics, and biomedical research. The framework provides specialized tools and algorithms for processing and analyzing spatio-temporal data.\n3. Scalable Architecture: Canvas SPW is built on a scalable architecture that can handle large datasets and high-performance computing requirements. The framework can be deployed on a range of computing resources, including local machines, clusters, grids, and cloud computing platforms.\n4. Integrated Data Management: Canvas SPW provides an integrated data management system that allows users to store, organize, and manage large datasets. The framework supports various data formats, including CSV, NetCDF, and HDF5.\n5. Advanced Visualization: Canvas SPW includes a range of advanced visualization tools for visualizing and exploring large datasets. Users can create interactive visualizations, create custom visualization templates, and share visualizations with collaborators.\n6. Collaboration and Sharing: Canvas SPW provides tools for collaboration and sharing of workflows, visualizations, and results. Users can create and share workflows, visualizations, and results with colleagues, and the framework supports version control and reproducibility.\n7. Extensibility and Customization: Canvas SPW is highly extensible and customizable, allowing users to create custom workflows, tools, and visualizations. The framework provides a modular architecture that allows users to extend the functionality of the platform.\nIn summary, Canvas SPW is a powerful HPC framework designed for large-scale data processing and",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW (Spatio-Temporal Workflow) is a high-performance computing framework for large-scale data processing and analysis.\n2. Canvas SPW is an open-source software platform.\n3. The framework is designed to handle spatio-temporal data, which is common in scientific domains such as climate modeling, geophysics, and biomedical research.\n4. Canvas SPW can be deployed on various computing resources, including local machines, clusters, grids, and cloud computing platforms.\n5. Canvas SPW includes advanced visualization tools for large datasets and supports data formats like CSV, NetCDF, and HDF5.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW (Spatio-Temporal Workflow) is a high-performance computing framework for large-scale data processing and analysis.",
      "Canvas SPW is an open-source software platform.",
      "The framework is designed to handle spatio-temporal data, which is common in scientific domains such as climate modeling, geophysics, and biomedical research.",
      "Canvas SPW can be deployed on various computing resources, including local machines, clusters, grids, and cloud computing platforms.",
      "Canvas SPW includes advanced visualization tools for large datasets and supports data formats like CSV, NetCDF, and HDF5."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about \"Canvas SPW\" and whether it is a real or fictional software framework, it is not possible to determine the truthfulness of these statements. If \"Canvas SPW\" is a fictional or hypothetical framework, the statements could be part of a scenario or example. If it is real, the statements would need to be verified against authoritative sources or documentation related to \"Canvas SPW.\"",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "STING (Stimulator of Interferon Genes) is a protein that plays a crucial role in the innate immune response to viral infections. STING agonists are compounds that activate the STING protein, leading to the production of interferons and other immune molecules. Here are some examples of STING agonists:\n1. CpG DNA: CpG dinucleotides are found in the genomes of bacteria and viruses, and they are recognized by STING as a sign of infection. CpG DNA is a common STING agonist that activates the protein in immune cells.\n2. DNA-based vaccines: Some DNA-based vaccines, such as the HPV vaccine, contain CpG oligonucleotides that act as STING agonists, stimulating an immune response against the encoded antigens.\n3. Small molecule agonists: There are several small molecules that have been identified as STING agonists, including cyclic dinucleotides (CDNs) and imidazolediones (IMDs). These compounds can activate STING through different mechanisms, including direct binding to the protein or inhibition of its inhibitor.\n4. Peptide agonists: Some peptides, such as the synthetic peptide STING ligand (sSTL), have been identified as STING agonists. These peptides can bind to STING and activate it, leading to the production of interferons and other immune molecules.\n5. Viral proteins: Some viral proteins, such as the poxvirus protein K3L, have been shown to inhibit STING and prevent its activation. However, some other viral proteins, such as the adenovirus protein E1B 19K, can activate STING and stimulate an immune response.\n6. Toll-like receptor (TLR) agonists: Some TLR agonists, such as flagellin and lipopolysaccharide (LPS), can activate STING and stimulate an immune response.\n7. RNA-based agonists: Some RNA molecules, such as small inter",
    "llama-2-7b-chat-hf_fact_raw": "1. CpG DNA is a STING agonist that activates the STING protein in immune cells.\n2. Some DNA-based vaccines, like the HPV vaccine, contain CpG oligonucleotides that act as STING agonists.\n3. Cyclic dinucleotides (CDNs) and imidazolediones (IMDs) are small molecules identified as STING agonists.\n4. Synthetic peptide STING ligand (sSTL) is a peptide identified as a STING agonist.\n5. The adenovirus protein E1B 19K can activate STING and stimulate an immune response.",
    "llama-2-7b-chat-hf_fact": [
      "CpG DNA is a STING agonist that activates the STING protein in immune cells.",
      "Some DNA-based vaccines, like the HPV vaccine, contain CpG oligonucleotides that act as STING agonists.",
      "Cyclic dinucleotides (CDNs) and imidazolediones (IMDs) are small molecules identified as STING agonists.",
      "Synthetic peptide STING ligand (sSTL) is a peptide identified as a STING agonist.",
      "The adenovirus protein E1B 19K can activate STING and stimulate an immune response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The HPV vaccine does not contain CpG oligonucleotides. It is a virus-like particle vaccine that does not contain any DNA, hence it does not act as a STING agonist.\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: The adenovirus protein E1B 19K is known to inhibit apoptosis by binding to and inactivating p53 and Bcl-2 family members, not to activate STING.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SLIC-CAGE (Slicing-based Chromatin Conformation Assay using Genome Editing) is a powerful tool for studying the three-dimensional (3D) structure of chromosomes and their interactions in cells. It combines the advantages of both CRISPR-Cas9 genome editing and chromatin conformation capture (3C) techniques to provide a more comprehensive understanding of chromosome organization and gene regulation.\nIn a typical SLIC-CAGE experiment, the following steps are performed:\n1. Genome editing: The CRISPR-Cas9 system is used to introduce specific double-stranded breaks (DSBs) in the genome at specific locations.\n2. Homology-directed repair (HDR): The breaks are repaired using the cell's own repair machinery, which often results in the introduction of specific genetic changes (e.g., point mutations or insertions/deletions) at the break sites.\n3. Chromatin conformation capture: The 3C technique is used to isolate chromatin fragments that are in close proximity to each other in the nucleus. This is done by crosslinking chromatin with formaldehyde, followed by the isolation of chromatin fragments and their analysis by sequencing.\n4. Assembly of chromatin fragments: The isolated chromatin fragments are then reconstructed using computational methods to create a 3D map of chromosome organization.\n5. Visualization and analysis: The resulting 3D map is visualized and analyzed using various bioinformatic tools to identify regions of the genome that are in close proximity to each other, as well as to study the dynamics of chromosome organization and gene regulation.\nThe advantages of SLIC-CAGE include:\n* High resolution: SLIC-CAGE can resolve chromatin structures at the level of individual nucleosomes, providing a more detailed view of chromosome organization than other 3C techniques.\n* Genetic labeling: By using genome editing to introduce specific genetic changes, SLIC-CAGE can identify the genomic locations of specific regulatory elements and their interactions with other regions of the genome.\n* Efficient data generation: The combination of genome editing and 3C techniques allows for efficient generation of large amounts of data, making it possible to study",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE combines CRISPR-Cas9 genome editing with chromatin conformation capture (3C) techniques.\n2. The CRISPR-Cas9 system in SLIC-CAGE is used to introduce specific double-stranded breaks in the genome.\n3. Homology-directed repair (HDR) is used in SLIC-CAGE to repair the breaks introduced by CRISPR-Cas9.\n4. Chromatin conformation capture in SLIC-CAGE involves crosslinking chromatin with formaldehyde and isolating chromatin fragments for analysis.\n5. SLIC-CAGE can resolve chromatin structures at the level of individual nucleosomes.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE combines CRISPR-Cas9 genome editing with chromatin conformation capture (3C) techniques.",
      "The CRISPR-Cas9 system in SLIC-CAGE is used to introduce specific double-stranded breaks in the genome.",
      "Homology-directed repair (HDR) is used in SLIC-CAGE to repair the breaks introduced by CRISPR-Cas9.",
      "Chromatin conformation capture in SLIC-CAGE involves crosslinking chromatin with formaldehyde and isolating chromatin fragments for analysis.",
      "SLIC-CAGE can resolve chromatin structures at the level of individual nucleosomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN: While homology-directed repair (HDR) is a mechanism that can repair double-stranded breaks introduced by CRISPR-Cas9, without specific context it is not clear whether HDR is used in SLIC-CAGE or if non-homologous end joining (NHEJ) or another repair mechanism is used.\n4. TRUE: Chromatin conformation capture techniques generally involve crosslinking chromatin with formaldehyde, followed by various steps to isolate and analyze chromatin fragments to study their interactions and organization.\n5. UNKNOWN: The resolution of chromatin structures that SLIC-CAGE can resolve is not specified in the statement, and without additional context, it is not possible to confirm whether it can resolve structures at the level of individual nucleosomes.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "LEM-3 (LEucine-rich repeat-containing protein 3) is a protein that plays several important roles in various cellular processes. Here are some of the key roles of LEM-3:\n1. Chromatin remodeling: LEM-3 is a chromatin remodeling protein that is involved in the regulation of chromatin structure and gene expression. It works by altering the positioning of nucleosomes along DNA strands, allowing for more efficient transcriptional activation or repression.\n2. Transcriptional activation: LEM-3 can bind to specific DNA sequences and recruit other transcription factors to activate transcription of target genes. It has been shown to play a role in the activation of genes involved in cell cycle progression, apoptosis, and DNA repair.\n3. Nuclear organization: LEM-3 is involved in the organization of the nuclear compartment and the regulation of nuclear transport. It helps to maintain the proper localization of proteins and RNA within the nucleus, which is important for proper cellular function.\n4. Cell cycle regulation: LEM-3 has been implicated in the regulation of the cell cycle, particularly in the G1/S transition. It has been shown to interact with key regulators of the cell cycle, such as cyclin-dependent kinases (CDKs) and retinoblastoma protein (Rb), and to modulate their activity.\n5. Apoptosis: LEM-3 has been shown to play a role in the regulation of programmed cell death (apoptosis). It can interact with pro-apoptotic proteins, such as BAX and BAK, and promote their activation, leading to the induction of apoptosis.\n6. DNA repair: LEM-3 has been implicated in the regulation of DNA repair pathways. It can interact with DNA repair proteins, such as XRCC1 and XRCC2, and modulate their activity.\n7. Cancer: LEM-3 has been implicated in the development and progression of cancer. It has been shown to be overexpressed in various types of cancer, including breast, lung, and colon cancer, and to promote the growth and survival of cancer cells.\nIn summary, LEM-3 is a multifunctional protein that plays a variety of",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 is involved in chromatin remodeling and the regulation of chromatin structure and gene expression.\n2. LEM-3 can activate transcription of target genes by binding to specific DNA sequences and recruiting transcription factors.\n3. LEM-3 is involved in the organization of the nuclear compartment and the regulation of nuclear transport.\n4. LEM-3 has been implicated in the regulation of the cell cycle, particularly in the G1/S transition.\n5. LEM-3 plays a role in the regulation of programmed cell death (apoptosis).",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 is involved in chromatin remodeling and the regulation of chromatin structure and gene expression.",
      "LEM-3 can activate transcription of target genes by binding to specific DNA sequences and recruiting transcription factors.",
      "LEM-3 is involved in the organization of the nuclear compartment and the regulation of nuclear transport.",
      "LEM-3 has been implicated in the regulation of the cell cycle, particularly in the G1/S transition.",
      "LEM-3 plays a role in the regulation of programmed cell death (apoptosis)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: LEM-3 does not directly activate transcription of target genes by binding to specific DNA sequences and recruiting transcription factors. LEM domain proteins are generally involved in maintaining nuclear structure and integrity, but they are not typically known for directly binding DNA to activate transcription.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "I'm just an AI, I don't have access to real-time information about the releases of specific software or tools, including tmVar. However, I can suggest some general resources where you may be able to find this information:\n1. GitHub: Many software projects, including tmVar, are hosted on GitHub, a popular platform for hosting and sharing code. You can search for releases on GitHub by visiting the project's repository and looking for the \"releases\" tab.\n2. Project website: Many software projects have their own websites where they post information about releases, updates, and other news. You can visit the tmVar website to see if they have any information about recent releases.\n3. Release notes: Many software projects include release notes with information about new features, bug fixes, and other changes in each release. You can search for release notes for tmVar on the project's website or on other platforms like GitHub.\n4. Online forums: Online forums and discussion groups can be a good place to ask for information about releases of specific software, including tmVar. You can search for relevant forums and join in on discussions to see if anyone has information about recent releases.\nI hope this helps! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "There are several databases of somatic mutations in normal cells, including:\n1. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) that aims to catalogue the genomic changes in various types of cancer. As part of this effort, TCGA has also collected and analyzed genomic data from normal tissues, including somatic mutations.\n2. The 1000 Genomes Project: The 1000 Genomes Project is a large-scale effort to catalogue the genetic variation in the human population. As part of this project, the project has also collected and analyzed genomic data from normal tissues, including somatic mutations.\n3. The ExAC (Exome Aggregation Consortium) database: The ExAC database is a collection of exome data from over 60,000 individuals, including both normal and diseased tissues. The database includes information on somatic mutations in normal tissues.\n4. The GTEx (Genotype-Tissue Expression) database: The GTEx database is a collection of genomic and transcriptomic data from over 500 human tissues, including normal tissues. The database includes information on somatic mutations in normal tissues.\n5. The COSMIC (Catalogue of Somatic Mutations in Cancer) database: The COSMIC database is a comprehensive catalogue of somatic mutations found in various types of cancer. While the database primarily focuses on cancer mutations, it also includes some information on somatic mutations in normal tissues.\n6. The MutSig database: The MutSig database is a collection of somatic mutations found in normal tissues, including DNA samples from blood, saliva, and other tissues. The database includes information on the frequency and distribution of somatic mutations in normal tissues.\n7. The Normal Tissue Mutation Spectrum (NTMS) database: The NTMS database is a collection of somatic mutations found in normal tissues, including DNA samples from various tissues, such as blood, saliva, and tumor tissues. The database includes information on the frequency and distribution of somatic mutations in normal tissues.\n8",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).\n2. The 1000 Genomes Project is a large-scale effort to catalogue genetic variation in the human population.\n3. The ExAC (Exome Aggregation Consortium) database contains exome data from over 60,000 individuals.\n4. The GTEx (Genotype-Tissue Expression) database includes genomic and transcriptomic data from over 500 human tissues.\n5. The COSMIC (Catalogue of Somatic Mutations in Cancer) database is a comprehensive catalogue of somatic mutations found in various types of cancer and includes some information on somatic mutations in normal tissues.",
    "llama-2-7b-chat-hf_fact": [
      "The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).",
      "The 1000 Genomes Project is a large-scale effort to catalogue genetic variation in the human population.",
      "The ExAC (Exome Aggregation Consortium) database contains exome data from over 60,000 individuals.",
      "The GTEx (Genotype-Tissue Expression) database includes genomic and transcriptomic data from over 500 human tissues.",
      "The COSMIC (Catalogue of Somatic Mutations in Cancer) database is a comprehensive catalogue of somatic mutations found in various types of cancer and includes some information on somatic mutations in normal tissues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The ExAC (Exome Aggregation Consortium) database contains exome data from over 60,000 unrelated individuals.\n4. FALSE [correction]: The GTEx (Genotype-Tissue Expression) project includes genomic and transcriptomic data from a wide range of tissues, but not over 500. As of my knowledge cutoff in 2023, GTEx has data from 54 non-diseased tissue sites.\n5. FALSE [correction]: The COSMIC (Catalogue of Somatic Mutations in Cancer) database is a comprehensive catalogue of somatic mutations found in cancer. It does not include information on somatic mutations in normal tissues.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available that can be implemented in Java. Here are some of them:\n1. JGraphT: JGraphT is a Java library for graph theory. It provides a simple and efficient way to create and manipulate graphs, including directed and undirected graphs, weighted and unweighted graphs, and more. It also supports graph algorithms and graph visualization.\n2. Graphlib: Graphlib is a Java library for graph algorithms and data structures. It provides a set of classes for representing and manipulating graphs, including breadth-first search, depth-first search, and more. It also includes a graph visualization tool.\n3. Graph-based algorithms in Java (GBAJ): GBAJ is a collection of graph algorithms implemented in Java. It includes a variety of algorithms for graph traversal, graph optimization, and graph clustering, among others. The algorithms are implemented in a modular and flexible way, making it easy to use and integrate them into larger applications.\n4. JGraph: JGraph is a Java library for graph algorithms and data structures. It provides a simple and efficient way to create and manipulate graphs, including directed and undirected graphs, weighted and unweighted graphs, and more. It also includes a graph visualization tool.\n5. Graph-based data structures in Java (GDBJ): GDBJ is a collection of graph-based data structures implemented in Java. It includes a variety of data structures for representing graphs, such as adjacency matrices, adjacency lists, and more. The data structures are implemented in a modular and flexible way, making it easy to use and integrate them into larger applications.\n6. Weisfeiler-Lehman Java library (WLJ): WLJ is a Java library for the Weisfeiler-Lehman algorithm, a graph isomorphism algorithm. It provides a simple and efficient way to perform graph isomorphism testing and graph clustering. It also includes a graph visualization tool.\n7. Java Graph Library (JGL): JGL is a Java library for graph theory. It provides a simple and efficient way to create and manipulate graphs, including directed and undirected graphs, weighted and unweighted graphs, and more. It also includes a graph visualization tool.\n8. Graph-based data structures in Java (GDJ): GDJ is a collection of graph-based data structures implemented in",
    "llama-2-7b-chat-hf_fact_raw": "1. JGraphT is a Java library for graph theory that supports various types of graphs and graph algorithms.\n2. Graphlib is a Java library that includes classes for graph algorithms, data structures, and a graph visualization tool.\n3. The Graph-based algorithms in Java (GBAJ) collection includes algorithms for graph traversal, optimization, and clustering.\n4. JGraph is a Java library for graph algorithms and data structures that also includes a graph visualization tool.\n5. The Weisfeiler-Lehman Java library (WLJ) is designed for graph isomorphism testing and graph clustering.",
    "llama-2-7b-chat-hf_fact": [
      "JGraphT is a Java library for graph theory that supports various types of graphs and graph algorithms.",
      "Graphlib is a Java library that includes classes for graph algorithms, data structures, and a graph visualization tool.",
      "The Graph-based algorithms in Java (GBAJ) collection includes algorithms for graph traversal, optimization, and clustering.",
      "JGraph is a Java library for graph algorithms and data structures that also includes a graph visualization tool.",
      "The Weisfeiler-Lehman Java library (WLJ) is designed for graph isomorphism testing and graph clustering."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Graphlib is not a Java library; it is a JavaScript library that includes classes for graph algorithms, data structures, and sometimes graph visualization tools.\n3. UNKNOWN: Without specific information about a collection named \"Graph-based algorithms in Java (GBAJ),\" it is not possible to verify the accuracy of this statement.\n4. TRUE: JGraph is indeed a Java library that provides functionality for graph algorithms and data structures, and it includes a graph visualization tool.\n5. UNKNOWN: Without specific information about a library named \"Weisfeiler-Lehman Java library (WLJ),\" it is not possible to verify the accuracy of this statement. However, the Weisfeiler-Lehman algorithm is a known method for graph isomorphism testing, so a library with such a name could plausibly exist.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "SHERLOCK (Specific High-Sensitivity Enzyme-Linked ImmunoSensors) is a diagnostic platform that integrates several advances in molecular biology, nanotechnology, and microfluidics to detect pathogens and other biomarkers with high sensitivity and specificity. The SHERLOCKv2 platform, in particular, has been improved upon with the following four advances:\n1. Nucleic acid amplification: SHERLOCKv2 uses a novel nucleic acid amplification technique called \"NASBA-3\" (Nucleic Acid Sequence-Based Amplification), which is more efficient and specific than traditional methods like PCR.\n2. Isothermal amplification: Unlike traditional PCR, which requires a series of temperature cycling steps, SHERLOCKv2's NASBA-3 technique performs the amplification reaction at a single temperature, making it faster and more convenient.\n3. High-sensitivity detection: SHERLOCKv2 uses a nanoparticle-based detection system that can detect even low levels of target DNA or RNA, making it more sensitive than traditional methods.\n4. Multiplexing capabilities: SHERLOCKv2 can detect multiple targets simultaneously, allowing for the detection of multiple pathogens or biomarkers in a single reaction, which is not possible with traditional methods.",
    "llama-2-7b-chat-hf_fact_raw": "1. SHERLOCKv2 uses a nucleic acid amplification technique called \"NASBA-3\".\n2. The NASBA-3 technique used in SHERLOCKv2 performs amplification at a single temperature.\n3. SHERLOCKv2 employs a nanoparticle-based detection system for high-sensitivity detection.\n4. SHERLOCKv2 has the capability to detect multiple targets simultaneously in a single reaction.",
    "llama-2-7b-chat-hf_fact": [
      "SHERLOCKv2 uses a nucleic acid amplification technique called \"NASBA-3\".",
      "The NASBA-3 technique used in SHERLOCKv2 performs amplification at a single temperature.",
      "SHERLOCKv2 employs a nanoparticle-based detection system for high-sensitivity detection.",
      "SHERLOCKv2 has the capability to detect multiple targets simultaneously in a single reaction."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: SHERLOCKv2 uses a nucleic acid amplification technique called \"recombinase polymerase amplification\" (RPA).\n2. TRUE\n3. FALSE [correction]: SHERLOCKv2 employs a CRISPR-based detection system for high-sensitivity detection.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The Bartender algorithm is a machine learning algorithm used for feature selection and dimensionality reduction in high-dimensional datasets. It was introduced by T. Hastie, R. Tibshirani, and J. Friedman in 2003.\nThe Bartender algorithm is a greedy algorithm that works as follows:\n1. Initialize the set of selected features to be empty.\n2. At each step, consider the most highly correlated feature with the current set of selected features.\n3. Add the current feature to the set of selected features if it is not already in the set.\n4. Remove the least highly correlated feature from the set of selected features.\n5. Repeat steps 2-4 until all features have been considered.\nThe algorithm is called the Bartender because it works by \"serving\" the most highly correlated features first, just as a bartender might serve the most popular drinks first in a bar.\nThe Bartender algorithm has several desirable properties, including:\n* It is easy to implement and interpret.\n* It is robust to outliers and noisy data.\n* It can handle high-dimensional datasets and is computationally efficient.\n* It can be used for both feature selection and dimensionality reduction.\nThe Bartender algorithm is often used in applications where feature selection and dimensionality reduction are important, such as in bioinformatics, image analysis, and text mining.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bartender algorithm was introduced by T. Hastie, R. Tibshirani, and J. Friedman in 2003.\n2. The Bartender algorithm is used for feature selection and dimensionality reduction in high-dimensional datasets.\n3. It is a greedy algorithm that iteratively adds and removes features based on their correlation with the current set of selected features.\n4. The algorithm is robust to outliers and noisy data.\n5. The Bartender algorithm is applicable in fields such as bioinformatics, image analysis, and text mining.",
    "llama-2-7b-chat-hf_fact": [
      "The Bartender algorithm was introduced by T. Hastie, R. Tibshirani, and J. Friedman in 2003.",
      "The Bartender algorithm is used for feature selection and dimensionality reduction in high-dimensional datasets.",
      "It is a greedy algorithm that iteratively adds and removes features based on their correlation with the current set of selected features.",
      "The algorithm is robust to outliers and noisy data.",
      "The Bartender algorithm is applicable in fields such as bioinformatics, image analysis, and text mining."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Bartender algorithm does not exist. The authors T. Hastie, R. Tibshirani, and J. Friedman are known for their work on statistical learning methods, but they did not introduce an algorithm called \"Bartender.\" They are, however, known for the LASSO and elastic-net methods, among others.\n2. FALSE [correction]: Since the Bartender algorithm does not exist, it cannot be used for feature selection and dimensionality reduction in high-dimensional datasets.\n3. FALSE [correction]: As the Bartender algorithm does not exist, it cannot be described as a greedy algorithm or characterized by its approach to adding and removing features.\n4. FALSE [correction]: The Bartender algorithm cannot be robust to outliers and noisy data because it does not exist.\n5. FALSE [correction]: The Bartender algorithm cannot be applicable in fields such as bioinformatics, image analysis, and text mining because it does not exist.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "There are several web-based pedigree editors available, including:\n1. Pedigree-Online: This is a popular web-based platform that provides a comprehensive database of ancestral lines, including birth, marriage, and death records.\n2. FamilySearch: This is a free online tool that allows users to create and share family trees, as well as access historical records and documents.\n3. MyHeritage: This platform offers a range of tools and resources for building and sharing family trees, including a large database of historical records and a DNA testing service.\n4. Ancestry.com: This is a well-known genealogy research platform that provides access to a vast collection of historical records and offers a range of tools for building and sharing family trees.\n5. GenoPro: This is a professional genealogy software that allows users to create and publish their family trees online, as well as access historical records and documents.\n6. Legacy Family Tree: This is a popular genealogy software that provides a range of tools for building and sharing family trees, including a large database of historical records and a DNA testing service.\n7. FamilyTreeMaker: This is a genealogy software that provides a range of tools for building and sharing family trees, including a large database of historical records and a DNA testing service.\n8. RootsMagic: This is a genealogy software that provides a range of tools for building and sharing family trees, including a large database of historical records and a DNA testing service.\n9. Gramps: This is a free and open-source genealogy software that allows users to create and publish their family trees online, as well as access historical records and documents.\n10. GRAMPS-Wiki: This is a web-based genealogy software that allows users to create and publish their family trees online, as well as access historical records and documents.\nPlease note that this list is not exhaustive and there may be other web-based pedigree editors available.",
    "llama-2-7b-chat-hf_fact_raw": "1. Pedigree-Online is a web-based platform that provides a database of ancestral lines, including birth, marriage, and death records.\n2. FamilySearch is a free online tool that allows users to create and share family trees and access historical records and documents.\n3. MyHeritage offers a DNA testing service in addition to tools for building and sharing family trees.\n4. Ancestry.com is a genealogy research platform that provides access to historical records and tools for building and sharing family trees.\n5. Gramps is a free and open-source genealogy software that allows users to create and publish their family trees online.",
    "llama-2-7b-chat-hf_fact": [
      "Pedigree-Online is a web-based platform that provides a database of ancestral lines, including birth, marriage, and death records.",
      "FamilySearch is a free online tool that allows users to create and share family trees and access historical records and documents.",
      "MyHeritage offers a DNA testing service in addition to tools for building and sharing family trees.",
      "Ancestry.com is a genealogy research platform that provides access to historical records and tools for building and sharing family trees.",
      "Gramps is a free and open-source genealogy software that allows users to create and publish their family trees online."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Gramps is a free and open-source genealogy software, but it is primarily designed for users to download and use on their personal computers, not to publish their family trees online.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "There are several curated databases available for spider-venom toxins, including:\n1. ToxinDB: A comprehensive database of toxins from various sources, including spider venoms. It contains information on the structure, function, and pharmacological properties of toxins, as well as their potential applications in medicine and biotechnology.\n2. Spider Toxin Database (Spidex): A database of spider venom peptides and proteins, including their sequences, structures, and biological activities. It also includes information on the species of spiders from which the toxins were derived and their potential applications in medicine and agriculture.\n3. VenomDB: A database of venom peptides and proteins from various animal sources, including spiders, snakes, and scorpions. It contains information on the structure, function, and pharmacological properties of venom peptides and proteins, as well as their potential applications in medicine and biotechnology.\n4. Natural Products Alliance Database (NPAD): A database of natural products, including peptides and proteins from spider venoms, with information on their structures, spectra, and biological activities. It also includes information on the species of spiders from which the toxins were derived and their potential applications in medicine and biotechnology.\n5. Spider Toxin Gene Database (STGD): A database of genes encoding spider venom toxins, including their sequences, structures, and biological activities. It also includes information on the species of spiders from which the toxins were derived and their potential applications in medicine and biotechnology.\n6. Venomous Animal Toxin Database (VAT): A database of toxins from venomous animals, including spiders, snakes, and scorpions. It contains information on the structure, function, and pharmacological properties of toxins, as well as their potential applications in medicine and biotechnology.\n7. ToxinTracer: A database of toxins from various sources, including spider venoms, with information on their structures, functions, and pharmacological properties. It also includes information on the species of spiders from which the toxins were derived and their potential applications in medicine and biotechnology.\n8. Spider",
    "llama-2-7b-chat-hf_fact_raw": "1. ToxinDB is a database that contains information on toxins from various sources, including spider venoms.\n2. The Spider Toxin Database (Spidex) includes information on spider venom peptides and proteins, their sequences, structures, and biological activities.\n3. VenomDB is a database that contains information on venom peptides and proteins from various animal sources, including spiders.\n4. The Natural Products Alliance Database (NPAD) includes peptides and proteins from spider venoms and provides information on their structures, spectra, and biological activities.\n5. The Spider Toxin Gene Database (STGD) is a database of genes encoding spider venom toxins, including their sequences and structures.",
    "llama-2-7b-chat-hf_fact": [
      "ToxinDB is a database that contains information on toxins from various sources, including spider venoms.",
      "The Spider Toxin Database (Spidex) includes information on spider venom peptides and proteins, their sequences, structures, and biological activities.",
      "VenomDB is a database that contains information on venom peptides and proteins from various animal sources, including spiders.",
      "The Natural Products Alliance Database (NPAD) includes peptides and proteins from spider venoms and provides information on their structures, spectra, and biological activities.",
      "The Spider Toxin Gene Database (STGD) is a database of genes encoding spider venom toxins, including their sequences and structures."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements are true as they describe the purpose and content of databases that are related to toxins and venoms, and such databases do exist. However, without specific knowledge about the Natural Products Alliance Database (NPAD) and the Spider Toxin Gene Database (STGD), I cannot confirm the accuracy of statements 4 and 5. These databases may or may not exist, and if they do, the details provided would need to be verified.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Axitinib, a tyrosine kinase inhibitor, has been investigated in clinical trials for the treatment of pancreatic cancer. The results of these trials have shown that axitinib can have a positive impact on overall survival in patients with pancreatic cancer.\nA phase 2 clinical trial published in the Journal of Clinical Oncology in 2018 found that axitinib therapy significantly improved overall survival in patients with advanced pancreatic cancer compared to standard chemotherapy. The median overall survival was 10.6 months in the axitinib group versus 7.2 months in the chemotherapy group.\nAnother phase 3 clinical trial, known as the EXP3103 trial, compared axitinib to gemcitabine plus nab-paclitaxel in patients with metastatic pancreatic cancer. The results of this trial, published in the New England Journal of Medicine in 2020, showed that axitinib therapy did not meet the primary endpoint of overall survival, but it did demonstrate a statistically significant improvement in progression-free survival.\nWhile these findings are promising, it is important to note that the overall survival benefit observed in these trials was relatively modest, and the exact mechanism by which axitinib works in pancreatic cancer is not fully understood. Additionally, axitinib can have significant side effects, including fatigue, nausea, and diarrhea, which can impact quality of life.\nIn summary, while axitinib has shown promise in improving overall survival in patients with pancreatic cancer, further research is needed to fully understand its efficacy and safety in this patient population.",
    "llama-2-7b-chat-hf_fact_raw": "1. Axitinib is a tyrosine kinase inhibitor used in the treatment of pancreatic cancer.\n2. A phase 2 clinical trial published in the Journal of Clinical Oncology in 2018 reported that axitinib therapy improved overall survival in patients with advanced pancreatic cancer compared to standard chemotherapy.\n3. The median overall survival was 10.6 months for patients treated with axitinib versus 7.2 months for those receiving chemotherapy, according to the phase 2 clinical trial.\n4. The phase 3 clinical trial, EXP3103, showed that axitinib did not meet the primary endpoint of overall survival but did improve progression-free survival in patients with metastatic pancreatic cancer.\n5. The results of the EXP3103 trial were published in the New England Journal of Medicine in 2020.",
    "llama-2-7b-chat-hf_fact": [
      "Axitinib is a tyrosine kinase inhibitor used in the treatment of pancreatic cancer.",
      "A phase 2 clinical trial published in the Journal of Clinical Oncology in 2018 reported that axitinib therapy improved overall survival in patients with advanced pancreatic cancer compared to standard chemotherapy.",
      "The median overall survival was 10.6 months for patients treated with axitinib versus 7.2 months for those receiving chemotherapy, according to the phase 2 clinical trial.",
      "The phase 3 clinical trial, EXP3103, showed that axitinib did not meet the primary endpoint of overall survival but did improve progression-free survival in patients with metastatic pancreatic cancer.",
      "The results of the EXP3103 trial were published in the New England Journal of Medicine in 2020."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Axitinib is a tyrosine kinase inhibitor used in the treatment of renal cell carcinoma, not specifically approved for pancreatic cancer.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe corrections and assessments of the statements are based on the knowledge that axitinib is primarily used for renal cell carcinoma. However, without access to the specific clinical trial publications mentioned, the veracity of statements 2, 3, 4, and 5 cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "MLP (Myosin Light Chain Phosphatase) regulates F-actin dynamics through its interaction with actin-binding proteins, such as cofilin and gelsolin. MLP dephosphorylates and inactivates these proteins, leading to the relaxation of F-actin filaments and the regulation of cellular processes such as cell migration, adhesion, and signaling.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP (Myosin Light Chain Phosphatase) interacts with actin-binding proteins to regulate F-actin dynamics.\n2. Cofilin and gelsolin are examples of actin-binding proteins that interact with MLP.\n3. MLP dephosphorylates and inactivates actin-binding proteins like cofilin and gelsolin.\n4. The relaxation of F-actin filaments is a result of MLP's interaction with actin-binding proteins.\n5. MLP's regulation of F-actin dynamics affects cellular processes such as cell migration, adhesion, and signaling.",
    "llama-2-7b-chat-hf_fact": [
      "MLP (Myosin Light Chain Phosphatase) interacts with actin-binding proteins to regulate F-actin dynamics.",
      "Cofilin and gelsolin are examples of actin-binding proteins that interact with MLP.",
      "MLP dephosphorylates and inactivates actin-binding proteins like cofilin and gelsolin.",
      "The relaxation of F-actin filaments is a result of MLP's interaction with actin-binding proteins.",
      "MLP's regulation of F-actin dynamics affects cellular processes such as cell migration, adhesion, and signaling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MLP (Myosin Light Chain Phosphatase) does not interact with actin-binding proteins to regulate F-actin dynamics; instead, it dephosphorylates myosin light chains to regulate muscle contraction and relaxation.\n2. TRUE (assuming the context is about actin-binding proteins in general, not their interaction with MLP)\n3. FALSE [correction]: MLP dephosphorylates myosin light chains, not actin-binding proteins like cofilin and gelsolin.\n4. FALSE [correction]: The relaxation of F-actin filaments is not a direct result of MLP's interaction with actin-binding proteins; MLP affects muscle contraction and relaxation by dephosphorylating myosin light chains.\n5. TRUE (assuming the context is about the regulation of F-actin dynamics in general, which involves various proteins and affects cellular processes)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "Pseudokinases are proteins that have some structural and functional similarities to kinases, but lack the active catalytic site for phosphorylation. The exact number of pseudokinases in the human kinome is still a matter of debate and ongoing research, as the definition and classification of pseudokinases can be complex and sometimes overlapping.\nHowever, based on current estimates, there are approximately 20-30 pseudokinases in the human kinome. These pseudokinases are scattered across different protein families and are involved in various cellular processes, including signal transduction, cytoskeleton organization, and regulation of gene expression.\nSome examples of pseudokinases in the human kinome include:\n1. Pseudokinase 1 (PRK1): a protein that regulates the cytoskeleton and cell adhesion\n2. Pseudokinase 2 (PRK2): a protein that is involved in cell signaling and regulation of gene expression\n3. Pseudokinase 3 (PRK3): a protein that is involved in regulation of the actin cytoskeleton\n4. Pseudokinase 4 (PRK4): a protein that is involved in regulation of cell adhesion and migration\n5. Pseudokinase 5 (PRK5): a protein that is involved in regulation of cell signaling and gene expression\n6. Pseudokinase 6 (PRK6): a protein that is involved in regulation of the actin cytoskeleton\n7. Pseudokinase 7 (PRK7): a protein that is involved in regulation of cell signaling and gene expression\n8. Pseudokinase 8 (PRK8): a protein that is involved in regulation of the actin cytoskeleton\n9. Pseudokinase 9 (PRK9): a protein that is involved in regulation of cell signaling and gene expression\n10. Pseudokinase 10 (PRK10): a protein that is involved in regulation of cell adhesion and migration\nIt's worth noting that the number of pseudokinases in the human kinome can vary depending on the source and method of classification, and some studies may group these proteins differently. However, the above list provides a general overview of",
    "llama-2-7b-chat-hf_fact_raw": "1. Pseudokinases are proteins that have structural and functional similarities to kinases but lack an active catalytic site for phosphorylation.\n2. There are approximately 20-30 pseudokinases in the human kinome based on current estimates.\n3. Pseudokinases are involved in various cellular processes, including signal transduction, cytoskeleton organization, and regulation of gene expression.\n4. The exact number of pseudokinases in the human kinome is a matter of debate and ongoing research.\n5. The classification of pseudokinases can be complex and sometimes overlapping.",
    "llama-2-7b-chat-hf_fact": [
      "Pseudokinases are proteins that have structural and functional similarities to kinases but lack an active catalytic site for phosphorylation.",
      "There are approximately 20-30 pseudokinases in the human kinome based on current estimates.",
      "Pseudokinases are involved in various cellular processes, including signal transduction, cytoskeleton organization, and regulation of gene expression.",
      "The exact number of pseudokinases in the human kinome is a matter of debate and ongoing research.",
      "The classification of pseudokinases can be complex and sometimes overlapping."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There are approximately 50-60 pseudokinases in the human kinome based on current estimates.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "ApoE mimetics are compounds that mimic the structure and function of apolipoprotein E (apoE), a protein involved in lipid metabolism and cholesterol transport. Here are three examples of apoE mimetics:\n1. ApoEMimetic-100: This is a synthetic peptide that mimics the sequence of apoE and has been shown to inhibit cholesterol absorption in the intestine and reduce cholesterol levels in the blood.\n2. AZD-7203: This is an orally available small molecule that mimics the apoE structure and has been shown to reduce cholesterol levels and improve cardiovascular outcomes in animal models of hypercholesterolemia.\n3. CERC-001: This is a recombinant apolipoprotein mimetic that has been shown to increase HDL cholesterol levels and reduce LDL cholesterol levels in animal models of dyslipidemia.",
    "llama-2-7b-chat-hf_fact_raw": "1. ApoEMimetic-100 is a synthetic peptide designed to mimic the sequence of apolipoprotein E (apoE).\n2. AZD-7203 is an orally available small molecule that mimics the structure of apoE.\n3. CERC-001 is a recombinant apolipoprotein mimetic.\n4. ApoEMimetic-100 has been shown to inhibit cholesterol absorption in the intestine and reduce cholesterol levels in the blood.\n5. CERC-001 has been shown to increase HDL cholesterol levels and reduce LDL cholesterol levels in animal models.",
    "llama-2-7b-chat-hf_fact": [
      "ApoEMimetic-100 is a synthetic peptide designed to mimic the sequence of apolipoprotein E (apoE).",
      "AZD-7203 is an orally available small molecule that mimics the structure of apoE.",
      "CERC-001 is a recombinant apolipoprotein mimetic.",
      "ApoEMimetic-100 has been shown to inhibit cholesterol absorption in the intestine and reduce cholesterol levels in the blood.",
      "CERC-001 has been shown to increase HDL cholesterol levels and reduce LDL cholesterol levels in animal models."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first statement is true if ApoEMimetic-100 is indeed designed to mimic apolipoprotein E, as the name suggests. However, without specific context or additional information, it is not possible to verify the accuracy of statements 2 through 5. These statements would require specific knowledge about the compounds AZD-7203, ApoEMimetic-100, and CERC-001, including their mechanisms of action and results from scientific studies. Without access to the relevant scientific literature or data, the truthfulness of these statements remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "SAMHD1 (SAM and HD-like protein 1) is an enzyme that plays a crucial role in regulating the innate immune response to viral infections. There are sex differences in SAMHD1 activity, which have been observed in various studies. Here are some of the key findings:\n1. SAMHD1 expression: Studies have shown that SAMHD1 is expressed at lower levels in female mice compared to males. This lower expression may contribute to the higher susceptibility of females to certain viral infections.\n2. Viral sensitivity: Female mice are more susceptible to certain viral infections, such as HIV-1, than males. SAMHD1 has been shown to play a role in regulating the innate immune response to these viruses, and the lower expression of SAMHD1 in females may contribute to their increased susceptibility.\n3. Enzymatic activity: SAMHD1 has been shown to have different enzymatic activity in males and females. For example, one study found that SAMHD1 from female mice had higher activity against the viral protein RNA-dependent protein kinase (PKR) compared to males.\n4. Regulation by estrogen: Estrogen has been shown to regulate SAMHD1 expression and activity in various tissues, including the immune system. For example, estrogen has been shown to increase SAMHD1 expression in the uterus and breast, and to decrease SAMHD1 activity in the liver.\n5. Implications for disease susceptibility: The sex differences in SAMHD1 activity and expression may have implications for disease susceptibility. For example, the lower expression of SAMHD1 in females may contribute to their increased susceptibility to certain viral infections, such as HIV-1.\n6. Implications for drug development: Understanding the sex differences in SAMHD1 activity and expression may also have implications for drug development. For example, drugs that target SAMHD1 may be more effective in males than females, or may have different side effects in the two sexes.\nIn summary, there are several sex differences in SAMHD1 activity and expression, which may have implications for disease susceptibility and drug development. Further research is needed to fully understand",
    "llama-2-7b-chat-hf_fact_raw": "1. SAMHD1 is expressed at lower levels in female mice compared to males.\n2. Female mice are more susceptible to certain viral infections, such as HIV-1, than males.\n3. SAMHD1 from female mice had higher activity against the viral protein RNA-dependent protein kinase (PKR) compared to males.\n4. Estrogen has been shown to regulate SAMHD1 expression and activity in various tissues.\n5. The sex differences in SAMHD1 activity and expression may have implications for disease susceptibility and drug development.",
    "llama-2-7b-chat-hf_fact": [
      "SAMHD1 is expressed at lower levels in female mice compared to males.",
      "Female mice are more susceptible to certain viral infections, such as HIV-1, than males.",
      "SAMHD1 from female mice had higher activity against the viral protein RNA-dependent protein kinase (PKR) compared to males.",
      "Estrogen has been shown to regulate SAMHD1 expression and activity in various tissues.",
      "The sex differences in SAMHD1 activity and expression may have implications for disease susceptibility and drug development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE: Estrogen has been shown to regulate the expression and activity of various proteins, including SAMHD1, in different tissues.\n5. TRUE: The sex differences in the activity and expression of proteins like SAMHD1 can have implications for disease susceptibility and drug development, as these differences can affect how diseases progress and how drugs are metabolized.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "No, RUNX2 (RUNX2 is a transcription factor that plays a crucial role in the regulation of hematopoiesis and bone development) does not inhibit astrocyte differentiation. In fact, RUNX2 has been shown to play a critical role in the differentiation of astrocytes, specifically in the process of glial cell fate determination.\nStudies have shown that RUNX2 is required for the proper differentiation of astrocytes in the developing brain, and that loss of RUNX2 function leads to abnormalities in astrocyte differentiation and maturation. Additionally, RUNX2 has been shown to regulate the expression of genes involved in astrocyte differentiation, such as GFAP and A2B5, and to modulate the activity of transcription factors involved in astrocyte differentation, such as PDGFRA and PDGFRB.\nTherefore, it can be concluded that RUNX2 plays a crucial role in the regulation of astrocyte differentiation and is not involved in its inhibition.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 is a transcription factor that plays a crucial role in the regulation of hematopoiesis and bone development.\n2. RUNX2 is required for the proper differentiation of astrocytes in the developing brain.\n3. Loss of RUNX2 function leads to abnormalities in astrocyte differentiation and maturation.\n4. RUNX2 regulates the expression of genes involved in astrocyte differentiation, such as GFAP and A2B5.\n5. RUNX2 modulates the activity of transcription factors involved in astrocyte differentiation, such as PDGFRA and PDGFRB.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 is a transcription factor that plays a crucial role in the regulation of hematopoiesis and bone development.",
      "RUNX2 is required for the proper differentiation of astrocytes in the developing brain.",
      "Loss of RUNX2 function leads to abnormalities in astrocyte differentiation and maturation.",
      "RUNX2 regulates the expression of genes involved in astrocyte differentiation, such as GFAP and A2B5.",
      "RUNX2 modulates the activity of transcription factors involved in astrocyte differentiation, such as PDGFRA and PDGFRB."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: RUNX2 is indeed a transcription factor that is important for bone development. It is known for its role in osteoblast differentiation and skeletal morphogenesis.\n2. FALSE [correction]: RUNX2 is not primarily known for the differentiation of astrocytes in the developing brain. It is mainly associated with bone development. The transcription factor that is more commonly associated with astrocyte differentiation is not RUNX2, but rather factors like NFIA or SOX9.\n3. FALSE [correction]: Since RUNX2 is not primarily involved in astrocyte differentiation, loss of RUNX2 function is not typically associated with abnormalities in astrocyte differentiation and maturation. Instead, loss of RUNX2 function is known to lead to cleidocranial dysplasia, a condition affecting the development of bones and teeth.\n4. FALSE [correction]: RUNX2 does not regulate the expression of genes involved in astrocyte differentiation such as GFAP and A2B5. GFAP is a glial fibrillary acidic protein that is a marker of astrocytes, and its expression is regulated by other factors involved in astrocyte differentiation.\n5. FALSE [correction]: RUNX2 is not known to modulate the activity of transcription factors involved in astrocyte differentiation, such as PDGFRA and PDGFRB. These factors are involved in the signaling pathways that promote the proliferation and differentiation of various cell types, including cells in the central nervous system, but RUNX2's role in modulating these factors is not established in the context of astrocyte differentiation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "Cobb-Stansby excision arthroplasty is a surgical procedure that is typically performed in the knee joint. It is a type of arthroplasty, which is a surgical procedure that involves replacing a damaged or diseased joint with an artificial joint. The Cobb-Stansby excision arthroplasty specifically involves removing a portion of the femur (thigh bone) and replacing it with an artificial component. This procedure is typically performed to treat advanced degenerative conditions of the knee joint, such as osteoarthritis or post-traumatic arthritis. The goal of the procedure is to relieve pain, improve mobility, and restore function to the knee joint.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the knee joint.\n2. The procedure involves replacing a damaged or diseased joint with an artificial joint.\n3. A portion of the femur is removed during the Cobb-Stainsby excision arthroplasty.\n4. The procedure is typically used to treat advanced degenerative conditions of the knee joint, such as osteoarthritis or post-traumatic arthritis.\n5. The goal of Cobb-Stainsby excision arthroplasty is to relieve pain, improve mobility, and restore function to the knee joint.",
    "llama-2-7b-chat-hf_fact": [
      "Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the knee joint.",
      "The procedure involves replacing a damaged or diseased joint with an artificial joint.",
      "A portion of the femur is removed during the Cobb-Stainsby excision arthroplasty.",
      "The procedure is typically used to treat advanced degenerative conditions of the knee joint, such as osteoarthritis or post-traumatic arthritis.",
      "The goal of Cobb-Stainsby excision arthroplasty is to relieve pain, improve mobility, and restore function to the knee joint."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the hip joint, not the knee joint.\n2. FALSE [correction]: The procedure does not involve replacing the joint with an artificial joint. Instead, it involves the removal of the femoral head and the interposition of soft tissue to create a pseudoarthrosis.\n3. TRUE\n4. FALSE [correction]: Since the procedure is performed on the hip joint, it is typically used to treat advanced degenerative conditions of the hip joint, not the knee joint.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "GRHL2 (Growth Hormone-Releasing Hormone-Like 2) over-expression has been shown to promote Epithelial-to-Mesenchymal Transition (EMT) in various cell types, including cancer cells. EMT is a process by which epithelial cells lose their cell-cell adhesion and gain mesenchymal characteristics, such as increased motility and invasiveness, which can contribute to cancer progression and metastasis.\nStudies have shown that GRHL2 over-expression can lead to EMT by suppressing the expression of epithelial markers (such as E-cadherin) and increasing the expression of mesenchymal markers (such as N-cadherin and vimentin) in various cell types, including breast, lung, and colon cancer cells. GRHL2 over-expression can also activate key transcription factors involved in EMT, such as β-catenin and Snail.\nIn summary, GRHL2 over-expression has been shown to promote EMT in various cell types, contributing to cancer progression and metastasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. GRHL2 over-expression promotes Epithelial-to-Mesenchymal Transition (EMT) in various cell types, including cancer cells.\n2. EMT is a process where epithelial cells lose cell-cell adhesion and gain mesenchymal characteristics like increased motility and invasiveness.\n3. GRHL2 over-expression can suppress the expression of epithelial markers such as E-cadherin.\n4. GRHL2 over-expression can increase the expression of mesenchymal markers such as N-cadherin and vimentin in various cell types, including breast, lung, and colon cancer cells.\n5. GRHL2 over-expression can activate key transcription factors involved in EMT, such as β-catenin and Snail.",
    "llama-2-7b-chat-hf_fact": [
      "GRHL2 over-expression promotes Epithelial-to-Mesenchymal Transition (EMT) in various cell types, including cancer cells.",
      "EMT is a process where epithelial cells lose cell-cell adhesion and gain mesenchymal characteristics like increased motility and invasiveness.",
      "GRHL2 over-expression can suppress the expression of epithelial markers such as E-cadherin.",
      "GRHL2 over-expression can increase the expression of mesenchymal markers such as N-cadherin and vimentin in various cell types, including breast, lung, and colon cancer cells.",
      "GRHL2 over-expression can activate key transcription factors involved in EMT, such as β-catenin and Snail."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: GRHL2 over-expression can actually lead to the upregulation of epithelial markers such as E-cadherin, which is associated with the suppression of EMT.\n4. FALSE [correction]: GRHL2 over-expression is generally associated with the suppression of mesenchymal markers such as N-cadherin and vimentin, as it inhibits EMT.\n5. FALSE [correction]: GRHL2 over-expression is more likely to inhibit the activity of key transcription factors involved in EMT, such as β-catenin and Snail, rather than activate them.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "T-UCRs (tumor-associated circular RNAs) have been implicated in various types of cancer, including lung cancer. Here are some T-UCRs that have been linked to lung cancer:\n1. circRNA000001: This T-UCR has been shown to be upregulated in lung cancer tissues and promotes the proliferation and migration of lung cancer cells.\n2. circRNA000002: This T-UCR has been found to be downregulated in lung cancer tissues and inhibits the proliferation and migration of lung cancer cells.\n3. circRNA000003: This T-UCR has been shown to be upregulated in non-small cell lung cancer (NSCLC) and promotes the epithelial-to-mesenchymal transition (EMT) and the progression of NSCLC.\n4. circRNA000004: This T-UCR has been found to be downregulated in lung cancer tissues and inhibits the proliferation and migration of lung cancer cells by sponging miR-210.\n5. circRNA000005: This T-UCR has been shown to be upregulated in lung cancer tissues and promotes the progression of NSCLC by regulating the expression of PTEN.\nIt's worth noting that the expression of T-UCRs in lung cancer is complex and can vary depending on the type of lung cancer, the stage of disease, and other factors. Further research is needed to fully understand the role of T-UCRs in lung cancer and their potential as therapeutic targets.",
    "llama-2-7b-chat-hf_fact_raw": "1. T-UCRs (tumor-associated circular RNAs) have been implicated in various types of cancer, including lung cancer.\n2. circRNA000001 is upregulated in lung cancer tissues and promotes the proliferation and migration of lung cancer cells.\n3. circRNA000002 is downregulated in lung cancer tissues and inhibits the proliferation and migration of lung cancer cells.\n4. circRNA000003 is upregulated in non-small cell lung cancer (NSCLC) and promotes the epithelial-to-mesenchymal transition (EMT) and the progression of NSCLC.\n5. circRNA000005 is upregulated in lung cancer tissues and promotes the progression of NSCLC by regulating the expression of PTEN.",
    "llama-2-7b-chat-hf_fact": [
      "T-UCRs (tumor-associated circular RNAs) have been implicated in various types of cancer, including lung cancer.",
      "circRNA000001 is upregulated in lung cancer tissues and promotes the proliferation and migration of lung cancer cells.",
      "circRNA000002 is downregulated in lung cancer tissues and inhibits the proliferation and migration of lung cancer cells.",
      "circRNA000003 is upregulated in non-small cell lung cancer (NSCLC) and promotes the epithelial-to-mesenchymal transition (EMT) and the progression of NSCLC.",
      "circRNA000005 is upregulated in lung cancer tissues and promotes the progression of NSCLC by regulating the expression of PTEN."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - T-UCRs (tumor-associated circular RNAs) have been implicated in various types of cancer, including lung cancer.\n2. UNKNOWN - Without specific scientific literature or data to confirm the role of \"circRNA000001,\" the truth of this statement cannot be determined.\n3. UNKNOWN - Similar to statement 2, without specific scientific literature or data to confirm the role of \"circRNA000002,\" the truth of this statement cannot be determined.\n4. UNKNOWN - The role of \"circRNA000003\" in NSCLC and its effects on EMT and progression of NSCLC cannot be confirmed without specific scientific references.\n5. UNKNOWN - The statement about \"circRNA000005\" and its regulatory effect on PTEN in lung cancer tissues cannot be confirmed without specific scientific evidence.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "GPR151 (G protein-coupled receptor 151) is an orphan receptor, meaning that it does not have a well-defined endogenous ligand or a clear physiological function. However, research has shown that GPR151 is involved in various cellular processes, including:\n1. Inflammation: GPR151 has been implicated in the regulation of inflammatory responses, particularly in the context of arthritis and other inflammatory diseases.\n2. Immune cell function: GPR151 has been shown to play a role in the regulation of immune cell function, including the activation and proliferation of T cells and the differentiation of B cells.\n3. Metabolism: GPR151 has been linked to the regulation of glucose and lipid metabolism, and may be involved in the development of metabolic disorders such as obesity and type 2 diabetes.\n4. Cancer: GPR151 has been implicated in the development and progression of certain types of cancer, including breast, lung, and colon cancer.\n5. Neuroprotection: GPR151 has been shown to have neuroprotective effects, and may play a role in the regulation of synaptic plasticity and learning and memory.\n6. Cardiovascular health: GPR151 has been linked to the regulation of blood pressure and cardiovascular health, and may be involved in the development of cardiovascular disease.\nOverall, GPR151 is a complex receptor with a multifaceted role in various physiological processes, and further research is needed to fully understand its function and potential as a therapeutic target.",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is an orphan receptor without a well-defined endogenous ligand or clear physiological function.\n2. GPR151 has been implicated in the regulation of inflammatory responses.\n3. GPR151 plays a role in the regulation of immune cell function, including T cells activation and B cells differentiation.\n4. GPR151 has been linked to the regulation of glucose and lipid metabolism.\n5. GPR151 has been implicated in the development and progression of certain types of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is an orphan receptor without a well-defined endogenous ligand or clear physiological function.",
      "GPR151 has been implicated in the regulation of inflammatory responses.",
      "GPR151 plays a role in the regulation of immune cell function, including T cells activation and B cells differentiation.",
      "GPR151 has been linked to the regulation of glucose and lipid metabolism.",
      "GPR151 has been implicated in the development and progression of certain types of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GPR151 has not been widely implicated in the regulation of inflammatory responses. It is an orphan receptor, and its functions are not well-defined.\n3. FALSE [correction]: There is no clear evidence that GPR151 plays a role in the regulation of immune cell function, including T cells activation and B cells differentiation, as its physiological functions are not well-established.\n4. FALSE [correction]: GPR151 has not been directly linked to the regulation of glucose and lipid metabolism. Its functions remain unclear due to its status as an orphan receptor.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "Fluzone Intradermal Quadrivalent is a vaccine that contains four strains of attenuated live viruses:\n1. FluB (Brisbane/50) - a subtype of Influenza B virus\n2. FluA (H1N1) - a subtype of Influenza A virus\n3. FluA (H3N2) - a subtype of Influenza A virus\n4. FluB (Victoria/2573) - a subtype of Influenza B virus\nIt's important to note that the specific strains of viruses contained in any given vaccine may vary depending on factors such as the manufacturer and the year the vaccine was produced.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluzone Intradermal Quadrivalent vaccine contains a strain of Influenza B virus known as Brisbane/50.\n2. Fluzone Intradermal Quadrivalent vaccine contains a strain of Influenza A virus known as H1N1.\n3. Fluzone Intradermal Quadrivalent vaccine contains a strain of Influenza A virus known as H3N2.\n4. Fluzone Intradermal Quadrivalent vaccine contains a strain of Influenza B virus known as Victoria/2573.",
    "llama-2-7b-chat-hf_fact": [
      "Fluzone Intradermal Quadrivalent vaccine contains a strain of Influenza B virus known as Brisbane/50.",
      "Fluzone Intradermal Quadrivalent vaccine contains a strain of Influenza A virus known as H1N1.",
      "Fluzone Intradermal Quadrivalent vaccine contains a strain of Influenza A virus known as H3N2.",
      "Fluzone Intradermal Quadrivalent vaccine contains a strain of Influenza B virus known as Victoria/2573."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n\nThe Fluzone Intradermal Quadrivalent vaccine is designed to protect against two influenza A viruses (H1N1 and H3N2) and two influenza B viruses. However, without the specific year or season's formulation information, it is not possible to confirm the exact strains such as \"Brisbane/50\" or \"Victoria/2573\" as these can vary each year based on World Health Organization recommendations.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "The TNFR2 gene, also known as the Tumor Necrosis Factor Receptor 2 gene, has been associated with Systemic Lupus Erythematosus (SLE) in several genetic studies. Specifically, a variant of the TNFR2 gene, known as the -308G/A polymorphism, has been found to be more common in individuals with SLE compared to the general population.\nThis polymorphism occurs in the promoter region of the TNFR2 gene and is thought to affect the expression of the TNFR2 protein. Studies have shown that individuals with the -308A allele have a higher risk of developing SLE compared to those with the -308G allele. The -308A allele is also associated with a higher risk of severe disease and kidney involvement in SLE patients.\nIt's worth noting that while the -308G/A polymorphism is the most well-established genetic risk factor for SLE, other variants in the TNFR2 gene and other genes have also been associated with an increased risk of developing SLE.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE).\n2. The -308G/A polymorphism of the TNFR2 gene is more common in individuals with SLE than in the general population.\n3. The -308G/A polymorphism occurs in the promoter region of the TNFR2 gene.\n4. Individuals with the -308A allele of the TNFR2 gene have a higher risk of developing SLE compared to those with the -308G allele.\n5. The -308A allele is associated with a higher risk of severe disease and kidney involvement in SLE patients.",
    "llama-2-7b-chat-hf_fact": [
      "The TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE).",
      "The -308G/A polymorphism of the TNFR2 gene is more common in individuals with SLE than in the general population.",
      "The -308G/A polymorphism occurs in the promoter region of the TNFR2 gene.",
      "Individuals with the -308A allele of the TNFR2 gene have a higher risk of developing SLE compared to those with the -308G allele.",
      "The -308A allele is associated with a higher risk of severe disease and kidney involvement in SLE patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The TNFR2 gene has been associated with Systemic Lupus Erythematosus (SLE) in various studies, suggesting a potential role in the disease's pathogenesis.\n2. TRUE: Some studies have found that the -308G/A polymorphism of the TNFR2 gene is more common in individuals with SLE than in the general population, indicating a potential association with the disease.\n3. FALSE [correction]: The -308G/A polymorphism occurs in the promoter region of the TNF gene, not the TNFR2 gene. The TNF gene encodes the tumor necrosis factor, which is a cytokine involved in systemic inflammation.\n4. UNKNOWN: The risk associated with specific alleles can vary between studies, and without specific data or references, it is difficult to confirm the statement's accuracy.\n5. UNKNOWN: Similar to statement 4, the association of the -308A allele with severe disease and kidney involvement in SLE patients can vary between studies, and without specific data or references, it is difficult to confirm the statement's accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "There is currently no licensed vaccine available for the prevention of peanut allergy. However, researchers are actively working on developing a vaccine for peanut allergy, and several clinical trials are underway to evaluate the safety and efficacy of different vaccine candidates.\nOne of the most promising approaches is to use a type of virus called an adenovirus to deliver a gene that produces a protein that can help the body tolerate peanuts. This approach has shown some promise in early clinical trials, but more research is needed to determine its long-term safety and effectiveness.\nAnother approach being explored is the use of a bacterial toxin called cholera toxin, which has been shown to stimulate the immune system to produce antibodies that can help protect against peanut allergy. This approach has also shown some promise in early clinical trials, but more research is needed to determine its long-term safety and effectiveness.\nWhile these vaccine candidates show promise, it is important to note that a peanut allergy vaccine is still in the experimental stage and may not be available for many years. In the meantime, the best way to manage a peanut allergy is to avoid peanuts and peanut products and to carry an EpiPen or other emergency medication in case of an accidental exposure.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no licensed vaccine available for the prevention of peanut allergy as of the knowledge cutoff date.\n2. Researchers are conducting clinical trials to evaluate the safety and efficacy of different vaccine candidates for peanut allergy.\n3. An adenovirus is being used in one of the approaches to deliver a gene that produces a protein to help the body tolerate peanuts.\n4. The use of cholera toxin is another approach being explored to stimulate the immune system against peanut allergy.\n5. A peanut allergy vaccine is still in the experimental stage and may not be available for many years.",
    "llama-2-7b-chat-hf_fact": [
      "There is no licensed vaccine available for the prevention of peanut allergy as of the knowledge cutoff date.",
      "Researchers are conducting clinical trials to evaluate the safety and efficacy of different vaccine candidates for peanut allergy.",
      "An adenovirus is being used in one of the approaches to deliver a gene that produces a protein to help the body tolerate peanuts.",
      "The use of cholera toxin is another approach being explored to stimulate the immune system against peanut allergy.",
      "A peanut allergy vaccine is still in the experimental stage and may not be available for many years."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "The mouse Fxy gene is located on the X chromosome (Xq13.2). This is incorrect, as the Fxy gene is actually located on the autosome (chromosome 11) in mice, not on the X chromosome. The Fxy gene is a sex-linked gene that is responsible for the development of the female reproductive system in mice.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene is located on chromosome 11 in mice.\n2. The Fxy gene is not located on the X chromosome in mice.\n3. The Fxy gene is a sex-linked gene.\n4. The Fxy gene is responsible for the development of the female reproductive system in mice.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene is located on chromosome 11 in mice.",
      "The Fxy gene is not located on the X chromosome in mice.",
      "The Fxy gene is a sex-linked gene.",
      "The Fxy gene is responsible for the development of the female reproductive system in mice."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The mouse Fxy gene, also known as Fxyd5, is located on chromosome X in mice.\n2. FALSE [correction]: The Fxy gene is located on the X chromosome in mice.\n3. TRUE: Since the Fxy gene is located on the X chromosome, it is considered a sex-linked gene.\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "Methidiumpropyl-EDTA (MPE) sequencing, also known as MPE-seq, is a method for isolating and sequencing specific methylated DNA sequences in a sample. The basis of the MPE-seq method is the use of a chemical probe, methidiumpropyl-EDTA (MPE), which selectively binds to methylated cytosine residues in DNA.\nThe MPE probe is a modified version of EDTA, which is a commonly used chelating agent that binds to divalent cations such as calcium and iron. The addition of a methyl group to the probe creates a highly specific and stable interaction with methylated cytosine residues in DNA. This interaction allows for the selective isolation of methylated DNA sequences using a variety of methods, including PCR, sequencing, and microarray analysis.\nThe MPE-seq method involves the following steps:\n1. Sample preparation: The sample is first treated with MPE to selectively bind to methylated cytosine residues in the DNA.\n2. Purification: The MPE-bound DNA is then purified using a variety of methods, including precipitation, gel purification, or commercial kits.\n3. PCR amplification: The purified MPE-bound DNA is then amplified using PCR to generate enough material for sequencing.\n4. Sequencing: The amplified MPE-bound DNA is then sequenced using Next-Generation Sequencing (NGS) technologies, such as Illumina or PacBio.\n5. Data analysis: The resulting sequencing data is then analyzed to identify the methylated regions in the DNA.\nThe MPE-seq method offers several advantages over other methods for analyzing DNA methylation, including high sensitivity and specificity, simple sample preparation, and the ability to analyze large regions of the genome. It has been used to study a variety of biological processes, including cancer, aging, and development, and has the potential to be used as a diagnostic tool for diseases associated with aberrant DNA methylation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Methidiumpropyl-EDTA (MPE) sequencing is a method used for isolating and sequencing specific methylated DNA sequences.\n2. The MPE probe selectively binds to methylated cytosine residues in DNA.\n3. The MPE probe is a modified version of EDTA, which binds to divalent cations.\n4. The MPE-seq method includes steps such as sample preparation, purification, PCR amplification, sequencing, and data analysis.\n5. Next-Generation Sequencing (NGS) technologies, such as Illumina or PacBio, are used for sequencing in the MPE-seq method.",
    "llama-2-7b-chat-hf_fact": [
      "Methidiumpropyl-EDTA (MPE) sequencing is a method used for isolating and sequencing specific methylated DNA sequences.",
      "The MPE probe selectively binds to methylated cytosine residues in DNA.",
      "The MPE probe is a modified version of EDTA, which binds to divalent cations.",
      "The MPE-seq method includes steps such as sample preparation, purification, PCR amplification, sequencing, and data analysis.",
      "Next-Generation Sequencing (NGS) technologies, such as Illumina or PacBio, are used for sequencing in the MPE-seq method."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Methidiumpropyl-EDTA (MPE) is not a sequencing method. It is a chemical compound that can be used to cleave DNA at specific sites. The method for sequencing specific methylated DNA sequences is called bisulfite sequencing.\n2. UNKNOWN: Without specific context or additional information, it is unclear whether the MPE probe selectively binds to methylated cytosine residues in DNA. MPE itself is known to intercalate into DNA, but its selectivity for methylated cytosine without modification is not established.\n3. TRUE: Methidiumpropyl-EDTA (MPE) is indeed a modified version of EDTA. EDTA is known to bind divalent cations, and MPE is a derivative that has been modified to intercalate into DNA.\n4. UNKNOWN: The statement lists general steps that could be part of many DNA sequencing methods, but without specific context, it is unclear if these steps are part of a method involving MPE, as MPE is not typically associated with a sequencing method but rather with DNA cleavage.\n5. UNKNOWN: Next-Generation Sequencing (NGS) technologies such as Illumina or PacBio are indeed used for sequencing DNA, but it is unclear if they are specifically used in conjunction with MPE, as MPE is not a sequencing method. NGS is typically used after DNA has been appropriately prepared, which may or may not involve MPE depending on the experimental design.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "GWAR (Genome-Wide Association Study) is typically implemented using a programming language that is well-suited for genomic data analysis, such as Python.\nSome popular Python libraries for GWAS analysis include:\n1. GCTA: The Genome-Wide Complex Trait Analysis (GCTA) package is a popular Python library for GWAS analysis. It provides a comprehensive set of tools for genotype imputation, association mapping, and genomic regression.\n2. PLINK: PLINK is a popular command-line tool for GWAS analysis. It provides a simple and efficient way to perform association studies and can handle large datasets.\n3. SEQUIA: SEQUIA is a Python library for genome-wide association studies. It provides a variety of tools for genotype imputation, association mapping, and genomic regression, as well as methods for testing and interpreting the results.\n4. GIANT: GIANT is a large-scale genomic analysis platform that provides a variety of tools for GWAS analysis, including genotype imputation, association mapping, and genomic regression.\n5. HAPPHASE: HAPPHASE is a Python library for haplotype phase inference in GWAS. It provides a variety of methods for estimating the phase of genotypes and can handle large datasets.\nThese libraries are widely used in the scientific community and have been used in many GWAS studies. However, it is important to note that the choice of library will depend on the specific requirements of the study and the research question being investigated.",
    "llama-2-7b-chat-hf_fact_raw": "1. Python is a programming language used for implementing Genome-Wide Association Studies (GWAS).\n2. GCTA is a Python library used for GWAS analysis.\n3. PLINK is a command-line tool used for GWAS analysis.\n4. SEQUIA is a Python library designed for genome-wide association studies.\n5. HAPPHASE is a Python library used for haplotype phase inference in GWAS.",
    "llama-2-7b-chat-hf_fact": [
      "Python is a programming language used for implementing Genome-Wide Association Studies (GWAS).",
      "GCTA is a Python library used for GWAS analysis.",
      "PLINK is a command-line tool used for GWAS analysis.",
      "SEQUIA is a Python library designed for genome-wide association studies.",
      "HAPPHASE is a Python library used for haplotype phase inference in GWAS."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GCTA is not a Python library; it is a standalone software tool for complex trait analysis, including GWAS.\n3. TRUE\n4. FALSE [correction]: There is no widely recognized Python library named SEQUIA designed for genome-wide association studies. This might be a typo or a fictional library.\n5. FALSE [correction]: The correct name of the software is HAPLOVIEW, and it is not a Python library but a standalone tool for haplotype analysis, including haplotype phase inference in GWAS.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Xaliproden (also known as remacemide) is an investigational drug that has been studied for its potential to improve the prognosis of amyotrophic lateral sclerosis (ALS). However, there is currently no conclusive evidence to support its use in treating ALS.\nA phase II clinical trial conducted by the National Institute of Neurological Disorders and Stroke (NINDS) found that xaliproden did not meet the primary endpoint of slowing the progression of ALS. The study, which enrolled 160 participants with ALS, found that xaliproden did not significantly reduce the decline in motor function compared to a placebo.\nMore recent studies have also failed to show a significant benefit of xaliproden in slowing the progression of ALS. A phase III clinical trial conducted by the ALS Clinical Trials Network found that xaliproden did not significantly improve the progression-free survival of participants with ALS compared to a placebo.\nWhile these results are disappointing, it's important to note that ALS is a complex and heterogeneous disease, and there is still much work to be done to develop effective treatments. Researchers are continuing to explore new therapeutic approaches, including gene therapy, stem cell therapy, and small molecule treatments, to slow or halt the progression of ALS.\nIn summary, while xaliproden has shown promise in early-stage clinical trials, there is currently no conclusive evidence to support its use in improving the prognosis of ALS. Further research is needed to determine the safety and efficacy of this drug in treating this devastating disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xaliproden is an investigational drug that has been studied for its potential to improve the prognosis of amyotrophic lateral sclerosis (ALS).\n2. A phase II clinical trial by the National Institute of Neurological Disorders and Stroke (NINDS) found that xaliproden did not meet the primary endpoint of slowing the progression of ALS.\n3. The phase II study enrolled 160 participants with ALS and found that xaliproden did not significantly reduce the decline in motor function compared to a placebo.\n4. A phase III clinical trial conducted by the ALS Clinical Trials Network found that xaliproden did not significantly improve the progression-free survival of participants with ALS compared to a placebo.\n5. Researchers are exploring new therapeutic approaches for ALS, including gene therapy, stem cell therapy, and small molecule treatments.",
    "llama-2-7b-chat-hf_fact": [
      "Xaliproden is an investigational drug that has been studied for its potential to improve the prognosis of amyotrophic lateral sclerosis (ALS).",
      "A phase II clinical trial by the National Institute of Neurological Disorders and Stroke (NINDS) found that xaliproden did not meet the primary endpoint of slowing the progression of ALS.",
      "The phase II study enrolled 160 participants with ALS and found that xaliproden did not significantly reduce the decline in motor function compared to a placebo.",
      "A phase III clinical trial conducted by the ALS Clinical Trials Network found that xaliproden did not significantly improve the progression-free survival of participants with ALS compared to a placebo.",
      "Researchers are exploring new therapeutic approaches for ALS, including gene therapy, stem cell therapy, and small molecule treatments."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN (The statement does not provide enough information to verify the specific results of the NINDS phase II clinical trial for xaliproden.)\n3. UNKNOWN (The statement does not provide enough information to verify the specific results of the phase II study regarding the number of participants and the impact on motor function decline.)\n4. UNKNOWN (The statement does not provide enough information to verify the specific results of a phase III clinical trial conducted by the ALS Clinical Trials Network for xaliproden.)\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "The LiPS-A3S line is a transgenic mouse line that expresses the gene encoding the enzyme acetyl-CoA carboxylase (ACC) under the control of the α-myosin heavy chain (MHC) promoter. This line has been used to study the role of ACC in lipid metabolism and related diseases.\nIn the LiPS-A3S line, the transgene is inserted into chromosome 17. Specifically, the transgene is located on chromosome 17p13.3, which is the location of the human MHC gene. The MHC promoter is used to drive the expression of the ACC gene in a tissue-specific manner, resulting in the overexpression of ACC in various tissues, including the liver, muscle, and adipose tissue.",
    "llama-2-7b-chat-hf_fact_raw": "1. The LiPS-A3S line is a transgenic mouse line.\n2. In the LiPS-A3S line, the gene encoding the enzyme acetyl-CoA carboxylase (ACC) is expressed under the control of the α-myosin heavy chain (MHC) promoter.\n3. The transgene in the LiPS-A3S line is inserted into chromosome 17.\n4. The specific location of the transgene in the LiPS-A3S line is chromosome 17p13.3.\n5. The α-myosin heavy chain (MHC) promoter drives tissue-specific expression of the ACC gene in the LiPS-A3S line.",
    "llama-2-7b-chat-hf_fact": [
      "The LiPS-A3S line is a transgenic mouse line.",
      "In the LiPS-A3S line, the gene encoding the enzyme acetyl-CoA carboxylase (ACC) is expressed under the control of the α-myosin heavy chain (MHC) promoter.",
      "The transgene in the LiPS-A3S line is inserted into chromosome 17.",
      "The specific location of the transgene in the LiPS-A3S line is chromosome 17p13.3.",
      "The α-myosin heavy chain (MHC) promoter drives tissue-specific expression of the ACC gene in the LiPS-A3S line."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "There are several deep learning tools and models that can be used for predicting drug synergy. Here are some of the most popular ones:\n1. DeepDrug: This is a deep learning model that predicts drug synergy by analyzing the protein-protein interaction networks of drug targets. It uses a convolutional neural network (CNN) architecture to identify potential drug combinations that can produce synergy.\n2. DrugCombo: This is a deep learning model that predicts drug synergy by analyzing the chemical structures of drugs and their targets. It uses a recurrent neural network (RNN) architecture to identify potential drug combinations that can produce synergy.\n3. Synergizer: This is a deep learning model that predicts drug synergy by analyzing the gene expression profiles of drug-treated cells. It uses a multi-task learning approach, where the model is trained to predict both drug synergy and drug toxicity.\n4. DrugNet: This is a deep learning model that predicts drug synergy by analyzing the protein-protein interaction networks of drug targets. It uses a graph convolutional neural network (CNN) architecture to identify potential drug combinations that can produce synergy.\n5. DeepSynth: This is a deep learning model that predicts drug synergy by analyzing the chemical structures of drugs and their targets. It uses a CNN architecture to identify potential drug combinations that can produce synergy.\n6. DrugSynergyNet: This is a deep learning model that predicts drug synergy by analyzing the protein-protein interaction networks of drug targets. It uses a CNN architecture to identify potential drug combinations that can produce synergy.\n7. ChEA-Net: This is a deep learning model that predicts drug synergy by analyzing the chemical structures of drugs and their targets. It uses a CNN architecture to identify potential drug combinations that can produce synergy.\n8. DrugCombo-GAN: This is a deep learning model that predicts drug synergy by analyzing the chemical structures of drugs and their targets. It uses a generative adversarial network (GAN) architecture to identify potential drug combinations that can produce synergy.\n9. DrugSynergyGNN: This is a deep learning model that predicts drug synergy by analyzing the",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepDrug is a deep learning model that predicts drug synergy using a convolutional neural network (CNN) to analyze protein-protein interaction networks.\n2. DrugCombo is a deep learning model that predicts drug synergy using a recurrent neural network (RNN) to analyze the chemical structures of drugs and their targets.\n3. Synergizer is a deep learning model that predicts drug synergy and drug toxicity using a multi-task learning approach based on gene expression profiles of drug-treated cells.\n4. DrugNet is a deep learning model that predicts drug synergy using a graph convolutional neural network (CNN) to analyze protein-protein interaction networks.\n5. DrugCombo-GAN is a deep learning model that predicts drug synergy using a generative adversarial network (GAN) to analyze the chemical structures of drugs and their targets.",
    "llama-2-7b-chat-hf_fact": [
      "DeepDrug is a deep learning model that predicts drug synergy using a convolutional neural network (CNN) to analyze protein-protein interaction networks.",
      "DrugCombo is a deep learning model that predicts drug synergy using a recurrent neural network (RNN) to analyze the chemical structures of drugs and their targets.",
      "Synergizer is a deep learning model that predicts drug synergy and drug toxicity using a multi-task learning approach based on gene expression profiles of drug-treated cells.",
      "DrugNet is a deep learning model that predicts drug synergy using a graph convolutional neural network (CNN) to analyze protein-protein interaction networks.",
      "DrugCombo-GAN is a deep learning model that predicts drug synergy using a generative adversarial network (GAN) to analyze the chemical structures of drugs and their targets."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe truthfulness of these statements cannot be determined without specific information about these deep learning models. The names \"DeepDrug,\" \"DrugCombo,\" \"Synergizer,\" \"DrugNet,\" and \"DrugCombo-GAN\" could be hypothetical or proprietary models, and their descriptions involve technical details that would need to be verified against authoritative sources or scientific literature. Without additional context or references, it is not possible to confirm the accuracy of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "There are several cloud-based platforms that have been developed for comparing genome-wide association studies (GWAS). Here are a few examples:\n1. Cloud GWAS: This is a cloud-based platform developed by the University of California, San Diego, that allows researchers to compare GWAS data from different studies. It provides a user-friendly interface for uploading and analyzing GWAS data, and allows researchers to perform meta-analyses and identify novel associations.\n2. Meta-Analyses of Genome-Wide Association Studies (MAGWAS): This is a cloud-based platform developed by the University of California, Los Angeles, that allows researchers to perform meta-analyses of GWAS data. It provides a range of tools for analyzing GWAS data, including methods for identifying novel associations and quantifying the strength of associations.\n3. GWAS Central: This is a cloud-based platform developed by the National Center for Biotechnology Information (NCBI) that allows researchers to access and analyze GWAS data from a variety of sources. It provides a user-friendly interface for uploading and analyzing GWAS data, and allows researchers to perform meta-analyses and identify novel associations.\n4. The GWAS Platform: This is a cloud-based platform developed by the Broad Institute that allows researchers to perform GWAS and meta-analyses of large-scale genomic data sets. It provides a range of tools for analyzing GWAS data, including methods for identifying novel associations and quantifying the strength of associations.\n5. WASutils: This is a cloud-based platform developed by the University of California, San Diego, that allows researchers to perform meta-analyses of GWAS data. It provides a range of tools for analyzing GWAS data, including methods for identifying novel associations and quantifying the strength of associations.\n6. GWAS-TK: This is a cloud-based platform developed by the University of California, San Francisco, that allows researchers to perform meta-analyses of GWAS data. It provides a range of tools for analyzing GWAS data, including methods for identifying novel associations and quantifying the strength of associations.\n7. Meta-Analysis of Genome-Wide Association Studies (MAGWAS): This",
    "llama-2-7b-chat-hf_fact_raw": "1. Cloud GWAS is a cloud-based platform developed by the University of California, San Diego.\n2. Meta-Analyses of Genome-Wide Association Studies (MAGWAS) is a cloud-based platform developed by the University of California, Los Angeles.\n3. GWAS Central is a cloud-based platform developed by the National Center for Biotechnology Information (NCBI).\n4. The GWAS Platform is a cloud-based platform developed by the Broad Institute.\n5. GWAS-TK is a cloud-based platform developed by the University of California, San Francisco.",
    "llama-2-7b-chat-hf_fact": [
      "Cloud GWAS is a cloud-based platform developed by the University of California, San Diego.",
      "Meta-Analyses of Genome-Wide Association Studies (MAGWAS) is a cloud-based platform developed by the University of California, Los Angeles.",
      "GWAS Central is a cloud-based platform developed by the National Center for Biotechnology Information (NCBI).",
      "The GWAS Platform is a cloud-based platform developed by the Broad Institute.",
      "GWAS-TK is a cloud-based platform developed by the University of California, San Francisco."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: GWAS Central is a database and online resource for genome-wide association studies, developed by the European Bioinformatics Institute (EBI) and the Wellcome Trust Sanger Institute, not by the National Center for Biotechnology Information (NCBI).\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the development of the cloud-based platforms mentioned in statements 1, 2, 4, and 5, it is not possible to determine the accuracy of these statements. Therefore, the response is \"UNKNOWN\" for those statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "CMB305 is a monoclonal antibody that targets the Wilms' Tumor 1 (WT1) protein, which is overexpressed in various types of cancer, including sarcomas. Therefore, CMB305 can be used against sarcomas, as it targets a protein that is overexpressed in these types of cancer.\nSarcomas are a group of rare and complex cancers that arise from the mesenchyme, a type of connective tissue in the body. They can arise in any part of the body and are often aggressive and difficult to treat. WT1 is overexpressed in many types of sarcomas, including leiomyosarcoma, liposarcoma, and chondrosarcoma, among others.\nCMB305 has been shown to be effective in preclinical studies against sarcomas, including those that are resistant to conventional chemotherapy and radiation therapy. In these studies, CMB305 has been shown to induce apoptosis (cell death) in sarcoma cells, inhibit their growth and proliferation, and reduce their ability to migrate and invade surrounding tissues.\nWhile CMB305 has shown promise in preclinical studies against sarcomas, it is important to note that it is still an investigational drug and has not yet been approved by regulatory authorities for use in humans. Further clinical trials are needed to determine its safety and efficacy in humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is a monoclonal antibody that targets the Wilms' Tumor 1 (WT1) protein.\n2. The WT1 protein is overexpressed in various types of cancer, including sarcomas.\n3. Sarcomas can arise in any part of the body and are often aggressive and difficult to treat.\n4. In preclinical studies, CMB305 has been shown to induce apoptosis in sarcoma cells, inhibit their growth and proliferation, and reduce their ability to migrate and invade surrounding tissues.\n5. CMB305 is still an investigational drug and has not yet been approved by regulatory authorities for use in humans.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is a monoclonal antibody that targets the Wilms' Tumor 1 (WT1) protein.",
      "The WT1 protein is overexpressed in various types of cancer, including sarcomas.",
      "Sarcomas can arise in any part of the body and are often aggressive and difficult to treat.",
      "In preclinical studies, CMB305 has been shown to induce apoptosis in sarcoma cells, inhibit their growth and proliferation, and reduce their ability to migrate and invade surrounding tissues.",
      "CMB305 is still an investigational drug and has not yet been approved by regulatory authorities for use in humans."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "The Saint's Triad is a clinical entity that consists of three key manifestations:\n1. Ophthalmoplegia: weakness or paralysis of the extraocular muscles, leading to droopy eyelids, double vision, or difficulty moving the eyes.\n2. Facial weakness or paralysis: weakness or paralysis of the facial muscles, leading to weakness or paralysis of facial movements, including eyelid closure, smiling, and facial expression.\n3. Cerebellar ataxia: a degeneration of the cerebellum, leading to problems with coordination, balance, and movement. Symptoms may include unsteadiness, stumbling, and difficulty with fine motor movements.\nThese three manifestations are the hallmark signs of the Saint's Triad, although the exact combination and severity of symptoms can vary from person to person. The Saint's Triad is a rare condition, and its cause is not fully understood. However, it is believed to be related to a genetic mutation that affects the functioning of the cerebellum and other parts of the nervous system.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Saint's Triad consists of ophthalmoplegia, facial weakness or paralysis, and cerebellar ataxia.\n2. Ophthalmoplegia involves weakness or paralysis of the extraocular muscles.\n3. Facial weakness or paralysis in the Saint's Triad affects movements such as eyelid closure, smiling, and facial expression.\n4. Cerebellar ataxia in the Saint's Triad leads to issues with coordination, balance, and movement.\n5. The Saint's Triad is considered a rare condition.",
    "llama-2-7b-chat-hf_fact": [
      "The Saint's Triad consists of ophthalmoplegia, facial weakness or paralysis, and cerebellar ataxia.",
      "Ophthalmoplegia involves weakness or paralysis of the extraocular muscles.",
      "Facial weakness or paralysis in the Saint's Triad affects movements such as eyelid closure, smiling, and facial expression.",
      "Cerebellar ataxia in the Saint's Triad leads to issues with coordination, balance, and movement.",
      "The Saint's Triad is considered a rare condition."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Saint's Triad is not a recognized medical condition. The term \"Saint's triad\" does not correspond to a known medical syndrome involving ophthalmoplegia, facial weakness or paralysis, and cerebellar ataxia. However, there is a condition known as \"Miller Fisher Syndrome\" which is characterized by ophthalmoplegia, ataxia, and areflexia.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "No, overexpression of LY6K is associated with poor prognosis in non-small cell lung cancer (NSCLC) patients. LY6K is a protein that is involved in the regulation of cell migration and invasion, and high levels of LY6K expression have been correlated with increased tumor aggressiveness and poorer prognosis in various types of cancer, including NSCLC. Studies have shown that high levels of LY6K expression are associated with a higher risk of disease recurrence and mortality in NSCLC patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K is associated with poor prognosis in non-small cell lung cancer (NSCLC) patients.\n2. LY6K is a protein involved in the regulation of cell migration and invasion.\n3. High levels of LY6K expression have been correlated with increased tumor aggressiveness.\n4. High levels of LY6K expression in NSCLC patients are associated with a higher risk of disease recurrence.\n5. High levels of LY6K expression in NSCLC patients are associated with a higher risk of mortality.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K is associated with poor prognosis in non-small cell lung cancer (NSCLC) patients.",
      "LY6K is a protein involved in the regulation of cell migration and invasion.",
      "High levels of LY6K expression have been correlated with increased tumor aggressiveness.",
      "High levels of LY6K expression in NSCLC patients are associated with a higher risk of disease recurrence.",
      "High levels of LY6K expression in NSCLC patients are associated with a higher risk of mortality."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with scientific findings that suggest overexpression of LY6K (Lymphocyte Antigen 6 Complex, Locus K) is associated with poor prognosis in non-small cell lung cancer patients, and it is involved in processes such as cell migration and invasion. High levels of LY6K expression have been correlated with increased tumor aggressiveness, a higher risk of disease recurrence, and a higher risk of mortality in NSCLC patients.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "During cytokinesis, the protein kinase Cdk1 (also known as Cyclin-dependent kinase 1) is inactivated through dephosphorylation. This is a critical step in the process of cytokinesis, as it allows the cell to separate its duplicated sets of chromosomes and complete cell division. Here are some of the Cdk targets that are dephosphorylated during cytokinesis:\n1. Cyclin-dependent kinase 1 (Cdk1): Cdk1 is the primary Cdk involved in regulating the progression of the cell cycle, including the G2/M checkpoint and the metaphase-anaphase transition. During cytokinesis, Cdk1 is inactivated through dephosphorylation by the protein phosphatase Cdc25A.\n2. Cyclin B: Cyclin B is a regulatory protein that binds and activates Cdk1 during the G2 phase of the cell cycle. During cytokinesis, cyclin B is dephosphorylated and inactivated, leading to the inactivation of Cdk1 and the arrest of the cell cycle.\n3. Cyclin E: Cyclin E is another regulatory protein that binds and activates Cdk2 during the G1 phase of the cell cycle. During cytokinesis, cyclin E is dephosphorylated and inactivated, leading to the inactivation of Cdk2 and the arrest of the cell cycle.\n4. Polo-like kinase 1 (Plk1): Plk1 is a Cdk that is involved in the regulation of mitosis, including the separation of chromosomes during cytokinesis. During cytokinesis, Plk1 is dephosphorylated and inactivated, leading to the proper separation of chromosomes.\n5. Aurora kinase A (Aurora A): Aurora A is a Cdk that is involved in the regulation of mitosis, including the separation of chromosomes during cytokinesis. During cytokinesis, Aurora A is dephosphorylated and inactivated, leading to the proper separation of chromosomes.\nThese are some of the key Cdk targets that are dephosphorylated",
    "llama-2-7b-chat-hf_fact_raw": "1. Cdk1 is inactivated through dephosphorylation during cytokinesis.\n2. Cyclin B is dephosphorylated and inactivated during cytokinesis.\n3. Cyclin E is dephosphorylated and inactivated during cytokinesis.\n4. Polo-like kinase 1 (Plk1) is dephosphorylated and inactivated during cytokinesis.\n5. Aurora kinase A (Aurora A) is dephosphorylated and inactivated during cytokinesis.",
    "llama-2-7b-chat-hf_fact": [
      "Cdk1 is inactivated through dephosphorylation during cytokinesis.",
      "Cyclin B is dephosphorylated and inactivated during cytokinesis.",
      "Cyclin E is dephosphorylated and inactivated during cytokinesis.",
      "Polo-like kinase 1 (Plk1) is dephosphorylated and inactivated during cytokinesis.",
      "Aurora kinase A (Aurora A) is dephosphorylated and inactivated during cytokinesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cdk1 is inactivated through dephosphorylation during mitosis, not specifically during cytokinesis. Cdk1 is typically inactivated by the degradation of its cyclin partner, cyclin B, which leads to its dephosphorylation.\n2. FALSE [correction]: Cyclin B is not dephosphorylated during cytokinesis; rather, it is targeted for degradation by the anaphase-promoting complex/cyclosome (APC/C), which leads to the inactivation of Cdk1.\n3. UNKNOWN: The statement about Cyclin E is not clear in the context of cytokinesis. Cyclin E is associated with the control of the cell cycle at the G1/S transition, not typically during cytokinesis.\n4. UNKNOWN: The statement about Polo-like kinase 1 (Plk1) is not clear without additional context. Plk1 is involved in various stages of mitosis and its activity is regulated by phosphorylation and dephosphorylation, but the specific timing and regulation during cytokinesis are not specified.\n5. UNKNOWN: The statement about Aurora kinase A (Aurora A) is not clear without additional context. Aurora A is involved in mitotic entry, spindle assembly, and centrosome maturation. Its regulation by phosphorylation and dephosphorylation is complex and not limited to cytokinesis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Xanamem is a drug that inhibits the enzyme glycogen synthase kinase-3β (GSK-3β). GSK-3β is a key regulator of various cellular processes, including cell signaling, gene expression, and protein degradation. Xanamem is used in scientific research as an inhibitor of GSK-3β to study the role of this enzyme in various biological processes, including cancer, neurodegeneration, and metabolic disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is a drug that inhibits the enzyme glycogen synthase kinase-3β (GSK-3β).\n2. GSK-3β is involved in regulating cellular processes such as cell signaling, gene expression, and protein degradation.\n3. Xanamem is utilized in scientific research to study the role of GSK-3β.\n4. Research on Xanamem includes its effects on biological processes related to cancer, neurodegeneration, and metabolic disorders.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is a drug that inhibits the enzyme glycogen synthase kinase-3β (GSK-3β).",
      "GSK-3β is involved in regulating cellular processes such as cell signaling, gene expression, and protein degradation.",
      "Xanamem is utilized in scientific research to study the role of GSK-3β.",
      "Research on Xanamem includes its effects on biological processes related to cancer, neurodegeneration, and metabolic disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n\nThe statements about Xanamem, its inhibition of GSK-3β, its use in scientific research, and the specific areas of research it is involved in would require specific scientific knowledge or literature that is current as of my last update. Without access to the latest research or information about Xanamem, I cannot confirm or correct these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "In yeast, the Hof1-Cyk3 interaction plays a crucial role in regulating the cell cycle and preventing premature activation of the sporulation pathway. Here's how:\nHof1 is a transcriptional activator that regulates the expression of genes involved in the sporulation pathway, while Cyk3 is a kinase that phosphorylates and inactivates Hof1. When the cell is in the G1 phase of the cell cycle, Cyk3 phosphorylates and inactivates Hof1, preventing it from activating the sporulation pathway. This ensures that the cell remains in the G1 phase and continues to grow and replicate.\nIn addition to its role in regulating the cell cycle, the Hof1-Cyk3 interaction also plays a role in the regulation of stress response pathways in yeast. When the cell is exposed to stress, Hof1 is activated and translocates to the nucleus, where it regulates the expression of genes involved in the stress response. Cyk3 inhibits this process by phosphorylating and inactivating Hof1, preventing it from activating the stress response genes.\nIn summary, the Hof1-Cyk3 interaction plays a crucial role in regulating the cell cycle and preventing premature activation of the sporulation pathway in yeast, while also playing a role in regulating stress response pathways.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction regulates the cell cycle in yeast.\n2. Hof1 is a transcriptional activator that regulates genes involved in the sporulation pathway in yeast.\n3. Cyk3 is a kinase that phosphorylates and inactivates Hof1 in yeast.\n4. The Hof1-Cyk3 interaction prevents premature activation of the sporulation pathway by keeping Hof1 inactivated during the G1 phase of the cell cycle.\n5. The Hof1-Cyk3 interaction also plays a role in the regulation of stress response pathways in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction regulates the cell cycle in yeast.",
      "Hof1 is a transcriptional activator that regulates genes involved in the sporulation pathway in yeast.",
      "Cyk3 is a kinase that phosphorylates and inactivates Hof1 in yeast.",
      "The Hof1-Cyk3 interaction prevents premature activation of the sporulation pathway by keeping Hof1 inactivated during the G1 phase of the cell cycle.",
      "The Hof1-Cyk3 interaction also plays a role in the regulation of stress response pathways in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hof1 is not a transcriptional activator that regulates genes involved in the sporulation pathway in yeast. Hof1 is a protein involved in cytokinesis, the final stage of the cell cycle.\n3. FALSE [correction]: Cyk3 is not a kinase, and it does not phosphorylate Hof1. Cyk3 is a protein that interacts with Hof1 to facilitate cytokinesis.\n4. FALSE [correction]: The Hof1-Cyk3 interaction does not prevent premature activation of the sporulation pathway by keeping Hof1 inactivated during the G1 phase of the cell cycle. The interaction is involved in cytokinesis, not the regulation of the sporulation pathway during the G1 phase.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "T-uridine cyclic nucleotide (UCR) is a type of non-coding RNA that has been implicated in various cellular processes, including gene regulation and cell proliferation. In gastric cancer, several T-UCRs have been found to be dysregulated or mutated, leading to the development and progression of this disease. Here are some examples of T-UCRs that have been implicated in gastric cancer:\n1. TUCB1: TUCB1 is a T-UCR that has been shown to be overexpressed in gastric cancer tissues and cell lines. Overexpression of TUCB1 has been linked to increased cell proliferation, migration, and invasion, as well as poor prognosis in gastric cancer patients.\n2. TUCP1: TUCP1 is another T-UCR that has been implicated in gastric cancer. Studies have shown that TUCP1 is overexpressed in gastric cancer tissues and cell lines, and that high levels of TUCP1 are associated with poor prognosis in gastric cancer patients.\n3. TUF1: TUF1 is a T-UCR that has been linked to the development and progression of gastric cancer. Overexpression of TUF1 has been observed in gastric cancer tissues and cell lines, and high levels of TUF1 have been associated with poor prognosis in gastric cancer patients.\n4. TUFA1: TUFA1 is a T-UCR that has been implicated in gastric cancer. Studies have shown that TUFA1 is overexpressed in gastric cancer tissues and cell lines, and that high levels of TUFA1 are associated with poor prognosis in gastric cancer patients.\n5. TUFL1: TUFL1 is a T-UCR that has been linked to the development and progression of gastric cancer. Overexpression of TUFL1 has been observed in gastric cancer tissues and cell lines, and high levels of TUFL1 have been associated with poor prognosis in gastric cancer patients.\nIt is important to note that the expression of these T-UCRs in gastric cancer is complex and can vary depending on",
    "llama-2-7b-chat-hf_fact_raw": "1. TUCB1 is a T-UCR that has been shown to be overexpressed in gastric cancer tissues and cell lines.\n2. Overexpression of TUCB1 in gastric cancer is linked to increased cell proliferation, migration, and invasion.\n3. TUCP1 is a T-UCR that is overexpressed in gastric cancer tissues and cell lines, and high levels are associated with poor prognosis in patients.\n4. TUF1 is a T-UCR whose overexpression has been observed in gastric cancer tissues and cell lines.\n5. TUFL1 is a T-UCR that is overexpressed in gastric cancer tissues and cell lines, and high levels of TUFL1 are associated with poor prognosis in patients.",
    "llama-2-7b-chat-hf_fact": [
      "TUCB1 is a T-UCR that has been shown to be overexpressed in gastric cancer tissues and cell lines.",
      "Overexpression of TUCB1 in gastric cancer is linked to increased cell proliferation, migration, and invasion.",
      "TUCP1 is a T-UCR that is overexpressed in gastric cancer tissues and cell lines, and high levels are associated with poor prognosis in patients.",
      "TUF1 is a T-UCR whose overexpression has been observed in gastric cancer tissues and cell lines.",
      "TUFL1 is a T-UCR that is overexpressed in gastric cancer tissues and cell lines, and high levels of TUFL1 are associated with poor prognosis in patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: The correct acronym for the T-UCR mentioned should be TUCB1, not TUCP1. Assuming the rest of the statement is accurate, it should read: \"TUCB1 is a T-UCR that is overexpressed in gastric cancer tissues and cell lines, and high levels are associated with poor prognosis in patients.\"\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements regarding TUCB1, TUF1, and TUFL1 being T-UCRs (transcribed ultraconserved regions) overexpressed in gastric cancer tissues and cell lines require specific scientific data to verify their accuracy. Without access to the relevant research or literature, the truthfulness of these statements cannot be determined. The correction provided for statement 3 assumes that TUCB1 was the intended T-UCR to be mentioned, based on the context of the first statement.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a clinical index used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects multiple organ systems. The LSI was developed to provide a standardized way of evaluating the severity of SLE and to help clinicians identify patients who require more intensive treatment.\nThe LSI is composed of 11 items that assess various organ systems and disease activities, including:\n1. Skin: The number of skin lesions and their severity (e.g., rash, malar rash, discoid rash)\n2. Joints: The number of swollen and tender joints\n3. Serositis: The degree of pleural or pericardial effusion (fluid buildup in the lining of the heart or lungs)\n4. Renal: The level of proteinuria (excess protein in the urine) and/or hematuria (blood in the urine)\n5. Neurological: The presence and severity of neurological symptoms such as headache, confusion, seizures, or psychosis\n6. Haematological: The level of anemia (low red blood cell count), leukopenia (low white blood cell count), or thrombocytopenia (low platelet count)\n7. Fatigue: The degree of fatigue or weakness\n8. Pain: The level of pain or discomfort\n9. Lymphadenopathy: The size and tenderness of lymph nodes\n10. Infections: The number and severity of infections (e.g., urinary tract infections, respiratory infections)\n11. Functional status: The patient's overall functional status and ability to perform daily activities\nEach item is assigned a score from 0 to 3, with higher scores indicating greater severity. The total LSI score ranges from 0 to 33, with higher scores indicating more severe disease. The LSI has been shown to be a reliable and valid measure of SLE severity in clinical trials and has been used in clinical practice to monitor disease activity and response to treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI is composed of 11 items that assess various organ systems and disease activities.\n3. Each item on the LSI is assigned a score from 0 to 3.\n4. The total LSI score ranges from 0 to 33, with higher scores indicating more severe disease.\n5. The LSI has been used in clinical practice to monitor disease activity and response to treatment.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI is composed of 11 items that assess various organ systems and disease activities.",
      "Each item on the LSI is assigned a score from 0 to 3.",
      "The total LSI score ranges from 0 to 33, with higher scores indicating more severe disease.",
      "The LSI has been used in clinical practice to monitor disease activity and response to treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The SLE Disease Activity Index (SLEDAI) is composed of 24 items that assess various organ systems and disease activities, not the Lupus Severity Index (LSI).\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "ZSWIM6 is a gene that has been associated with several rare genetic disorders, including:\n1. Cornelia de Lange syndrome (CdLS): CdLS is a rare genetic disorder that affects the development of various body systems, including the brain, face, limbs, and digestive system. Mutations in the ZSWIM6 gene have been identified as a common cause of CdLS.\n2. Intellectual disability: ZSWIM6 mutations have been identified in individuals with intellectual disability, which is characterized by below-average intelligence and cognitive abilities.\n3. Autism spectrum disorder (ASD): Some studies have found that individuals with ASD are more likely to have mutations in the ZSWIM6 gene.\n4. Congenital anomalies: ZSWIM6 mutations have been identified in individuals with congenital anomalies, such as heart defects and craniofacial abnormalities.\n5. Cancer: ZSWIM6 has been implicated in cancer development and progression, and mutations in the gene have been identified in various types of cancer, including breast, ovarian, and colorectal cancer.\nIt is important to note that the prevalence of these disorders is rare and that the exact mechanism by which ZSWIM6 mutations lead to these disorders is not yet fully understood. Further research is needed to determine the full spectrum of ZSWIM6-related disorders and to develop effective treatments.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the ZSWIM6 gene have been identified as a cause of Cornelia de Lange syndrome (CdLS).\n2. ZSWIM6 mutations have been associated with intellectual disability.\n3. Studies have found a correlation between mutations in the ZSWIM6 gene and autism spectrum disorder (ASD).\n4. Individuals with congenital anomalies, such as heart defects and craniofacial abnormalities, have been identified to have ZSWIM6 mutations.\n5. Mutations in the ZSWIM6 gene have been implicated in various types of cancer, including breast, ovarian, and colorectal cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the ZSWIM6 gene have been identified as a cause of Cornelia de Lange syndrome (CdLS).",
      "ZSWIM6 mutations have been associated with intellectual disability.",
      "Studies have found a correlation between mutations in the ZSWIM6 gene and autism spectrum disorder (ASD).",
      "Individuals with congenital anomalies, such as heart defects and craniofacial abnormalities, have been identified to have ZSWIM6 mutations.",
      "Mutations in the ZSWIM6 gene have been implicated in various types of cancer, including breast, ovarian, and colorectal cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the ZSWIM6 gene have been associated with developmental disorders, but Cornelia de Lange syndrome (CdLS) is typically caused by mutations in other genes, such as NIPBL, SMC1A, SMC3, RAD21, and HDAC8.\n2. TRUE\n3. TRUE: While the statement is true, it's important to note that the relationship between ZSWIM6 mutations and ASD is complex and not fully understood. The presence of a mutation does not necessarily mean an individual will have ASD, and ASD can be caused by a variety of genetic and environmental factors.\n4. TRUE: Mutations in the ZSWIM6 gene can result in developmental disorders that may include congenital anomalies such as heart defects and craniofacial abnormalities.\n5. FALSE [correction]: While mutations in various genes have been implicated in different types of cancer, there is no widely recognized association between ZSWIM6 mutations and cancer. The statement may be conflating ZSWIM6 with other genes that are more commonly linked to these cancers.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "The Koos Classification is a system used to classify neurodegenerative diseases based on the type of neurofilament protein that is affected. The diseases that can be classified using the Koos Classification are:\n1. Alzheimer's disease: The loss of neurons and neurofibrillary tangles are caused by the misfolding of the amyloid precursor protein (APP).\n2. Frontotemporal dementia: The loss of neurons and neurofibrillary tangles are caused by the misfolding of the TDP-43 protein.\n3. Progressive supranuclear palsy: The loss of neurons and neurofibrillary tangles are caused by the misfolding of the tau protein.\n4. Parkinson's disease: The loss of dopaminergic neurons is caused by the misfolding of the alpha-synuclein protein.\n5. Multiple system atrophy: The loss of neurons and neurofibrillary tangles are caused by the misfolding of the alpha-synuclein protein.\n6. Corticobasal degeneration: The loss of neurons and neurofibrillary tangles are caused by the misfolding of the tau protein.\n7. Primary lateral sclerosis: The loss of motor neurons is caused by the misfolding of the TDP-43 protein.\n8. Spinocerebellar ataxia: The loss of neurons and neurofibrillary tangles are caused by the misfolding of the tau protein.\n9. Machado-Joseph disease: The loss of neurons and neurofibrillary tangles are caused by the misfolding of the ATXN3 protein.\n10. Spinal muscular atrophy: The loss of motor neurons is caused by the misfolding of the survival motor neuron (SMN) protein.\nEach of these diseases has a distinct set of clinical features and pathological hallmarks, and the Koos Classification helps to identify the underlying molecular mechanisms that contribute to their development.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is used to classify neurodegenerative diseases based on the type of neurofilament protein affected.\n2. Alzheimer's disease is associated with the misfolding of the amyloid precursor protein (APP).\n3. Parkinson's disease involves the loss of dopaminergic neurons caused by the misfolding of the alpha-synuclein protein.\n4. Progressive supranuclear palsy is associated with the misfolding of the tau protein.\n5. Spinal muscular atrophy involves the loss of motor neurons caused by the misfolding of the survival motor neuron (SMN) protein.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is used to classify neurodegenerative diseases based on the type of neurofilament protein affected.",
      "Alzheimer's disease is associated with the misfolding of the amyloid precursor protein (APP).",
      "Parkinson's disease involves the loss of dopaminergic neurons caused by the misfolding of the alpha-synuclein protein.",
      "Progressive supranuclear palsy is associated with the misfolding of the tau protein.",
      "Spinal muscular atrophy involves the loss of motor neurons caused by the misfolding of the survival motor neuron (SMN) protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Koos Classification is not used to classify neurodegenerative diseases based on the type of neurofilament protein affected. It is actually a grading system used for cerebellar arteriovenous malformations. Neurodegenerative diseases are typically classified by their clinical and pathological features, not by a system called the Koos Classification.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Spinal muscular atrophy involves the loss of motor neurons caused by a genetic defect in the SMN1 gene, which leads to a deficiency in the survival motor neuron (SMN) protein. It is not due to the misfolding of the SMN protein.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "AZD8601 is a small molecule inhibitor of the enzyme protease-activated receptor 2 (PAR2), which is involved in the regulation of inflammation and immune responses. In vivo, AZD8601 has been shown to have a variety of effects, including:\n1. Anti-inflammatory effects: AZD8601 has been shown to reduce inflammation in various animal models of inflammation, including colitis, arthritis, and asthma.\n2. Immunosuppressive effects: AZD8601 has been shown to suppress the activation and proliferation of immune cells, such as T cells and macrophages, which can help to reduce inflammation and prevent autoimmune diseases.\n3. Anti-tumor effects: AZD8601 has been shown to have anti-tumor effects in various animal models of cancer, including breast, lung, and colon cancer.\n4. Cardiovascular effects: AZD8601 has been shown to have protective effects on the cardiovascular system, including reducing blood pressure and improving cardiac function in animal models of hypertension and heart failure.\n5. Neuroprotective effects: AZD8601 has been shown to have neuroprotective effects in animal models of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.\nIt is important to note that the specific in vivo effects of AZD8601 can vary depending on the disease model being studied and the dosage and route of administration used. Further research is needed to fully understand the mechanisms of action of AZD8601 and its potential therapeutic applications.",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 is a small molecule inhibitor of the enzyme protease-activated receptor 2 (PAR2).\n2. AZD8601 has been shown to reduce inflammation in various animal models of diseases such as colitis, arthritis, and asthma.\n3. AZD8601 has been shown to suppress the activation and proliferation of immune cells like T cells and macrophages.\n4. AZD8601 has demonstrated anti-tumor effects in animal models of cancers including breast, lung, and colon cancer.\n5. AZD8601 has shown protective effects on the cardiovascular system, including reducing blood pressure and improving cardiac function in animal models of hypertension and heart failure.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 is a small molecule inhibitor of the enzyme protease-activated receptor 2 (PAR2).",
      "AZD8601 has been shown to reduce inflammation in various animal models of diseases such as colitis, arthritis, and asthma.",
      "AZD8601 has been shown to suppress the activation and proliferation of immune cells like T cells and macrophages.",
      "AZD8601 has demonstrated anti-tumor effects in animal models of cancers including breast, lung, and colon cancer.",
      "AZD8601 has shown protective effects on the cardiovascular system, including reducing blood pressure and improving cardiac function in animal models of hypertension and heart failure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: AZD8601 is not a small molecule inhibitor; it is an experimental mRNA-based therapy designed to increase the production of vascular endothelial growth factor A (VEGF-A) for regenerative medicine.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe correction for statement 1 is based on the known information about AZD8601 as of my knowledge cutoff date. The other statements pertain to specific research findings that are not provided in the context, so their veracity cannot be determined without additional information.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "SAHFs (Spatially-Organized Histone Fragments) are created through a process called \"Histone Fragmentation.\" This process involves the breakage of larger histone molecules into smaller fragments, which are then organized into specific spatial patterns along the DNA.\nThere are several mechanisms that can lead to histone fragmentation and the formation of SAHFs, including:\n1. DNA damage: When DNA is damaged, histones can become broken or lost, leading to the formation of SAHFs.\n2. Chromatin remodeling complexes: Certain complexes, such as SWI/SNF and ISWI, can remove histones from the DNA, leading to fragmentation and the formation of SAHFs.\n3. Transcriptional elongation: During transcriptional elongation, RNA polymerase II can cause histone H3 to fragment, leading to the formation of SAHFs.\n4. Ubiquitination: The covalent attachment of ubiquitin to histones can lead to their degradation and fragmentation, resulting in the formation of SAHFs.\n5. Acetylation: The removal of histone acetylation can also lead to histone fragmentation and the formation of SAHFs.\nOnce histone fragments are generated, they can be organized into specific spatial patterns along the DNA through various mechanisms, including:\n1. Chromatin looping: The interaction of histone fragments with other chromatin structures can lead to the formation of higher-order chromatin structures, such as loops.\n2. Nucleosome positioning: The positioning of histone fragments in relation to one another and to the DNA can also contribute to the formation of specific spatial patterns.\n3. Histone modification: The covalent attachment of various histone modifications, such as methyl or acetyl groups, can also influence the organization of histone fragments along the DNA.\nOverall, the creation of SAHFs is a complex process that involves the coordinated action of multiple mechanisms, including histone fragmentation, chromatin remodeling, transcriptional elongation, ubiquitination, and acetylation. These processes work together to create specific spatial patterns of histone fragments along the DNA, which play important roles in regulating chromatin structure and gene expression",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFs (Spatially-Organized Histone Fragments) are created through a process called \"Histone Fragmentation.\"\n2. DNA damage can lead to the breakage of histones and the formation of SAHFs.\n3. Chromatin remodeling complexes such as SWI/SNF and ISWI can remove histones from DNA, leading to fragmentation and SAHF formation.\n4. During transcriptional elongation, RNA polymerase II can cause histone H3 to fragment, which contributes to SAHF formation.\n5. The covalent attachment of ubiquitin to histones can lead to their degradation and fragmentation, resulting in SAHF formation.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFs (Spatially-Organized Histone Fragments) are created through a process called \"Histone Fragmentation.\"",
      "DNA damage can lead to the breakage of histones and the formation of SAHFs.",
      "Chromatin remodeling complexes such as SWI/SNF and ISWI can remove histones from DNA, leading to fragmentation and SAHF formation.",
      "During transcriptional elongation, RNA polymerase II can cause histone H3 to fragment, which contributes to SAHF formation.",
      "The covalent attachment of ubiquitin to histones can lead to their degradation and fragmentation, resulting in SAHF formation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: SAHFs (Senescence-Associated Heterochromatin Foci) are not created through a process called \"Histone Fragmentation.\" They are formed during cellular senescence and represent a reorganization of chromatin into tightly packed heterochromatin regions.\n2. UNKNOWN: While DNA damage can lead to chromatin changes, the direct link between DNA damage and the formation of SAHFs through histone breakage is not clearly established and may not be a general mechanism for SAHF formation.\n3. UNKNOWN: Chromatin remodeling complexes such as SWI/SNF and ISWI are involved in the repositioning and removal of nucleosomes, but their direct role in leading to histone fragmentation and SAHF formation is not well-defined.\n4. UNKNOWN: While RNA polymerase II does interact with histones during transcriptional elongation, the statement that it causes histone H3 to fragment, contributing to SAHF formation, is not a well-established fact and requires more specific evidence.\n5. UNKNOWN: Ubiquitination of histones is a post-translational modification that can signal for their degradation, but whether this leads to fragmentation and SAHF formation specifically is not clearly established in the literature.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "The PDZ (PSD-95, Discs-large, ZO-1) domain is a protein-binding domain found in the SATB1 (Steroidogenic factor 1) transcription factor. SATB1 is a transcriptional regulator that plays a crucial role in the development and maintenance of various tissues, including the nervous system, adrenal gland, and gonads. The PDZ domain in SATB1 is involved in the following functions:\n1. Protein-protein interactions: The PDZ domain of SATB1 can bind to specific protein ligands, such as PDZ-binding motifs (PBMs) in target proteins, and mediate their interactions.\n2. Subcellular localization: The PDZ domain can influence the localization of SATB1 within the cell, directing it to specific subcellular regions or membranes.\n3. Protein stability: The PDZ domain can modulate the stability of SATB1 by interacting with other proteins that regulate protein degradation.\n4. Transcriptional regulation: The PDZ domain of SATB1 can also participate in the regulation of transcription by interacting with other transcription factors or coregulators, thereby modulating their activity.\nIn summary, the PDZ domain of SATB1 plays a multifaceted role in regulating various cellular processes, including protein-protein interactions, subcellular localization, protein stability, and transcriptional regulation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain is a protein-binding domain found in the SATB1 transcription factor.\n2. SATB1 plays a crucial role in the development and maintenance of various tissues, including the nervous system, adrenal gland, and gonads.\n3. The PDZ domain of SATB1 can bind to specific protein ligands, such as PDZ-binding motifs (PBMs) in target proteins.\n4. The PDZ domain can influence the localization of SATB1 within the cell, directing it to specific subcellular regions or membranes.\n5. The PDZ domain of SATB1 can modulate the stability of SATB1 by interacting with other proteins that regulate protein degradation.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain is a protein-binding domain found in the SATB1 transcription factor.",
      "SATB1 plays a crucial role in the development and maintenance of various tissues, including the nervous system, adrenal gland, and gonads.",
      "The PDZ domain of SATB1 can bind to specific protein ligands, such as PDZ-binding motifs (PBMs) in target proteins.",
      "The PDZ domain can influence the localization of SATB1 within the cell, directing it to specific subcellular regions or membranes.",
      "The PDZ domain of SATB1 can modulate the stability of SATB1 by interacting with other proteins that regulate protein degradation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The PDZ domain is a common protein-binding domain found in many proteins, but SATB1 does not contain a PDZ domain. SATB1 is known for its matrix attachment regions (MARs)-binding domains.\n2. TRUE\n3. FALSE [correction]: Since SATB1 does not contain a PDZ domain, it does not bind to PDZ-binding motifs (PBMs) in target proteins through a PDZ domain.\n4. UNKNOWN: Without specific information on the PDZ domain in SATB1, which is incorrect as SATB1 does not have a PDZ domain, it is not possible to determine the influence of the PDZ domain on the localization of SATB1 within the cell.\n5. UNKNOWN: As SATB1 does not have a PDZ domain, the statement regarding the PDZ domain modulating the stability of SATB1 by interacting with other proteins is not applicable. However, without additional context, it is unknown whether other domains or regions within SATB1 might interact with proteins that regulate its stability.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "BLISS (Bayesian Linear Inverse Scattering) is a statistical technique used to estimate the parameters of a linear inverse problem, where the goal is to recover the parameters of a linear model from a set of observed data. The basis of the BLISS technique is Bayesian inference, which is a statistical framework for making probabilistic statements about the parameters of a model based on observed data.\nIn the context of linear inverse problems, BLISS uses a Bayesian approach to estimate the parameters of a linear model by specifying a prior distribution over the parameters and updating this prior distribution with the observed data to obtain a posterior distribution over the parameters. The posterior distribution is then used to make inferences about the parameters of the linear model.\nThe key advantage of BLISS is that it can handle complex, non-linear inverse problems by using a Bayesian approach that can incorporate prior knowledge or beliefs about the parameters of the model. This makes it particularly useful in situations where the parameters of the linear model are uncertain or where there is limited data available for estimation.",
    "llama-2-7b-chat-hf_fact_raw": "1. BLISS stands for Bayesian Linear Inverse Scattering.\n2. The basis of the BLISS technique is Bayesian inference.\n3. BLISS is used to estimate the parameters of a linear model from observed data.\n4. The technique involves specifying a prior distribution over the parameters and updating it with observed data to obtain a posterior distribution.\n5. BLISS can handle complex, non-linear inverse problems by incorporating prior knowledge or beliefs about the model's parameters.",
    "llama-2-7b-chat-hf_fact": [
      "BLISS stands for Bayesian Linear Inverse Scattering.",
      "The basis of the BLISS technique is Bayesian inference.",
      "BLISS is used to estimate the parameters of a linear model from observed data.",
      "The technique involves specifying a prior distribution over the parameters and updating it with observed data to obtain a posterior distribution.",
      "BLISS can handle complex, non-linear inverse problems by incorporating prior knowledge or beliefs about the model's parameters."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: BLISS stands for Bayesian Linear Inverse Synthetic-aperture radar Scattering.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: BLISS is specifically for linear inverse problems, not complex, non-linear inverse problems. However, Bayesian inference, which is the basis for BLISS, can be used in non-linear inverse problems with appropriate modifications.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Sure, here are three NK3R antagonists:\n1. A-83-01: A-83-01 is a potent and selective NK3R antagonist that has been shown to have potential in the treatment of various conditions, including migraine, gastroparesis, and opioid-induced constipation.\n2. MK-0357: MK-0357 is a potent and selective NK3R antagonist that has been shown to have potential in the treatment of gastrointestinal disorders, including irritable bowel syndrome (IBS) and gastroparesis.\n3. RS-102895: RS-102895 is a potent and selective NK3R antagonist that has been shown to have potential in the treatment of various conditions, including migraine, gastroparesis, and opioid-induced constipation.",
    "llama-2-7b-chat-hf_fact_raw": "1. A-83-01 is a potent and selective NK3R antagonist.\n2. MK-0357 is a potent and selective NK3R antagonist.\n3. RS-102895 is a potent and selective NK3R antagonist.",
    "llama-2-7b-chat-hf_fact": [
      "A-83-01 is a potent and selective NK3R antagonist.",
      "MK-0357 is a potent and selective NK3R antagonist.",
      "RS-102895 is a potent and selective NK3R antagonist."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout specific information on the compounds A-83-01, MK-0357, and RS-102895, it is not possible to verify the accuracy of these statements. These compounds are likely to be research chemicals or pharmaceuticals, and their properties would need to be confirmed by consulting scientific literature or databases that provide information on their pharmacology.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is called BMS-986177.",
    "llama-2-7b-chat-hf_fact_raw": "1. BMS-986177 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
    "llama-2-7b-chat-hf_fact": [
      "BMS-986177 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nWithout additional context or a reliable source to confirm the statement about BMS-986177, it is not possible to determine the veracity of the claim that it is the \"first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\"",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Vaxchora, also known as Shanchol, is an oral cholera vaccine that has been shown to be effective in preventing moderate to severe cholera in individuals of all ages.\nThe protective efficacy of Vaxchora against moderate to severe cholera has been demonstrated in several clinical trials, including:\n* A phase 3 clinical trial published in 2016 in The Lancet, which found that Vaxchora provided 77% protection against moderate to severe cholera in individuals who received a single dose of the vaccine, and 86% protection in those who received a two-dose schedule.\n* A phase 2b clinical trial published in 2015 in Clinical Infectious Diseases, which found that Vaxchora provided 54% protection against moderate to severe cholera in individuals who received a single dose of the vaccine.\nOverall, the available data suggest that Vaxchora is effective in preventing moderate to severe cholera in individuals of all ages, including children and pregnant women. However, it's important to note that no vaccine is 100% effective, and the duration of protection provided by Vaxchora is not yet fully understood.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is an oral cholera vaccine.\n2. A phase 3 clinical trial published in 2016 in The Lancet reported that Vaxchora provided 77% protection against moderate to severe cholera with a single dose.\n3. The same phase 3 clinical trial indicated that Vaxchora provided 86% protection against moderate to severe cholera with a two-dose schedule.\n4. A phase 2b clinical trial published in 2015 in Clinical Infectious Diseases reported that Vaxchora provided 54% protection against moderate to severe cholera with a single dose.\n5. Vaxchora is considered effective in preventing moderate to severe cholera in individuals of all ages, including children and pregnant women.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is an oral cholera vaccine.",
      "A phase 3 clinical trial published in 2016 in The Lancet reported that Vaxchora provided 77% protection against moderate to severe cholera with a single dose.",
      "The same phase 3 clinical trial indicated that Vaxchora provided 86% protection against moderate to severe cholera with a two-dose schedule.",
      "A phase 2b clinical trial published in 2015 in Clinical Infectious Diseases reported that Vaxchora provided 54% protection against moderate to severe cholera with a single dose.",
      "Vaxchora is considered effective in preventing moderate to severe cholera in individuals of all ages, including children and pregnant women."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The phase 3 clinical trial published in 2016 in The Lancet did not report on a two-dose schedule for Vaxchora, as the vaccine is designed to be a single-dose oral vaccine.\n4. UNKNOWN (Without access to the specific results of the phase 2b clinical trial published in 2015 in Clinical Infectious Diseases, it is not possible to confirm the accuracy of this statement.)\n5. FALSE [correction]: Vaxchora is recommended for use in adults aged 18 through 64 years. It is not indicated for use in children or pregnant women due to a lack of sufficient data on safety and efficacy in these populations.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "The first cholera vaccine approved in the US was the oral cholera vaccine, also known as the Shanchol vaccine, which was approved by the US Food and Drug Administration (FDA) in 2006. This vaccine is made by the biotechnology company, Sanofi Pasteur, and is the first and only cholera vaccine approved for use in the US. It is recommended for individuals traveling to areas where cholera is common, particularly in Asia and Africa.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the US was an oral vaccine known as Shanchol.\n2. The Shanchol vaccine was approved by the US Food and Drug Administration (FDA) in 2006.\n3. Sanofi Pasteur is the biotechnology company that makes the Shanchol vaccine.\n4. The Shanchol vaccine is the first and only cholera vaccine approved for use in the US.\n5. The Shanchol vaccine is recommended for individuals traveling to areas where cholera is common, particularly in Asia and Africa.",
    "llama-2-7b-chat-hf_fact": [
      "The first cholera vaccine approved in the US was an oral vaccine known as Shanchol.",
      "The Shanchol vaccine was approved by the US Food and Drug Administration (FDA) in 2006.",
      "Sanofi Pasteur is the biotechnology company that makes the Shanchol vaccine.",
      "The Shanchol vaccine is the first and only cholera vaccine approved for use in the US.",
      "The Shanchol vaccine is recommended for individuals traveling to areas where cholera is common, particularly in Asia and Africa."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The first cholera vaccine approved in the US was not Shanchol; it was Vaxchora, which is an oral vaccine.\n2. FALSE [correction]: Shanchol was not approved by the US FDA in 2006; Vaxchora was approved by the FDA in 2016.\n3. FALSE [correction]: Sanofi Pasteur does not make the Shanchol vaccine. Shanchol is manufactured by Shantha Biotechnics, which is a part of Sanofi but operates under its own name.\n4. FALSE [correction]: Shanchol is not the first and only cholera vaccine approved for use in the US. Vaxchora is another cholera vaccine approved for use in the US.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is mutations in the X-linked genes encoding the immune protein Bruton's tyrosine kinase (BTK). These mutations are found in approximately 70-80% of CVID patients of European ancestry. BTK is a key component of the B-cell receptor signaling pathway, and mutations in this gene can lead to impaired B-cell development and function, resulting in the immunodeficiency seen in CVID. Other genetic causes of CVID include mutations in the genes encoding the immune proteins CD19, CD20, and CD21, as well as copy number variations in the genes encoding the cytokine receptors IL-21R and IL-13Rα1.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the genes encoding Bruton's tyrosine kinase (BTK) are the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.\n2. These BTK gene mutations are found in approximately 70-80% of CVID patients of European ancestry.\n3. BTK is a key component of the B-cell receptor signaling pathway.\n4. Mutations in BTK can lead to impaired B-cell development and function.\n5. Other genetic causes of CVID include mutations in the genes encoding immune proteins CD19, CD20, and CD21, as well as copy number variations in the genes encoding cytokine receptors IL-21R and IL-13Rα1.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the genes encoding Bruton's tyrosine kinase (BTK) are the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.",
      "These BTK gene mutations are found in approximately 70-80% of CVID patients of European ancestry.",
      "BTK is a key component of the B-cell receptor signaling pathway.",
      "Mutations in BTK can lead to impaired B-cell development and function.",
      "Other genetic causes of CVID include mutations in the genes encoding immune proteins CD19, CD20, and CD21, as well as copy number variations in the genes encoding cytokine receptors IL-21R and IL-13Rα1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the genes encoding Bruton's tyrosine kinase (BTK) cause X-linked agammaglobulinemia (XLA), not common variable immunodeficiency (CVID). CVID has a more heterogeneous genetic basis and is not most commonly caused by mutations in BTK.\n2. FALSE [correction]: Since BTK mutations are not the most common cause of CVID, the statement that these mutations are found in approximately 70-80% of CVID patients of European ancestry is incorrect. BTK mutations are associated with XLA.\n3. TRUE: BTK is indeed a key component of the B-cell receptor signaling pathway.\n4. TRUE: Mutations in BTK can lead to impaired B-cell development and function, which is characteristic of X-linked agammaglobulinemia.\n5. TRUE: Other genetic causes of CVID can include mutations in the genes encoding immune proteins such as CD19, CD20, and CD21, as well as copy number variations in the genes encoding cytokine receptors like IL-21R and IL-13Rα1.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "The IFIT1 gene has been implicated in the development and progression of Systemic Lupus Erythematosus (SLE), an autoimmune disease that affects multiple organ systems. Here are some of the key findings related to the role of the IFIT1 gene in SLE:\n1. Genetic variants: Studies have identified genetic variants in the IFIT1 gene that are associated with an increased risk of developing SLE. These variants may disrupt the normal function of the IFIT1 protein, leading to an imbalance in the immune response and contributing to the development of SLE.\n2. Expression levels: IFIT1 expression levels have been found to be altered in the peripheral blood mononuclear cells of SLE patients compared to healthy controls. Specifically, IFIT1 expression is decreased in active SLE patients, which may contribute to the dysregulation of the immune response.\n3. Splicing regulation: The IFIT1 gene has been shown to be regulated by splicing factors, which play a critical role in the splicing of the IFIT1 mRNA. Mutations in these splicing factors have been linked to SLE, highlighting the importance of the IFIT1 gene in the development of the disease.\n4. Immune cell function: IFIT1 has been shown to play a role in the regulation of immune cell function, including the activation and proliferation of T cells and B cells. Dysregulation of these processes may contribute to the development of autoantibodies and the immune dysfunction seen in SLE.\n5. Inflammation: IFIT1 has been shown to have anti-inflammatory properties, and its dysregulation may contribute to the inflammation seen in SLE.\nOverall, the IFIT1 gene plays a critical role in the regulation of the immune response and its dysregulation may contribute to the development of SLE. Further research is needed to fully understand the mechanisms by which the IFIT1 gene contributes to the disease and to identify potential therapeutic targets for the treatment of SLE.",
    "llama-2-7b-chat-hf_fact_raw": "1. Genetic variants in the IFIT1 gene are associated with an increased risk of developing Systemic Lupus Erythematosus (SLE).\n2. IFIT1 expression levels are altered in the peripheral blood mononuclear cells of SLE patients compared to healthy controls.\n3. Mutations in splicing factors that regulate the IFIT1 gene have been linked to SLE.\n4. IFIT1 plays a role in the regulation of immune cell function, including the activation and proliferation of T cells and B cells.\n5. IFIT1 has anti-inflammatory properties, and its dysregulation may contribute to the inflammation seen in SLE.",
    "llama-2-7b-chat-hf_fact": [
      "Genetic variants in the IFIT1 gene are associated with an increased risk of developing Systemic Lupus Erythematosus (SLE).",
      "IFIT1 expression levels are altered in the peripheral blood mononuclear cells of SLE patients compared to healthy controls.",
      "Mutations in splicing factors that regulate the IFIT1 gene have been linked to SLE.",
      "IFIT1 plays a role in the regulation of immune cell function, including the activation and proliferation of T cells and B cells.",
      "IFIT1 has anti-inflammatory properties, and its dysregulation may contribute to the inflammation seen in SLE."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Genetic variants in the IFIT1 gene have been associated with an increased risk of developing Systemic Lupus Erythematosus (SLE) in some studies, although the genetic basis of SLE is complex and involves multiple genes.\n2. TRUE: Altered expression levels of IFIT1 have been observed in the peripheral blood mononuclear cells of SLE patients compared to healthy controls, suggesting a potential role in the disease.\n3. UNKNOWN: Without specific evidence or studies cited, it is difficult to confirm whether mutations in splicing factors that regulate the IFIT1 gene have been directly linked to SLE.\n4. TRUE: IFIT1 is known to play a role in the regulation of immune cell function, which includes the activation and proliferation of T cells and B cells, both of which are important in the pathogenesis of SLE.\n5. FALSE [correction]: IFIT1 typically has antiviral properties, and its dysregulation may contribute to the pathogenesis of SLE, but it is not primarily characterized as having anti-inflammatory properties. Instead, its dysregulation may contribute to the inappropriate immune response seen in SLE.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a clinical assessment tool used to evaluate the severity of elbow osteoarthritis (OA). It is a simple and reliable method for measuring the impact of elbow OA on an individual's quality of life. The score is based on a series of questions that assess the patient's level of pain, stiffness, and functional ability in the affected elbow. The LES is used to evaluate the severity of elbow OA and to monitor the effectiveness of treatment interventions.\nThe Liverpool Elbow Score consists of 10 items that are rated on a 5-point Likert scale, resulting in a total score ranging from 0 to 50. Higher scores indicate greater severity of elbow OA and lower scores indicate better function. The items included in the LES are:\n1. Pain (0-3)\n2. Stiffness (0-3)\n3. Grip strength (0-2)\n4. Pain with flexion (0-2)\n5. Pain with extension (0-2)\n6. Pain with rotation (0-2)\n7. Functional ability (0-2)\n8. Activity level (0-2)\n9. Sleep disturbance (0-2)\n10. Overall score (0-50)\nThe LES has been validated in several studies and has been shown to have good reliability and sensitivity to change, making it a useful tool for clinicians to assess the severity of elbow OA and monitor the effectiveness of treatment interventions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is used to evaluate the severity of elbow osteoarthritis.\n2. The LES measures the impact of elbow osteoarthritis on an individual's quality of life.\n3. The Liverpool Elbow Score consists of 10 items rated on a 5-point Likert scale.\n4. The total score of the LES ranges from 0 to 50, with higher scores indicating greater severity.\n5. The LES has been validated in several studies and shown to have good reliability and sensitivity to change.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is used to evaluate the severity of elbow osteoarthritis.",
      "The LES measures the impact of elbow osteoarthritis on an individual's quality of life.",
      "The Liverpool Elbow Score consists of 10 items rated on a 5-point Likert scale.",
      "The total score of the LES ranges from 0 to 50, with higher scores indicating greater severity.",
      "The LES has been validated in several studies and shown to have good reliability and sensitivity to change."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The Liverpool Elbow Score consists of 10 items rated on a 4-point Likert scale.\n4. FALSE [correction]: The total score of the LES ranges from 10 to 40, with higher scores indicating better elbow function, not greater severity.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "The 100,000 Genomes Project was a UK-based initiative launched in 2012 to analyze the genetic makeup of 100,000 patients with rare and common diseases, including sarcoma. The project aimed to identify genetic variations associated with these diseases and develop new diagnostic and therapeutic approaches. Here are some key efforts on sarcoma from the 100,000 Genomes Project:\n1. Identification of novel sarcoma subtypes: The project identified new subtypes of sarcoma, including leiomyosarcoma, synovial sarcoma, and chondrosarcoma, based on the genetic mutations present in the tumors. These subtypes may have distinct clinical and biological characteristics, which could lead to more targeted treatments.\n2. Development of a sarcoma genomics resource: The project developed a comprehensive genomics resource for sarcoma, including a database of sarcoma tumors and their genetic mutations. This resource can be used by researchers to identify new therapeutic targets and develop personalized treatment strategies for sarcoma patients.\n3. Analysis of driver mutations: The project identified driver mutations in sarcoma, which are genetic alterations that promote the growth and progression of the tumor. These driver mutations can be targeted with specific therapies, such as kinase inhibitors, to slow or stop the growth of the tumor.\n4. Identification of potential biomarkers: The project identified potential biomarkers for sarcoma, which can be used to diagnose and monitor the disease. Biomarkers can also be used to predict the response of sarcoma to different treatments, allowing for more personalized and effective therapies.\n5. Investigation of the genetic heterogeneity of sarcoma: The project demonstrated the genetic heterogeneity of sarcoma, which means that different tumors have different genetic mutations. This genetic heterogeneity can make it challenging to develop effective treatments, but it also provides opportunities for targeting specific genetic mutations with personalized therapies.\n6. Development of new diagnostic tests: The project developed new diagnostic tests for sarcoma, including next-",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project was launched in 2012 in the UK to analyze the genetic makeup of patients with rare and common diseases, including sarcoma.\n2. The project identified new subtypes of sarcoma based on genetic mutations present in the tumors.\n3. A comprehensive genomics resource for sarcoma was developed by the project, which includes a database of sarcoma tumors and their genetic mutations.\n4. Driver mutations in sarcoma were identified by the project, which are genetic alterations that contribute to tumor growth and progression.\n5. The project investigated the genetic heterogeneity of sarcoma, demonstrating that different tumors have different genetic mutations.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project was launched in 2012 in the UK to analyze the genetic makeup of patients with rare and common diseases, including sarcoma.",
      "The project identified new subtypes of sarcoma based on genetic mutations present in the tumors.",
      "A comprehensive genomics resource for sarcoma was developed by the project, which includes a database of sarcoma tumors and their genetic mutations.",
      "Driver mutations in sarcoma were identified by the project, which are genetic alterations that contribute to tumor growth and progression.",
      "The project investigated the genetic heterogeneity of sarcoma, demonstrating that different tumors have different genetic mutations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 100,000 Genomes Project was launched in 2013 in the UK to analyze the genetic makeup of patients with rare diseases, cancer, and infectious diseases.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "No, protein ALEX1 does not contain armadillo repeats. ALEX1 (Armadillo-like Experimental Chromosome 1) is a protein that is involved in the regulation of gene expression and chromatin remodeling, but it does not contain armadillo repeats. Armadillo repeats are a specific structural motif found in some proteins that are involved in protein-protein interactions and chromatin remodeling. ALEX1 does not have this specific structural motif and functions through a different mechanism.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 does not contain armadillo repeats.\n2. ALEX1 is involved in the regulation of gene expression and chromatin remodeling.\n3. Armadillo repeats are a structural motif involved in protein-protein interactions and chromatin remodeling.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 does not contain armadillo repeats.",
      "ALEX1 is involved in the regulation of gene expression and chromatin remodeling.",
      "Armadillo repeats are a structural motif involved in protein-protein interactions and chromatin remodeling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Enzymes that remove histone modifications are called histone demethylases. These enzymes remove the methyl groups from the histone proteins, leading to changes in chromatin structure and gene expression. Some examples of histone demethylases include:\n1. histone demethylase KDM4B (also known as JMJD2B)\n2. histone demethylase KDM5B (also known as JMJD2A)\n3. histone demethylase KDM5C (also known as JMJD2C)\n4. histone demethylase KDM6A (also known as JMJD1A)\n5. histone demethylase KDM6B (also known as JMJD1B)\n6. histone demethylase KDM1A (also known as JMJD3)\n7. histone demethylase KDM1B (also known as JMJD3B)\n8. histone demethylase KDM2A (also known as JMJD1C)\n9. histone demethylase KDM2B (also known as JMJD1D)\n10. histone demethylase KDM3A (also known as JMJD2A2)\n11. histone demethylase KDM3B (also known as JMJD2A1)\n12. histone demethylase KDM4A (also known as JMJD2B1)\n13. histone demethylase KDM4B (also known as JMJD2B2)\n14. histone demethylase KDM5A (also known as JMJD2A1)\n15. histone demethylase KDM5B (also known as JMJD2A2)\n16. histone demethylase KDM6C (also known as JMJD1C1)\n17. histone demethylase KDM6D (also known as JMJD1C2)\n18. histone demethylase KDM7A (also known as JMJD2C)\n19. histone dem",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone demethylases are enzymes that remove methyl groups from histone proteins.\n2. KDM4B is also known as JMJD2B and is a histone demethylase.\n3. KDM5B is also known as JMJD2A and is a histone demethylase.\n4. KDM6A is also known as JMJD1A and is a histone demethylase.\n5. KDM6B is also known as JMJD1B and is a histone demethylase.",
    "llama-2-7b-chat-hf_fact": [
      "Histone demethylases are enzymes that remove methyl groups from histone proteins.",
      "KDM4B is also known as JMJD2B and is a histone demethylase.",
      "KDM5B is also known as JMJD2A and is a histone demethylase.",
      "KDM6A is also known as JMJD1A and is a histone demethylase.",
      "KDM6B is also known as JMJD1B and is a histone demethylase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: KDM5B is also known as JARID1B and is a histone demethylase, not JMJD2A.\n4. FALSE [correction]: KDM6A is also known as UTX and is a histone demethylase, not JMJD1A.\n5. FALSE [correction]: KDM6B is also known as JMJD3 and is a histone demethylase, not JMJD1B.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "There is some evidence to suggest that head computed tomography (CT) scans may increase the risk of developing a brain tumor. However, the relationship between head CT scans and brain tumors is complex and not fully understood.\nThe International Agency for Research on Cancer (IARC) has classified CT scans as possibly carcinogenic to humans, based on limited evidence in humans and sufficient evidence in animals. This classification suggests that there may be a small increased risk of cancer associated with CT scans, including brain tumors.\nSeveral studies have suggested that head CT scans may increase the risk of developing a brain tumor, particularly in children and young adults. For example, a study published in the Journal of the National Cancer Institute found that children and young adults who had more than 10 CT scans had a higher risk of developing a brain tumor compared to those who had fewer scans.\nHowever, it's important to note that the overall risk of developing a brain tumor from a single head CT scan is still very low. The risk is estimated to be less than 1 in 10,000 for a single scan. Additionally, the benefits of CT scans in diagnosing and treating medical conditions often outweigh the potential risks.\nIt's also worth noting that the risk of developing a brain tumor from CT scans may be higher for certain groups of people, such as those with a family history of brain tumors or those who have had previous radiation exposure.\nOverall, while there is some evidence to suggest that head CT scans may increase the risk of developing a brain tumor, the risk is still very low and the benefits of CT scans in medical diagnosis and treatment often outweigh the potential risks. If you have concerns about the potential risks of CT scans, it's important to discuss them with your healthcare provider.",
    "llama-2-7b-chat-hf_fact_raw": "1. The International Agency for Research on Cancer (IARC) has classified CT scans as possibly carcinogenic to humans.\n2. A study published in the Journal of the National Cancer Institute found that children and young adults who had more than 10 CT scans had a higher risk of developing a brain tumor.\n3. The overall risk of developing a brain tumor from a single head CT scan is estimated to be less than 1 in 10,000.\n4. The benefits of CT scans in diagnosing and treating medical conditions often outweigh the potential risks.\n5. The risk of developing a brain tumor from CT scans may be higher for certain groups of people, such as those with a family history of brain tumors or those who have had previous radiation exposure.",
    "llama-2-7b-chat-hf_fact": [
      "The International Agency for Research on Cancer (IARC) has classified CT scans as possibly carcinogenic to humans.",
      "A study published in the Journal of the National Cancer Institute found that children and young adults who had more than 10 CT scans had a higher risk of developing a brain tumor.",
      "The overall risk of developing a brain tumor from a single head CT scan is estimated to be less than 1 in 10,000.",
      "The benefits of CT scans in diagnosing and treating medical conditions often outweigh the potential risks.",
      "The risk of developing a brain tumor from CT scans may be higher for certain groups of people, such as those with a family history of brain tumors or those who have had previous radiation exposure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN (without specific reference to the study, its findings cannot be verified)\n3. UNKNOWN (the exact risk estimate can vary based on different studies and factors, and without a specific source, the accuracy of this statement cannot be determined)\n4. TRUE (this is a general consensus in the medical community, although it is a subjective statement)\n5. TRUE (it is generally accepted that certain factors, such as family history of cancer or previous radiation exposure, can increase the risk of developing cancer from radiation exposure, including CT scans)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Otx2 is associated with neural pluripotency. Otx2 is a transcription factor that is expressed in the early embryo and plays a crucial role in the development of the central nervous system (CNS). It is also involved in the maintenance of adult neural stem cells and their ability to differentiate into different cell types. Therefore, Otx2 is associated with neural pluripotency, which refers to the ability of neural stem cells to differentiate into any cell type in the CNS.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with neural pluripotency.\n2. Otx2 is a transcription factor expressed in the early embryo.\n3. Otx2 plays a crucial role in the development of the central nervous system (CNS).\n4. Otx2 is involved in the maintenance of adult neural stem cells.\n5. Neural pluripotency refers to the ability of neural stem cells to differentiate into any cell type in the CNS.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with neural pluripotency.",
      "Otx2 is a transcription factor expressed in the early embryo.",
      "Otx2 plays a crucial role in the development of the central nervous system (CNS).",
      "Otx2 is involved in the maintenance of adult neural stem cells.",
      "Neural pluripotency refers to the ability of neural stem cells to differentiate into any cell type in the CNS."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Otx2 is associated with neural development, but it is not directly associated with neural pluripotency. Pluripotency refers to the ability of a cell to develop into any type of cell in the body, a characteristic of embryonic stem cells, not typically attributed to specific neural transcription factors like Otx2.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "The murine beta-globin locus region contains several DNase I hypersensitive sites (DHS). According to a study published in the journal Genomics, there are at least 12 DHSs located throughout the beta-globin locus region in mice. These DHSs are specific regions of the genome that are more susceptible to cleavage by the enzyme DNase I, indicating a higher level of accessibility to the DNA. The presence of multiple DHSs in the beta-globin locus region suggests that this region is more dynamic and active than other regions of the genome, and may play a role in the regulation of gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. The murine beta-globin locus region contains at least 12 DNase I hypersensitive sites (DHS).\n2. DNase I hypersensitive sites are regions of the genome that are more susceptible to cleavage by the enzyme DNase I.\n3. The presence of multiple DHSs suggests that the beta-globin locus region is more dynamic and active than other regions of the genome.\n4. DHSs may play a role in the regulation of gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "The murine beta-globin locus region contains at least 12 DNase I hypersensitive sites (DHS).",
      "DNase I hypersensitive sites are regions of the genome that are more susceptible to cleavage by the enzyme DNase I.",
      "The presence of multiple DHSs suggests that the beta-globin locus region is more dynamic and active than other regions of the genome.",
      "DHSs may play a role in the regulation of gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Here are some European influenza vaccines that are currently available or have been approved for use in the past:\n1. Fluarix Tetra (GlaxoSmithKline): This is a quadrivalent vaccine that protects against four strains of influenza (two A strains and two B strains).\n2. Fluad (GlaxoSmithKline): This is a quadrivalent vaccine that protects against four strains of influenza (two A strains and two B strains). It is specifically designed for people over the age of 65.\n3. Fluarix (GlaxoSmithKline): This is a trivalent vaccine that protects against three strains of influenza (two A strains and one B strain).\n4. Fluvirin (Novartis): This is a trivalent vaccine that protects against three strains of influenza (two A strains and one B strain).\n5. FluMist (MedImmune): This is a quadrivalent nasal spray vaccine that protects against four strains of influenza (two A strains and two B strains).\n6. Aggrivax (BioProtection Systems): This is a quadrivalent vaccine that protects against four strains of influenza (two A strains and two B strains). It is specifically designed for use in developing countries.\n7. Influvac (Novartis): This is a trivalent vaccine that protects against three strains of influenza (two A strains and one B strain).\n8. Flu-C-Gam (Cangene): This is a trivalent vaccine that protects against three strains of influenza (two A strains and one B strain). It is specifically designed for use in Canada.\n9. Flu-Vac (EirGen): This is a trivalent vaccine that protects against three strains of influenza (two A strains and one B strain). It is specifically designed for use in Ireland.\n10. Flu-Vac-A (EirGen): This is a trivalent vaccine that protects against three strains of influenza (two A strains and one B strain).",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluarix Tetra is a quadrivalent influenza vaccine produced by GlaxoSmithKline.\n2. Fluad is a quadrivalent influenza vaccine designed for people over the age of 65 and is produced by GlaxoSmithKline.\n3. Fluvirin is a trivalent influenza vaccine produced by Novartis.\n4. FluMist is a quadrivalent nasal spray influenza vaccine produced by MedImmune.\n5. Influvac is a trivalent influenza vaccine produced by Novartis.",
    "llama-2-7b-chat-hf_fact": [
      "Fluarix Tetra is a quadrivalent influenza vaccine produced by GlaxoSmithKline.",
      "Fluad is a quadrivalent influenza vaccine designed for people over the age of 65 and is produced by GlaxoSmithKline.",
      "Fluvirin is a trivalent influenza vaccine produced by Novartis.",
      "FluMist is a quadrivalent nasal spray influenza vaccine produced by MedImmune.",
      "Influvac is a trivalent influenza vaccine produced by Novartis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Fluad is a trivalent influenza vaccine designed for people over the age of 65 and is produced by Seqirus, not GlaxoSmithKline.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Influvac is a trivalent influenza vaccine, but it is produced by Mylan (now part of Viatris), not Novartis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the Paramyxovirus geneome is segmented, negative-sense RNA. Paramyxoviruses are a family of viruses that include viruses such as measles virus, mumps virus, and respiratory syncytial virus (RSV). The genome of these viruses is composed of several segments of RNA, each of which encodes a different protein. The segments are arranged in a specific order, with the largest segment (segment 1) encoding the viral RNA-dependent RNA polymerase and the smallest segment (segment 5) encoding the viral phosphoprotein. The genome is negative-sense, meaning that the RNA molecule is complementary to its template strand, and it is transcribed in the opposite direction to the coding strand.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Paramyxovirus genome is negative-sense RNA.\n2. Paramyxoviruses include viruses such as measles virus, mumps virus, and respiratory syncytial virus (RSV).\n3. The genome of Paramyxoviruses is composed of several segments of RNA.\n4. The largest segment of the Paramyxovirus genome encodes the viral RNA-dependent RNA polymerase.\n5. The smallest segment of the Paramyxovirus genome encodes the viral phosphoprotein.",
    "llama-2-7b-chat-hf_fact": [
      "The Paramyxovirus genome is negative-sense RNA.",
      "Paramyxoviruses include viruses such as measles virus, mumps virus, and respiratory syncytial virus (RSV).",
      "The genome of Paramyxoviruses is composed of several segments of RNA.",
      "The largest segment of the Paramyxovirus genome encodes the viral RNA-dependent RNA polymerase.",
      "The smallest segment of the Paramyxovirus genome encodes the viral phosphoprotein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The genome of Paramyxoviruses is non-segmented; it consists of a single strand of RNA.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Roflumilast cream is effective for the treatment of plaque psoriasis. Roflumilast is a topical phosphodiesterase-4 (PDE4) inhibitor that has been shown to reduce inflammation and improve symptoms in patients with plaque psoriasis. It is applied directly to the affected skin area and can help to improve skin appearance, reduce redness and scaliness, and improve quality of life for patients with this condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used for the treatment of plaque psoriasis.\n2. Roflumilast is a phosphodiesterase-4 (PDE4) inhibitor.\n3. Roflumilast cream is applied directly to the affected skin area.\n4. Roflumilast cream has been shown to reduce inflammation in patients with plaque psoriasis.\n5. Roflumilast cream can improve skin appearance and reduce redness and scaliness in patients with plaque psoriasis.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used for the treatment of plaque psoriasis.",
      "Roflumilast is a phosphodiesterase-4 (PDE4) inhibitor.",
      "Roflumilast cream is applied directly to the affected skin area.",
      "Roflumilast cream has been shown to reduce inflammation in patients with plaque psoriasis.",
      "Roflumilast cream can improve skin appearance and reduce redness and scaliness in patients with plaque psoriasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nRoflumilast cream is indeed used for the treatment of plaque psoriasis, it is a PDE4 inhibitor, and it is applied directly to the affected skin area. It has been shown to reduce inflammation and can improve skin appearance by reducing redness and scaliness in patients with plaque psoriasis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "Several tools have been developed for identifying and visualizing non-coding RNA (ncRNA) promoters. Here are some of the commonly used tools:\n1. RNAhybrid: RNAhybrid is a tool for identifying RNA secondary structure and promoter sequences. It can predict the presence of promoter sequences in ncRNA genes and identify potential binding sites for transcription factors.\n2. Prognosticate: Prognosticate is a tool for predicting the probability of a given RNA sequence to be a ncRNA transcript. It uses a combination of machine learning algorithms and sequence features to identify potential ncRNA promoters.\n3. NCRNApromoter: NCRNApromoter is a tool for identifying potential ncRNA promoters in a given RNA sequence. It uses a combination of sequence features and machine learning algorithms to predict the presence of promoter sequences.\n4. RNApromoter: RNApromoter is a tool for identifying potential RNA promoters in a given RNA sequence. It uses a combination of sequence features and machine learning algorithms to predict the presence of promoter sequences, including ncRNA promoters.\n5. DeepPromoter: DeepPromoter is a deep learning-based tool for identifying ncRNA promoters. It uses a combination of sequence features and deep learning algorithms to predict the presence of promoter sequences in ncRNA genes.\n6. PROMoterFinder: PROMoterFinder is a tool for identifying potential promoter sequences in a given RNA sequence. It uses a combination of sequence features and machine learning algorithms to predict the presence of promoter sequences, including ncRNA promoters.\n7. RNApromoterFinder: RNApromoterFinder is a tool for identifying potential RNA promoters in a given RNA sequence. It uses a combination of sequence features and machine learning algorithms to predict the presence of promoter sequences, including ncRNA promoters.\n8. NCRNApromoterFinder: NCRNApromoterFinder is a tool for identifying potential ncRNA promoters in a given RNA sequence. It uses a combination of sequence features and machine learning algorithms to predict the presence of promoter sequences in ncRNA genes.\n9. DeepProm",
    "llama-2-7b-chat-hf_fact_raw": "1. RNAhybrid is a tool used for identifying RNA secondary structure and promoter sequences.\n2. Prognosticate is a tool that predicts the probability of an RNA sequence being a ncRNA transcript using machine learning algorithms and sequence features.\n3. NCRNApromoter is a tool designed to identify potential ncRNA promoters in RNA sequences through machine learning algorithms and sequence features.\n4. DeepPromoter is a deep learning-based tool for identifying ncRNA promoters.\n5. PROMoterFinder is a tool that identifies potential promoter sequences in RNA sequences, including ncRNA promoters, using machine learning algorithms and sequence features.",
    "llama-2-7b-chat-hf_fact": [
      "RNAhybrid is a tool used for identifying RNA secondary structure and promoter sequences.",
      "Prognosticate is a tool that predicts the probability of an RNA sequence being a ncRNA transcript using machine learning algorithms and sequence features.",
      "NCRNApromoter is a tool designed to identify potential ncRNA promoters in RNA sequences through machine learning algorithms and sequence features.",
      "DeepPromoter is a deep learning-based tool for identifying ncRNA promoters.",
      "PROMoterFinder is a tool that identifies potential promoter sequences in RNA sequences, including ncRNA promoters, using machine learning algorithms and sequence features."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RNAhybrid is a tool used for predicting the minimum free energy hybridization of a long and a short RNA molecule, not for identifying RNA secondary structure and promoter sequences.\n2. UNKNOWN\n3. FALSE [correction]: There is no widely recognized tool called NCRNApromoter for identifying ncRNA promoters. However, there are other tools designed for promoter prediction that may use machine learning algorithms.\n4. UNKNOWN\n5. UNKNOWN\n\nNote: While there are tools for predicting RNA secondary structures, promoters, and using machine learning for various bioinformatics tasks, the specific tools mentioned in statements 2, 4, and 5 are not well-known or may not exist under those names, hence the \"UNKNOWN\" status. Without additional context or information about these tools, it is not possible to accurately verify these statements.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "SWIM (Splicing Workbench for Integrative Modeling) is a tool that uses RNA-seq data to identify novel splicing events and to study their regulation in various diseases, including glioblastoma. Here are some examples of genes that SWIM has identified as down-regulated in glioblastoma:\n1. TP53INP1: TP53-induced nuclear protein 1 (TP53INP1) is a tumor suppressor gene that is frequently mutated or down-regulated in various types of cancer, including glioblastoma.\n2. MAP3K5: Mitogen-activated protein kinase kinase kinase 5 (MAP3K5) is a key regulator of the MAPK/ERK signaling pathway, which is commonly altered in glioblastoma.\n3. KCNQ2: Potassium voltage-gated channel subfamily Q, member 2 (KCNQ2) is a gene that encodes a potassium channel that is involved in the regulation of neuronal excitability and synaptic transmission.\n4. CDKN2A: Cyclin-dependent kinase inhibitor 2A (CDKN2A) is a tumor suppressor gene that is frequently mutated or down-regulated in various types of cancer, including glioblastoma.\n5. RBM38: RNA-binding motif protein 38 (RBM38) is a gene that is involved in the regulation of mRNA splicing and is down-regulated in glioblastoma.\n6. PTEN: Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene that is frequently mutated or down-regulated in various types of cancer, including glioblastoma.\n7. SLC25A25: Solute carrier family 25 member 25 (SLC25A25) is a gene that encodes a protein involved in the transport of neurotransmitters and is down-regulated in glioblastoma.\n8. KCNQ3: Potassium voltage-gated channel subfamily Q, member 3 (KCNQ3) is a gene that encodes a potassium",
    "llama-2-7b-chat-hf_fact_raw": "1. TP53-induced nuclear protein 1 (TP53INP1) is identified by SWIM as down-regulated in glioblastoma.\n2. Mitogen-activated protein kinase kinase kinase 5 (MAP3K5) is identified by SWIM as down-regulated in glioblastoma.\n3. Potassium voltage-gated channel subfamily Q, member 2 (KCNQ2) is identified by SWIM as down-regulated in glioblastoma.\n4. Cyclin-dependent kinase inhibitor 2A (CDKN2A) is identified by SWIM as down-regulated in glioblastoma.\n5. RNA-binding motif protein 38 (RBM38) is identified by SWIM as down-regulated in glioblastoma.",
    "llama-2-7b-chat-hf_fact": [
      "TP53-induced nuclear protein 1 (TP53INP1) is identified by SWIM as down-regulated in glioblastoma.",
      "Mitogen-activated protein kinase kinase kinase 5 (MAP3K5) is identified by SWIM as down-regulated in glioblastoma.",
      "Potassium voltage-gated channel subfamily Q, member 2 (KCNQ2) is identified by SWIM as down-regulated in glioblastoma.",
      "Cyclin-dependent kinase inhibitor 2A (CDKN2A) is identified by SWIM as down-regulated in glioblastoma.",
      "RNA-binding motif protein 38 (RBM38) is identified by SWIM as down-regulated in glioblastoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nThe truth value of these statements depends on specific research findings that are not provided in the context. SWIM (which could stand for a specific software, database, or research method) is not a universally recognized acronym in the context of glioblastoma research, and without access to the specific study or database that identified these genes as down-regulated in glioblastoma, it is not possible to verify these statements. Therefore, the response to each statement is UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "Several R packages have been developed for studying Topological Associating Domains (TADs), which are three-dimensional chromatin structures that are thought to play a crucial role in regulating gene expression. Here are some of the popular R packages for studying TADs:\n1. TADbit: This package provides a set of functions for identifying and characterizing TADs in ChIP-seq data. It uses a Bayesian approach to infer the 3D organization of chromatin and can be used to identify TADs, as well as to predict their functional properties.\n2. TADtrack: This package provides a comprehensive set of tools for identifying and characterizing TADs in ChIP-seq data. It can be used to identify TADs, predict their functional properties, and visualize their organization in 3D space.\n3. ChromHMM: This package provides a set of tools for analyzing chromatin structure and dynamics, including the ability to identify TADs. It uses a probabilistic model to infer the 3D organization of chromatin and can be used to predict the interactions between different regions of the genome.\n4. 3D-Genome: This package provides a set of tools for analyzing the three-dimensional structure of chromatin, including the ability to identify TADs. It uses a combination of computational and experimental methods to infer the 3D organization of chromatin and can be used to predict the interactions between different regions of the genome.\n5. Chromatin3D: This package provides a set of tools for analyzing the three-dimensional structure of chromatin, including the ability to identify TADs. It uses a combination of computational and experimental methods to infer the 3D organization of chromatin and can be used to predict the interactions between different regions of the genome.\n6. H3K27ac ChIP-seq peak caller: This package provides a set of functions for identifying and characterizing H3K27ac peaks, which are associated with active gene expression. It can be used to identify TADs and predict their functional properties.\n7. Chromatin Interaction Networks (ChIN): This package provides a set of tools for analyzing the interactions between different regions of the genome, including the ability to identify TADs. It uses a combination of computational and experimental methods to infer the interactions between different regions of the",
    "llama-2-7b-chat-hf_fact_raw": "1. TADbit is an R package designed for identifying and characterizing Topological Associating Domains (TADs) in ChIP-seq data.\n2. TADtrack is an R package that provides tools for identifying, characterizing, and visualizing TADs in 3D space.\n3. ChromHMM is an R package that includes tools for analyzing chromatin structure and dynamics, with the capability to identify TADs.\n4. 3D-Genome is an R package for analyzing the three-dimensional structure of chromatin, including the identification of TADs.\n5. Chromatin3D is an R package that offers tools for analyzing the three-dimensional structure of chromatin and identifying TADs.",
    "llama-2-7b-chat-hf_fact": [
      "TADbit is an R package designed for identifying and characterizing Topological Associating Domains (TADs) in ChIP-seq data.",
      "TADtrack is an R package that provides tools for identifying, characterizing, and visualizing TADs in 3D space.",
      "ChromHMM is an R package that includes tools for analyzing chromatin structure and dynamics, with the capability to identify TADs.",
      "3D-Genome is an R package for analyzing the three-dimensional structure of chromatin, including the identification of TADs.",
      "Chromatin3D is an R package that offers tools for analyzing the three-dimensional structure of chromatin and identifying TADs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: ChromHMM is a computational tool for understanding chromatin states, not specifically an R package, and it is not primarily focused on identifying TADs but rather on learning the hidden chromatin states from genome-wide chromatin data.\n4. UNKNOWN\n5. UNKNOWN\n\nThe responses to statements 2, 4, and 5 are marked as UNKNOWN because, without specific information about these R packages, it is not possible to confirm their purposes or functionalities.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "The Bioconductor package \"Rreg\" has been developed for accessing bacterial regulatory networks. Rreg is a tool for analyzing and modeling bacterial gene regulation, specifically the transcriptional regulation of Escherichia coli (E. coli). It provides a comprehensive framework for analyzing the regulatory interactions in E. coli, including the analysis of transcriptional regulatory networks, gene expression profiles, and the prediction of regulatory interactions. Rreg uses a combination of machine learning and statistical methods to integrate large-scale genomic and transcriptomic data sets, and to identify key regulators and their target genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bioconductor package \"Rreg\" is developed for accessing bacterial regulatory networks.\n2. Rreg is specifically designed for analyzing the transcriptional regulation of Escherichia coli (E. coli).\n3. Rreg provides a framework for analyzing regulatory interactions in E. coli.\n4. Rreg integrates large-scale genomic and transcriptomic data sets using machine learning and statistical methods.\n5. Rreg is used to identify key regulators and their target genes in bacterial gene regulation.",
    "llama-2-7b-chat-hf_fact": [
      "The Bioconductor package \"Rreg\" is developed for accessing bacterial regulatory networks.",
      "Rreg is specifically designed for analyzing the transcriptional regulation of Escherichia coli (E. coli).",
      "Rreg provides a framework for analyzing regulatory interactions in E. coli.",
      "Rreg integrates large-scale genomic and transcriptomic data sets using machine learning and statistical methods.",
      "Rreg is used to identify key regulators and their target genes in bacterial gene regulation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Bioconductor package for accessing bacterial regulatory networks is called \"RegulonDB\" not \"Rreg\".\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe corrections and responses are based on the assumption that \"Rreg\" is a typographical error or a fictional package, as there is no widely recognized Bioconductor package by that name. RegulonDB is a well-known resource for E. coli regulatory networks, which could be accessed through Bioconductor packages designed for such purposes. Without specific information about a package named \"Rreg,\" the statements about its design, framework, integration methods, and uses cannot be accurately assessed.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "The end products of the shikimate pathway are several aromatic amino acids, including:\n1. Phenylalanine (F)\n2. Tyrosine (Y)\n3. Tryptophan (W)\n4. Tryptophan (W)\n5. Quinates (Q)\nThese amino acids are essential for various physiological processes, including protein synthesis and neurotransmitter production.",
    "llama-2-7b-chat-hf_fact_raw": "1. The shikimate pathway produces aromatic amino acids.\n2. Phenylalanine is an end product of the shikimate pathway.\n3. Tyrosine is an end product of the shikimate pathway.\n4. Tryptophan is an end product of the shikimate pathway.\n5. Quinates are end products of the shikimate pathway.",
    "llama-2-7b-chat-hf_fact": [
      "The shikimate pathway produces aromatic amino acids.",
      "Phenylalanine is an end product of the shikimate pathway.",
      "Tyrosine is an end product of the shikimate pathway.",
      "Tryptophan is an end product of the shikimate pathway.",
      "Quinates are end products of the shikimate pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Quinates are not end products of the shikimate pathway; they are intermediates or precursors in the pathway. The primary end products are the aromatic amino acids phenylalanine, tyrosine, and tryptophan.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline is sometimes used to treat Nelson's syndrome, which is a rare condition that occurs after surgical removal of a pituitary tumor. Nelson's syndrome is characterized by the rapid growth of remaining pituitary tissue after tumor removal, leading to excessive secretion of hormones and hyperpituitarism. Cabergoline, a dopamine receptor agonist, has been shown to be effective in reducing the secretion of hormones in patients with Nelson's syndrome, and is sometimes used as a treatment option. However, it is important to note that cabergoline is not a cure for Nelson's syndrome, and other treatments such as surgery, radiation therapy, and hormone-lowering medications may also be necessary to manage the condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is sometimes used to treat Nelson's syndrome.\n2. Nelson's syndrome is a rare condition that can occur after the surgical removal of a pituitary tumor.\n3. Nelson's syndrome is characterized by the rapid growth of remaining pituitary tissue and excessive secretion of hormones.\n4. Cabergoline is a dopamine receptor agonist.\n5. Cabergoline has been shown to be effective in reducing hormone secretion in patients with Nelson's syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is sometimes used to treat Nelson's syndrome.",
      "Nelson's syndrome is a rare condition that can occur after the surgical removal of a pituitary tumor.",
      "Nelson's syndrome is characterized by the rapid growth of remaining pituitary tissue and excessive secretion of hormones.",
      "Cabergoline is a dopamine receptor agonist.",
      "Cabergoline has been shown to be effective in reducing hormone secretion in patients with Nelson's syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is not typically used to treat Nelson's syndrome; it is used to treat conditions associated with hyperprolactinemia, such as prolactinomas.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Liebenberg syndrome is a rare genetic disorder characterized by a combination of symptoms affecting the nervous system, skin, and other organs. The main manifestations of Liebenberg syndrome include:\n1. Neurological symptoms: Seizures, intellectual disability, ataxia (coordination problems), and pyramidal signs (such as weakness, tremors, and spasticity) are common.\n2. Skin manifestations: The skin is affected in various ways, including palmoplantar keratoderma (thickening and hardening of the skin on the palms and soles), skin fragility, and easy bruising.\n3. Ophthalmological problems: Vision loss, cataracts, and optic atrophy (shrinkage of the optic nerve) can occur.\n4. Musculoskeletal abnormalities: Arthritis, joint contractures (stiffness and limited mobility), and scoliosis (curvature of the spine) can occur.\n5. Respiratory problems: Respiratory failure and sleep apnea (pauses in breathing during sleep) can occur due to muscle weakness and abnormalities in the respiratory muscles.\n6. Cardiovascular problems: Heart valve problems, such as mitral valve prolapse (a condition where the mitral valve does not close properly), and cardiac arrhythmias (abnormal heart rhythms) can occur.\n7. Gastrointestinal problems: Gastroesophageal reflux disease (GERD), gastrointestinal motility disorders, and constipation can occur.\n8. Other problems: Hearing loss, vision loss, and kidney problems can also occur in some cases of Liebenberg syndrome.\nIt is important to note that the severity and range of symptoms can vary greatly among individuals with Liebenberg syndrome, and some individuals may have only a few of these manifestations, while others may have many.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome is a rare genetic disorder.\n2. Neurological symptoms of Liebenberg syndrome can include seizures, intellectual disability, ataxia, and pyramidal signs.\n3. Skin manifestations of Liebenberg syndrome may involve palmoplantar keratoderma, skin fragility, and easy bruising.\n4. Ophthalmological problems associated with Liebenberg syndrome can include vision loss, cataracts, and optic atrophy.\n5. Musculoskeletal abnormalities in Liebenberg syndrome can include arthritis, joint contractures, and scoliosis.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome is a rare genetic disorder.",
      "Neurological symptoms of Liebenberg syndrome can include seizures, intellectual disability, ataxia, and pyramidal signs.",
      "Skin manifestations of Liebenberg syndrome may involve palmoplantar keratoderma, skin fragility, and easy bruising.",
      "Ophthalmological problems associated with Liebenberg syndrome can include vision loss, cataracts, and optic atrophy.",
      "Musculoskeletal abnormalities in Liebenberg syndrome can include arthritis, joint contractures, and scoliosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: Liebenberg syndrome is not a well-recognized or commonly described genetic disorder in medical literature as of my knowledge cutoff date in 2023. It is possible that the syndrome is either extremely rare, not widely accepted, or fictional. Therefore, without specific and credible information regarding Liebenberg syndrome, the truthfulness of the statements cannot be determined.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "MPS1 (Microtubule-associated protein 1) kinase is an enzyme that plays a crucial role in regulating various cellular processes, including cell division, migration, and signaling. Here are some orally bioavailable MPS1 kinase inhibitors that have been identified or developed:\n1. Navitoclax: Navitoclax is a small molecule inhibitor of MPS1 that has shown potent and selective activity against various cancer cell lines, including those resistant to standard chemotherapy agents. It has been shown to inhibit the proliferation of cancer cells by blocking the activation of key signaling pathways, including the PI3K/Akt and MAPK pathways.\n2. BLU-667: BLU-667 is a highly selective and potent MPS1 inhibitor that has shown antitumor activity in preclinical studies. It has been shown to inhibit the growth of various cancer cell lines, including those resistant to standard chemotherapy agents, by blocking the activation of key signaling pathways.\n3. BLU-782: BLU-782 is a next-generation MPS1 inhibitor that has shown improved potency and selectivity compared to earlier generations of MPS1 inhibitors. It has shown antitumor activity in preclinical studies and is currently being investigated in clinical trials for the treatment of various cancers.\n4. GS-9973: GS-9973 is a small molecule MPS1 inhibitor that has shown potent and selective activity against various cancer cell lines, including those resistant to standard chemotherapy agents. It has been shown to inhibit the proliferation of cancer cells by blocking the activation of key signaling pathways, including the PI3K/Akt and MAPK pathways.\n5. HM78139 dihydrochloride: HM78139 dihydrochloride is a potent and selective MPS1 inhibitor that has shown antitumor activity in preclinical studies. It has been shown to inhibit the growth of various cancer cell lines, including those resistant to",
    "llama-2-7b-chat-hf_fact_raw": "1. Navitoclax is an orally bioavailable MPS1 kinase inhibitor.\n2. BLU-667 is an MPS1 inhibitor that has shown antitumor activity in preclinical studies.\n3. BLU-782 is a next-generation MPS1 inhibitor currently being investigated in clinical trials.\n4. GS-9973 is a small molecule MPS1 inhibitor with potent and selective activity against various cancer cell lines.\n5. HM78139 dihydrochloride is a potent and selective MPS1 inhibitor with antitumor activity demonstrated in preclinical studies.",
    "llama-2-7b-chat-hf_fact": [
      "Navitoclax is an orally bioavailable MPS1 kinase inhibitor.",
      "BLU-667 is an MPS1 inhibitor that has shown antitumor activity in preclinical studies.",
      "BLU-782 is a next-generation MPS1 inhibitor currently being investigated in clinical trials.",
      "GS-9973 is a small molecule MPS1 inhibitor with potent and selective activity against various cancer cell lines.",
      "HM78139 dihydrochloride is a potent and selective MPS1 inhibitor with antitumor activity demonstrated in preclinical studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Navitoclax is not an MPS1 kinase inhibitor; it is a Bcl-2 family protein inhibitor.\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: GS-9973, also known as Entospletinib, is a small molecule inhibitor of spleen tyrosine kinase (SYK), not MPS1.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Golimumab, a tumor necrosis factor (TNF) inhibitor, has been tested for the treatment of various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. However, it has not been specifically studied for the treatment of diabetes.\nGolimumab works by blocking the activity of TNF-alpha, a protein that is involved in the immune system and can cause inflammation in the body. By blocking TNF-alpha, golimumab can help reduce inflammation and slow the progression of joint damage in people with autoimmune diseases such as rheumatoid arthritis. However, it is not approved by the US Food and Drug Administration (FDA) for the treatment of diabetes.\nThere are other medications that have been approved by the FDA for the treatment of diabetes, including metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, and sodium-glucose cotransporter 2 (SGLT2) inhibitors. These medications work in different ways to help lower blood sugar levels and improve glycemic control in people with diabetes.\nIt is important to note that golimumab is a prescription medication that should only be used under the guidance and supervision of a healthcare professional. If you have diabetes and are interested in trying a new medication, it is important to discuss your options with your healthcare provider to determine the best course of treatment for you.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab has been tested for the treatment of various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.\n2. Golimumab has not been specifically studied for the treatment of diabetes.\n3. Golimumab works by blocking the activity of TNF-alpha, a protein involved in the immune system that can cause inflammation.\n4. The US Food and Drug Administration (FDA) has not approved golimumab for the treatment of diabetes.\n5. Medications approved by the FDA for the treatment of diabetes include metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab has been tested for the treatment of various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.",
      "Golimumab has not been specifically studied for the treatment of diabetes.",
      "Golimumab works by blocking the activity of TNF-alpha, a protein involved in the immune system that can cause inflammation.",
      "The US Food and Drug Administration (FDA) has not approved golimumab for the treatment of diabetes.",
      "Medications approved by the FDA for the treatment of diabetes include metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is caused by a mutation in the LMNA gene, which is located on chromosome 1. The LMNA gene encodes for a protein called lamin A/C, which is involved in the structure and maintenance of the nuclear lamina, a network of filaments that provides structural support to the nucleus.\nProgeria is an autosomal recessive disorder, meaning that a child must inherit two copies of the mutated LMNA gene, one from each parent, in order to develop the condition. When a child inherits only one mutated copy of the gene, they will be a carrier of the condition but are unlikely to develop symptoms themselves. However, they can pass the mutated gene on to their offspring, who may then develop progeria.",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria is also known as Hutchinson-Gilford progeria syndrome (HGPS).\n2. Progeria is caused by a mutation in the LMNA gene.\n3. The LMNA gene is located on chromosome 1.\n4. The LMNA gene encodes for a protein called lamin A/C.\n5. Lamin A/C is involved in the structure and maintenance of the nuclear lamina.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria is also known as Hutchinson-Gilford progeria syndrome (HGPS).",
      "Progeria is caused by a mutation in the LMNA gene.",
      "The LMNA gene is located on chromosome 1.",
      "The LMNA gene encodes for a protein called lamin A/C.",
      "Lamin A/C is involved in the structure and maintenance of the nuclear lamina."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Variants at 12q14 and 12q24 have been associated with various diseases and conditions, including:\n12q14:\n* Bipolar disorder: Several studies have found that individuals with bipolar disorder are more likely to have copy number variations (CNVs) or deletions at 12q14 compared to controls.\n* Schizophrenia: Some studies have suggested that 12q14 may be a risk locus for schizophrenia, although the findings are not consistent across all studies.\n* Autism spectrum disorder: Some studies have found that individuals with autism spectrum disorder (ASD) are more likely to have copy number variations (CNVs) or deletions at 12q14 compared to controls.\n* Intellectual disability: Variants at 12q14 have been identified as risk factors for intellectual disability, particularly in individuals with intellectual disability and congenital anomalies.\n* Cancer: Variants at 12q14 have been associated with an increased risk of certain types of cancer, including breast, ovarian, and colorectal cancer.\n12q24:\n* Breast cancer: Variants at 12q24 have been associated with an increased risk of breast cancer, particularly in premenopausal women.\n* Prostate cancer: Some studies have found that variants at 12q24 are associated with an increased risk of prostate cancer, although the findings are not consistent across all studies.\n* Colorectal cancer: Variants at 12q24 have been associated with an increased risk of colorectal cancer, particularly in individuals with a family history of the disease.\n* Intellectual disability: Variants at 12q24 have been identified as risk factors for intellectual disability, particularly in individuals with intellectual disability and congenital anomalies.\nIt's important to note that the findings for these associations are based on genome-wide association studies (GWAS) and may not be consistent across all studies or populations. Additionally, the functional impact of these variants is not always clear and may depend on the specific genetic context and other factors.",
    "llama-2-7b-chat-hf_fact_raw": "1. Variants at 12q14 have been associated with an increased risk of bipolar disorder, as found in several studies.\n2. Some studies suggest that 12q14 may be a risk locus for schizophrenia.\n3. Individuals with autism spectrum disorder (ASD) are more likely to have copy number variations (CNVs) or deletions at 12q14 compared to controls, according to some studies.\n4. Variants at 12q24 have been associated with an increased risk of breast cancer, particularly in premenopausal women.\n5. Variants at 12q24 have been linked to an increased risk of colorectal cancer, especially in individuals with a family history of the disease.",
    "llama-2-7b-chat-hf_fact": [
      "Variants at 12q14 have been associated with an increased risk of bipolar disorder, as found in several studies.",
      "Some studies suggest that 12q14 may be a risk locus for schizophrenia.",
      "Individuals with autism spectrum disorder (ASD) are more likely to have copy number variations (CNVs) or deletions at 12q14 compared to controls, according to some studies.",
      "Variants at 12q24 have been associated with an increased risk of breast cancer, particularly in premenopausal women.",
      "Variants at 12q24 have been linked to an increased risk of colorectal cancer, especially in individuals with a family history of the disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Variants at 12q14 have been associated with an increased risk of bipolar disorder in several studies.\n2. TRUE: Some studies suggest that 12q14 may be a risk locus for schizophrenia.\n3. UNKNOWN: Without specific studies to reference, it's difficult to confirm the association of 12q14 with autism spectrum disorder (ASD) and copy number variations (CNVs) or deletions. This statement would require more specific evidence to determine its accuracy.\n4. FALSE [correction]: Variants at 12q24 have been associated with an increased risk of type 2 diabetes and coronary artery disease, but there is no widely established link specifically to breast cancer in premenopausal women without further context or specific studies.\n5. UNKNOWN: The association of 12q24 with colorectal cancer risk is not widely established in the literature as of my knowledge cutoff date. Specific studies would need to be cited to confirm this statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "The ligands of the Roundabout (Robo) receptors are members of the Slit protein family. Slit proteins are secreted signaling molecules that bind to Robo receptors on the surface of neurons and other cells, modulating their activity and behavior. The specific ligands of each Robo receptor are:\n* Robo1: Slit1 and Slit2\n* Robo2: Slit3\n* Robo3: Slit4\n* Robo4: Slit5\nThese ligands can modulate the activity of Robo receptors in a variety of ways, including by inhibiting or activating their signaling properties, and by influencing their localization and stability.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ligands of the Roundabout (Robo) receptors are members of the Slit protein family.\n2. Slit proteins are secreted signaling molecules that bind to Robo receptors.\n3. Robo1 receptors have Slit1 and Slit2 as their specific ligands.\n4. Robo2 receptors have Slit3 as their specific ligand.\n5. Robo3 receptors have Slit4 as their specific ligand.",
    "llama-2-7b-chat-hf_fact": [
      "The ligands of the Roundabout (Robo) receptors are members of the Slit protein family.",
      "Slit proteins are secreted signaling molecules that bind to Robo receptors.",
      "Robo1 receptors have Slit1 and Slit2 as their specific ligands.",
      "Robo2 receptors have Slit3 as their specific ligand.",
      "Robo3 receptors have Slit4 as their specific ligand."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Robo2 receptors can bind to multiple Slit proteins, not exclusively Slit3.\n5. FALSE [correction]: There is no Slit4 ligand; Slit proteins are typically numbered Slit1, Slit2, and Slit3. Additionally, Robo3's interaction with Slit proteins is more complex and not limited to a single \"specific\" ligand.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "TFII-I (Transcription Factor II-I) is a general transcription factor that plays a crucial role in the initiation of transcription in eukaryotic cells. While TFII-I has been implicated in various cellular processes, including cell fate determination, differentiation, and cell cycle regulation, there is limited information on its specific role in megakaryopoiesis.\nMegakaryopoiesis is the process by which megakaryocytes, the precursors of platelets, are generated from hematopoietic stem cells. This process involves a complex interplay of transcription factors, growth factors, and other regulatory molecules.\nStudies have shown that TFII-I is expressed in megakaryocytes and plays a role in the regulation of megakaryocyte-specific genes, such as those involved in platelet membrane protein synthesis and secretion. For example, TFII-I has been shown to bind to the promoter region of the platelet-specific gene, GP3, and enhance its transcription.\nAdditionally, TFII-I has been implicated in the regulation of megakaryocyte differentiation and platelet production. For example, TFII-I has been shown to inhibit the expression of genes involved in myeloid differentiation, such as the myeloid-specific transcription factor, PU.1.\nWhile the exact role of TFII-I in megakaryopoiesis is not fully understood, it is clear that it plays a significant role in the regulation of megakaryocyte-specific genes and differentiation. Further research is needed to fully elucidate the mechanisms by which TFII-I contributes to megakaryopoiesis and platelet production.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I (Transcription Factor II-I) is a general transcription factor involved in the initiation of transcription in eukaryotic cells.\n2. TFII-I has been implicated in cell fate determination, differentiation, and cell cycle regulation.\n3. Megakaryopoiesis is the process of generating megakaryocytes, the precursors of platelets, from hematopoietic stem cells.\n4. TFII-I is expressed in megakaryocytes and regulates megakaryocyte-specific genes, such as those involved in platelet membrane protein synthesis and secretion.\n5. TFII-I has been shown to bind to the promoter region of the platelet-specific gene GP3 and enhance its transcription.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I (Transcription Factor II-I) is a general transcription factor involved in the initiation of transcription in eukaryotic cells.",
      "TFII-I has been implicated in cell fate determination, differentiation, and cell cycle regulation.",
      "Megakaryopoiesis is the process of generating megakaryocytes, the precursors of platelets, from hematopoietic stem cells.",
      "TFII-I is expressed in megakaryocytes and regulates megakaryocyte-specific genes, such as those involved in platelet membrane protein synthesis and secretion.",
      "TFII-I has been shown to bind to the promoter region of the platelet-specific gene GP3 and enhance its transcription."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: TFII-I has been shown to bind to the promoter region of the platelet-specific gene GP9 (CD42a), not GP3, and enhance its transcription.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Yes, atenolol is metabolized by the cytochrome P450 enzyme CYP2D6. CYP2D6 is one of the major enzymes responsible for the metabolism of atenolol, and it plays a significant role in the elimination of the drug from the body. Approximately 10-15% of the administered dose of atenolol is metabolized by CYP2D6, and the resulting metabolites are further conjugated and excreted. The activity of CYP2D6 can vary greatly between individuals, leading to inter-individual differences in the pharmacokinetics and pharmacodynamics of atenolol.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.\n2. CYP2D6 is one of the major enzymes responsible for the metabolism of atenolol.\n3. Approximately 10-15% of the administered dose of atenolol is metabolized by CYP2D6.\n4. The metabolites of atenolol are further conjugated and excreted.\n5. The activity of CYP2D6 can vary greatly between individuals, affecting the pharmacokinetics and pharmacodynamics of atenolol.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.",
      "CYP2D6 is one of the major enzymes responsible for the metabolism of atenolol.",
      "Approximately 10-15% of the administered dose of atenolol is metabolized by CYP2D6.",
      "The metabolites of atenolol are further conjugated and excreted.",
      "The activity of CYP2D6 can vary greatly between individuals, affecting the pharmacokinetics and pharmacodynamics of atenolol."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by the liver and thus not by the cytochrome P450 enzyme CYP2D6.\n2. FALSE [correction]: Since atenolol is not significantly metabolized by the liver, CYP2D6 is not one of the major enzymes responsible for its metabolism.\n3. FALSE [correction]: Atenolol is not significantly metabolized, so the statement that 10-15% of the administered dose is metabolized by CYP2D6 is incorrect.\n4. TRUE: The small amount of atenolol that is metabolized can form metabolites, which are further conjugated and excreted.\n5. TRUE: The activity of CYP2D6 can vary greatly between individuals, which can affect the pharmacokinetics and pharmacodynamics of drugs metabolized by CYP2D6. However, since atenolol is not significantly metabolized by CYP2D6, this variability would not have a significant impact on atenolol.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "ExpansionHunter is a software tool that is used to identify and characterize transcriptional gene regulatory elements (TGREs) in genomic sequences. Here are some versions of ExpansionHunter:\n1. ExpansionHunter 1.0: This was the initial version of the software, released in 2013. It could identify and classify TGREs based on their sequence features and predict their functional categories.\n2. ExpansionHunter 2.0: Released in 2016, this version included several new features, such as the ability to predict the orientation of TGREs and to identify novel TGRE types.\n3. ExpansionHunter 3.0: This version, released in 2019, included several major updates, including the ability to predict the activity of TGREs and to identify TGREs in non-coding RNA sequences.\n4. ExpansionHunter 4.0: The latest version of the software, released in 2022, includes several new features, such as improved prediction of TGRE activity and the ability to identify TGREs in long non-coding RNA sequences.",
    "llama-2-7b-chat-hf_fact_raw": "1. ExpansionHunter 1.0 was released in 2013.\n2. ExpansionHunter 2.0 was released in 2016.\n3. ExpansionHunter 3.0 was released in 2019.\n4. ExpansionHunter 4.0 was released in 2022.\n5. ExpansionHunter is a software tool used to identify and characterize transcriptional gene regulatory elements in genomic sequences.",
    "llama-2-7b-chat-hf_fact": [
      "ExpansionHunter 1.0 was released in 2013.",
      "ExpansionHunter 2.0 was released in 2016.",
      "ExpansionHunter 3.0 was released in 2019.",
      "ExpansionHunter 4.0 was released in 2022.",
      "ExpansionHunter is a software tool used to identify and characterize transcriptional gene regulatory elements in genomic sequences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: ExpansionHunter is a software tool used to identify and characterize expansions of short tandem repeats in genomic sequences.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Adamts18 (a disintegrin and metalloproteinase domain-containing protein 18) is a secreted protein that plays a crucial role in hormone receptor signaling, particularly in the regulation of estrogen receptor (ER) activity. Here's how Adamts18 influences hormone receptor signaling:\n1. Modulation of ER activity: Adamts18 can directly interact with the ER and modulate its activity by altering its ability to bind to estrogen. This can lead to changes in gene expression and cellular responses to estrogen.\n2. Cross-talk with other signaling pathways: Adamts18 can also interact with other signaling pathways, such as the PI3K/Akt pathway, to modulate the overall response to hormone stimulation.\n3. Regulation of cellular processes: Adamts18 has been implicated in the regulation of various cellular processes, including cell proliferation, differentiation, and survival. These processes are critical for maintaining tissue homeostasis and responding to hormonal changes.\n4. Role in cancer: Adamts18 has been shown to play a role in the development and progression of certain cancers, particularly those that are hormone-sensitive, such as breast and endometrial cancer.\nIn summary, Adamts18 plays a crucial role in regulating hormone receptor signaling by modulating ER activity, interacting with other signaling pathways, and influencing cellular processes. Its dysregulation has been implicated in various diseases, including cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is a secreted protein that plays a role in hormone receptor signaling.\n2. Adamts18 can directly interact with the estrogen receptor (ER) and modulate its activity.\n3. Adamts18 can alter the estrogen receptor's ability to bind to estrogen, leading to changes in gene expression.\n4. Adamts18 has been implicated in the regulation of cell proliferation, differentiation, and survival.\n5. Dysregulation of Adamts18 has been associated with the development and progression of certain hormone-sensitive cancers, such as breast and endometrial cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is a secreted protein that plays a role in hormone receptor signaling.",
      "Adamts18 can directly interact with the estrogen receptor (ER) and modulate its activity.",
      "Adamts18 can alter the estrogen receptor's ability to bind to estrogen, leading to changes in gene expression.",
      "Adamts18 has been implicated in the regulation of cell proliferation, differentiation, and survival.",
      "Dysregulation of Adamts18 has been associated with the development and progression of certain hormone-sensitive cancers, such as breast and endometrial cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ADAMTS18 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family, which is known for its roles in extracellular matrix organization and various other cellular functions, but it is not specifically characterized by its role in hormone receptor signaling.\n2. FALSE [correction]: There is no widely recognized or direct evidence that ADAMTS18 interacts with the estrogen receptor (ER) to modulate its activity. ADAMTS proteins generally have different functions.\n3. FALSE [correction]: Since ADAMTS18 is not established to interact with the estrogen receptor, it is not known to alter the receptor's ability to bind to estrogen or lead to changes in gene expression in that context.\n4. TRUE: ADAMTS18, like other members of the ADAMTS family, may be involved in the regulation of various cellular processes, including cell proliferation, differentiation, and survival, although the specific roles can vary and may not be fully characterized.\n5. UNKNOWN: While dysregulation of certain ADAMTS family members has been associated with cancer, the specific role of ADAMTS18 in hormone-sensitive cancers such as breast and endometrial cancer would require more specific evidence to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Thiazovivin is a small molecule inhibitor of the enzyme histone methyltransferase (HMT). HMTs are enzymes that add methyl groups to histone proteins, which are the chief proteins that DNA is wrapped around in the nucleus of eukaryotic cells. Thiazovivin specifically inhibits the HMT SUV39H1, which is known to play a role in the regulation of gene expression, particularly in the context of stem cells and development. By inhibiting SUV39H1, thiazovivin can alter the epigenetic landscape of cells, leading to changes in gene expression and potentially influencing cellular behavior.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is a small molecule inhibitor of the enzyme histone methyltransferase (HMT).\n2. Histone methyltransferases (HMTs) add methyl groups to histone proteins.\n3. Histone proteins are what DNA is wrapped around in the nucleus of eukaryotic cells.\n4. Thiazovivin specifically inhibits the HMT SUV39H1.\n5. SUV39H1 plays a role in the regulation of gene expression, particularly in stem cells and development.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is a small molecule inhibitor of the enzyme histone methyltransferase (HMT).",
      "Histone methyltransferases (HMTs) add methyl groups to histone proteins.",
      "Histone proteins are what DNA is wrapped around in the nucleus of eukaryotic cells.",
      "Thiazovivin specifically inhibits the HMT SUV39H1.",
      "SUV39H1 plays a role in the regulation of gene expression, particularly in stem cells and development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Thiazovivin is not an inhibitor of histone methyltransferase (HMT); it is a small molecule inhibitor that has been shown to enhance the survival of human embryonic stem cells.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Thiazovivin does not specifically inhibit the HMT SUV39H1; it is known to act as a ROCK inhibitor, which is involved in cell adhesion and survival.\n5. TRUE (Although the statement about SUV39H1 is true, it is unrelated to the action of Thiazovivin as previously corrected.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  }
]